6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
50_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
1_CD
General_NN
information_NOMZ
Shire_NN
plc_NN
Shire_NN
or_CC
the_DT
Company_NN
and_CC
its_PIT
subsidiaries_NN
together_RB
the_DT
Group_NN
develop_VB
and_CC
market_NN
products_NN
for_PIN
specialty_NN
physicians_NN
._.
The_DT
Group_NN
focuses_VPRT
on_PIN
four_CD
therapeutic_JJ
areas_NN
:_:
central_JJ
nervous_JJ
system_NN
,_,
gastro-intestinal_JJ
,_,
human_JJ
genetic_JJ
therapies_NN
and_CC
general_JJ
products_NN
._.
The_DT
Companys_NN
ordinary_JJ
shares_NN
are_VPRT [PASS]
traded_VBN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
LSE_NN
._.
On_PIN
November_NN
25_CD
,_,
2005_CD
a_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
,_,
approved_VBN [PASTP]
by_PIN
the_DT
High_NN
Court_NN
of_PIN
Justice_NN
in_PIN
England_NN
and_PHC
Wales_NN
,_,
became_VBD
effective_JJ
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
Scheme_NN
,_,
Shire_NN
replaced_VBD
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
SPG_NN
as_IN
the_DT
holding_VBG [PRIV]
company_NN
of_PIN
the_DT
Shire_NN
Group_NN
._.
SPGs_NN
ordinary_JJ
shareholders_NN
received_VBD
one_CD
Shire_NN
ordinary_JJ
share_NN
for_PIN
each_QUAN
SPG_NN
ordinary_JJ
share_NN
held_VBN [PRIV] [WZPAST]
at_PIN
5.30_CD
pm_NN
on_PIN
November_NN
24_CD
,_,
2005_CD
._.
The_DT
Shire_NN
ordinary_JJ
shares_NN
were_VBD [PASS]
admitted_VBN [PUBV]
to_PIN
the_DT
official_JJ
list_NN
and_CC
to_TO
trading_VBG
on_PIN
the_DT
LSE_NN
at_PIN
8.00_CD
am_VPRT
GMT_NN
on_PIN
November_NN
25_CD
,_,
2005_CD
._.
The_DT
listing_GER
of_PIN
SPGs_NN
ordinary_JJ
shares_NN
was_VBD [PASS]
canceled_VBN
at_PIN
the_DT
same_JJ
time_NN
._.
The_DT
Company_NN
also_RB
has_VPRT
American_JJ
Depositary_NN
Shares_NN
ADSs_NN
trading_GER
on_PIN
the_DT
NASDAQ_NN
National_NN
Market_NN
._.
Each_QUAN
ADS_NN
represents_VPRT
three_CD
ordinary_JJ
shares_NN
of_PIN
Shire_NN
._.
An_DT
ADS_NN
is_VPRT [BYPA]
evidenced_VBN
by_PIN
an_DT
American_JJ
Depositary_NN
Receipt_NN
ADR_NN
issued_VBN [WZPAST]
by_PIN
Morgan_NN
Guaranty_NN
Trust_NN
Company_NN
of_PIN
New_NN
York_NN
as_IN
depositary_NN
._.
As_IN
at_PIN
February_NN
21_CD
,_,
2006_CD
,_,
the_DT
proportion_NOMZ
of_PIN
ordinary_JJ
shares_NN
represented_VBN [WZPAST]
by_PIN
ADRs_NN
was_VBD [BEMA]
30_CD
%_NN
of_PIN
the_DT
outstanding_JJ
ordinary_JJ
shares_NN
._.
In_CONJ
consequence_NULL
of_PIN
the_DT
implementation_NOMZ
of_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
,_,
ADSs_NN
representing_VBG [WZPRES]
ordinary_JJ
shares_NN
of_PIN
SPG_NN
were_VBD [BYPA]
replaced_VBN
by_PIN
ADSs_NN
representing_VBG [WZPRES]
ordinary_JJ
shares_NN
of_PIN
Shire_NN
on_PIN
a_DT
one-for-one_JJ
basis_NN
._.
Dealings_GER
in_PIN
ADSs_NN
representing_VBG [WZPRES]
ordinary_JJ
shares_NN
of_PIN
Shire_NN
on_PIN
NASDAQ_NN
commenced_VBD
at_PIN
9.30_CD
am_VPRT
EST_NN
on_PIN
November_NN
25_CD
,_,
2005_CD
._.
ADSs_NN
representing_VBG [WZPRES]
ordinary_JJ
shares_NN
of_PIN
SPG_NN
were_VBD [PASS]
canceled_VBN
at_PIN
the_DT
same_JJ
time_NN
._.
Exchangeable_JJ
shares_NN
are_VPRT [PASS]
included_VBN
as_IN
part_NN
of_PIN
share_NN
capital_NN
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
to_TO
present_VB
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
of_PIN
the_DT
consolidated_JJ
Groups_NN
capital_NN
structure_NN
._.
Further_JJ
details_NN
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
Note_NN
30_CD
._.
The_DT
Company_NN
is_VPRT [BEMA]
a_DT
public_JJ
limited_JJ
company_NN
incorporated_VBN
under_IN
the_DT
Companies_NN
Act_NN
,_,
1985_CD
and_CC
domiciled_VBD
in_PIN
the_DT
United_NN
Kingdom_NN
._.
The_DT
address_NN
of_PIN
its_PIT
registered_JJ
office_NN
is_VPRT
Hampshire_NN
International_NN
Business_NOMZ
Park_NN
,_,
Chineham_NN
,_,
Basingstoke_NN
,_,
Hampshire_NN
,_,
United_NN
Kingdom_NN
._.
These_DEMO
accounts_NN
are_VPRT [PASS]
presented_VBN
in_PIN
US_FPP1
Dollars_NN
as_IN
this_DEMP
is_VPRT [BEMA]
the_DT
currency_NN
of_PIN
the_DT
primary_JJ
economic_JJ
environment_NOMZ
in_PIN
which_WDT [PIRE]
the_DT
Group_NN
operates_VPRT
._.
2_CD
Significant_JJ
accounting_GER
policies_NN
The_DT
principal_JJ
accounting_GER
policies_NN
adopted_VBN [WZPAST]
in_PIN
the_DT
preparation_NOMZ
of_PIN
these_DEMO
consolidated_JJ
financial_JJ
statements_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
a_DT
Basis_NN
of_PIN
accounting_GER
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
for_PIN
the_DT
first_JJ
time_NN
._.
The_DT
disclosures_NN
required_VBN [SUAV] [WZPAST]
by_PIN
IFRS_NN
1_CD
concerning_VBG
the_DT
transition_NOMZ
from_PIN
UK_NN
GAAP_NN
to_PIN
IFRS_NN
are_VPRT [PASS]
given_VBN
in_PIN
Note_NN
40_CD
._.
The_DT
financial_JJ
statements_NOMZ
have_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
IFRS_NN
adopted_VBD
for_PIN
use_NN
in_PIN
the_DT
European_NN
Union_NN
and_ANDC
therefore_CONJ
comply_VB
with_PIN
Article_NN
4_CD
of_PIN
the_DT
EU_NN
IAS_NN
Regulation_NOMZ
._.
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
on_PIN
the_DT
historical_JJ
cost_NN
basis_NN
,_,
except_PIN
for_PIN
the_DT
revaluation_NOMZ
of_PIN
financial_JJ
assets_NN
,_,
borrowings_GER
and_PHC
derivatives_NN
._.
The_DT
principal_JJ
accounting_GER
policies_NN
adopted_VBN [WZPAST]
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
b_NN
Consolidation_NOMZ
Subsidiaries_NN
Subsidiaries_NN
are_VPRT [BEMA]
all_QUAN
entities_NOMZ
over_IN
which_WDT
the_DT
Group_NN
has_VPRT
the_DT
power_NN
to_TO
govern_VB
the_DT
financial_JJ
and_CC
operating_VBG
policies_NN
of_PIN
the_DT
entity_NOMZ
concerned_VBN
,_,
generally_RB
accompanying_VBG
a_DT
shareholding_GER
of_PIN
more_EMPH
than_PIN
one_CD
half_NN
of_PIN
the_DT
voting_NN
rights_NN
._.
Subsidiaries_NN
are_VPRT [SPAU] [PASS]
fully_AMP
consolidated_VBN
from_PIN
the_DT
date_NN
on_PIN
which_WDT [PIRE]
control_NN
is_VPRT [PASS]
transferred_VBN
to_PIN
the_DT
Group_NN
._.
They_TPP3
are_VPRT [PASS]
fide-consolidated_VBN
from_PIN
the_DT
date_NN
on_PIN
which_WDT [PIRE]
control_NN
ceases_VPRT
._.
The_DT
purchase_NN
method_NN
of_PIN
accounting_GER
is_VPRT [PASS]
used_VBN
to_TO
account_VB
for_PIN
the_DT
acquisition_NOMZ
of_PIN
subsidiaries_NN
by_PIN
the_DT
Group_NN
._.
The_DT
cost_NN
of_PIN
an_DT
acquisition_NOMZ
is_VPRT [PASS]
measured_VBN
as_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
assets_NN
exchanged_VBD
,_,
equity_NOMZ
instruments_NOMZ
issued_VBN
and_CC
liabilities_NOMZ
incurred_VBN
or_CC
assumed_VBN [PRIV]
at_PIN
the_DT
date_NN
of_PIN
exchange_NN
,_,
plus_PIN
costs_NN
directly_RB
attributable_JJ
to_PIN
the_DT
acquisition_NOMZ
._.
Identifiable_JJ
assets_NN
acquired_VBN [WZPAST]
together_RB
with_PIN
liabilities_NOMZ
and_CC
contingent_JJ
liabilities_NOMZ
assumed_VBD [PRIV]
in_PIN
a_DT
business_NOMZ
combination_NOMZ
are_VPRT [PASS]
measured_VBN
initially_TIME
at_PIN
their_TPP3
fair_JJ
values_NN
at_PIN
the_DT
acquisition_NOMZ
date_NN
,_,
irrespective_RB
of_PIN
the_DT
extent_NN
of_PIN
any_QUAN
minority_NOMZ
interest_NN
._.
The_DT
excess_NN
of_PIN
the_DT
cost_NN
of_PIN
acquisition_NOMZ
over_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
identifiable_JJ
net_JJ
assets_NN
acquired_VBN [WZPAST]
is_VPRT [PASS]
recorded_VBN
as_IN
goodwill_NN
._.
Where_RB
necessary_JJ
,_,
adjustments_NOMZ
are_VPRT [PASS]
made_VBN
to_PIN
the_DT
financial_JJ
statements_NOMZ
of_PIN
subsidiaries_NN
to_TO
bring_VB
the_DT
accounting_GER
policies_NN
used_VBN [WZPAST]
in_PIN
line_NN
with_PIN
those_DEMP
used_VBN
by_PIN
the_DT
Group_NN
._.
Inter-company_JJ
transactions_NOMZ
,_,
balances_NN
and_CC
unrealized_JJ
gains_NN
on_PIN
transactions_NOMZ
between_PIN
companies_NN
in_PIN
the_DT
Group_NN
are_VPRT [PASS]
eliminated_VBN
on_PIN
consolidation_NOMZ
._.
Unrealized_JJ
losses_NN
on_PIN
transactions_NOMZ
between_PIN
companies_NN
in_PIN
the_DT
Group_NN
are_VPRT [SPAU] [PASS]
also_RB
eliminated_VBN
unless_COND
the_DT
transaction_NOMZ
provides_VPRT
evidence_NN
of_PIN
an_DT
impairment_NOMZ
of_PIN
the_DT
asset_NN
transferred_VBN
._.
Associates_NN
Associates_NN
are_VPRT [BEMA]
all_QUAN
entities_NOMZ
over_IN
which_WDT
the_DT
Group_NN
is_VPRT [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
exercise_VB
significant_JJ
influence_NN
but_CC
not_XX0
control_VB
or_CC
joint_JJ
control_NN
,_,
through_PIN
participation_NOMZ
in_PIN
the_DT
financial_JJ
and_CC
operating_GER
policy_NN
decisions_NN
of_PIN
the_DT
investee_NN
._.
Significant_JJ
influence_NN
is_VPRT [BEMA]
the_DT
power_NN
to_TO
participate_VB
in_PIN
the_DT
financial_JJ
and_CC
operating_GER
policy_NN
decisions_NN
of_PIN
the_DT
investee_NN
but_CC
not_XX0
the_DT
control_NN
or_CC
joint_JJ
control_NN
over_IN
those_DEMO
policies_NN
._.
In_PIN
general_JJ
this_DEMP
would_PRMD
be_VB [BEMA]
a_DT
shareholding_GER
in_PIN
an_DT
entity_NOMZ
entitling_VBG [WZPRES]
the_DT
Group_NN
to_PIN
between_PIN
20_CD
%_NN
and_CC
50_CD
%_NN
of_PIN
the_DT
voting_NN
rights_NN
of_PIN
that_DEMO
entity_NOMZ
._.
50_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
51_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
Investments_NOMZ
in_PIN
associates_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
by_PIN
the_DT
equity_NOMZ
method_NN
of_PIN
accounting_GER
and_CC
are_VPRT [SPAU] [PASS]
initially_TIME
recognized_VBN [PRIV]
at_PIN
cost_NN
._.
The_DT
Groups_NN
share_NN
of_PIN
its_PIT
associates_NN
post-acquisition_JJ
profits_NN
or_CC
losses_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
and_CC
its_PIT
share_NN
of_PIN
post-acquisition_JJ
movements_NOMZ
in_PIN
reserves_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
reserves_NN
._.
The_DT
cumulative_JJ
post-acquisition_NOMZ
movements_NOMZ
are_VPRT [PASS]
adjusted_VBN
against_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
the_DT
investment_NOMZ
._.
When_RB
the_DT
Groups_NN
share_NN
of_PIN
losses_NN
in_PIN
an_DT
associate_JJ
equals_VPRT
or_CC
exceeds_VPRT
its_PIT
interest_NN
in_PIN
the_DT
associate_NN
,_,
including_VBG [PRESP]
any_QUAN
unsecured_JJ
receivables_NN
due_JJ
from_PIN
that_DEMO
associate_NN
,_,
the_DT
Group_NN
does_VPRT
not_XX0
recognize_VB [PRIV]
such_JJ
excess_JJ
losses_NN
,_,
unless_COND
,_,
and_ANDC
to_PIN
the_DT
extent_NN
it_PIT
has_VPRT [PEAS]
incurred_VBN
obligations_NOMZ
or_CC
made_VBN
payments_NOMZ
on_PIN
behalf_NN
of_PIN
the_DT
associate_NN
._.
Any_QUAN
excess_NN
of_PIN
the_DT
cost_NN
of_PIN
acquisition_NOMZ
over_IN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
fair_JJ
values_NN
of_PIN
the_DT
identifiable_JJ
net_JJ
assets_NN
of_PIN
the_DT
associate_NN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
goodwill_NN
._.
Any_QUAN
deficiency_NN
of_PIN
the_DT
cost_NN
of_PIN
acquisition_NOMZ
below_PLACE
the_DT
Groups_NN
share_NN
of_PIN
fair_JJ
values_NN
of_PIN
the_DT
identifiable_JJ
net_JJ
assets_NN
of_PIN
the_DT
associate_NN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
i._FW
e._FW
discount_NN
on_PIN
acquisition_NOMZ
is_VPRT [PASS]
credited_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
in_PIN
the_DT
period_NN
of_PIN
acquisition_NOMZ
._.
Unrealized_JJ
gains_NN
on_PIN
transactions_NOMZ
between_PIN
the_DT
Group_NN
and_CC
its_PIT
associates_NN
are_VPRT [PASS]
eliminated_VBN
to_PIN
the_DT
extent_NN
of_PIN
the_DT
Groups_NN
interest_NN
in_PIN
the_DT
associate_NN
._.
Unrealized_JJ
losses_NN
between_PIN
the_DT
Group_NN
and_CC
its_PIT
associates_NN
are_VPRT [SPAU] [PASS]
also_RB
eliminated_VBN
unless_COND
the_DT
transaction_NOMZ
provides_VPRT
evidence_NN
of_PIN
an_DT
impairment_NOMZ
of_PIN
the_DT
asset_NN
transferred_VBN
._.
Joint_NN
ventures_NN
The_DT
Groups_NN
interests_NN
in_PIN
jointly_RB
controlled_VBN
entities_NOMZ
are_VPRT [PASS]
accounted_VBN
for_PIN
by_PIN
the_DT
equity_NOMZ
method_NN
._.
c_NN
Foreign_JJ
currency_NN
translation_NOMZ
Functional_NN
and_CC
presentational_JJ
currency_NN
Items_NN
included_VBD
in_PIN
the_DT
individual_JJ
financial_JJ
statements_NOMZ
of_PIN
each_QUAN
of_PIN
the_DT
Groups_NN
entities_NOMZ
are_VPRT [PASS]
measured_VBN
using_VBG
the_DT
currency_NN
of_PIN
the_DT
primary_JJ
economic_JJ
environment_NOMZ
in_PIN
which_WDT [PIRE]
the_DT
entity_NOMZ
operates_VPRT
the_DT
functional_JJ
currency_NN
._.
The_DT
consolidated_JJ
financial_JJ
statements_NOMZ
are_VPRT [PASS]
presented_VBN
in_PIN
US_FPP1
Dollars_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
Groups_NN
presentational_JJ
currency_NN
._.
Transactions_NOMZ
and_PHC
balances_NN
Foreign_JJ
currency_NN
transactions_NOMZ
are_VPRT [PASS]
translated_VBN
into_PIN
the_DT
functional_JJ
currency_NN
using_VBG [WZPRES]
the_DT
exchange_NN
rates_NN
prevailing_VBG [WZPRES]
at_PIN
the_DT
dates_NN
of_PIN
the_DT
transactions_NOMZ
in_PIN
question_NOMZ
._.
Foreign_JJ
exchange_NN
gains_NN
and_PHC
losses_NN
resulting_VBG [WZPRES]
from_PIN
the_DT
settlement_NOMZ
of_PIN
such_JJ
transactions_NOMZ
and_CC
from_PIN
the_DT
translation_NOMZ
at_PIN
the_DT
year-end_JJ
exchange_NN
rates_NN
of_PIN
monetary_JJ
assets_NN
and_PHC
liabilities_NOMZ
denominated_VBN [WZPAST]
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Group_NN
companies_NN
The_DT
results_NN
and_PHC
balance_NN
sheets_NN
of_PIN
all_QUAN
Group_NN
entities_NOMZ
that_TSUB
have_VPRT
a_DT
functional_JJ
currency_NN
different_JJ
from_PIN
the_DT
presentational_JJ
currency_NN
are_VPRT [PASS]
translated_VBN
into_PIN
the_DT
presentational_JJ
currency_NN
as_IN
follows_VPRT
:_:
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
closing_GER
rate_NN
on_PIN
the_DT
balance_NN
sheet_NN
date_NN
:_:
income_NN
and_PHC
expense_NN
are_VPRT [PASS]
translated_VBN
at_PIN
average_JJ
exchange_NN
rates_NN
for_PIN
the_DT
periods_NN
of_PIN
the_DT
income_NN
statement_NOMZ
unless_COND
this_DEMO
average_NN
is_VPRT [BEMA]
not_XX0
a_DT
reasonable_JJ
approximation_NOMZ
of_PIN
the_DT
cumulative_JJ
effect_NN
of_PIN
the_DT
rates_NN
prevailing_VBG [WZPRES]
on_PIN
the_DT
transaction_NOMZ
dates_NN
,_,
in_PIN
which_WDT [PIRE]
case_NN
income_NN
and_PHC
expenses_NN
are_VPRT [PASS]
translated_VBN
at_PIN
the_DT
dates_NN
of_PIN
the_DT
transactions_NOMZ
:_:
and_ANDC
all_QUAN
resulting_VBG
exchange_NN
differences_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
a_DT
separate_JJ
component_NN
of_PIN
equity_NOMZ
._.
On_PIN
consolidation_NOMZ
,_,
exchange_NN
differences_NN
arising_VBG [WZPRES]
from_PIN
the_DT
translation_NOMZ
of_PIN
the_DT
net_JJ
investment_NOMZ
in_PIN
entities_NOMZ
in_PIN
the_DT
Group_NN
are_VPRT [PASS]
taken_VBN
to_PIN
shareholders_NN
equity_NOMZ
._.
When_RB
an_DT
entity_NOMZ
of_PIN
the_DT
Group_NN
is_VPRT [PASS]
sold_VBN
,_,
any_QUAN
such_JJ
exchange_NN
differences_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
as_IN
part_NN
of_PIN
the_DT
gain_NN
or_CC
loss_NN
on_PIN
sale_NN
._.
Goodwill_NN
and_CC
fair_JJ
value_NN
adjustments_NOMZ
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
of_PIN
an_DT
operation_NOMZ
are_VPRT [PASS]
treated_VBN
as_IN
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
a_DT
company_NN
in_PIN
the_DT
Group_NN
and_CC
translated_VBN
at_PIN
the_DT
closing_GER
rate_NN
on_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
d_LS
Segment_NOMZ
reporting_VBG [PUBV] [WZPRES]
A_DT
business_NOMZ
segment_NOMZ
is_VPRT [BEMA]
a_DT
group_NN
of_PIN
assets_NN
and_PHC
operations_NOMZ
engaged_VBD
in_PIN
providing_VBG
products_NN
or_CC
services_NN
that_TSUB
are_VPRT [BEMA]
subject_PRED
to_PIN
risks_NN
and_PHC
returns_NN
that_TSUB
are_VPRT [BEMA]
different_PRED
from_PIN
those_DEMO
of_PIN
other_JJ
business_NOMZ
segments_NOMZ
._.
A_DT
geographical_JJ
segment_NOMZ
is_VPRT [PASS]
engaged_VBN
in_PIN
providing_VBG
products_NN
or_CC
services_NN
within_PIN
a_DT
particular_JJ
economic_JJ
environment_NOMZ
that_DEMP
is_VPRT [BEMA]
subject_PRED
to_PIN
risks_NN
and_PHC
returns_NN
that_TSUB
are_VPRT [BEMA]
different_PRED
from_PIN
those_DEMO
of_PIN
components_NN
operating_VBG [WZPRES]
in_PIN
other_JJ
economic_JJ
environments_NOMZ
._.
e_LS
Revenue_NN
recognition_NOMZ
Revenues_NN
are_VPRT [PASS]
stated_VBN [PUBV]
net_NN
of_PIN
VAT_NN
and_CC
similar_JJ
taxes_NN
,_,
trade_NN
discounts_NN
and_CC
intra-Group_JJ
transactions_NOMZ
._.
The_DT
principal_JJ
components_NN
of_PIN
the_DT
Groups_NN
turnover_NN
and_CC
their_TPP3
respective_JJ
accounting_GER
treatments_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
:_:
Product_NN
sales_NN
revenue_NN
from_PIN
the_DT
sales_NN
of_PIN
products_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
upon_PIN
shipment_NOMZ
to_PIN
customers_NN
or_CC
at_PIN
the_DT
time_NN
of_PIN
delivery_NN
depending_VBG [WZPRES]
on_PIN
the_DT
terms_NN
of_PIN
sale_NN
._.
Provisions_NN
for_PIN
certain_JJ
rebates_NN
,_,
product_NN
returns_NN
and_PHC
discounts_NN
to_PIN
customers_NN
are_VPRT [PASS]
provided_VBN
for_PIN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
are_VPRT [PASS]
recorded_VBN
:_:
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
51_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
52_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
Licensing_VBG [WZPRES]
and_CC
development_NOMZ
fees_NN
licensing_GER
and_PHC
development_NOMZ
fees_NN
represent_VPRT
revenues_NN
derived_VBN [WZPAST]
from_PIN
license_NN
agreements_NOMZ
and_CC
from_PIN
collaborative_JJ
research_NN
and_PHC
development_NOMZ
arrangements_NOMZ
:_:
initial_JJ
license_NN
fees_NN
are_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
separable_PRED
from_PIN
the_DT
associated_VBN
research_NN
and_PHC
development_NOMZ
activities_NOMZ
,_,
even_RB
where_RB
such_JJ
fees_NN
are_VPRT [BEMA]
nonrefundable_PRED
and_CC
not_XX0
creditable_JJ
against_PIN
research_NN
and_PHC
development_NOMZ
services_NN
to_TO
be_VB [PASS]
rendered_VBN
._.
Initial_JJ
license_NN
fees_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
of_PIN
the_DT
license_NN
term_NN
or_CC
the_DT
period_NN
of_PIN
the_DT
associated_VBN
research_NN
and_PHC
development_NOMZ
agreement_NOMZ
._.
In_PIN
circumstances_NN
where_RB
initial_JJ
license_NN
fees_NN
are_VPRT [BEMA]
not_XX0
for_PIN
a_DT
defined_VBN
period_NN
,_,
revenues_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
over_IN
the_DT
period_NN
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
relevant_JJ
patent_NN
to_PIN
which_WDT [PIRE]
the_DT
license_NN
relates_VPRT
:_:
Milestones_NN
during_PIN
the_DT
term_NN
of_PIN
certain_JJ
research_NN
and_PHC
development_NOMZ
agreements_NOMZ
,_,
the_DT
Group_NN
receives_VPRT
non-refundable_JJ
milestones_NN
as_IN
certain_JJ
technical_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
._.
Revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
achievement_NOMZ
of_PIN
milestones_NN
:_:
and_ANDC
the_DT
Group_NN
also_RB
receives_VPRT
non-refundable_JJ
clinical_JJ
milestones_NN
when_RB
certain_JJ
targets_NN
are_VPRT [PASS]
achieved_VBN
during_PIN
the_DT
clinical_JJ
phases_NN
of_PIN
development_NOMZ
,_,
such_JJ
as_IN
the_DT
submission_NN
of_PIN
clinical_JJ
data_NN
to_PIN
a_DT
regulatory_JJ
authority_NOMZ
._.
These_DEMO
clinical_JJ
milestones_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
receivable_NN
._.
If_COND
milestone_NN
payments_NOMZ
are_VPRT [BEMA]
creditable_PRED
against_PIN
future_JJ
royalty_NN
payments_NOMZ
,_,
the_DT
milestones_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
released_VBN
over_IN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
the_DT
royalties_NN
are_VPRT [PASS]
anticipated_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
._.
No_SYNE
revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
for_PIN
consideration_NOMZ
,_,
the_DT
value_NN
or_CC
receipt_NN
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
dependent_PRED
on_PIN
future_JJ
events_NN
,_,
future_JJ
performance_NN
,_,
or_CC
refund_NN
obligations_NOMZ
._.
Royalty_NN
income_NN
royalty_NN
income_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
an_DT
accruals_NN
basis_NN
in_PIN
accordance_NN
with_PIN
the_DT
substance_NN
of_PIN
the_DT
relevant_JJ
agreements_NOMZ
._.
Interest_NN
income_NN
interest_NN
income_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
a_DT
time-proportion_JJ
basis_NN
using_VBG [WZPRES]
the_DT
effective_JJ
interest_NN
method_NN
._.
Dividend_NN
income_NN
dividend_NN
income_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
right_NN
to_TO
receive_VB
payment_NOMZ
is_VPRT [PASS]
established_VBN [PRIV]
._.
f_LS
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
at_PIN
cost_NN
,_,
less_JJ
subsequent_JJ
depreciation_NOMZ
and_PHC
impairment_NOMZ
,_,
except_PIN
for_PIN
land_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
shown_VBN [PRIV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realizable_JJ
value_NN
._.
Cost_NN
includes_VPRT
expenditure_NN
that_DEMP
is_VPRT [BEMA]
directly_RB
attributable_PRED
to_PIN
the_DT
acquisition_NOMZ
of_PIN
the_DT
assets_NN
._.
Subsequent_JJ
costs_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
assets_NN
carrying_VBG [WZPRES]
amount_NN
or_CC
recognized_VBN [PRIV]
as_IN
a_DT
separate_JJ
asset_NN
,_,
as_IN
appropriate_JJ
,_,
only_DWNT
when_RB
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
future_JJ
economic_JJ
benefits_NN
associated_VBN [WZPAST]
with_PIN
the_DT
item_NN
will_PRMD
flow_VB
to_PIN
the_DT
Group_NN
and_CC
the_DT
cost_NN
of_PIN
the_DT
item_NN
can_POMD
be_VB [PASS]
measured_VBN
reliably_RB
._.
Where_RB
the_DT
expenditure_NN
constitutes_VPRT
repairs_NN
and_PHC
maintenance_NN
,_,
it_PIT
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
during_PIN
the_DT
financial_JJ
period_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [PASS]
incurred_VBN
._.
Depreciation_NOMZ
is_VPRT [PASS]
calculated_VBN [PRIV]
using_VBG
the_DT
straight-line_JJ
method_NN
to_TO
allocate_VB
the_DT
difference_NN
between_PIN
the_DT
cost_NN
of_PIN
each_QUAN
asset_NN
and_CC
its_PIT
residual_JJ
value_NN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
life_NN
as_IN
follows_VPRT
:_:
Land_NN
Buildings_GER
20_CD
to_PIN
50_CD
years_NN
Furniture_NN
and_PHC
fittings_GER
3_CD
to10_CD
years_NN
Equipment_NOMZ
and_CC
other_JJ
3_CD
to10_CD
years_NN
Motor_NN
vehicles_NN
4_CD
to_PIN
5_CD
years_NN
Residual_JJ
values_NN
and_CC
the_DT
useful_JJ
lives_NN
of_PIN
assets_NN
are_VPRT [PASS]
reviewed_VBN
,_,
and_ANDC
adjusted_VBN
if_COND
appropriate_JJ
,_,
at_PIN
each_QUAN
balance_NN
sheet_NN
date_NN
._.
An_DT
assets_NN
carrying_VBG [WZPRES]
amount_NN
is_VPRT [PASS]
written_VBN [PUBV]
down_RP
immediately_TIME
to_PIN
its_PIT
recoverable_JJ
amount_NN
if_COND
the_DT
assets_NN
carrying_VBG [WZPRES]
amount_NN
is_VPRT [BEMA]
greater_PRED
than_PIN
its_PIT
estimated_VBN [PRIV]
recoverable_JJ
amount_NN
._.
Gains_NN
and_PHC
losses_NN
on_PIN
disposals_NN
are_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
comparing_VBG
the_DT
disposal_NN
proceeds_NN
with_PIN
the_DT
carrying_VBG
amount_NN
and_CC
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
are_VPRT [PASS]
depreciated_VBN
over_IN
their_TPP3
expected_VBN [PRIV]
useful_JJ
lives_NN
on_PIN
the_DT
same_JJ
basis_NN
as_IN
owned_VBN
assets_NN
,_,
or_CC
where_RB
shorter_JJ
,_,
over_IN
the_DT
term_NN
of_PIN
the_DT
relevant_JJ
lease_NN
._.
Properties_NN
in_PIN
the_DT
course_NN
of_PIN
construction_NOMZ
are_VPRT [PASS]
carried_VBN
at_PIN
cost_NN
less_JJ
any_QUAN
recognized_VBN [PRIV]
impairment_NOMZ
loss_NN
._.
Cost_NN
includes_VPRT
professional_JJ
fees_NN
and_CC
,_,
for_PIN
qualifying_VBG
assets_NN
,_,
borrowing_VBG
costs_NN
capitalized_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
the_DT
Groups_NN
accounting_VBG [WZPRES]
policy_NN
._.
Depreciation_NOMZ
of_PIN
these_DEMO
assets_NN
commences_NN
when_RB
the_DT
assets_NN
are_VPRT [BEMA]
ready_PRED
for_PIN
their_TPP3
intended_VBN [SUAV]
use_NN
._.
52_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
53_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
g_VPRT
Borrowing_GER
costs_NN
Borrowing_VBG [WZPRES]
costs_NN
directly_RB
attributable_JJ
to_PIN
the_DT
acquisition_NOMZ
,_,
construction_NOMZ
or_CC
production_NOMZ
of_PIN
qualifying_VBG
assets_NN
,_,
which_WDT [SERE]
are_VPRT
assets_NN
that_TSUB
necessarily_RB
take_VB
a_DT
substantial_JJ
period_NN
of_PIN
time_NN
to_TO
get_VB
ready_JJ
for_PIN
their_TPP3
intended_VBN [SUAV]
use_NN
or_CC
sale_NN
,_,
are_VPRT [PASS]
added_VBN [PUBV]
to_PIN
the_DT
cost_NN
of_PIN
those_DEMO
assets_NN
,_,
until_IN
such_JJ
time_NN
as_IN
the_DT
assets_NN
are_VPRT [BEMA]
substantially_RB
ready_PRED
for_PIN
their_TPP3
intended_VBN [SUAV]
use_NN
or_CC
sale_NN
._.
Investment_NOMZ
income_NN
earned_VBN [WZPAST]
on_PIN
the_DT
temporary_JJ
investment_NOMZ
of_PIN
specific_JJ
borrowings_GER
pending_VBG [WZPRES]
their_TPP3
expenditure_NN
on_PIN
qualifying_VBG
assets_NN
is_VPRT [PASS]
deducted_VBN
from_PIN
the_DT
borrowing_GER
costs_VPRT
eligible_JJ
for_PIN
capitalization_NOMZ
._.
All_QUAN
other_JJ
borrowing_GER
costs_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
profit_NN
or_CC
loss_NN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
incurred_VBN
._.
h_NN
Intangible_JJ
assets_NN
Goodwill_NN
Goodwill_NN
represents_VPRT
the_DT
excess_NN
of_PIN
the_DT
cost_NN
of_PIN
an_DT
acquisition_NOMZ
over_IN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
Groups_NN
share_NN
of_PIN
the_DT
net_JJ
identifiable_JJ
assets_NN
of_PIN
the_DT
acquired_VBN
subsidiary_NN
associate_NN
or_CC
jointly_RB
controlled_VBN
entity_NOMZ
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
Goodwill_NN
is_VPRT [PASS]
tested_VBN
annually_RB
for_PIN
impairment_NOMZ
and_CC
carried_VBD
at_PIN
cost_NN
less_JJ
accumulated_VBN
impairment_NOMZ
losses_NN
._.
Any_QUAN
impairment_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
immediately_TIME
in_PIN
profit_NN
or_CC
loss_NN
and_CC
is_VPRT
not_XX0
subsequently_TIME
reversed_PRED
._.
For_PIN
the_DT
purpose_NN
of_PIN
impairment_NOMZ
testing_GER
,_,
goodwill_NN
is_VPRT [PASS]
allocated_VBN
to_PIN
each_QUAN
of_PIN
the_DT
Groups_NN
cash-generating_JJ
units_NN
expected_VBN [PRIV]
to_TO
benefit_VB
from_PIN
the_DT
synergies_NN
of_PIN
the_DT
combination_NOMZ
._.
Each_QUAN
of_PIN
those_DEMO
cash_NN
generating_VBG [WZPRES]
units_NN
represents_VPRT
the_DT
Groups_NN
investment_NOMZ
in_PIN
operations_NOMZ
by_PIN
each_QUAN
primary_JJ
reporting_GER
segment_NOMZ
._.
Cash-generating_VBG
units_NN
to_PIN
which_WDT [PIRE]
goodwill_NN
had_VBD [PEAS]
been_VBN [PASS]
allocated_VBN
are_VPRT [PASS]
tested_VBN
for_PIN
impairment_NOMZ
annually_RB
,_,
or_CC
more_EMPH
frequently_RB
when_RB
there_EX
is_VPRT
an_DT
indication_NOMZ
that_TOBJ
the_DT
unit_NN
may_POMD
be_VB [PASS]
impaired_VBN
._.
If_COND
the_DT
recoverable_JJ
amount_NN
of_PIN
the_DT
cash-generating_JJ
unit_NN
is_VPRT [BEMA]
less_PRED
than_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
the_DT
unit_NN
,_,
the_DT
impairment_NOMZ
loss_NN
is_VPRT [PASS]
allocated_VBN
first_RB
to_TO
reduce_VB
the_DT
carrying_VBG
amount_NN
of_PIN
any_QUAN
goodwill_NN
allocated_VBN [WZPAST]
to_PIN
the_DT
unit_NN
and_CC
then_RB
to_PIN
the_DT
other_JJ
assets_NN
of_PIN
the_DT
unit_NN
pro-rata_JJ
on_PIN
the_DT
basis_NN
of_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
each_QUAN
asset_NN
in_PIN
the_DT
unit_NN
._.
On_PIN
disposal_NN
of_PIN
a_DT
subsidiary_NN
,_,
associate_NN
or_CC
jointly_RB
controlled_VBN
entity_NOMZ
,_,
the_DT
attributable_JJ
amount_NN
of_PIN
goodwill_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
determination_NOMZ
of_PIN
the_DT
profit_NN
or_CC
loss_NN
on_PIN
disposal_NN
._.
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
before_IN
the_DT
date_NN
of_PIN
transition_NOMZ
to_PIN
IFRS_NN
has_VPRT [PEAS]
been_VBN [PASS]
retained_VBN
at_PIN
the_DT
previous_JJ
UK_NN
GAAP_NN
amounts_VPRT
subject_JJ
to_TO
being_VBG [PASS]
tested_VBN
for_PIN
impairment_NOMZ
at_PIN
that_DEMO
date_NN
._.
Goodwill_NN
written_VBN [PUBV] [WZPAST]
off_PIN
to_PIN
reserves_NN
under_IN
UK_NN
GAAP_NN
prior_RB
to_PIN
1998_CD
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
reinstated_VBN
and_PHC
is_VPRT [PASS]
not_XX0
included_VBN
in_PIN
determining_VBG [SUAV] [PRIV]
any_QUAN
subsequent_JJ
profit_NN
or_CC
loss_NN
disposal_NN
._.
Research_NN
and_PHC
development_NOMZ
Research_NN
expenditure_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
expense_NN
as_IN
incurred_VBN
._.
Internal_NN
development_NOMZ
costs_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
intangible_JJ
assets_NN
when_RB
an_DT
asset_NN
is_VPRT [PASS]
created_VBN
that_DEMP
can_POMD
be_VB [PASS]
identified_VBN
,_,
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
future_JJ
economic_JJ
benefits_NN
will_PRMD
flow_VB
to_PIN
the_DT
Group_NN
and_PHC
costs_NN
can_POMD
be_VB [PASS]
measured_VBN
reliably_RB
._.
The_DT
Group_NN
considers_VPRT [PRIV]
that_THVC
regulatory_JJ
and_PHC
other_JJ
uncertainties_NN
inherent_JJ
in_PIN
the_DT
development_NOMZ
of_PIN
new_JJ
products_NN
mean_VPRT [PRIV]
that_THVC
such_JJ
criteria_NN
are_VPRT [PASS]
not_XX0
met_VBN
until_IN
the_DT
commercial_JJ
launch_NN
of_PIN
the_DT
product_NN
and_ANDC
therefore_CONJ
,_,
pre-launch_JJ
internal_JJ
development_NOMZ
costs_NN
are_VPRT [PASS]
expensed_VBN
as_IN
incurred_VBN
._.
No_SYNE
significant_JJ
direct_JJ
development_NOMZ
costs_NN
are_VPRT [PASS]
incurred_VBN
post_NN
commercial_JJ
launch_NN
._.
Where_RB
the_DT
recognition_NOMZ
criteria_NN
are_VPRT [PASS]
met_VBN
,_,
internal_JJ
development_NOMZ
costs_NN
are_VPRT [PASS]
capitalized_VBN
and_PHC
amortised_VBN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
their_TPP3
useful_JJ
economic_JJ
lives_NN
from_PIN
product_NN
launch_NN
._.
Payments_NOMZ
to_PIN
in-license_JJ
products_NN
and_PHC
compounds_NN
from_PIN
third_JJ
parties_NN
,_,
generally_RB
taking_VBG
the_DT
form_NN
of_PIN
up-front_JJ
payments_NOMZ
and_PHC
milestones_NN
,_,
are_VPRT [PASS]
capitalized_VBN
._.
Development_NOMZ
costs_VPRT
previously_TIME
recognized_VBN [PRIV]
as_IN
an_DT
expense_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
as_IN
an_DT
asset_NN
in_PIN
subsequent_JJ
periods_NN
._.
Intellectual_NN
property_NN
Intellectual_NN
property_NN
,_,
including_VBG
trademarks_NN
,_,
is_VPRT [PASS]
recognized_VBN [PRIV]
at_PIN
purchase_NN
cost_NN
and_CC
amortised_VBN
in_PIN
equal_JJ
annual_JJ
instalments_NOMZ
over_IN
the_DT
estimated_VBN [PRIV]
useful_JJ
life_NN
of_PIN
the_DT
product_NN
post_NN
its_PIT
launch_NN
generally_RB
not_XX0
exceeding_VBG
20_CD
years_NN
._.
Intellectual_NN
property_NN
related_VBN [WZPAST]
to_PIN
a_DT
marketed_VBN
product_NN
can_POMD
have_VB
a_DT
useful_JJ
life_NN
exceeding_VBG [WZPRES]
20_CD
years_NN
when_RB
the_DT
Group_NN
believes_VPRT [PRIV]
that_THVC
the_DT
product_NN
is_VPRT [SPAU] [PASS]
well_RB
established_VBN [PRIV]
in_PIN
its_PIT
market_NN
._.
Computer_NN
software_NN
The_DT
costs_NN
of_PIN
acquiring_VBG
computer_NN
software_NN
licenses_NN
and_CC
implementing_VBG
the_DT
specific_JJ
software_NN
are_VPRT [PASS]
capitalized_VBN
._.
These_DEMO
costs_NN
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
lives_NN
three_CD
to_PIN
five_CD
years_NN
._.
Costs_NN
associated_VBN [WZPAST]
with_PIN
maintaining_VBG [PUBV]
computer_NN
software_NN
programs_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
expense_NN
as_IN
incurred_VBN
._.
i_FPP1
Impairment_NOMZ
of_PIN
tangible_JJ
and_PHC
intangible_JJ
assets_NN
excluding_VBG [WZPRES]
goodwill_NN
At_PIN
each_QUAN
balance_NN
sheet_NN
date_NN
,_,
the_DT
Group_NN
reviews_VPRT
the_DT
carrying_VBG
amounts_NN
of_PIN
its_PIT
tangible_JJ
and_PHC
intangible_JJ
assets_NN
to_TO
determine_VB [SUAV] [PRIV]
whether_IN [WHCL]
there_EX
is_VPRT
any_QUAN
indication_NOMZ
that_TOBJ
those_DEMO
assets_NN
have_VPRT [PEAS]
suffered_VBN
an_DT
impairment_NOMZ
loss_NN
._.
If_COND
any_QUAN
such_JJ
indication_NOMZ
exists_VPRT
,_,
the_DT
recoverable_JJ
amount_NN
of_PIN
the_DT
asset_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
in_PIN
order_NN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
extent_NN
of_PIN
the_DT
impairment_NOMZ
loss_NN
if_COND
any_QUAN
._.
Where_RB
the_DT
asset_NN
does_VPRT
not_XX0
generate_VB
cash_NN
flows_NN
that_TSUB
are_VPRT [BEMA]
independent_PRED
from_PIN
other_JJ
assets_NN
,_,
the_DT
Group_NN
estimates_VPRT [PRIV]
the_DT
recoverable_JJ
amount_NN
of_PIN
the_DT
cash-generating_JJ
unit_NN
to_PIN
which_WDT [PIRE]
the_DT
asset_NN
belongs_VPRT
._.
An_DT
intangible_JJ
asset_NN
with_PIN
an_DT
indefinite_JJ
useful_JJ
life_NN
is_VPRT [PASS]
tested_VBN
for_PIN
impairment_NOMZ
annually_RB
and_ANDC
whenever_RB
there_EX
is_VPRT
an_DT
indication_NOMZ
that_TOBJ
the_DT
asset_NN
may_POMD
be_VB [PASS]
impaired_VBN
._.
The_DT
recoverable_JJ
amount_NN
is_VPRT [BEMA]
the_DT
higher_JJ
of_PIN
fair_JJ
value_NN
less_RB
costs_NN
to_TO
sell_VB
and_CC
value_NN
in_PIN
use_NN
._.
In_PIN
assessing_VBG
value_NN
in_PIN
use_NN
,_,
the_DT
estimated_JJ
future_JJ
cash_NN
flows_NN
are_VPRT [PASS]
discounted_VBN
to_PIN
their_TPP3
present_JJ
value_NN
using_VBG [WZPRES]
a_DT
pre-tax_JJ
discount_NN
rate_NN
that_TSUB
reflects_VPRT [PRIV]
current_JJ
market_NN
assessments_NOMZ
of_PIN
the_DT
time_NN
value_NN
of_PIN
money_NN
and_CC
the_DT
risks_NN
specific_JJ
to_PIN
the_DT
asset_NN
for_PIN
which_WDT [PIRE]
the_DT
estimates_NN
of_PIN
future_JJ
cash_NN
flows_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
adjusted_VBN
._.
If_COND
the_DT
recoverable_JJ
amount_NN
of_PIN
an_DT
asset_NN
or_CC
cash-generating_JJ
unit_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
to_TO
be_VB [BEMA]
less_PRED
than_PIN
its_PIT
carrying_VBG
amount_NN
,_,
the_DT
carrying_VBG
amount_NN
of_PIN
the_DT
asset_NN
or_CC
cash-generating_JJ
unit_NN
is_VPRT [PASS]
reduced_VBN
to_PIN
its_PIT
recoverable_JJ
amount_NN
._.
An_DT
impairment_NOMZ
loss_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
expense_NN
immediately_TIME
,_,
unless_COND
the_DT
relevant_JJ
asset_NN
is_VPRT [PASS]
carried_VBN
at_PIN
a_DT
revalued_VBN
amount_NN
,_,
in_PIN
which_WDT [PIRE]
case_NN
the_DT
impairment_NOMZ
loss_NN
is_VPRT [PASS]
treated_VBN
as_IN
a_DT
revaluation_NOMZ
decrease_NN
to_PIN
the_DT
extent_NN
that_TOBJ
a_DT
revaluation_NOMZ
surplus_NN
exists_VPRT
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
53_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
54_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
Where_RB
an_DT
impairment_NOMZ
loss_NN
subsequently_TIME
reverses_VPRT
,_,
the_DT
carrying_VBG
amount_NN
of_PIN
the_DT
asset_NN
or_CC
cash-generating_JJ
unit_NN
is_VPRT [PASS]
increased_VBN
to_PIN
the_DT
revised_VBN
estimate_NN
of_PIN
its_PIT
recoverable_JJ
amount_NN
,_,
but_CC
only_DWNT
to_PIN
the_DT
extent_NN
that_TOBJ
the_DT
increased_VBN
carrying_VBG
amount_NN
does_VPRT
not_XX0
exceed_VB
the_DT
carrying_VBG
amount_NN
that_TSUB
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
determined_VBN [SUAV] [PRIV]
had_VBD
no_SYNE
impairment_NOMZ
loss_NN
been_VBN [PASS]
recognized_VBN [PRIV]
._.
A_DT
reversal_NN
of_PIN
an_DT
impairment_NOMZ
loss_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
income_NN
immediately_TIME
,_,
unless_COND
the_DT
relevant_JJ
asset_NN
is_VPRT [PASS]
carried_VBN
at_PIN
a_DT
revalued_VBN
amount_NN
,_,
in_PIN
which_WDT [PIRE]
case_NN
the_DT
reversal_NN
of_PIN
the_DT
impairment_NOMZ
loss_NN
is_VPRT [PASS]
treated_VBN
as_IN
a_DT
revaluation_NOMZ
increase_NN
._.
j_NN
Financial_NN
assets_NN
From_PIN
January_NN
1_CD
,_,
2004_CD
to_PIN
December_NN
31_CD
,_,
2004_CD
:_:
Financial_NN
assets_NN
include_VPRT
investments_NOMZ
in_PIN
companies_NN
other_JJ
than_PIN
subsidiaries_NN
,_,
associates_NN
and_CC
joint_JJ
ventures_NN
,_,
financial_JJ
receivables_NN
held_VBN [PRIV] [WZPAST]
for_PIN
investment_NOMZ
purposes_NN
,_,
treasury_NN
stock_NN
and_CC
other_JJ
securities_NOMZ
._.
Financial_JJ
assets_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
cost_NN
,_,
including_VBG
additional_JJ
direct_JJ
charges_NN
,_,
less_JJ
provision_NN
for_PIN
any_QUAN
impairment_NOMZ
._.
From_PIN
January_NN
1,2005_CD
:_:
From_PIN
January_NN
1_CD
,_,
2005_CD
the_DT
Group_NN
applied_VBD
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
._.
The_DT
Group_NN
has_VPRT [PEAS]
chosen_VBN
to_TO
apply_VB
these_DEMO
standards_NN
prospectively_RB
,_,
which_WDT [SERE]
has_VPRT [PEAS]
resulted_VBN
in_PIN
the_DT
accounting_GER
policy_NN
described_VBD
below_PLACE
:_:
The_DT
Group_NN
classifies_VPRT
its_PIT
investments_NOMZ
in_PIN
the_DT
following_VBG
categories_NN
:_:
financial_JJ
assets_NN
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
,_,
loans_NN
and_PHC
receivables_NN
,_,
held-tomaturity_JJ
investments_NOMZ
and_CC
available-for-sale_JJ
financial_JJ
assets_NN
._.
The_DT
classification_NOMZ
depends_VPRT
on_PIN
the_DT
purpose_NN
for_PIN
which_WDT [PIRE]
the_DT
investments_NOMZ
were_VBD [PASS]
acquired_VBN
._.
Management_NOMZ
determines_VPRT [SUAV] [PRIV]
the_DT
classification_NOMZ
of_PIN
its_PIT
investments_NOMZ
at_PIN
initial_JJ
recognition_NOMZ
and_CC
re-evaluates_VPRT
this_DEMO
designation_NOMZ
at_PIN
every_QUAN
reporting_GER
date_NN
._.
Financial_JJ
assets_NN
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
This_DEMO
category_NN
has_VPRT
two_CD
sub-categories_NN
:_:
financial_JJ
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
trading_GER
,_,
and_ANDC
those_DEMP
designated_VBN
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
at_PIN
inception_NOMZ
._.
A_DT
financial_JJ
asset_NN
is_VPRT [PASS]
classified_VBN
in_PIN
this_DEMO
latter_JJ
category_NN
if_COND
acquired_VBN
principally_RB
for_PIN
the_DT
purpose_NN
of_PIN
selling_VBG
in_PIN
the_DT
short_JJ
term_NN
or_CC
if_COND
so_RB
designated_VBN
by_PIN
management_NOMZ
._.
Derivatives_NN
are_VPRT [SPAU] [PASS]
also_RB
categorised_VBN
as_IN
held_VBN [PRIV]
for_PIN
trading_GER
unless_COND
they_TPP3
are_VPRT [PASS]
designated_VBN
as_IN
hedges_NN
._.
Assets_NN
in_PIN
this_DEMO
category_NN
are_VPRT [PASS]
classified_VBN
as_IN
current_JJ
assets_NN
if_COND
they_TPP3
are_VPRT [SPAU] [PASS]
either_RB
held_VBN [PRIV]
for_PIN
trading_GER
or_CC
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
realized_VBN [PRIV]
within_PIN
12_CD
months_NN
of_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
Group_NN
allocates_VPRT
derivatives_NN
to_PIN
this_DEMO
category_NN
._.
Loans_NN
and_PHC
receivables_NN
Loans_NN
and_PHC
receivables_NN
are_VPRT [BEMA]
non-derivative_JJ
financial_JJ
assets_NN
with_PIN
fixed_VBN
or_CC
determinable_JJ
payments_NOMZ
that_TSUB
are_VPRT [PASS]
not_XX0
quoted_VBN
in_PIN
an_DT
active_JJ
market_NN
._.
They_TPP3
arise_VPRT
when_RB
the_DT
Group_NN
provides_VPRT
money_NN
,_,
goods_NN
or_CC
services_NN
directly_RB
to_PIN
a_DT
debtor_NN
with_PIN
no_SYNE
intention_NOMZ
of_PIN
trading_VBG
the_DT
receivable_NN
._.
They_TPP3
are_VPRT [PASS]
included_VBN
in_PIN
current_JJ
assets_NN
,_,
except_PIN
for_PIN
maturities_NOMZ
greater_JJ
than_PIN
12_CD
months_NN
after_IN
the_DT
balance_NN
sheet_NN
date_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
classified_VBN
as_IN
non-current_JJ
assets_NN
._.
Held-to-maturity_JJ
investments_NOMZ
Held-to-maturity_JJ
investments_NOMZ
are_VPRT [BEMA]
non-derivative_JJ
financial_JJ
assets_NN
with_PIN
fixed_VBN
or_CC
determinable_JJ
payments_NOMZ
and_CC
fixed_VBN
maturities_NOMZ
that_TOBJ
the_DT
Groups_NN
management_NOMZ
has_VPRT
the_DT
positive_JJ
intention_NOMZ
and_PHC
ability_NOMZ
to_TO
hold_VB [PRIV]
to_PIN
maturity_NOMZ
._.
There_EX
are_VPRT
no_SYNE
investments_NOMZ
allocated_VBN [WZPAST]
to_PIN
this_DEMO
category_NN
._.
Available-for-sale_JJ
financial_JJ
assets_NN
Available-for-sale_JJ
financial_JJ
assets_NN
are_VPRT
non-derivatives_NN
that_TSUB
are_VPRT [SPAU] [PASS]
either_RB
designated_VBN
in_PIN
this_DEMO
category_NN
or_CC
not_XX0
classified_VBN
in_PIN
any_QUAN
of_PIN
the_DT
other_JJ
categories_NN
._.
They_TPP3
are_VPRT [PASS]
included_VBN
in_PIN
non-current_JJ
assets_NN
unless_COND
management_NOMZ
intends_VPRT [SUAV]
to_TO
dispose_VB
of_PIN
the_DT
investment_NOMZ
within_PIN
12_CD
months_NN
of_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
Group_NN
allocates_VPRT
all_QUAN
its_PIT
equity_NOMZ
investments_NOMZ
which_WDT [WHSUB]
are_VPRT
not_XX0
investments_NOMZ
in_PIN
subsidiaries_NN
,_,
associates_NN
or_CC
joint_JJ
ventures_NN
to_PIN
this_DEMO
category_NN
._.
Purchases_NN
and_PHC
sales_NN
of_PIN
investments_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
trade-date_NN
the_DT
date_NN
on_PIN
which_WDT [PIRE]
the_DT
Group_NN
commits_VPRT
to_TO
purchase_VB
or_CC
sell_VB
the_DT
asset_NN
._.
Investments_NOMZ
are_VPRT [SPAU] [PASS]
initially_TIME
recognized_VBN [PRIV]
at_PIN
fair_JJ
value_NN
plus_PIN
transaction_NOMZ
costs_NN
for_PIN
all_QUAN
financial_JJ
assets_NN
not_XX0
carried_VBD
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
._.
Investments_NOMZ
are_VPRT [PASS]
derecognised_VBN
when_RB
the_DT
rights_NN
to_TO
receive_VB
cash_NN
flows_NN
from_PIN
the_DT
investments_NOMZ
have_VPRT [PEAS]
expired_VBN
or_CC
have_VPRT [PEAS]
been_VBN [PASS]
transferred_VBN
and_CC
the_DT
Group_NN
has_VPRT [PEAS]
transferred_VBN
substantially_RB
all_QUAN
risks_NN
and_PHC
rewards_NN
of_PIN
ownership_NN
._.
Available-for-sale_JJ
financial_JJ
assets_NN
and_CC
financial_JJ
assets_NN
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
are_VPRT [SPAU] [PASS]
subsequently_TIME
carried_VBN
at_PIN
fair_JJ
value_NN
._.
Loans_NN
and_PHC
receivables_NN
and_CC
held-to-maturity_JJ
investments_NOMZ
are_VPRT [PASS]
carried_VBN
at_PIN
amortised_JJ
cost_NN
using_VBG [WZPRES]
the_DT
effective_JJ
interest_NN
method_NN
._.
Realised_VBN [PRIV]
and_CC
unrealized_JJ
gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
from_PIN
changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
financial_JJ
assets_NN
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
category_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
they_TPP3
arise_VPRT
._.
Unrealized_JJ
gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
from_PIN
changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
non-monetary_JJ
securities_NOMZ
classified_VBN
as_IN
available-for-sale_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
equity_NOMZ
._.
When_RB
securities_NOMZ
classified_VBN
as_IN
available-for-sale_NN
are_VPRT [PASS]
sold_VBN
or_CC
impaired_VBN
,_,
the_DT
accumulated_VBN
fair_JJ
value_NN
adjustments_NOMZ
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
income_NN
statement_NOMZ
as_IN
gains_NN
and_PHC
losses_NN
from_PIN
investment_NOMZ
securities_NOMZ
._.
The_DT
fair_JJ
values_NN
of_PIN
quoted_VBN
investments_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
current_JJ
bid_NN
prices_NN
._.
If_COND
the_DT
market_NN
for_PIN
a_DT
financial_JJ
asset_NN
is_VPRT [BEMA]
not_XX0
active_PRED
and_CC
for_PIN
unlisted_JJ
securities_NOMZ
,_,
the_DT
Group_NN
establishes_VPRT [PRIV]
fair_JJ
value_NN
by_PIN
using_VBG
valuation_NOMZ
techniques_NN
unless_COND
fair_JJ
value_NN
can_POMD
not_XX0
be_VB [SPAU] [PASS]
reliably_RB
measured_VBN
._.
In_PIN
this_DEMO
case_NN
such_JJ
unquoted_JJ
equity_NOMZ
instruments_NOMZ
are_VPRT [PASS]
measured_VBN
at_PIN
cost_NN
._.
The_DT
Group_NN
assesses_VPRT
at_PIN
each_QUAN
balance_NN
sheet_NN
date_NN
whether_IN
there_EX
is_VPRT
objective_JJ
evidence_NN
that_TOBJ
a_DT
financial_JJ
asset_NN
or_CC
a_DT
group_NN
of_PIN
financial_JJ
assets_NN
is_VPRT [PASS]
impaired_VBN
._.
In_PIN
the_DT
case_NN
of_PIN
equity_NOMZ
securities_NOMZ
classified_VBN
as_IN
available-for-sale_JJ
,_,
a_DT
significant_JJ
or_CC
prolonged_JJ
decline_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
security_NOMZ
below_PLACE
its_PIT
cost_NN
is_VPRT [PASS]
considered_VBN [PRIV]
in_PIN
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
the_DT
securities_NOMZ
are_VPRT [PASS]
impaired_VBN
._.
If_COND
any_QUAN
such_JJ
evidence_NN
exists_VPRT
for_PIN
available-for-sale_JJ
financial_JJ
assets_NN
,_,
the_DT
cumulative_JJ
loss_NN
measured_VBN
as_IN
the_DT
difference_NN
between_PIN
the_DT
acquisition_NOMZ
cost_NN
and_CC
the_DT
current_JJ
fair_JJ
value_NN
,_,
less_JJ
any_QUAN
impairment_NOMZ
loss_NN
on_PIN
that_DEMO
financial_JJ
asset_NN
previously_TIME
recognized_VBN [PRIV]
in_PIN
profit_NN
or_CC
loss_NN
is_VPRT [PASS]
removed_VBN
from_PIN
equity_NOMZ
and_CC
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Impairment_NOMZ
losses_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
income_NN
statement_NOMZ
on_PIN
equity_NOMZ
instruments_NOMZ
are_VPRT [PASS]
not_XX0
reversed_VBN
through_PIN
the_DT
income_NN
statement_NOMZ
._.
54_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
55_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
k_NN
Accounting_GER
for_PIN
derivative_JJ
financial_JJ
instruments_NOMZ
and_CC
hedging_VBG
activities_NOMZ
From_PIN
January_NN
1_CD
,_,
2004_CD
to_PIN
December_NN
31_CD
,_,
2004_CD
:_:
The_DT
Group_NN
uses_VPRT
derivative_JJ
financial_JJ
instruments_NOMZ
to_TO
reduce_VB
exposure_NN
to_PIN
foreign_JJ
exchange_NN
risk_NN
and_PHC
interest_NN
rate_NN
movements_NOMZ
._.
The_DT
Group_NN
does_VPRT
not_XX0
hold_VB [PRIV]
or_CC
issue_VB
derivative_JJ
financial_JJ
instruments_NOMZ
for_PIN
speculative_JJ
purposes_NN
._.
For_PIN
a_DT
forward_RB
foreign_JJ
exchange_NN
contract_NN
to_TO
be_VB [PASS]
treated_VBN
as_IN
a_DT
hedge_NN
,_,
the_DT
instrument_NOMZ
must_NEMD
be_VB [PASS]
related_VBN
to_PIN
actual_JJ
foreign_JJ
currency_NN
assets_NN
or_CC
liabilities_NOMZ
or_CC
to_PIN
a_DT
probable_JJ
commitment_NOMZ
._.
It_PIT
must_NEMD
involve_VB
the_DT
same_JJ
currency_NN
or_CC
similar_JJ
currencies_NN
as_IN
the_DT
hedged_VBN
item_NN
and_CC
must_NEMD [SPAU]
also_RB
reduce_VB
the_DT
risk_NN
of_PIN
foreign_JJ
currency_NN
exchange_NN
movements_NOMZ
on_PIN
the_DT
Groups_NN
operations_NOMZ
._.
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
on_PIN
these_DEMO
contracts_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
,_,
or_CC
as_IN
adjustments_NOMZ
to_PIN
the_DT
carrying_VBG
amount_NN
of_PIN
fixed_JJ
assets_NN
,_,
only_DWNT
when_RB
the_DT
hedged_VBN
transaction_NOMZ
has_VPRT [PEAS]
itself_PIT
been_VBN [PASS]
reflected_VBN [PRIV]
in_PIN
the_DT
Groups_NN
accounts_NN
._.
For_PIN
an_DT
interest_NN
rate_NN
swap_NN
to_TO
be_VB [PASS]
treated_VBN
as_IN
a_DT
hedge_NN
the_DT
instrument_NOMZ
must_NEMD
be_VB [PASS]
related_VBN
to_PIN
actual_JJ
assets_NN
or_CC
liabilities_NOMZ
or_CC
a_DT
probable_JJ
commitment_NOMZ
and_CC
must_NEMD
change_VB
the_DT
nature_NN
of_PIN
the_DT
interest_NN
rate_NN
by_PIN
converting_VBG
a_DT
fixed_JJ
rate_NN
to_PIN
a_DT
variable_JJ
rate_NN
or_CC
vice_NN
versa_RB
._.
Interest_NN
differentials_NN
under_IN
these_DEMO
swaps_NN
are_VPRT [BYPA]
recognized_VBN [PRIV]
by_PIN
adjusting_VBG
net_JJ
interest_NN
payable_JJ
over_IN
the_DT
periods_NN
of_PIN
the_DT
contracts_NN
._.
If_COND
an_DT
instrument_NOMZ
ceases_VPRT
to_TO
be_VB [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
hedge_NN
,_,
for_CONJ
example_NULL
because_CAUS
the_DT
underlying_VBG
hedged_JJ
position_NOMZ
is_VPRT [PASS]
eliminated_VBN
,_,
the_DT
instrument_NOMZ
is_VPRT [PASS]
marked_VBN
to_PIN
market_NN
and_CC
any_QUAN
resulting_JJ
profit_NN
or_CC
loss_NN
recognized_VBN [PRIV] [WZPAST]
at_PIN
that_DEMO
time_NN
._.
From_PIN
January_NN
1_CD
,_,
2005_CD
onwards_NN
From_PIN
January_NN
1_CD
,_,
2005_CD
the_DT
Group_NN
applied_VBD
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
._.
The_DT
Group_NN
has_VPRT [PEAS]
chosen_VBN
to_TO
apply_VB
these_DEMO
standards_NN
prospectively_RB
,_,
which_WDT [SERE]
has_VPRT [PEAS]
resulted_VBN
in_PIN
the_DT
accounting_GER
policy_NN
described_VBD
below_PLACE
:_:
Derivatives_NN
are_VPRT [SPAU] [PASS]
initially_TIME
recognized_VBN [PRIV]
at_PIN
fair_JJ
value_NN
on_PIN
the_DT
date_NN
on_PIN
which_WDT [PIRE]
a_DT
derivative_JJ
contract_NN
is_VPRT [PASS]
entered_VBN
into_PIN
and_CC
are_VPRT [BEMA]
subsequently_TIME
re-measured_PRED
at_PIN
their_TPP3
fair_JJ
value_NN
._.
The_DT
method_NN
of_PIN
recognizing_VBG [PRIV]
the_DT
resulting_VBG
gain_NN
or_CC
loss_NN
depends_VPRT
on_PIN
whether_IN
the_DT
derivative_NN
is_VPRT [PASS]
designated_VBN
as_IN
a_DT
hedging_GER
instrument_NOMZ
,_,
and_ANDC
if_COND
so_RB
,_,
the_DT
nature_NN
of_PIN
the_DT
item_NN
being_VBG [WZPRES] [PASS]
hedged_VBN
._.
Currently_RB
,_,
the_DT
Group_NN
does_VPRT
not_XX0
designate_VB
any_QUAN
of_PIN
its_PIT
derivatives_NN
as_IN
a_DT
hedging_GER
instrument_NOMZ
and_ANDC
therefore_CONJ
none_INPR
qualify_VB
for_PIN
hedge_JJ
accounting_GER
._.
Changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
any_QUAN
derivative_JJ
instruments_NOMZ
that_TSUB
do_VPRT
not_XX0
qualify_VB
for_PIN
hedge_JJ
accounting_GER
are_VPRT [PASS]
recognized_VBN [PRIV]
immediately_TIME
in_PIN
the_DT
income_NN
statement_NOMZ
._.
l_NN
Leases_VPRT
Leases_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
where_RB
the_DT
Group_NN
has_VPRT
substantially_RB
all_QUAN
the_DT
risks_NN
and_PHC
rewards_NN
of_PIN
ownership_NN
are_VPRT [PASS]
classified_VBN
as_IN
finance_NN
leases_NN
._.
Finance_NN
leases_NN
are_VPRT [PASS]
capitalized_VBN
at_PIN
the_DT
leases_NN
inception_NOMZ
at_PIN
the_DT
lower_JJ
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
leased_VBN
asset_NN
and_CC
the_DT
present_JJ
value_NN
of_PIN
the_DT
future_JJ
minimum_NN
lease_NN
payments_NOMZ
._.
Each_QUAN
lease_NN
payment_NOMZ
is_VPRT [PASS]
allocated_VBN
between_PIN
the_DT
underlying_VBG
liability_NOMZ
to_PIN
the_DT
lessor_NN
and_CC
the_DT
associated_VBN
finance_NN
charges_NN
so_RB
as_IN
to_TO
achieve_VB
a_DT
constant_JJ
rate_NN
on_PIN
the_DT
finance_NN
balance_NN
outstanding_JJ
._.
The_DT
corresponding_JJ
rental_JJ
obligations_NOMZ
,_,
net_NN
of_PIN
finance_NN
charges_NN
,_,
are_VPRT [PASS]
included_VBN
in_PIN
Borrowings_GER
._.
The_DT
interest_NN
element_NOMZ
of_PIN
the_DT
finance_NN
cost_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
over_IN
the_DT
lease_NN
period_NN
so_RB
as_IN
to_TO
produce_VB
a_DT
constant_JJ
periodic_JJ
rate_NN
of_PIN
interest_NN
on_PIN
the_DT
remaining_VBG
balance_NN
of_PIN
the_DT
liability_NOMZ
for_PIN
each_QUAN
period_NN
._.
The_DT
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
acquired_VBN
under_IN
finance_NN
leases_NN
are_VPRT [PASS]
depreciated_VBN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
assets_NN
useful_JJ
life_NN
and_CC
the_DT
lease_NN
term_NN
._.
Leases_NN
where_RB
the_DT
lessor_JJ
retains_VPRT
a_DT
significant_JJ
portion_NOMZ
of_PIN
the_DT
risks_NN
and_PHC
rewards_NN
of_PIN
ownership_NN
are_VPRT [PASS]
classified_VBN
as_IN
operating_VBG
leases_NN
._.
Payments_NOMZ
made_VBN
under_IN
operating_VBG
leases_NN
net_NN
of_PIN
any_QUAN
incentives_NN
received_VBD
from_PIN
the_DT
lessor_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
period_NN
of_PIN
the_DT
lease_NN
._.
m_FW
Inventories_NN
Inventories_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realizable_JJ
value_NN
except_PIN
where_RB
arising_VBG
on_PIN
business_NOMZ
combination_NOMZ
._.
Cost_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
using_VBG
the_DT
firstin-first-out_PIN
FIFO_NN
method_NN
._.
The_DT
cost_NN
of_PIN
finished_VBN
goods_NN
and_PHC
work_NN
in_PIN
progress_NN
comprises_VPRT
raw_JJ
materials_NN
,_,
direct_JJ
labor_NN
,_,
other_JJ
direct_JJ
costs_NN
and_CC
related_JJ
production_NOMZ
overheads_NN
based_VBN [WZPAST]
on_PIN
normal_JJ
operating_GER
capacity_NOMZ
._.
Net_JJ
realizable_JJ
value_NN
is_VPRT [BEMA]
the_DT
estimated_VBN [PRIV]
selling_GER
price_NN
in_PIN
the_DT
ordinary_JJ
course_NN
of_PIN
business_NOMZ
,_,
less_JJ
all_QUAN
estimated_VBN [PRIV]
costs_NN
of_PIN
completion_NOMZ
and_PHC
costs_NN
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
marketing_GER
,_,
selling_VBG
and_CC
distribution_NOMZ
._.
n_NN
Trade_NN
receivables_NN
Trade_NN
receivables_NN
do_VPRT
not_XX0
carry_VB
any_QUAN
interest_NN
and_CC
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
their_TPP3
nominal_JJ
value_NN
as_IN
reduced_VBN
by_PIN
appropriate_JJ
allowances_NN
for_PIN
estimated_VBN [PRIV]
irrecoverable_JJ
amounts_NN
._.
o_NN
Cash_NN
,_,
cash_NN
equivalents_NN
and_CC
restricted_VBN
cash_NN
Cash_NN
and_PHC
cash_NN
equivalents_NN
are_VPRT [PASS]
carried_VBN
in_PIN
the_DT
balance_NN
sheet_NN
at_PIN
cost_NN
._.
Cash_NN
and_PHC
cash_NN
equivalents_NN
comprise_VPRT
cash_NN
on_PIN
hand_NN
,_,
deposits_NN
held_VBD [PRIV]
at_PIN
call_NN
with_PIN
banks_NN
and_CC
other_JJ
short-term_JJ
,_,
highly_AMP
liquid_JJ
investments_NOMZ
with_PIN
original_JJ
maturities_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
._.
Restricted_VBN
cash_NN
is_VPRT [PASS]
carried_VBN
in_PIN
the_DT
balance_NN
sheet_NN
at_PIN
cost_NN
._.
Restricted_VBN
cash_NN
comprises_VPRT
reserve_NN
funds_NN
required_VBN [SUAV] [WZPAST]
for_PIN
financial_JJ
guarantee_NN
contracts_NN
and_PHC
collateral_NN
against_PIN
certain_JJ
leased_VBN
assets_NN
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
55_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
56_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
p_VPRT
Share_NN
capital_NN
Ordinary_NN
shares_NN
are_VPRT [PASS]
classified_VBN
as_IN
equity_NOMZ
._.
Incremental_JJ
costs_NN
directly_RB
attributable_JJ
to_PIN
the_DT
issue_NN
of_PIN
new_JJ
shares_NN
or_CC
options_NOMZ
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
equity_NOMZ
as_IN
a_DT
deduction_NOMZ
,_,
net_NN
of_PIN
tax_NN
,_,
from_PIN
the_DT
proceeds_NN
other_JJ
than_PIN
where_RB
the_DT
issue_NN
of_PIN
new_JJ
shares_NN
or_CC
options_NOMZ
relates_VPRT
to_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
in_PIN
which_WDT [PIRE]
case_NN
such_JJ
incremental_JJ
costs_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
cost_NN
of_PIN
acquisition_NOMZ
as_IN
part_NN
of_PIN
the_DT
purchase_NN
consideration_NOMZ
._.
Where_RB
any_QUAN
company_NN
in_PIN
the_DT
Group_NN
purchases_NN
the_DT
Companys_NN
equity_NOMZ
share_NN
capital_NN
treasury_NN
shares_NN
,_,
the_DT
consideration_NOMZ
paid_VBN
,_,
including_VBG [PRESP]
any_QUAN
directly_RB
attributable_JJ
incremental_JJ
costs_NN
net_JJ
of_PIN
income_NN
taxes_NN
,_,
is_VPRT [PASS]
deducted_VBN
from_PIN
equity_NOMZ
attributable_JJ
to_PIN
the_DT
Companys_NN
equity_NOMZ
holders_NN
until_IN
the_DT
shares_NN
are_VPRT [PASS]
canceled_VBN
,_,
reissued_VBN
or_CC
disposed_VBN
of_PIN [STPR]
._.
Where_RB
such_JJ
shares_NN
are_VPRT [SPAU] [PASS]
subsequently_TIME
sold_VBN
or_CC
reissued_VBN
,_,
any_QUAN
consideration_NOMZ
received_VBD
,_,
net_NN
of_PIN
any_QUAN
directly_RB
attributable_JJ
incremental_JJ
transaction_NOMZ
costs_NN
and_CC
the_DT
related_JJ
income_NN
tax_NN
effects_NN
,_,
is_VPRT [PASS]
included_VBN
in_PIN
equity_NOMZ
attributable_JJ
to_PIN
the_DT
Companys_NN
equity_NOMZ
holders_NN
._.
q_NN
Borrowings_GER
From_PIN
January_NN
1_CD
,_,
2004_CD
to_PIN
December_NN
31_CD
,_,
2004_CD
:_:
Borrowings_GER
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
amount_NN
of_PIN
the_DT
net_JJ
proceeds_NN
after_IN
deduction_NOMZ
of_PIN
issue_NN
costs_NN
._.
The_DT
carrying_VBG
amount_NN
is_VPRT [BYPA]
increased_VBN
by_PIN
the_DT
finance_NN
cost_NN
in_PIN
respect_NN
of_PIN
the_DT
accounting_GER
period_NN
and_CC
reduced_VBN
by_PIN
payments_NOMZ
made_VBN [WZPAST]
in_PIN
the_DT
period_NN
._.
From_PIN
January_NN
1_CD
,_,
2005_CD
:_:
From_PIN
January_NN
1_CD
,_,
2005_CD
the_DT
Group_NN
applied_VBD
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
._.
The_DT
Group_NN
has_VPRT [PEAS]
chosen_VBN
to_TO
apply_VB
these_DEMO
standards_NN
prospectively_RB
,_,
which_WDT [SERE]
has_VPRT [PEAS]
resulted_VBN
in_PIN
the_DT
accounting_GER
policy_NN
described_VBD
below_PLACE
:_:
Borrowings_GER
are_VPRT [PASS]
recognized_VBN [PRIV]
initially_TIME
at_PIN
fair_JJ
value_NN
,_,
net_NN
of_PIN
transaction_NOMZ
costs_NN
incurred_VBN
._.
Borrowings_GER
are_VPRT [SPAU] [PASS]
subsequently_TIME
stated_VBN [PUBV]
at_PIN
amortised_JJ
cost_NN
:_:
any_QUAN
difference_NN
between_PIN
proceeds_NN
net_NN
of_PIN
transaction_NOMZ
costs_NN
and_CC
the_DT
redemption_NOMZ
value_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
over_IN
the_DT
period_NN
of_PIN
the_DT
borrowings_GER
using_VBG [WZPRES]
the_DT
effective_JJ
interest_NN
method_NN
._.
Convertible_JJ
loan_NN
notes_NN
are_VPRT [PASS]
regarded_VBN
as_IN
compound_NN
instruments_NOMZ
,_,
consisting_VBG [PRESP]
of_PIN
a_DT
liability_NOMZ
component_NN
and_CC
an_DT
equity_NOMZ
component_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
liability_NOMZ
portion_NOMZ
of_PIN
a_DT
convertible_JJ
bond_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
using_VBG
a_DT
market_NN
interest_NN
rate_NN
for_PIN
an_DT
equivalent_JJ
non-convertible_JJ
bond_NN
._.
This_DEMO
amount_NN
is_VPRT [PASS]
recorded_VBN
as_IN
a_DT
liability_NOMZ
on_PIN
an_DT
amortised_JJ
cost_NN
basis_NN
until_IN
extinguished_VBN
on_PIN
conversion_NN
or_CC
maturity_NOMZ
of_PIN
the_DT
bonds_NN
._.
The_DT
remainder_NN
of_PIN
the_DT
proceeds_NN
is_VPRT [PASS]
allocated_VBN
to_PIN
the_DT
conversion_NN
option_NOMZ
._.
This_DEMP
is_VPRT [PASS]
recognized_VBN [PRIV]
and_PHC
included_VBN
in_PIN
shareholders_NN
equity_NOMZ
,_,
net_NN
of_PIN
income_NN
tax_NN
effects_NN
._.
Borrowings_GER
are_VPRT [PASS]
classified_VBN
as_IN
current_JJ
liabilities_NOMZ
unless_COND
the_DT
Group_NN
has_VPRT
an_DT
unconditional_JJ
right_NN
to_TO
defer_VB
settlement_NOMZ
of_PIN
the_DT
liability_NOMZ
for_PIN
at_PIN
least_JJ
12_CD
months_NN
after_IN
the_DT
balance_NN
sheet_NN
date_NN
._.
r_NN
Taxation_NOMZ
The_NN
tax_NN
expense_NN
represents_VPRT
the_DT
sum_NN
of_PIN
the_DT
current_JJ
and_PHC
deferred_JJ
tax_NN
._.
Taxable_JJ
profit_NN
differs_VPRT
from_PIN
net_JJ
profit_NN
as_IN
reported_VBN [PUBV]
in_PIN
the_DT
income_NN
statement_NOMZ
because_CAUS
it_PIT
excludes_VPRT
items_NN
of_PIN
income_NN
or_CC
expense_NN
that_TSUB
are_VPRT [BEMA]
taxable_PRED
or_CC
deductible_JJ
in_PIN
other_JJ
years_NN
and_CC
it_PIT
further_RB
excludes_VPRT
items_NN
that_TSUB
are_VPRT [BEMA]
never_RB
taxable_PRED
or_CC
deductible_JJ
._.
The_DT
Groups_NN
liability_NOMZ
for_PIN
current_JJ
tax_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
using_VBG
tax_NN
rates_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
enacted_VBN
or_CC
substantively_RB
enacted_VBN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Deferred_JJ
tax_NN
is_VPRT [BEMA]
the_DT
tax_NN
expected_VBN [PRIV]
to_TO
be_VB [BEMA]
payable_PRED
or_CC
recoverable_JJ
on_PIN
differences_NN
between_PIN
the_DT
carrying_VBG
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
the_DT
financial_JJ
statements_NOMZ
and_CC
the_DT
corresponding_JJ
tax_NN
bases_NN
used_VBN [WZPAST]
in_PIN
the_DT
computation_NOMZ
of_PIN
taxable_JJ
profit_NN
,_,
and_ANDC
is_VPRT [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
balance_NN
sheet_NN
liability_NOMZ
method_NN
._.
Deferred_JJ
tax_NN
liabilities_NOMZ
are_VPRT [SPAU] [PASS]
generally_RB
recognized_VBN [PRIV]
for_PIN
all_QUAN
taxable_JJ
temporary_JJ
differences_NN
and_CC
deferred_VBN
tax_NN
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
taxable_JJ
profits_NN
will_PRMD
be_VB [BEMA]
available_PRED
against_PIN
which_WDT [PIRE]
deductible_JJ
temporary_JJ
differences_NN
can_POMD
be_VB [PASS]
utilised_VBN
._.
Such_JJ
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
if_COND
the_DT
temporary_JJ
difference_NN
arises_VPRT
from_PIN
the_DT
initial_JJ
recognition_NOMZ
of_PIN
goodwill_NN
or_CC
from_PIN
the_DT
initial_JJ
recognition_NOMZ
other_JJ
than_PIN
in_PIN
a_DT
business_NOMZ
combination_NOMZ
of_PIN
other_JJ
assets_NN
and_PHC
liabilities_NOMZ
in_PIN
a_DT
transaction_NOMZ
that_TSUB
affects_VPRT
neither_SYNE
the_DT
tax_NN
profit_NN
not_XX0
the_DT
accounting_GER
profit_NN
._.
Deferred_JJ
tax_NN
liabilities_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
for_PIN
taxable_JJ
temporary_JJ
differences_NN
arising_VBG [WZPRES]
on_PIN
investments_NOMZ
in_PIN
subsidiaries_NN
and_PHC
associates_NN
,_,
and_ANDC
interests_NN
in_PIN
joint_JJ
ventures_NN
,_,
except_PIN
where_RB
the_DT
Group_NN
is_VPRT [BEMA]
able_PRED
to_TO
control_VB
the_DT
reversal_NN
of_PIN
the_DT
temporary_JJ
difference_NN
and_CC
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
the_DT
temporary_JJ
difference_NN
will_PRMD
not_XX0
reverse_VB
in_PIN
the_DT
foreseeable_JJ
future_NN
._.
The_DT
carrying_VBG
amount_NN
of_PIN
deferred_JJ
tax_NN
assets_NN
is_VPRT [PASS]
reviewed_VBN
at_PIN
each_QUAN
balance_NN
sheet_NN
date_NN
and_CC
reduced_VBN
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT
no_RB
longer_RB
probable_JJ
that_THAC
sufficient_JJ
taxable_JJ
profits_NN
will_PRMD
be_VB [BEMA]
available_PRED
to_TO
allow_VB [SUAV]
all_QUAN
or_CC
part_NN
of_PIN
the_DT
asset_NN
to_TO
be_VB [PASS]
recovered_VBN
._.
Deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
offset_VBN
when_RB
there_EX
is_VPRT
a_DT
legally_RB
enforceable_JJ
right_NN
to_TO
set_VB
off_PIN
current_JJ
tax_NN
assets_NN
against_PIN
current_JJ
tax_NN
liabilities_NOMZ
and_ANDC
when_RB
they_TPP3
relate_VPRT
to_PIN
income_NN
taxes_NN
levied_VBN [WZPAST]
by_PIN
the_DT
same_JJ
taxation_NOMZ
authority_NOMZ
and_CC
the_DT
Group_NN
intends_VPRT [SUAV]
to_TO
settle_VB
its_PIT
current_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
on_PIN
a_DT
net_JJ
basis_NN
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
at_PIN
the_DT
tax_NN
rates_NN
that_TSUB
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
apply_VB
in_PIN
the_DT
period_NN
when_RB
the_DT
liability_NOMZ
is_VPRT [PASS]
settled_VBN
or_CC
the_DT
asset_NN
is_VPRT [PASS]
realized_VBN [PRIV]
._.
Deferred_JJ
tax_NN
is_VPRT [PASS]
charged_VBN
or_CC
credited_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
,_,
except_PIN
when_RB
it_PIT
relates_VPRT
to_PIN
items_NN
charged_VBN
or_CC
credited_VBN
directly_RB
to_PIN
equity_NOMZ
,_,
in_PIN
which_WDT [PIRE]
case_NN
the_DT
deferred_JJ
tax_NN
is_VPRT [SPAU] [PASS]
also_RB
dealt_VBN
with_PIN
in_PIN
equity_NOMZ
._.
56_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
57_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
s_VPRT
Employee_NN
benefits_NN
Retirement_NOMZ
obligations_NOMZ
defined_VBD
contribution_NOMZ
plans_NN
The_DT
Group_NN
operates_VPRT
personal_JJ
defined_VBN
contribution_NOMZ
plans_NN
for_PIN
employees_NN
._.
A_DT
defined_VBN
contribution_NOMZ
plan_NN
is_VPRT [BEMA]
a_DT
pension_NN
plan_NN
under_IN
which_WDT
the_DT
Group_NN
pays_VPRT
fixed_VBN
percentage_NN
contributions_NOMZ
into_PIN
a_DT
separate_JJ
entity_NOMZ
._.
The_DT
Group_NN
has_VPRT
no_SYNE
legal_JJ
or_CC
constructive_JJ
obligations_NOMZ
to_TO
pay_VB
further_JJ
contributions_NOMZ
if_COND
the_DT
fund_NN
does_VPRT
not_XX0
hold_VB [PRIV]
sufficient_JJ
assets_NN
to_TO
pay_VB
all_QUAN
employees_NN
the_DT
benefits_NN
relating_VBG [WZPRES]
to_PIN
employee_NN
service_NN
in_PIN
the_DT
current_JJ
and_PHC
prior_JJ
periods_NN
._.
The_DT
Group_NN
pays_VPRT
contributions_NOMZ
to_TO
publicly_RB
or_CC
privately_RB
administered_VBN
pension_NN
insurance_NN
plans_VPRT
on_PIN
a_DT
mandatory_JJ
,_,
contractual_JJ
or_CC
voluntary_JJ
basis_NN
._.
The_DT
Group_NN
has_VPRT
no_SYNE
further_JJ
payment_NOMZ
obligations_NOMZ
once_TIME
the_DT
contributions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
paid_VBN
._.
The_DT
contributions_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
employee_NN
benefit_NN
expense_NN
when_RB
they_TPP3
are_VPRT [BEMA]
due_PRED
._.
Prepaid_JJ
contributions_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
asset_NN
to_PIN
the_DT
extent_NN
that_TOBJ
a_DT
cash_NN
refund_NN
or_CC
a_DT
reduction_NOMZ
in_PIN
future_JJ
payments_NOMZ
is_VPRT [BEMA]
available_PRED
._.
Retirement_NOMZ
obligations_NOMZ
defined_VBD
benefit_NN
plans_NN
The_DT
Group_NN
operates_VPRT
defined_VBN
benefit_NN
plans_NN
SERPs_NN
for_PIN
certain_JJ
senior_JJ
employees_NN
._.
The_DT
liability_NOMZ
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
balance_NN
sheet_NN
in_PIN
respect_NN
of_PIN
these_DEMO
plans_NN
shown_VBN [PRIV] [WZPAST]
in_PIN
Note_NN
27_CD
is_VPRT [BEMA]
the_DT
present_JJ
value_NN
of_PIN
the_DT
defined_VBN
benefit_NN
obligations_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Assets_NN
relating_VBG [WZPRES]
to_PIN
a_DT
closed_JJ
defined_VBN
benefit_NN
plan_NN
are_VPRT [PASS]
held_VBN [PRIV]
in_PIN
a_DT
Rabbi_NN
Trust_NN
,_,
the_DT
legal_JJ
form_NN
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
such_OSUB
that_NULL
the_DT
assets_NN
held_VBD [PRIV]
to_TO
cover_VB
the_DT
pension_NN
liabilities_NOMZ
are_VPRT [BEMA]
available_PRED
to_PIN
the_DT
general_JJ
creditors_NN
of_PIN
the_DT
company_NN
on_PIN
winding_VBG
up_RP
and_CC
are_VPRT [SPAU] [PASS]
therefore_CONJ
shown_VBN [PRIV]
on_PIN
the_DT
balance_NN
sheet_NN
Note_VB [PRIV]
24_CD
._.
Changes_NN
in_PIN
the_DT
present_JJ
value_NN
of_PIN
the_DT
benefit_NN
obligation_NOMZ
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Further_JJ
information_NOMZ
on_PIN
the_DT
Groups_NN
defined_VBN
benefit_NN
plans_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
Note_NN
29_CD
Retirement_NOMZ
obligations_NOMZ
._.
Share-based_JJ
compensation_NOMZ
The_DT
Group_NN
has_VPRT [PEAS]
applied_VBN
the_DT
requirements_NOMZ
of_PIN
IFRS_NN
2_CD
,_,
Share-based_JJ
Payment_NOMZ
._.
In_PIN
accordance_NN
with_PIN
the_DT
transitional_JJ
provisions_NN
,_,
IFRS_NN
2_CD
has_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
to_PIN
all_QUAN
grants_NN
of_PIN
equity_NOMZ
instruments_NOMZ
after_IN
November_NN
7_CD
,_,
2002_CD
that_DEMP
were_VBD [BEMA]
unvested_PRED
at_PIN
December_NN
31_CD
,_,
2004_CD
._.
The_DT
Group_NN
operates_VPRT
equity-settled_JJ
,_,
share-based_JJ
compensation_NOMZ
plans_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
employee_NN
services_NN
received_VBN [WZPAST]
in_PIN
exchange_NN
for_PIN
the_DT
grant_NN
of_PIN
the_DT
options_NOMZ
is_VPRT [PASS]
calculated_VBN [PRIV]
using_VBG
the_DT
Black-Scholes_NN
model_NN
._.
In_PIN
accordance_NN
with_PIN
IFRS_NN
2_CD
Share-based_JJ
Payments_NOMZ
,_,
the_DT
resulting_VBG
cost_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
an_DT
expense_NN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
vesting_JJ
period_NN
of_PIN
the_DT
options_NOMZ
._.
The_DT
value_NN
of_PIN
the_DT
charge_NN
is_VPRT [PASS]
adjusted_VBN
to_TO
reflect_VB [PRIV]
expected_VBN [PRIV]
and_CC
actual_JJ
levels_NN
of_PIN
options_NOMZ
vesting_GER
._.
The_DT
Group_NN
also_RB
provides_VPRT
employees_NN
with_PIN
the_DT
option_NOMZ
to_TO
purchase_VB
ordinary_JJ
shares_NN
of_PIN
Shire_NN
:_:
under_IN
the_DT
Sharesave_NN
Scheme_NN
at_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
employees_NN
:_:
and_ANDC
under_IN
the_DT
Employee_NN
Share_NN
Purchase_NN
Plan_NN
at_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
a_DT
share_NN
on_PIN
the_DT
enrolment_NOMZ
date_NN
the_DT
first_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
or_CC
the_DT
exercise_NN
date_NN
the_DT
last_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
,_,
whichever_WDT
is_VPRT [BEMA]
the_DT
lower_JJ
._.
The_DT
proceeds_NN
received_VBD
,_,
net_NN
of_PIN
any_QUAN
directly_RB
attributable_JJ
transaction_NOMZ
costs_NN
,_,
are_VPRT [PASS]
credited_VBN
to_TO
share_VB
capital_NN
nominal_JJ
value_NN
and_PHC
share_NN
premium_NN
when_RB
the_DT
options_NOMZ
are_VPRT [PASS]
exercised_VBN
._.
Termination_NOMZ
benefits_NN
Termination_NOMZ
benefits_NN
are_VPRT [BEMA]
payable_PRED
when_RB
employment_NOMZ
is_VPRT [PASS]
terminated_VBN
before_IN
the_DT
normal_JJ
retirement_NOMZ
date_NN
,_,
or_CC
whenever_RB
an_DT
employee_NN
accepts_VPRT [PRIV]
voluntary_JJ
redundancy_NN
in_PIN
exchange_NN
for_PIN
these_DEMO
benefits_NN
._.
The_DT
Group_NN
recognizes_VPRT [PRIV]
termination_NOMZ
benefits_NN
when_RB
it_PIT
is_VPRT [SPAU] [PASS]
demonstrably_RB
committed_VBN
to_PIN
either_DT
:_:
i_FPP1
terminating_VBG
the_DT
employment_NOMZ
of_PIN
current_JJ
employees_NN
according_VBG [WZPRES]
to_PIN
a_DT
detailed_JJ
formal_JJ
plan_NN
without_PIN
possibility_NOMZ
of_PIN
withdrawal_NN
:_:
or_CC
ii_FW
providing_VBG
termination_NOMZ
benefits_NN
as_CONJ
a_NULL
result_NULL
of_PIN
an_DT
offer_NN
made_VBD
to_TO
encourage_VB
voluntary_JJ
redundancy_NN
._.
Benefits_NN
falling_VBG [WZPRES]
due_RB
more_EMPH
than_PIN
12_CD
months_NN
after_IN
the_DT
balance_NN
sheet_NN
date_NN
are_VPRT [PASS]
discounted_VBN
to_PIN
present_JJ
value_NN
._.
t_NN
Provisions_NN
Provisions_NN
for_PIN
restructuring_VBG
costs_NN
and_CC
legal_JJ
claims_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
Group_NN
has_VPRT
a_DT
present_JJ
legal_JJ
or_CC
constructive_JJ
obligation_NOMZ
as_CONJ
a_NULL
result_NULL
of_PIN
past_JJ
events_NN
:_:
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
an_DT
outflow_NN
of_PIN
resources_NN
will_PRMD
be_VB [PASS]
required_VBN [SUAV]
to_TO
settle_VB
the_DT
obligation_NOMZ
:_:
the_DT
amount_NN
can_POMD
be_VB [SPAU] [PASS]
reliably_RB
estimated_VBN [PRIV]
and_ANDC
when_RB
a_DT
detailed_JJ
formal_JJ
plan_NN
for_PIN
the_DT
restructuring_GER
has_VPRT [PEAS]
been_VBN [PASS]
communicated_VBN
to_PIN
affected_JJ
parties_NN
._.
Provisions_NN
are_VPRT [PASS]
measured_VBN
at_PIN
the_DT
Directors_NN
best_JJ
estimate_NN
of_PIN
the_DT
expenditure_NN
required_VBN [SUAV]
to_TO
settle_VB
the_DT
obligation_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
,_,
and_ANDC
are_VPRT [PASS]
discounted_VBN
to_PIN
present_JJ
value_NN
where_RB
the_DT
effect_NN
is_VPRT
material_NN
._.
Restructuring_GER
provisions_NN
comprise_VPRT
lease_NN
termination_NOMZ
penalties_NN
and_PHC
employee_NN
termination_NOMZ
payments_NOMZ
._.
Provisions_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
for_PIN
future_JJ
operating_GER
losses_NN
._.
Where_RB
there_EX
are_VPRT
a_DT
number_NN
of_PIN
similar_JJ
obligations_NOMZ
,_,
the_DT
likelihood_NN
that_TOBJ
an_DT
outflow_NN
will_PRMD
be_VB [PASS]
required_VBN [SUAV]
in_PIN
settlement_NOMZ
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
considering_VBG [PRIV]
the_DT
class_NN
of_PIN
obligations_NOMZ
as_IN
a_DT
whole_NN
._.
A_DT
provision_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
even_RB
if_COND
the_DT
likelihood_NN
of_PIN
an_DT
outflow_NN
with_PIN
respect_NN
to_PIN
any_QUAN
one_CD
item_NN
included_VBN [WZPAST]
in_PIN
the_DT
same_JJ
class_NN
of_PIN
obligations_NOMZ
may_POMD
be_VB [BEMA]
small_PRED
._.
u_NN
Dividend_NN
distribution_NOMZ
Dividend_NN
distribution_NOMZ
to_PIN
the_DT
Companys_NN
shareholders_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
a_DT
liability_NOMZ
in_PIN
the_DT
Groups_NN
financial_JJ
statements_NOMZ
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
the_DT
shareholders_NN
right_RB
to_TO
receive_VB
payment_NOMZ
is_VPRT [PASS]
established_VBN [PRIV]
._.
This_DEMP
occurs_VPRT
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
the_DT
dividends_NN
are_VPRT [BYPA]
approved_VBN
by_PIN
the_DT
Companys_NN
shareholders_NN
,_,
or_CC
in_PIN
the_DT
case_NN
of_PIN
an_DT
interim_JJ
dividend_NN
,_,
when_RB
the_DT
dividend_NN
is_VPRT [PASS]
paid_VBN
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
57_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
58_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
v_VPRT
Non-current_JJ
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
sale_NN
Non-current_JJ
assets_NN
and_PHC
disposal_NN
groups_NN
classified_VBN
as_IN
held_VBN [PRIV]
for_PIN
sale_NN
are_VPRT [PASS]
measured_VBN
at_PIN
the_DT
lower_JJ
of_PIN
carrying_VBG
amount_NN
and_CC
fair_JJ
value_NN
less_RB
costs_NN
to_TO
sell_VB
._.
Non-current_JJ
assets_NN
and_PHC
disposal_NN
groups_NN
are_VPRT [PASS]
classified_VBN
as_IN
held_VBN [PRIV]
for_PIN
sale_NN
if_COND
their_TPP3
carrying_VBG
amount_NN
will_PRMD
be_VB [PASS]
recovered_VBN
through_PIN
a_DT
sale_NN
transaction_NOMZ
rather_RB
than_PIN
continuing_VBG
use_NN
._.
This_DEMO
condition_NOMZ
is_VPRT [PASS]
considered_VBN [PRIV]
met_VBD
only_DWNT
when_RB
the_DT
sale_NN
is_VPRT [BEMA]
highly_AMP
probable_PRED
and_CC
the_DT
asset_NN
or_CC
disposal_NN
group_NN
is_VPRT [BEMA]
available_PRED
for_PIN
immediate_JJ
sale_NN
in_PIN
its_PIT
present_JJ
condition_NOMZ
._.
Management_NOMZ
must_NEMD
be_VB [PASS]
committed_VBN
to_PIN
the_DT
sale_NN
,_,
which_WDT [SERE]
should_NEMD
be_VB [PASS]
expected_VBN [PRIV]
to_TO
qualify_VB
for_PIN
recognition_NOMZ
as_IN
a_DT
completed_VBN
sale_NN
within_PIN
one_CD
year_NN
from_PIN
the_DT
date_NN
of_PIN
classification_NOMZ
._.
w_VB
Government_NOMZ
grants_NN
Government_NOMZ
grants_NN
relating_VBG [WZPRES]
to_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
are_VPRT [PASS]
treated_VBN
as_IN
deferred_JJ
income_NN
and_CC
released_VBN
to_TO
profit_VB
and_CC
loss_NN
over_IN
the_DT
expected_VBN [PRIV]
useful_JJ
lives_NN
of_PIN
the_DT
assets_NN
concerned_VBN
._.
3_CD
Change_NN
in_PIN
reporting_VBG [PUBV]
entity_NOMZ
On_PIN
November_NN
25_CD
,_,
2005_CD
,_,
Shire_NN
plc_NN
,_,
a_DT
public_JJ
limited_JJ
company_NN
incorporated_VBN [WZPAST]
in_PIN
England_NN
and_PHC
Wales_NN
Shire_NN
,_,
became_VBD
the_DT
holding_VBG [PRIV]
company_NN
of_PIN
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
SPG_NN
pursuant_JJ
to_PIN
a_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
under_IN
Section_NOMZ
425_CD
of_PIN
the_DT
UK_NN
Companies_NN
Act_NN
1985_CD
that_DEMP
was_VBD [BYPA]
approved_VBN
by_PIN
the_DT
High_NN
Court_NN
of_PIN
Justice_NN
in_PIN
England_NN
and_PHC
Wales_NN
and_CC
the_DT
shareholders_NN
of_PIN
SPG_NN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
._.
Pursuant_JJ
to_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
,_,
ordinary_JJ
shares_NN
,_,
each_QUAN
having_VBG
a_DT
nominal_JJ
value_NN
of_PIN
3.50_CD
,_,
of_PIN
Shire_NN
Shire_NN
Ordinary_NN
Shares_NN
were_VBD [PASS]
exchanged_VBN
for_PIN
ordinary_JJ
shares_NN
,_,
each_QUAN
having_VBG
a_DT
nominal_JJ
value_NN
of_PIN
0.05_CD
of_PIN
SPG_NN
SPG_NN
Ordinary_NN
Shares_NN
,_,
on_PIN
a_DT
one-for-one_JJ
basis_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
,_,
SPG_NN
is_VPRT [BEMA]
now_TIME
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Shire_NN
and_CC
has_VPRT [PEAS]
been_VBN [PASS]
re-registered_VBN
as_IN
a_DT
private_JJ
company_NN
under_IN
the_DT
name_NN
Shire_NN
Pharmaceuticals_NN
Limited_NN
._.
The_DT
Shire_NN
Ordinary_NN
Shares_NN
carry_VPRT
substantially_RB
the_DT
same_JJ
rights_NN
as_IN
did_VBD [PROD]
the_DT
SPG_NN
Ordinary_NN
Shares_NN
._.
The_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
did_VBD
not_XX0
involve_VB
any_QUAN
payment_NOMZ
for_PIN
the_DT
new_JJ
Shire_NN
Ordinary_NN
Shares_NN
._.
Shires_NN
Board_NN
of_PIN
Directors_NN
,_,
management_NOMZ
and_CC
corporate_JJ
governance_NN
arrangements_NOMZ
immediately_TIME
following_VBG
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
were_VBD [BEMA]
the_DT
same_JJ
as_IN
SPG_NN
immediately_TIME
before_IN
the_DT
effectiveness_NOMZ
of_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
._.
The_DT
consolidated_JJ
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
Shire_NN
immediately_TIME
after_IN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
were_VBD [BEMA]
the_DT
same_JJ
as_IN
the_DT
consolidated_JJ
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
SPG_NN
immediately_TIME
prior_RB
thereto_RB
._.
In_CONJ
consequence_NULL
of_PIN
the_DT
implementation_NOMZ
of_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
,_,
American_NN
Depositary_NN
Shares_NN
ADSs_NN
representing_VBG [WZPRES]
ordinary_JJ
shares_NN
of_PIN
SPG_NN
were_VBD [BYPA]
replaced_VBN
by_PIN
ADSs_NN
representing_VBG [WZPRES]
ordinary_JJ
shares_NN
of_PIN
Shire_NN
on_PIN
a_DT
one-for-one_JJ
basis_NN
._.
Shire_NN
was_VBD [PASS]
incorporated_VBN
on_PIN
June_NN
27_CD
,_,
2005_CD
._.
Prior_RB
to_PIN
November_NN
25_CD
,_,
2005_CD
Shire_NN
had_VBD [PEAS]
not_XX0
commenced_VBN
trading_GER
or_CC
made_VBN
any_QUAN
profits_NN
or_CC
trading_GER
losses_NN
._.
On_PIN
November_NN
28_CD
,_,
2005_CD
the_DT
High_NN
Court_NN
of_PIN
Justice_NN
in_PIN
England_NN
and_PHC
Wales_NN
approved_VBD
a_DT
reduction_NOMZ
of_PIN
Shires_NN
share_NN
capital_NN
to_TO
take_VB
effect_NN
on_PIN
November_NN
29_CD
,_,
2005_CD
,_,
when_RB
the_DT
nominal_JJ
value_NN
of_PIN
each_QUAN
Shire_NN
ordinary_JJ
share_NN
was_VBD [PASS]
reduced_VBN
from_PIN
3.50_CD
to_PIN
0.05_CD
._.
This_DEMO
reduction_NOMZ
increased_VBD
the_DT
distributable_JJ
reserves_NN
potentially_RB
available_JJ
to_TO
Shire_VB
to_TO
approximately_RB
$_$
2.95_CD
billion_CD
,_,
which_WDT [SERE]
the_DT
Directors_NN
of_PIN
Shire_NN
can_POMD
utilise_VB
for_PIN
future_JJ
dividend_NN
payments_NOMZ
at_PIN
their_TPP3
discretion_NOMZ
._.
The_DT
corporate_JJ
restructuring_GER
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
reverse_JJ
acquisition_NOMZ
._.
Accordingly_RB
,_,
the_DT
historical_JJ
financial_JJ
statements_NOMZ
prior_RB
to_PIN
the_DT
reorganization_NOMZ
are_VPRT [PASS]
labeled_VBN
as_IN
those_DEMO
of_PIN
Shire_NN
,_,
but_CC
represent_VPRT
the_DT
operations_NOMZ
of_PIN
SPG_NN
._.
For_PIN
periods_NN
prior_RB
to_PIN
the_DT
corporate_JJ
restructuring_GER
,_,
the_DT
equity_NOMZ
of_PIN
Shire_NN
represents_VPRT
the_DT
historical_JJ
equity_NOMZ
of_PIN
SPG_NN
._.
After_IN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
,_,
shareholders_NN
equity_NOMZ
represents_VPRT
the_DT
equity_NOMZ
of_PIN
Shire_NN
._.
The_DT
effect_NN
on_PIN
share_NN
capital_NN
,_,
the_DT
share_NN
premium_NN
account_NN
,_,
the_DT
capital_NN
reserve_NN
and_CC
other_JJ
reserve_NN
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
Shareholders_NN
funds_NN
and_PHC
statement_NOMZ
of_PIN
shareholders_NN
equity_NOMZ
table_NN
in_PIN
Note_NN
33_CD
._.
The_DT
capital_NN
reduction_NOMZ
has_VPRT [PEAS]
resulted_VBN
in_PIN
a_DT
new_JJ
distributable_JJ
reserve_NN
the_DT
Capital_NN
Reduction_NOMZ
Reserve_NN
._.
The_DT
increase_NN
in_PIN
the_DT
value_NN
of_PIN
common_JJ
stock_NN
at_PIN
January_NN
1_CD
,_,
2005_CD
from_PIN
$_$
36.1_CD
million_CD
to_TO
$_$
41.8_CD
million_CD
on_PIN
restatement_NOMZ
is_VPRT [BEMA]
due_PRED
to_PIN
differences_NN
between_PIN
the_DT
historic_JJ
exchange_NN
rates_NN
used_VBN
to_TO
convert_VB
SPGs_NN
Sterling_GER
denominated_VBD
nominal_JJ
share_NN
capital_NN
into_PIN
US_FPP1
Dollars_NN
,_,
and_ANDC
the_DT
exchange_NN
rate_NN
at_PIN
the_DT
time_NN
of_PIN
the_DT
corporate_JJ
restructuring_GER
._.
Earnings_GER
per_PIN
share_NN
are_VPRT [BEMA]
unaffected_PRED
by_PIN
the_DT
reorganization_NOMZ
._.
All_QUAN
SPG_NN
stock_NN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
Directors_NN
and_PHC
employees_NN
under_IN
stock_NN
option_NOMZ
plans_NN
that_TSUB
were_VBD [BEMA]
in_PIN
existence_NN
immediately_TIME
prior_RB
to_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
were_VBD [BEMA]
exchangeable_PRED
for_PIN
stock_NN
options_NOMZ
in_PIN
Shire_NN
on_PIN
a_DT
one-for-one_JJ
basis_NN
with_PIN
no_SYNE
change_NN
in_PIN
any_QUAN
of_PIN
the_DT
terms_NN
or_CC
conditions_NOMZ
._.
The_DT
number_NN
of_PIN
stock_NN
options_NOMZ
for_PIN
which_WDT [PIRE]
this_DEMO
exchange_NN
did_VBD
not_XX0
take_VB
place_NN
was_VBD
not_XX0
material_NN
._.
58_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
59_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
4_CD
Financial_NN
risk_NN
management_NOMZ
Financial_NN
risk_NN
factors_NN
The_DT
Groups_NN
activities_NOMZ
expose_VB
it_PIT
to_PIN
a_DT
variety_NN
of_PIN
financial_JJ
risks_NN
:_:
market_NN
risk_NN
including_VBG [WZPRES]
foreign_JJ
exchange_NN
risk_NN
and_PHC
price_NN
risk_NN
:_:
cash_NN
flow_NN
and_CC
fair_JJ
value_NN
interest_NN
rate_NN
risk_NN
:_:
credit_NN
risk_NN
:_:
and_ANDC
liquidity_NOMZ
risk_NN
._.
The_DT
Groups_NN
overall_JJ
risk_NN
management_NOMZ
program_NN
focuses_VPRT
on_PIN
the_DT
unpredictability_NOMZ
of_PIN
financial_JJ
markets_NN
and_CC
seeks_VPRT
to_TO
minimize_VB
potential_JJ
adverse_JJ
effects_NN
on_PIN
the_DT
Groups_NN
financial_JJ
performance_NN
._.
The_DT
Group_NN
uses_VPRT
derivative_JJ
financial_JJ
instruments_NOMZ
to_TO
hedge_VB
certain_JJ
risk_NN
exposures_NN
._.
Financial_NN
Risk_NN
management_NOMZ
is_VPRT [PASS]
carried_VBN
out_PIN
by_PIN
a_DT
central_JJ
treasury_NN
department_NOMZ
Group_NN
Treasury_NN
under_IN
policies_NN
approved_VBN [WZPAST]
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
._.
Group_NN
Treasury_NN
identifies_VPRT
,_,
evaluates_VPRT
and_CC
hedges_NN
financial_JJ
risks_NN
in_PIN
close_JJ
co-operation_NOMZ
with_PIN
the_DT
Groups_NN
operating_VBG [WZPRES]
units_NN
._.
All_QUAN
Group_NN
Treasury_NN
operations_NOMZ
are_VPRT [PASS]
conducted_VBN
within_PIN
a_DT
framework_NN
of_PIN
policies_NN
and_PHC
procedures_NN
reviewed_VBN
and_PHC
approved_VBN
by_PIN
the_DT
Board_NN
._.
As_IN
a_DT
matter_NN
of_PIN
policy_NN
,_,
the_DT
Group_NN
does_VPRT
not_XX0
undertake_VB
speculative_JJ
transactions_NOMZ
that_TSUB
would_PRMD
increase_VB
currency_NN
or_CC
interest_NN
rate_NN
exposure_NN
._.
a_DT
Market_NN
risk_NN
Foreign_JJ
exchange_NN
risk_NN
The_DT
Groups_NN
net_JJ
income_NN
and_CC
financial_JJ
position_NOMZ
,_,
as_IN
expressed_VBN
in_PIN
US_FPP1
Dollars_NN
,_,
are_VPRT [PASS]
exposed_VBN
to_PIN
movements_NOMZ
in_PIN
foreign_JJ
exchange_NN
rates_NN
against_PIN
the_DT
US_FPP1
Dollar_NN
._.
The_DT
main_JJ
trading_GER
currencies_NN
of_PIN
the_DT
Group_NN
are_VPRT [BEMA]
the_DT
US_FPP1
Dollar_NN
,_,
Pounds_NN
Sterling_GER
,_,
the_DT
Euro_NN
and_CC
the_DT
Canadian_JJ
Dollar_NN
._.
Foreign_JJ
exchange_NN
risk_NN
arises_VPRT
when_RB
future_JJ
commercial_JJ
transactions_NOMZ
,_,
recognized_VBN [PRIV]
assets_NN
,_,
liabilities_NOMZ
and_CC
net_JJ
investments_NOMZ
in_PIN
subsidiaries_NN
are_VPRT [PASS]
denominated_VBN
in_PIN
a_DT
currency_NN
that_DEMP
is_VPRT [BEMA]
not_XX0
the_DT
subsidiarys_NN
functional_JJ
currency_NN
._.
The_DT
exposure_NN
to_PIN
foreign_JJ
exchange_NN
is_VPRT [PASS]
managed_VBN
and_PHC
monitored_VBN
by_PIN
Group_NN
Treasury_NN
._.
Exposures_NN
are_VPRT [SPAU] [PASS]
generally_RB
managed_VBN
through_PIN
natural_JJ
hedging_GER
via_PIN
the_DT
currency_NN
denomination_NOMZ
of_PIN
cash_NN
balances_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Group_NN
had_VBD
five_CD
outstanding_JJ
forward_RB
foreign_JJ
exchange_NN
contracts_NN
with_PIN
a_DT
total_JJ
principal_JJ
amount_NN
of_PIN
$_$
206_CD
million_CD
to_TO
manage_VB
the_DT
risk_NN
associated_VBN [WZPAST]
with_PIN
inter-company_JJ
loans_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
there_EX
were_VBD
no_SYNE
material_NN
unrealized_JJ
gains_NN
or_CC
losses_NN
on_PIN
these_DEMO
contracts_NN
._.
Price_NN
risk_NN
As_IN
of_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Group_NN
has_VPRT
$_$
34.1_CD
million_CD
2004_CD
:_:
$_$
401.4_CD
million_CD
of_PIN
financial_JJ
assets_NN
comprizing_VBG [WZPRES]
private_JJ
companies_NN
,_,
publicly_RB
quoted_VBN
equities_NOMZ
,_,
institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
and_CC
commercial_JJ
paper_NN
._.
The_DT
publicly_RB
quoted_VBN
assets_NN
are_VPRT [PASS]
exposed_VBN
to_PIN
market_NN
risk_NN
._.
No_SYNE
financial_JJ
instruments_NOMZ
or_CC
derivatives_NN
have_VPRT [PEAS]
been_VBN [PASS]
employed_VBN
to_TO
hedge_VB
this_DEMO
risk_NN
._.
b_NN
Cash_NN
flow_NN
and_CC
fair_JJ
value_NN
interest_NN
rate_NN
risk_NN
The_DT
Groups_NN
income_NN
and_PHC
operating_GER
cash_NN
flows_NN
are_VPRT [BEMA]
substantially_RB
independent_PRED
of_PIN
changes_NN
in_PIN
market_NN
interest_NN
rates_NN
._.
The_DT
majority_NOMZ
of_PIN
the_DT
Groups_NN
debt_NN
was_VBD [PASS]
repaid_VBN
during_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
and_ANDC
therefore_CONJ
the_DT
Groups_NN
interest_NN
charge_NN
is_VPRT [BEMA]
low_PRED
._.
Consequently_CONJ
the_DT
Group_NN
has_VPRT [PEAS]
limited_VBN
exposure_NN
to_PIN
interest_NN
rate_NN
movements_NOMZ
._.
In_PIN
2005_CD
the_DT
average_JJ
interest_NN
rate_NN
received_VBN [WZPAST]
on_PIN
cash_NN
and_CC
liquid_JJ
investments_NOMZ
was_VBD [BEMA]
approximately_RB
2.9_CD
%_NN
per_PIN
annum_NN
2004_CD
:_:
1.44_CD
%_NN
._.
The_DT
largest_JJ
proportion_NOMZ
of_PIN
investments_NOMZ
was_VBD [BEMA]
in_PIN
US_FPP1
Dollar_NN
liquidity_NOMZ
funds_NN
._.
No_SYNE
financial_JJ
instruments_NOMZ
or_CC
derivatives_NN
have_VPRT [PEAS]
been_VBN [PASS]
employed_VBN
to_TO
hedge_VB
this_DEMO
exposure_NN
._.
c_NN
Credit_NN
risk_NN
The_DT
Groups_NN
revenues_NN
are_VPRT [SPAU] [PASS]
mainly_RB
derived_VBN
from_PIN
agreements_NOMZ
with_PIN
major_JJ
pharmaceutical_JJ
companies_NN
and_PHC
relationships_NN
with_PIN
pharmaceutical_JJ
wholesale_JJ
distributors_NN
and_CC
retail_JJ
pharmacy_NN
chains_NN
._.
Such_JJ
clients_NN
typically_RB
have_VPRT
significant_JJ
cash_NN
resources_NN
and_CC
as_IN
such_JJ
the_DT
risk_NN
is_VPRT [PASS]
considered_VBN [PRIV]
minimal_JJ
._.
The_DT
Group_NN
has_VPRT [PEAS]
taken_VBN
positive_JJ
steps_NN
to_TO
manage_VB
any_QUAN
credit_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
these_DEMO
transactions_NOMZ
._.
The_DT
Group_NN
operates_VPRT
clearly_RB
defined_VBN
credit_NN
evaluation_NOMZ
procedures_NN
._.
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
,_,
there_EX
were_VBD
three_CD
customers_NN
in_PIN
the_DT
US_FPP1
who_WP [WHSUB]
accounted_VBD
for_PIN
69_CD
%_NN
of_PIN
the_DT
Groups_NN
total_VPRT
revenues_NN
._.
Financial_NN
instruments_NOMZ
that_TSUB
potentially_RB
expose_VPRT
the_DT
Group_NN
to_PIN
concentrations_NOMZ
of_PIN
credit_NN
risk_NN
consist_VPRT
primarily_RB
of_PIN
short-term_JJ
cash_NN
investments_NOMZ
and_PHC
trade_NN
accounts_NN
receivable_JJ
._.
Excess_JJ
cash_NN
is_VPRT [PASS]
invested_VBN
in_PIN
short-term_JJ
money_NN
market_NN
instruments_NOMZ
,_,
including_VBG
bank_NN
and_PHC
building_GER
society_NN
term_NN
deposits_NN
,_,
commercial_JJ
paper_NN
and_CC
other_JJ
debt_NN
securities_NOMZ
from_PIN
a_DT
variety_NN
of_PIN
companies_NN
with_PIN
strong_JJ
credit_NN
ratings_GER
._.
These_DEMO
investments_NOMZ
typically_RB
bear_VPRT
minimal_JJ
risk_NN
._.
d_LS
Liquidity_NOMZ
risk_NN
Prudent_JJ
liquidity_NOMZ
risk_NN
management_NOMZ
implies_VPRT [PRIV]
maintaining_VBG [PUBV]
sufficient_JJ
cash_NN
and_CC
marketable_JJ
securities_NOMZ
,_,
the_DT
availability_NOMZ
of_PIN
funding_VBG
through_PIN
an_DT
adequate_JJ
amount_NN
of_PIN
committed_JJ
credit_NN
facilities_NOMZ
,_,
and_ANDC
the_DT
ability_NOMZ
to_TO
close_VB
out_PIN
market_NN
positions_NOMZ
._.
The_DT
Group_NN
ordinarily_RB
finances_VPRT
its_PIT
activities_NOMZ
through_PIN
cash_NN
generated_VBD
from_PIN
operating_VBG
activities_NOMZ
,_,
private_JJ
and_PHC
public_JJ
offerings_GER
of_PIN
equity_NOMZ
and_PHC
debt_NN
securities_NOMZ
and_CC
the_DT
proceeds_NN
of_PIN
asset_NN
or_CC
investment_NOMZ
disposals_NN
._.
The_DT
Group_NN
anticipates_VPRT [PRIV]
that_THVC
its_PIT
operating_GER
cash_NN
flow_NN
together_RB
with_PIN
available_JJ
cash_NN
,_,
cash_NN
equivalents_NN
and_CC
short-term_JJ
investments_NOMZ
will_PRMD
be_VB [BEMA]
sufficient_PRED
to_TO
meet_VB
its_PIT
anticipated_JJ
future_NN
operating_GER
expenses_NN
,_,
capital_NN
expenditures_NN
and_PHC
debt_NN
service_NN
and_PHC
lease_NN
obligations_NOMZ
as_IN
they_TPP3
become_VPRT
due_JJ
over_IN
the_DT
next_JJ
12_CD
months_NN
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
59_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
60_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
5_CD
Critical_JJ
accounting_GER
estimates_NN
and_CC
key_JJ
sources_NN
of_PIN
estimation_NOMZ
uncertainty_NN
The_DT
preparation_NOMZ
of_PIN
consolidated_JJ
financial_JJ
statements_NOMZ
,_,
in_PIN
conformity_NOMZ
with_PIN
IFRS_NN
accounting_GER
principles_NN
,_,
requires_VPRT [SUAV]
management_NOMZ
to_TO
make_VB
estimates_NN
and_PHC
assumptions_NOMZ
that_TSUB
affect_VPRT
the_DT
reported_VBN [PUBV]
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
,_,
the_DT
disclosure_NN
of_PIN
contingent_JJ
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
the_DT
date_NN
of_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
and_CC
reported_VBD [PUBV]
amounts_NN
of_PIN
revenues_NN
and_PHC
expenses_NN
during_PIN
the_DT
reporting_GER
period_NN
._.
Actual_JJ
results_NN
could_POMD
differ_VB
from_PIN
those_DEMO
estimates_NN
._.
The_DT
estimates_NN
and_PHC
assumptions_NOMZ
that_TSUB
have_VPRT
a_DT
significant_JJ
risk_NN
of_PIN
causing_VBG
a_DT
material_NN
adjustment_NOMZ
to_PIN
the_DT
carrying_VBG
amounts_NN
of_PIN
assets_NN
and_PHC
liabilities_NOMZ
within_PIN
the_DT
next_JJ
financial_JJ
year_NN
are_VPRT [PASS]
discussed_VBN
below_PLACE
._.
a_DT
Estimated_JJ
impairment_NOMZ
of_PIN
goodwill_NN
The_DT
Group_NN
tests_NN
annually_RB
whether_IN
goodwill_NN
has_VPRT [PEAS]
suffered_VBN
any_QUAN
impairment_NOMZ
,_,
in_PIN
accordance_NN
with_PIN
the_DT
accounting_GER
policy_NN
stated_VBN [PUBV] [WZPAST]
in_PIN
Note_NN
2_CD
h._NN
The_DT
recoverable_JJ
amounts_NN
of_PIN
cash-generating_JJ
units_NN
have_VPRT [PEAS]
been_VBN [PASS]
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
value-in-use_JJ
calculations_NOMZ
._.
These_DEMO
calculations_NOMZ
require_VPRT [SUAV]
the_DT
use_NN
of_PIN
estimates_NN
._.
The_DT
Group_NN
uses_VPRT
discounted_JJ
cash_NN
flow_NN
models_NN
to_TO
value_VB
the_DT
recoverable_JJ
amounts_NN
of_PIN
cash-generating_JJ
units_NN
,_,
which_WDT [SERE]
require_VPRT [SUAV]
assumptions_NOMZ
about_IN
the_DT
timing_NN
and_PHC
amount_NN
of_PIN
future_JJ
cash_NN
inflows_NN
and_PHC
outflows_NN
,_,
risk_NN
,_,
the_DT
cost_NN
of_PIN
capital_NN
and_PHC
terminal_NN
values_NN
._.
Each_QUAN
of_PIN
these_DEMO
assumptions_NOMZ
is_VPRT [BEMA]
significant_PRED
to_PIN
the_DT
value_NN
of_PIN
the_DT
intangible_JJ
asset_NN
._.
A_DT
prolonged_JJ
general_JJ
economic_JJ
downturn_NN
,_,
new_JJ
products_NN
,_,
loss_NN
of_PIN
IP_NN
protection_NOMZ
,_,
sustained_VBD
government_NOMZ
pressure_NN
on_PIN
prices_NN
and_CC
,_,
specifically_RB
,_,
competitive_JJ
pricing_GER
,_,
could_POMD
create_VB
an_DT
imbalance_NN
of_PIN
industry_NN
supply_NN
and_PHC
demand_NN
,_,
or_CC
otherwise_CONJ
diminish_VB
volumes_NN
or_CC
profits_NN
._.
Such_JJ
events_NN
,_,
combined_VBN [PASTP]
with_PIN
changes_NN
in_PIN
interest_NN
rates_NN
,_,
could_POMD [SPAU]
adversely_RB
affect_VB
the_DT
Groups_NN
valuation_NOMZ
of_PIN
the_DT
estimated_JJ
future_JJ
net_JJ
cash_NN
flows_VPRT
generated_VBN
by_PIN
its_PIT
cash-generating_JJ
units_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
future_JJ
operating_GER
results_NN
could_POMD
be_VB
materially_RB
and_PHC
adversely_RB
affected_VBN
by_PIN
additional_JJ
impairment_NOMZ
charges_NN
related_VBN [WZPAST]
to_PIN
the_DT
recoverability_NOMZ
of_PIN
goodwill_NN
._.
The_DT
carrying_VBG
amount_NN
of_PIN
goodwill_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
was_VBD
$_$
2,209_CD
million_CD
,_,
after_IN
an_DT
impairment_NOMZ
loss_NN
of_PIN
$_$
527_CD
million_CD
was_VBD [PASS]
recognized_VBN [PRIV]
during_PIN
2005_CD
._.
Details_NN
of_PIN
the_DT
impairment_NOMZ
loss_NN
calculation_NOMZ
are_VPRT [PASS]
provided_VBN
in_PIN
Note_NN
17_CD
._.
b_NN
Valuation_NOMZ
of_PIN
intangible_JJ
assets_NN
general_JJ
The_DT
Group_NN
has_VPRT [PEAS]
acquired_VBN
and_PHC
continues_VPRT
to_TO
acquire_VB
significant_JJ
intangible_JJ
assets_NN
,_,
recorded_VBN [PASTP]
at_PIN
acquisition_NOMZ
cost_NN
or_CC
fair_JJ
value_NN
and_CC
amortised_VBN
over_IN
the_DT
assets_NN
useful_JJ
economic_JJ
lives_NN
._.
Managements_NOMZ
estimate_NN
of_PIN
the_DT
useful_JJ
life_NN
considers_VPRT [PRIV]
,_,
inter_VB
alia_NN
,_,
the_DT
following_VBG
factors_NN
:_:
the_DT
expected_VBN [PRIV]
use_NN
of_PIN
the_DT
asset_NN
by_PIN
the_DT
Group_NN
:_:
any_QUAN
legal_JJ
,_,
regulatory_JJ
,_,
or_CC
contractual_JJ
provisions_NN
that_TSUB
may_POMD
limit_VB
the_DT
useful_JJ
life_NN
and_CC
the_DT
effects_NN
of_PIN
demand_NN
:_:
competition_NOMZ
:_:
levels_NN
of_PIN
maintenance_NN
expenditure_NN
required_VBN [SUAV]
:_:
and_ANDC
other_JJ
economic_JJ
factors_NN
such_JJ
as_IN
the_DT
stability_NOMZ
of_PIN
the_DT
industry_NN
,_,
known_VBN [PRIV]
technological_JJ
advances_NN
,_,
legislative_JJ
action_NOMZ
that_TSUB
results_VPRT
in_PIN
an_DT
uncertain_JJ
or_CC
changing_VBG
regulatory_JJ
environment_NOMZ
,_,
and_ANDC
expected_VBN [PRIV]
changes_NN
in_PIN
distribution_NOMZ
channels_NN
._.
There_EX
is_VPRT
a_DT
high_JJ
occurrence_NN
of_PIN
transactions_NOMZ
involving_VBG [WZPRES]
the_DT
transfer_NN
of_PIN
intangible_JJ
assets_NN
between_PIN
companies_NN
in_PIN
the_DT
health_NN
care_NN
field_NN
,_,
and_ANDC
valuations_NOMZ
are_VPRT [SPAU] [PASS]
usually_RB
based_VBN
on_PIN
discounted_JJ
cash_NN
flow_NN
analysis_NN
._.
The_DT
Group_NN
uses_VPRT
a_DT
discounted_JJ
cash_NN
flow_NN
model_NN
to_PIN
value_NN
intangible_JJ
assets_NN
acquired_VBN
,_,
which_WDT [SERE]
requires_VPRT [SUAV]
assumptions_NOMZ
about_IN
the_DT
timing_NN
and_PHC
amount_NN
of_PIN
future_JJ
cash_NN
inflows_NN
and_PHC
outflows_NN
,_,
risk_NN
,_,
the_DT
cost_NN
of_PIN
capital_NN
,_,
and_ANDC
terminal_NN
values_NN
._.
The_DT
Group_NN
engages_VPRT
independent_JJ
valuation_NOMZ
experts_NN
who_WP [WHSUB]
review_VPRT
critical_JJ
assumptions_NOMZ
for_PIN
significant_JJ
acquisitions_NOMZ
of_PIN
intangibles_NN
._.
The_DT
Group_NN
reviews_VPRT
intangible_JJ
assets_NN
for_PIN
impairment_NOMZ
periodically_RB
in_PIN
accordance_NN
with_PIN
IAS_NN
36_CD
Impairment_NOMZ
of_PIN
Assets_NN
._.
Such_JJ
events_NN
,_,
combined_VBN [PASTP]
with_PIN
changes_NN
in_PIN
interest_NN
rates_NN
,_,
could_POMD [SPAU]
adversely_RB
affect_VB
the_DT
Groups_NN
valuation_NOMZ
of_PIN
the_DT
estimated_JJ
future_JJ
net_JJ
cash_NN
flows_VPRT
generated_VBN
by_PIN
its_PIT
intangible_JJ
assets_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
future_JJ
operating_GER
results_NN
could_POMD
be_VB
materially_RB
and_PHC
adversely_RB
affected_VBN
by_PIN
additional_JJ
impairment_NOMZ
charges_NN
related_VBN [WZPAST]
to_PIN
the_DT
recoverability_NOMZ
of_PIN
intangible_JJ
assets_NN
._.
c_NN
Valuation_NOMZ
of_PIN
intangible_JJ
assets_NN
TKT_NN
acquisition_NOMZ
The_DT
fair_JJ
value_NN
of_PIN
all_QUAN
of_PIN
the_DT
identifiable_JJ
intangible_JJ
assets_NN
acquired_VBN [WZPAST]
through_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
has_VPRT [PEAS]
been_VBN [PASS]
determined_VBN [SUAV] [PRIV]
using_VBG
an_DT
income_NN
approach_NN
on_PIN
a_DT
project-by-project_JJ
basis_NN
,_,
by_PIN
independent_JJ
valuation_NOMZ
specialists_NN
._.
This_DEMO
method_NN
starts_VPRT
with_PIN
a_DT
forecast_NN
of_PIN
all_QUAN
of_PIN
the_DT
expected_JJ
future_JJ
net_JJ
cash_NN
flows_VPRT
either_CC
generated_VBD
or_CC
saved_VBD
as_CONJ
a_NULL
result_NULL
of_PIN
ownership_NN
of_PIN
the_DT
intellectual_JJ
property_NN
,_,
the_DT
customer_NN
relationships_NN
and_CC
the_DT
other_JJ
intangible_JJ
assets_NN
._.
These_DEMO
cash_NN
flows_NN
are_VPRT [SPAU] [PASS]
then_RB
adjusted_VBN
to_PIN
present_JJ
value_NN
by_PIN
applying_VBG
an_DT
appropriate_JJ
discount_NN
rate_NN
that_TSUB
reflects_VPRT [PRIV]
the_DT
risk_NN
factors_NN
associated_VBN [WZPAST]
with_PIN
the_DT
cash_NN
flow_NN
streams_NN
._.
The_DT
forecast_NN
of_PIN
future_JJ
cash_NN
flows_VPRT
requires_VPRT [SUAV]
various_JJ
assumptions_NOMZ
to_TO
be_VB [PASS]
made_VBN
,_,
including_VBG
:_:
revenue_NN
that_DEMP
is_VPRT [BEMA]
reasonably_RB
likely_PRED
to_TO
result_VB
from_PIN
the_DT
sale_NN
of_PIN
products_NN
including_VBG [WZPRES]
the_DT
estimated_VBN [PRIV]
number_NN
of_PIN
units_NN
to_TO
be_VB [PASS]
sold_VBN
,_,
estimated_VBN [PRIV]
selling_GER
prices_NN
,_,
estimated_VBN [PRIV]
market_NN
penetration_NOMZ
and_CC
estimated_VBN [PRIV]
market_NN
share_NN
and_CC
year-over-year_JJ
growth_NN
rates_NN
over_IN
the_DT
product_NN
life_NN
cycles_NN
:_:
royalty_NN
or_CC
license_NN
fees_NN
saved_VBN [WZPAST]
by_PIN
owning_VBG
the_DT
intellectual_JJ
property_NN
associated_VBN [WZPAST]
with_PIN
the_DT
products_NN
:_:
cost_NN
of_PIN
sales_NN
for_PIN
the_DT
products_NN
using_VBG [WZPRES]
historical_JJ
data_NN
,_,
industry_NN
data_NN
or_CC
other_JJ
sources_NN
of_PIN
market_NN
data_NN
:_:
sales_NN
and_PHC
marketing_GER
expense_NN
using_VBG [WZPRES]
historical_JJ
data_NN
,_,
industry_NN
data_NN
or_CC
other_JJ
sources_NN
of_PIN
market_NN
data_NN
:_:
general_JJ
and_PHC
administrative_JJ
expenses_NN
:_:
research_NN
and_PHC
development_NOMZ
expenses_NN
:_:
and_ANDC
the_DT
estimated_VBN [PRIV]
life_NN
of_PIN
the_DT
products_NN
._.
60_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
61_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
5_CD
Critical_JJ
accounting_GER
estimates_NN
and_CC
key_JJ
sources_NN
of_PIN
estimation_NOMZ
uncertainty_NN
continued_VBD
The_DT
valuations_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
information_NOMZ
at_PIN
the_DT
time_NN
of_PIN
the_DT
acquisition_NOMZ
and_CC
the_DT
expectations_NOMZ
and_PHC
assumptions_NOMZ
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
deemed_VBN [PRIV]
reasonable_JJ
by_PIN
the_DT
Groups_NN
management_NOMZ
._.
No_SYNE
assurance_NN
can_POMD
be_VB [PASS]
given_VBN
,_,
however_CONJ
,_,
that_THVC
the_DT
underlying_VBG
assumptions_NOMZ
or_CC
events_NN
associated_VBN [WZPAST]
with_PIN
such_JJ
assets_NN
will_PRMD
occur_VB
as_IN
projected_VBN
._.
For_PIN
these_DEMO
reasons_NN
,_,
among_PIN
others_NN
,_,
the_DT
actual_JJ
cash_NN
flows_NN
may_POMD
vary_VB
from_PIN
forecasts_NN
of_PIN
future_JJ
cash_NN
flows_NN
._.
d_LS
Valuation_NOMZ
of_PIN
financial_JJ
assets_NN
and_PHC
equity_NOMZ
accounted_VBD
investments_NOMZ
The_DT
Group_NN
has_VPRT
investments_NOMZ
in_PIN
certain_JJ
public_JJ
and_PHC
private_JJ
pharmaceutical_JJ
and_CC
biotechnology_NN
companies_NN
and_PHC
partnerships_NN
._.
These_DEMO
investments_NOMZ
are_VPRT [PASS]
designated_VBN
as_IN
either_DT
available-for-sale_JJ
,_,
joint_JJ
venture_NN
investments_NOMZ
or_CC
associate_JJ
companies_NN
._.
Those_DEMO
investments_NOMZ
designated_VBN
as_IN
available-for-sale_NN
are_VPRT [PASS]
held_VBN [PRIV]
at_PIN
fair_JJ
value_NN
,_,
in_PIN
accordance_NN
with_PIN
IAS_NN
39_CD
,_,
with_PIN
any_QUAN
unrealized_JJ
movements_NOMZ
in_PIN
fair_JJ
value_NN
being_VBG [WZPRES] [PASS]
recognized_VBN [PRIV]
directly_RB
within_PIN
equity_NOMZ
._.
Associates_NN
and_CC
joint_JJ
ventures_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
under_IN
the_DT
equity_NOMZ
method_NN
,_,
with_PIN
the_DT
companys_NN
share_NN
or_CC
profit_NN
or_CC
loss_NN
after_IN
tax_NN
presented_VBN
as_IN
a_DT
separate_JJ
item_NN
on_PIN
the_DT
face_NN
of_PIN
the_DT
income_NN
statement_NOMZ
._.
e_LS
Sales_NN
deductions_NOMZ
Sales_NN
deductions_NOMZ
primarily_RB
consist_VPRT
of_PIN
statutory_JJ
rebates_NN
to_PIN
state_NN
Medicaid_NN
and_CC
other_JJ
government_NOMZ
agencies_NN
,_,
contractual_JJ
rebates_NN
with_PIN
healthmaintenance_NN
organizations_NOMZ
HMOs_NN
,_,
product_NN
returns_NN
,_,
trade_NN
discounts_NN
,_,
wholesaler_NN
chargebacks_NN
and_PHC
allowances_NN
for_PIN
the_DT
coupon_NN
sampling_VBG [WZPRES]
program_NN
._.
Statutory_JJ
rebates_NN
to_PIN
state_NN
Medicaid_NN
agencies_NN
and_CC
contractual_JJ
rebates_NN
with_PIN
HMOs_NN
are_VPRT [PASS]
based_VBN
on_PIN
price_NN
differentials_NN
between_PIN
a_DT
base_NN
price_NN
and_CC
the_DT
selling_GER
price_NN
._.
Rebates_NN
generally_RB
increase_VB
as_IN
a_DT
percentage_NN
of_PIN
the_DT
selling_GER
price_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
product_NN
as_IN
prices_NN
increase_NN
._.
Provisions_NN
for_PIN
rebates_NN
are_VPRT [PASS]
recorded_VBN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
with_PIN
estimates_NN
of_PIN
future_JJ
utilization_NOMZ
derived_VBN [WZPAST]
from_PIN
historical_JJ
trends_NN
._.
Revisions_NN
or_CC
clarification_NOMZ
from_PIN
Centres_NN
for_PIN
Medicare_NN
and_PHC
Medicaid_NN
Services_NN
CMS_NN
related_VBN [WZPAST]
to_PIN
state_NN
Medicaid_NN
and_CC
other_JJ
government_NOMZ
program_NN
reimbursement_NOMZ
practices_NN
with_PIN
retroactive_JJ
application_NOMZ
can_POMD
result_VB
in_PIN
changes_NN
to_PIN
managements_NOMZ
estimates_NN
of_PIN
the_DT
rebates_NN
reported_VBD [PUBV]
in_PIN
prior_JJ
periods_NN
._.
However_CONJ
,_,
at_PIN
the_DT
time_NN
of_PIN
sale_NN
,_,
the_DT
prices_NN
of_PIN
the_DT
Groups_NN
products_NN
are_VPRT [PASS]
fixed_VBN
and_ANDC
consequently_CONJ
the_DT
rebates_NN
can_POMD
be_VB [SPAU] [PASS]
reasonably_RB
determined_VBN [SUAV] [PRIV]
at_PIN
the_DT
outset_NN
of_PIN
each_QUAN
transaction_NOMZ
it_PIT
undertakes_VPRT
with_PIN
its_PIT
customers_NN
and_CC
,_,
therefore_CONJ
,_,
these_DEMO
factors_NN
would_PRMD
not_XX0
impact_VB
the_DT
recording_GER
of_PIN
revenues_NN
in_PIN
accordance_NN
with_PIN
IFRS_NN
._.
Provisions_NN
for_PIN
product_NN
returns_NN
and_PHC
trade_NN
discounts_NN
to_PIN
customers_NN
are_VPRT [PASS]
recorded_VBN
as_IN
reductions_NOMZ
to_PIN
revenue_NN
in_PIN
the_DT
same_JJ
period_NN
as_IN
the_DT
related_JJ
sales_NN
with_PIN
estimates_NN
based_VBN [WZPAST]
upon_PIN
past_JJ
activity_NOMZ
levels_NN
:_:
the_DT
duration_NOMZ
of_PIN
time_NN
in_PIN
the_DT
processing_GER
of_PIN
deductions_NOMZ
:_:
and_ANDC
other_JJ
factors_NN
such_JJ
as_IN
the_DT
launch_NN
of_PIN
a_DT
new_JJ
drug_NN
,_,
the_DT
loss_NN
of_PIN
patent_NN
protection_NOMZ
or_CC
new_JJ
competition_NOMZ
._.
Where_RB
such_JJ
factors_NN
are_VPRT [BEMA]
relevant_PRED
,_,
the_DT
Group_NN
develops_VPRT
provisions_NN
for_PIN
returns_NN
based_VBN [WZPAST]
on_PIN
wholesaler_NN
customer_NN
channel_NN
checks_NN
for_PIN
slow-moving_JJ
product_NN
and_CC
a_DT
separate_JJ
management_NOMZ
review_NN
of_PIN
estimated_VBN [PRIV]
customer_NN
inventory_NN
levels_NN
,_,
by_PIN
product_NN
._.
To_PIN
the_DT
extent_NN
that_TOBJ
the_DT
Group_NN
is_VPRT [BEMA]
unable_PRED
to_TO
estimate_VB [PRIV]
returns_NN
,_,
recognition_NOMZ
of_PIN
revenue_NN
is_VPRT [PASS]
deferred_VBN
until_IN
either_CC
the_DT
product_NN
is_VPRT [PASS]
sold_VBN
to_PIN
the_DT
pharmacy_NN
or_CC
until_IN
the_DT
Group_NN
receives_VPRT
payment_NOMZ
from_PIN
the_DT
wholesaler_NN
._.
The_DT
Groups_NN
policy_NN
is_VPRT
to_TO
accept_VB [PRIV]
customer_NN
returns_NN
in_PIN
the_DT
following_VBG
circumstances_NN
:_:
a_DT
expiration_NOMZ
of_PIN
product_NN
,_,
b_NN
product_NN
damaged_VBN
while_OSUB
in_PIN
the_DT
possession_NN
of_PIN
the_DT
Group_NN
,_,
or_CC
c_NN
specific_JJ
sales_NN
terms_NN
,_,
at_PIN
product_NN
launch_NN
,_,
that_DEMP
allow_VPRT [SUAV]
for_PIN
unconditional_JJ
return_NN
of_PIN
product_NN
guaranteed_VBN [PUBV]
sales_NN
._.
Customer_NN
return_NN
periods_NN
range_VPRT
from_PIN
one_CD
to_PIN
twenty-four_CD
months_NN
with_PIN
an_DT
average_JJ
return_NN
period_NN
of_PIN
six_CD
months_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Group_NN
monitors_VPRT
customer_NN
inventory_NN
levels_NN
,_,
based_VBN [PASTP]
on_PIN
estimated_VBN [PRIV]
prescription_NOMZ
demand_NN
,_,
and_ANDC
limits_VPRT
the_DT
amount_NN
of_PIN
product_NN
shipped_VBN [WZPAST]
to_PIN
a_DT
customer_NN
when_RB
there_EX
appears_VPRT [SMP]
to_TO
be_VB [BEMA]
a_DT
protracted_JJ
pattern_NN
of_PIN
customer_NN
ordering_VBG [SUAV] [THATD] [WZPRES]
that_DEMP
exceeds_VPRT
the_DT
Groups_NN
estimate_NN
of_PIN
underlying_VBG
demand_NN
._.
The_DT
practice_NN
of_PIN
monitoring_VBG
inventory_NN
levels_NN
allows_VPRT [SUAV]
the_DT
Group_NN
to_TO [SPIN]
more_EMPH
accurately_RB
predict_VB [PUBV]
customer_NN
returns_NN
._.
The_DT
actual_JJ
experience_NN
and_CC
the_DT
level_NN
of_PIN
these_DEMO
deductions_NOMZ
to_PIN
revenue_NN
may_POMD
deviate_VB
from_PIN
the_DT
estimate_NN
._.
The_DT
Group_NN
revises_VPRT
its_PIT
estimates_NN
every_QUAN
period_NN
and_CC
may_POMD
be_VB [PASS]
required_VBN [SUAV]
to_TO
adjust_VB
the_DT
estimate_NN
in_PIN
a_DT
subsequent_JJ
period_NN
._.
There_EX
have_VPRT [PEAS]
been_VBN
no_SYNE
material_NN
adjustments_NOMZ
to_PIN
the_DT
estimates_NN
recognized_VBN [PRIV]
related_VBN
to_PIN
the_DT
Groups_NN
provisions_NN
for_PIN
sales_NN
rebates_NN
or_CC
returns_NN
,_,
in_PIN
the_DT
period_NN
presented_VBN
._.
f_LS
Income_NN
taxes_NN
The_DT
Group_NN
operates_VPRT
in_PIN
numerous_JJ
countries_NN
where_RB
its_PIT
income_NN
tax_NN
returns_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
audits_NN
and_PHC
adjustments_NOMZ
._.
Because_CAUS
the_DT
Group_NN
operates_VPRT
globally_RB
,_,
the_DT
nature_NN
of_PIN
the_DT
audit_NN
items_NN
are_VPRT
often_RB
very_AMP
complex_JJ
._.
The_DT
Group_NN
employs_VPRT
internal_JJ
and_PHC
external_JJ
tax_NN
professionals_NN
to_TO
minimize_VB
audit_NN
adjustment_NOMZ
amounts_NN
where_RB
possible_JJ
._.
The_DT
Group_NN
also_RB
has_VPRT
significant_JJ
deferred_VBN
assets_NN
due_JJ
to_PIN
net_JJ
operating_GER
losses_NN
NOLs_NN
in_PIN
the_DT
United_NN
States_NN
,_,
Canada_NN
and_CC
other_JJ
countries_NN
._.
The_DT
realization_NOMZ
of_PIN
these_DEMO
assets_NN
is_VPRT [PASS]
not_XX0
assured_VBN
and_PHC
is_VPRT [BEMA]
dependent_PRED
on_PIN
the_DT
generation_NOMZ
of_PIN
sufficient_JJ
taxable_JJ
income_NN
in_PIN
the_DT
future_NN
._.
Management_NOMZ
has_VPRT [PEAS]
exercised_VBN
judgement_NOMZ
in_PIN
determining_VBG [SUAV] [PRIV]
the_DT
extent_NN
of_PIN
the_DT
realization_NOMZ
of_PIN
these_DEMO
losses_NN
based_VBN [WZPAST]
upon_PIN
estimates_NN
of_PIN
future_JJ
taxable_JJ
income_NN
in_PIN
the_DT
various_JJ
jurisdictions_NOMZ
in_PIN
which_WDT [PIRE]
these_DEMO
NOLs_NN
exist_VPRT
._.
Where_RB
there_EX
is_VPRT
an_DT
expectation_NOMZ
that_DEMO
on_PIN
the_DT
balance_NN
of_PIN
probabilities_NOMZ
there_RB
will_PRMD
not_XX0
be_VB [BEMA]
sufficient_JJ
taxable_JJ
profits_NN
to_TO
utilise_VB
these_DEMO
NOLs_NN
a_DT
provision_NN
is_VPRT [PASS]
made_VBN
against_PIN
these_DEMP
deferred_VBN
tax_NN
assets_NN
._.
If_COND
actual_JJ
events_NN
differ_VPRT
from_PIN
managements_NOMZ
estimates_NN
,_,
or_CC
to_PIN
the_DT
extent_NN
that_TOBJ
these_DEMO
estimates_NN
are_VPRT [PASS]
adjusted_VBN
in_PIN
the_DT
future_NN
,_,
any_QUAN
changes_NN
to_PIN
the_DT
valuation_NOMZ
allowance_NN
could_POMD [SPAU]
materially_RB
impact_VB
the_DT
Groups_NN
financial_JJ
position_NOMZ
and_PHC
results_NN
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
61_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
62_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
5_CD
Critical_JJ
accounting_GER
estimates_NN
and_CC
key_JJ
sources_NN
of_PIN
estimation_NOMZ
uncertainty_NN
continued_VBD
g_JJ
Litigation_NOMZ
The_DT
Group_NN
accounts_NN
for_PIN
litigation_NOMZ
losses_NN
in_PIN
accordance_NN
with_PIN
IAS_NN
37_CD
Provisions_NN
,_,
Contingent_NN
Liabilities_NOMZ
and_PHC
Contingent_NN
Assets_NN
._.
Under_IN
IAS_NN
37_CD
,_,
provisions_NN
are_VPRT [PASS]
recorded_VBN
for_PIN
probable_JJ
litigation_NOMZ
losses_NN
when_RB
management_NOMZ
is_VPRT [BEMA]
able_PRED
to_TO [SPIN]
reliably_RB
estimate_VB [PRIV]
the_DT
loss_NN
._.
The_DT
amount_NN
recognized_VBN [PRIV]
as_IN
a_DT
provision_NN
is_VPRT
managements_NOMZ
best_JJ
estimate_NN
of_PIN
the_DT
expenditure_NN
required_VBN [SUAV]
to_TO
settle_VB
the_DT
present_JJ
obligation_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
:_:
in_CONJ
other_NULL
words_NULL
the_DT
amount_NN
that_TOBJ
an_DT
entity_NOMZ
would_PRMD [SPAU]
rationally_RB
pay_VB
to_TO
settle_VB
the_DT
obligation_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
or_CC
transfer_VB
it_PIT
to_PIN
a_DT
third_JJ
party_NN
at_PIN
that_DEMO
time_NN
._.
These_DEMO
estimates_NN
are_VPRT [PASS]
developed_VBN
substantially_RB
earlier_TIME
than_PIN
the_DT
ultimate_JJ
loss_NN
is_VPRT [PASS]
known_VBN [PRIV]
and_CC
the_DT
estimates_NN
are_VPRT [PASS]
refined_VBN
each_QUAN
accounting_GER
period_NN
,_,
as_IN
additional_JJ
information_NOMZ
becomes_VPRT
known_VBN [PRIV]
._.
In_PIN
instances_NN
where_RB
there_EX
is_VPRT
a_DT
continuous_JJ
range_NN
of_PIN
possible_JJ
outcomes_NN
,_,
and_ANDC
each_QUAN
point_NN
in_PIN
that_DEMO
range_NN
is_VPRT
as_IN
likely_JJ
as_IN
any_QUAN
other_JJ
,_,
the_DT
mid-point_NN
of_PIN
the_DT
range_NN
is_VPRT [PASS]
recorded_VBN
as_IN
a_DT
loss_NN
._.
The_DT
best_JJ
estimates_NN
are_VPRT [PASS]
reviewed_VBN
quarterly_JJ
and_CC
the_DT
estimates_NN
are_VPRT [PASS]
changed_VBN
when_RB
expectations_NOMZ
are_VPRT [PASS]
revised_VBN
._.
Any_QUAN
outcome_NN
upon_PIN
settlement_NOMZ
that_TSUB
deviates_VPRT
from_PIN
the_DT
Groups_NN
best_JJ
estimate_NN
may_POMD
result_VB
in_PIN
an_DT
additional_JJ
expense_NN
in_PIN
a_DT
future_JJ
accounting_GER
period_NN
._.
h_NN
TKT_NN
acquisition_NOMZ
The_DT
acquisition_NOMZ
of_PIN
TKT_NN
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
purchase_NN
business_NOMZ
combination_NOMZ
in_PIN
accordance_NN
with_PIN
IFRS_NN
3_CD
,_,
Business_NOMZ
Combinations_NOMZ
._.
Under_IN
the_DT
purchase_NN
method_NN
of_PIN
accounting_GER
,_,
the_DT
Group_NN
has_VPRT [PEAS]
measured_VBN
the_DT
cost_NN
of_PIN
the_DT
business_NOMZ
combination_NOMZ
as_IN
the_DT
aggregate_NN
of_PIN
the_DT
assets_NN
acquired_VBN
,_,
the_DT
liabilities_NOMZ
assumed_VBD [PRIV]
from_PIN
TKT_NN
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
at_PIN
their_TPP3
respective_JJ
fair_JJ
values_NN
,_,
and_ANDC
any_QUAN
costs_NN
directly_RB
attributable_JJ
to_PIN
the_DT
business_NOMZ
combination_NOMZ
._.
The_DT
valuation_NOMZ
of_PIN
in-process_JJ
R&D_NN
,_,
the_DT
inventory_NN
acquired_VBN [WZPAST]
with_PIN
TKT_NN
and_CC
the_DT
amount_NN
payable_JJ
to_PIN
those_DEMO
TKT_NN
shareholders_NN
who_WP [WHSUB]
have_VPRT [PEAS]
asserted_VBN [PUBV]
appraisal_NN
rights_NN
in_PIN
relation_NOMZ
to_PIN
the_DT
Groups_NN
acquisition_NOMZ
of_PIN
TKT_NN
on_PIN
July_NN
27_CD
,_,
2005_CD
are_VPRT [PASS]
based_VBN
on_PIN
managements_NOMZ
best_JJ
estimates_NN
._.
Finished_VBN
goods_NN
were_VBD [BEMA]
fair_PRED
valued_VBN
at_PIN
estimated_VBN [PRIV]
selling_GER
price_NN
less_CC
the_DT
sum_NN
of_PIN
costs_NN
of_PIN
disposal_NN
and_CC
a_DT
reasonable_JJ
profit_NN
allowance_NN
for_PIN
the_DT
selling_GER
effort_NN
of_PIN
the_DT
company_NN
._.
Work_NN
in-process_NN
was_VBD [BEMA]
fair_PRED
valued_VBN
on_PIN
the_DT
same_JJ
basis_NN
less_RB
costs_NN
to_TO
complete_VB
._.
All_QUAN
cost_NN
of_PIN
product_NN
sales_NN
of_PIN
REPLAGAL_NN
,_,
since_OSUB
the_DT
acquisition_NOMZ
,_,
are_VPRT [BEMA]
at_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
inventory_NN
acquired_VBN
._.
The_DT
fair_JJ
value_NN
of_PIN
certain_JJ
pre-acquisition_JJ
contingencies_NN
,_,
in_CONJ
particular_NULL
those_DEMP
relating_VBG
to_PIN
the_DT
Purported_NN
Class_NN
Action_NOMZ
Shareholder_NN
Suit_NN
see_VPRT [PRIV]
Note_NN
35_CD
are_VPRT
yet_RB
to_TO
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
._.
The_DT
Group_NN
currently_RB
does_VPRT
not_XX0
have_VB
sufficient_JJ
information_NOMZ
to_TO
measure_VB
the_DT
contingencies_NN
reliably_RB
._.
6_CD
Segment_NOMZ
information_NOMZ
Primary_JJ
reporting_GER
format_NN
business_NOMZ
segments_NOMZ
For_PIN
management_NOMZ
purposes_NN
,_,
the_DT
Group_NN
is_VPRT [PASS]
organised_VBN
into_PIN
two_CD
main_JJ
reporting_GER
segments_NOMZ
pharmaceutical_JJ
products_NN
and_PHC
royalties_NN
._.
Certain_JJ
revenues_NN
and_PHC
profits_NN
from_PIN
product_NN
licensing_GER
,_,
development_NOMZ
and_CC
other_JJ
items_NN
are_VPRT [PASS]
not_XX0
included_VBN
within_PIN
these_DEMO
two_CD
segments_NOMZ
and_CC
are_VPRT [SPAU] [PASS]
therefore_CONJ
presented_VBN
as_IN
unallocated_JJ
._.
The_DT
Group_NN
was_VBD [SPAU] [PASS]
also_RB
previously_TIME
involved_VBN
in_PIN
a_DT
vaccines_NN
business_NOMZ
Biologics_NN
,_,
that_DEMO
operation_NOMZ
was_VBD [PASS]
disposed_VBN
of_PIN
during_PIN
2004_CD
._.
Pharmaceutical_NN
products_NN
Royalties_NN
Unallocated_NN
Group_NN
2005_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Continuing_VBG
operations_NOMZ
Revenue_NN
external_JJ
customers_NN
1,327,660_CD
242,910_CD
28,746_CD
1,599,316_CD
Segment_NOMZ
result_NN
:_:
Operating_GER
loss_NN
profit_NN
42,072_CD
140,179_CD
23,378_CD
158,873_CD
Finance_NN
costs_NN
17,420_CD
Investment_NOMZ
revenues_NN
35,300_CD
Share_NN
of_PIN
post_NN
tax_NN
profit_NN
from_PIN
:_:
associates_NN
6,325_CD
joint_JJ
ventures_NN
5,325_CD
Loss_NN
before_IN
tax_NN
141,993_CD
Taxation_NOMZ
38,510_CD
Loss_NN
for_PIN
the_DT
year_NN
from_PIN
continuing_VBG
operations_NOMZ
180,503_CD
Discontinued_VBN
operations_NOMZ
Profit_NN
on_PIN
disposal_NN
of_PIN
operations_NOMZ
3,125_CD
Profit_NN
before_IN
income_NN
tax_NN
3,125_CD
Taxation_NOMZ
Profit_NN
for_PIN
the_DT
year_NN
from_PIN
discontinued_VBN
operations_NOMZ
3,125_CD
62_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
63_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
6_CD
Segment_NOMZ
information_NOMZ
continued_VBD
Pharmaceutical_NN
products_NN
Royalties_NN
Unallocated_NN
Group_NN
2005_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Balance_NN
Sheet_NN
Segment_NOMZ
assets_NN
4,211,231_CD
926,368_CD
5,137,599_CD
Investment_NOMZ
in_PIN
equity_NOMZ
accounted_VBD
:_:
joint_JJ
ventures_NN
5,954_CD
associates_NN
17,069_CD
Group_NN
assets_NN
deferred_VBN
tax_NN
67,283_CD
Total_JJ
assets_NN
4,211,231_CD
926,368_CD
5,227,905_CD
Segment_NOMZ
liabilities_NOMZ
1,017,081_CD
1,017,081_CD
Group_NN
liabilities_NOMZ
deferred_VBN
tax_NN
127,691_CD
Total_JJ
liabilities_NOMZ
1,017,081_CD
1,144,772_CD
Other_JJ
segment_NOMZ
items_NN
Capital_NN
expenditure_NN
638,538_CD
638,538_CD
Depreciation_NOMZ
23,003_CD
23,003_CD
Amortization_NOMZ
49,516_CD
49,516_CD
Impairment_NOMZ
charges_NN
154,735_CD
383,089_CD
537,824_CD
Share-based_JJ
payments_NOMZ
27,383_CD
27,383_CD
Provisions_NN
20,420_CD
20,420_CD
Reorganization_NOMZ
costs_NN
2,301_CD
2,301_CD
Primary_JJ
reporting_GER
format_NN
business_NOMZ
segments_NOMZ
Pharmaceutical_NN
products_NN
Royalties_NN
Biologics_NN
Unallocated_NN
Group_NN
2004_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Continuing_VBG
operations_NOMZ
Revenue_NN
external_JJ
customers_NN
1,112,457_CD
230,364_CD
20,386_CD
1,363,207_CD
Segment_NOMZ
result_NN
:_:
Operating_GER
profit_NN
43,344_CD
230,364_CD
17,078_CD
290,786_CD
Interest_NN
expense_NN
and_CC
similar_JJ
charges_NN
14,771_CD
Interest_NN
income_NN
21,901_CD
Share_NN
of_PIN
post_NN
tax_NN
profit_NN
from_PIN
:_:
associates_NN
75_CD
joint_JJ
ventures_NN
4,433_CD
Profit_NN
before_IN
income_NN
tax_NN
302,424_CD
Taxation_NOMZ
141,623_CD
Profit_NN
for_PIN
the_DT
year_NN
from_PIN
continuing_VBG
operations_NOMZ
160,801_CD
Discontinued_VBN
operations_NOMZ
Revenue_NN
external_JJ
customers_NN
3,626_CD
3,626_CD
Segment_NOMZ
result_NN
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
20,135_CD
20,135_CD
Loss_NN
on_PIN
disposal_NN
of_PIN
operations_NOMZ
44,157_CD
44,157_CD
Loss_NN
before_IN
income_NN
tax_NN
64,292_CD
64,292_CD
Taxation_NOMZ
Loss_NN
for_PIN
the_DT
year_NN
from_PIN
discontinued_VBN
operations_NOMZ
64,292_CD
64,292_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
63_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
64_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
6_CD
Segment_NOMZ
information_NOMZ
continued_VBD
Pharmaceutical_NN
products_NN
Royalties_NN
Biologics_NN
Unallocated_NN
Group_NN
2004_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Balance_NN
Sheet_NN
Segment_NOMZ
assets_NN
3,299,958_CD
1,311,163_CD
4,611,121_CD
Investment_NOMZ
in_PIN
equity_NOMZ
accounted_VBD
:_:
joint_JJ
ventures_NN
6,179_CD
associates_NN
24,669_CD
Group_NN
assets_NN
deferred_VBN
tax_NN
85,041_CD
Total_JJ
assets_NN
3,299,958_CD
1,311,163_CD
4,727,010_CD
Segment_NOMZ
liabilities_NOMZ
482,078_CD
482,078_CD
Total_JJ
liabilities_NOMZ
482,078_CD
482,078_CD
Other_JJ
segment_NOMZ
items_NN
Capital_NN
expenditure_NN
101,997_CD
12,715_CD
114,712_CD
Depreciation_NOMZ
22,668_CD
2,033_CD
24,701_CD
Amortization_NOMZ
42,138_CD
42,138_CD
Impairment_NOMZ
charges_NN
153,789_CD
153,789_CD
Share-based_JJ
payments_NOMZ
15,815_CD
15,815_CD
Provisions_NN
23,125_CD
43,161_CD
66,286_CD
Reorganization_NOMZ
costs_NN
55,505_CD
55,505_CD
On_PIN
September_NN
9_CD
,_,
2004_CD
the_DT
Group_NN
completed_VBD
its_PIT
disposal_NN
of_PIN
the_DT
vaccines_NN
Biologics_NN
business_NOMZ
,_,
which_WDT [SERE]
was_VBD [BEMA]
a_DT
separate_JJ
business_NOMZ
segment_NOMZ
and_CC
was_VBD
part_NN
of_PIN
the_DT
North_NN
America_NN
geographic_JJ
segment_NOMZ
Note_NN
14_CD
._.
Secondary_JJ
reporting_GER
format_NN
geographical_JJ
segments_NOMZ
The_DT
Groups_NN
operations_NOMZ
are_VPRT [PASS]
located_VBN
in_PIN
the_DT
US_FPP1
and_PHC
Canada_NN
North_NN
America_NN
and_CC
throughout_PIN
the_DT
rest_NN
of_PIN
the_DT
world_NN
primarily_RB
the_DT
UK_NN
and_CC
other_JJ
European_NN
Union_NN
countries_NN
._.
The_DT
revenue_NN
analysis_NN
in_PIN
the_DT
following_VBG
table_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
location_NOMZ
of_PIN
the_DT
customer_NN
,_,
which_WDT [SERE]
is_VPRT
not_XX0
materially_RB
different_PRED
from_PIN
the_DT
location_NOMZ
where_RB
the_DT
assets_NN
are_VPRT [PASS]
located_VBN
._.
Capital_NN
expenditure_NN
is_VPRT [PASS]
allocated_VBN
based_VBN
on_PIN
where_RB
the_DT
assets_NN
are_VPRT [PASS]
located_VBN
._.
Capital_NN
expenditures_VPRT
on_PIN
plant_NN
,_,
Segment_NOMZ
property_NN
and_PHC
equipment_NOMZ
Revenue_NN
assets_NN
and_CC
intangible_JJ
assets_NN
2005_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Continuing_VBG
operations_NOMZ
North_NN
America_NN
1,233,511_CD
3,357,313_CD
616,647_CD
Rest_VPRT
of_PIN
the_DT
world_NN
365,805_CD
1,847,569_CD
21,891_CD
1,599,316_CD
5,204,882_CD
638,538_CD
Investment_NOMZ
in_PIN
equity_NOMZ
accounted_VBD
:_:
joint_JJ
ventures_NN
5,954_CD
associates_NN
17,069_CD
Total_JJ
1,599,316_CD
5,227,905_CD
638,538_CD
Secondary_JJ
reporting_GER
format_NN
geographical_JJ
segments_NOMZ
Capital_NN
expenditures_VPRT
on_PIN
plant_NN
,_,
Segment_NOMZ
property_NN
and_PHC
equipment_NOMZ
Revenue_NN
assets_NN
and_CC
intangible_JJ
assets_NN
2004_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Continuing_VBG
operations_NOMZ
North_NN
America_NN
1,086,087_CD
3,006,662_CD
33,962_CD
Rest_VPRT
of_PIN
the_DT
world_NN
277,120_CD
1,689,500_CD
68,035_CD
1,363,207_CD
4,696,162_CD
101,997_CD
Discontinued_VBN
operations_NOMZ
North_NN
America_NN
3,626_CD
12,715_CD
Investment_NOMZ
in_PIN
equity_NOMZ
accounted_VBD
:_:
joint_JJ
ventures_NN
6,179_CD
associates_NN
24,669_CD
Total_JJ
1,366,833_CD
4,727,010_CD
114,712_CD
64_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
65_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
6_CD
Segment_NOMZ
information_NOMZ
continued_VBD
Analysis_NN
of_PIN
revenue_NN
by_PIN
category_NN
continuing_VBG [WZPRES]
operations_NOMZ
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Continuing_VBG
operations_NOMZ
Product_NN
sales_NN
1,327,660_CD
1,112,457_CD
Royalties_NN
242,910_CD
230,364_CD
Licensing_GER
and_PHC
development_NOMZ
15,002_CD
13,479_CD
Other_JJ
revenues_NN
13,744_CD
6,907_CD
1,599,316_CD
1,363,207_CD
Investment_NOMZ
revenues_NN
35,300_CD
21,901_CD
1,634,616_CD
1,385,108_CD
Discontinued_VBN
operations_NOMZ
3,626_CD
Total_JJ
revenue_NN
including_VBG [WZPRES]
investment_NOMZ
revenues_NN
1,634,616_CD
1,388,734_CD
For_PIN
discontinued_VBN
operations_NOMZ
see_VPRT [PRIV]
Note_NN
14_CD
._.
7_CD
Loss_NN
profit_NN
for_PIN
the_DT
year_NN
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
The_DT
following_JJ
items_NN
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
arriving_VBG
at_PIN
the_DT
loss_NN
profit_NN
from_PIN
continuing_VBG
operations_NOMZ
:_:
Staff_NN
costs_NN
:_:
wages_NN
and_PHC
salaries_NN
234,425_CD
179,174_CD
social_JJ
security_NOMZ
costs_NN
20,674_CD
15,333_CD
pensions_NN
costs_NN
defined_VBN
contribution_NOMZ
plans_NN
13,461_CD
8,722_CD
pensions_NN
costs_NN
defined_VBN
benefit_NN
plans_NN
607_CD
284_CD
share-based_JJ
payments_NOMZ
to_PIN
Directors_NN
and_PHC
employees_NN
27,383_CD
15,815_CD
296,550_CD
219,328_CD
Inventories_NN
:_:
cost_NN
of_PIN
inventories_NN
recognized_VBN [PRIV]
as_IN
expense_NN
included_VBN [WZPAST]
in_PIN
cost_NN
of_PIN
sales_NN
184,353_CD
119,943_CD
inventory_NN
write_VB [PUBV]
down_RP
included_VBN
in_PIN
cost_NN
of_PIN
sales_NN
9,432_CD
3,788_CD
Depreciation_NOMZ
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
:_:
owned_VBN
assets_NN
20,099_CD
20,140_CD
under_IN
finance_NN
leases_NN
2,904_CD
2,528_CD
Impairment_NOMZ
of_PIN
goodwill_NN
526,956_CD
132,576_CD
Impairment_NOMZ
of_PIN
intangible_JJ
assets_NN
4,410_CD
19,626_CD
Impairment_NOMZ
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
6,458_CD
1,587_CD
Amortization_NOMZ
of_PIN
intangible_JJ
assets_NN
included_VBN [WZPAST]
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
all_QUAN
acquired_VBN
49,516_CD
42,138_CD
Operating_GER
lease_NN
rentals_NN
:_:
property_NN
,_,
plant_NN
and_PHC
machinery_NN
14,445_CD
6,563_CD
other_JJ
2,673_CD
3,495_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
financial_JJ
assets_NN
4,100_CD
14,805_CD
Impairment_NOMZ
of_PIN
financial_JJ
assets_NN
1,974_CD
17,455_CD
Net_JJ
foreign_JJ
exchange_NN
losses_NN
10,212_CD
2,466_CD
Reorganization_NOMZ
costs_NN
2,301_CD
55,505_CD
Integration_NOMZ
costs_NN
11,727_CD
Government_NOMZ
grants_NN
towards_PIN
research_NN
26_CD
Auditors_NN
remuneration_NOMZ
for_PIN
audit_NN
services_NN
5,121_CD
5,401_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
65_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
66_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
7_CD
Loss_NN
profit_NN
for_PIN
the_DT
year_NN
continued_VBD
Accounts_NN
payable_JJ
to_PIN
Deloitte_NN
&_CC
Touche_NN
LLP_NN
and_CC
their_TPP3
associates_NN
by_PIN
the_DT
Group_NN
in_PIN
respect_NN
of_PIN
non-audit_JJ
services_NN
were_VBD
$_$
2.8_CD
million_CD
2004_CD
:_:
$_$
4.9_CD
million_CD
._.
A_DT
more_EMPH
detailed_JJ
analysis_NN
of_PIN
auditors_NN
remuneration_NOMZ
on_PIN
a_DT
worldwide_JJ
basis_NN
is_VPRT [PASS]
provided_VBN
below_PLACE
._.
2005_CD
2004_CD
Year_NN
to_PIN
December_NN
31_CD
,_,
$_$
000_CD
$_$
000_CD
i_FPP1
Audit_NN
fees_NN
2,731_CD
3,253_CD
ii_FW
Audit-related_JJ
fees_NN
2,390_CD
2,148_CD
iii_FW
Tax_NN
fees_NN
2,066_CD
4,734_CD
iv_NN
All_QUAN
other_JJ
fees_NN
708_CD
183_CD
Total_JJ
fees_NN
7,895_CD
10,318_CD
Notes_NN
i_FPP1
Audit_NN
fees_NN
consisted_VBD
of_PIN
audit_NN
work_NN
only_DWNT
the_DT
Independent_NN
Registered_NN
Public_NN
Accountant_NN
can_POMD [SPAU]
reasonably_RB
be_VB [PASS]
expected_VBN [PRIV]
to_TO
perform_VB
,_,
such_JJ
as_IN
statutory_JJ
audits_NN
,_,
and_ANDC
included_VBD
the_DT
audit_NN
of_PIN
managements_NOMZ
assessment_NOMZ
that_TOBJ
the_DT
Group_NN
maintained_VBD [PUBV]
effective_JJ
internal_JJ
control_NN
over_IN
10-K_JJ
financial_JJ
reporting_GER
and_CC
the_DT
audit_NN
of_PIN
the_DT
effectiveness_NOMZ
of_PIN
the_DT
Groups_NN
internal_JJ
control_NN
over_IN
10-K_JJ
financial_JJ
reporting_GER
._.
ii_FW
Audit-related_JJ
fees_NN
consist_VPRT
of_PIN
work_NN
generally_RB
only_DWNT
the_DT
Independent_NN
Registered_NN
Public_NN
Accountant_NN
can_POMD [SPAU]
reasonably_RB
be_VB [PASS]
expected_VBN [PRIV]
to_TO
perform_VB
,_,
such_JJ
as_IN
procedures_NN
relating_VBG [WZPRES]
to_PIN
regulatory_JJ
filings_GER
._.
iii_FW
Tax_NN
fees_NN
consisted_VBD
principally_RB
of_PIN
assistance_NN
with_PIN
matters_NN
related_VBN [WZPAST]
to_PIN
compliance_NN
,_,
planning_GER
and_PHC
advice_NN
in_PIN
various_JJ
tax_NN
jurisdictions_NOMZ
._.
iv_NN
All_QUAN
other_JJ
fees_NN
relate_VPRT
to_TO
assisting_VBG
the_DT
remuneration_NOMZ
committee_NN
and_CC
corporate_JJ
responsibility_NOMZ
._.
A_DT
description_NOMZ
of_PIN
the_DT
work_NN
of_PIN
the_DT
audit_NN
committee_NN
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
Audit_NN
Committee_NN
Report_NN
on_PIN
pages_NN
31_CD
to_PIN
32_CD
._.
The_DT
loss_NN
for_PIN
the_DT
financial_JJ
year_NN
under_IN
UK_NN
GAAP_NN
dealt_VBD
with_PIN
in_PIN
the_DT
accounts_NN
of_PIN
the_DT
Company_NN
was_VBD
$_$
363,000_CD
2004_CD
:_:
Not_XX0
Applicable_JJ
._.
The_DT
loss_NN
for_PIN
the_DT
financial_JJ
year_NN
ended_VBD
December_NN
31_CD
,_,
2004_CD
under_IN
UK_NN
GAAP_NN
dealt_VBD
with_PIN
in_PIN
the_DT
accounts_NN
of_PIN
the_DT
previous_JJ
holding_VBG [PRIV]
company_NN
,_,
Shire_NN
Pharmaceuticals_NN
Group_NN
plc_NN
,_,
was_VBD
$_$
32,061,087_CD
._.
As_IN
provided_VBN
by_PIN
Section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
no_SYNE
profit_NN
and_PHC
loss_NN
account_NN
is_VPRT [PASS]
presented_VBN
in_PIN
respect_NN
of_PIN
the_DT
Company_NN
accounts_VPRT
shown_VBN [PRIV]
on_PIN
pages_NN
106_CD
to_PIN
112_CD
._.
8_CD
Investment_NOMZ
revenue_NN
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Interest_NN
on_PIN
bank_NN
deposits_NN
and_CC
managed_VBD
cash_NN
funds_NN
35,300_CD
21,901_CD
9_CD
Finance_NN
costs_NN
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Interest_NN
expense_NN
and_CC
similar_JJ
charges_NN
:_:
convertible_JJ
loan_NN
notes_NN
12,197_CD
obligations_NOMZ
under_IN
finance_NN
leases_NN
360_CD
329_CD
interest_NN
provision_NN
for_PIN
dissenting_VBG
shareholders_NN
7,690_CD
other_JJ
interest_NN
payable_JJ
4,334_CD
97_CD
12,384_CD
12,623_CD
Net_JJ
foreign_JJ
exchange_NN
transaction_NOMZ
losses_NN
5,036_CD
2,148_CD
17,420_CD
14,771_CD
All_QUAN
items_NN
relate_VPRT
materially_RB
to_TO
continuing_VBG
operations_NOMZ
._.
In_PIN
August_NN
2004_CD
,_,
$_$
370.1_CD
million_CD
of_PIN
the_DT
2_CD
%_NN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
due_JJ
2011_CD
were_VBD [PASS]
redeemed_VBN
at_PIN
cost_NN
by_PIN
the_DT
note_NN
holders_NN
and_ANDC
as_CONJ
a_NULL
result_NULL
debt_NN
issuance_NN
costs_NN
of_PIN
$_$
7.4_CD
million_CD
were_VBD [PASS]
expensed_VBN
in_PIN
the_DT
year_NN
._.
These_DEMO
costs_NN
were_VBD
being_VBG [PASS]
amortised_VBN
through_PIN
the_DT
income_NN
statement_NOMZ
over_IN
the_DT
life_NN
of_PIN
the_DT
loan_NN
notes_NN
._.
These_DEMO
costs_NN
were_VBD [SPAU] [BYPA]
partly_DWNT
offset_VBN
by_PIN
a_DT
reduction_NOMZ
in_PIN
interest_NN
payable_JJ
for_PIN
the_DT
period_NN
from_PIN
redemption_NOMZ
of_PIN
the_DT
loan_NN
notes_VPRT [PRIV]
up_RP
to_PIN
December_NN
31_CD
,_,
2004_CD
._.
66_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
67_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
10_CD
Taxation_NOMZ
2005_CD
2004_CD
Notes_NN
$_$
000_CD
$_$
000_CD
Analysis_NN
of_PIN
charge_NN
in_PIN
the_DT
year_NN
Current_JJ
tax_NN
charge_NN
continuing_VBG [WZPRES]
operations_NOMZ
70,097_CD
146,782_CD
discontinued_VBN
operations_NOMZ
Deferred_JJ
tax_NN
income_NN
expense_NN
20_CD
continuing_VBG
operations_NOMZ
31,587_CD
18,590_CD
discontinued_VBN
operations_NOMZ
recognition_NOMZ
of_PIN
a_DT
deferred_JJ
tax_NN
asset_NN
within_PIN
goodwill_NN
23,749_CD
Taxation_NOMZ
38,510_CD
141,623_CD
Corporation_NOMZ
tax_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
at_PIN
30_CD
%_NN
2004_CD
:_:
30_CD
%_NN
of_PIN
the_DT
estimated_VBN [PRIV]
assessable_JJ
profit_NN
in_PIN
the_DT
year_NN
._.
Taxation_NOMZ
for_PIN
other_JJ
jurisdictions_NOMZ
is_VPRT [PASS]
calculated_VBN [PRIV]
at_PIN
the_DT
rates_NN
prevailing_VBG [WZPRES]
in_PIN
the_DT
respective_JJ
jurisdictions_NOMZ
._.
The_DT
effective_JJ
tax_NN
rate_NN
for_PIN
the_DT
year_NN
is_VPRT [BEMA]
-27_CD
%_NN
._.
The_DT
difference_NN
between_PIN
this_DEMP
and_CC
the_DT
standard_JJ
rate_NN
of_PIN
corporation_NOMZ
tax_NN
in_PIN
the_DT
UK_NN
of_PIN
30_CD
%_NN
is_VPRT [PASS]
explained_VBN [PUBV]
below_PLACE
:_:
2005_CD
2004_CD
Loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
tax_NN
$_$
000_CD
141,993_CD
302,424_CD
%_NN
%_NN
Tax_NN
at_PIN
the_DT
UK_NN
corporation_NOMZ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
2004_CD
:_:
30_CD
%_NN
30.0_CD
30.0_CD
Effects_NN
of_PIN
:_:
adjustments_NOMZ
to_PIN
tax_NN
in_PIN
respect_NN
of_PIN
prior_JJ
periods_NN
0.4_CD
5.9_CD
permanent_JJ
differences_NN
29.8_CD
6.1_CD
non_NN
deductible_JJ
goodwill_NN
111.4_CD
13.4_CD
stock_NN
option_NOMZ
benefit_NN
1.2_CD
change_NN
in_PIN
opening_VBG
tax_NN
rates_NN
1.6_CD
movement_NOMZ
on_PIN
deferred_JJ
tax_NN
22.2_CD
6.4_CD
capital_NN
taxes_NN
and_PHC
withholding_GER
taxes_NN
0.1_CD
different_JJ
tax_NN
rates_NN
on_PIN
overseas_PLACE
earnings_GER
1.6_CD
3.0_CD
other_JJ
1.5_CD
0.3_CD
Effective_JJ
tax_NN
rate_NN
for_PIN
the_DT
year_NN
27.1_CD
46.8_CD
The_DT
Group_NN
earns_VPRT
profits_NN
in_PIN
various_JJ
territories_NN
,_,
which_WDT [SERE]
have_VPRT
different_JJ
tax_NN
rates_NN
compared_VBN [WZPAST]
to_PIN
the_DT
UK_NN
._.
The_DT
tax_NN
credit_NN
expense_NN
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
consists_VPRT
of_PIN
a_DT
UK_NN
taxation_NOMZ
credit_NN
of_PIN
$_$
50.1_CD
million_CD
2004_CD
:_:
$_$
0.3_CD
million_CD
expense_NN
and_CC
overseas_PLACE
tax_NN
expenses_NN
of_PIN
$_$
88.6_CD
million_CD
2004_CD
:_:
$_$
141.3_CD
million_CD
expense_NN
._.
No_SYNE
tax_NN
deduction_NOMZ
is_VPRT [BEMA]
available_PRED
on_PIN
the_DT
impairment_NOMZ
of_PIN
goodwill_NN
that_TSUB
was_VBD [PASS]
created_VBN
on_PIN
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
._.
Of_PIN
the_DT
charge_NN
to_PIN
current_JJ
tax_NN
,_,
$_$
nil_JJ
2004_CD
:_:
$_$
nil_JJ
related_VBN
to_PIN
profits_NN
arising_VBG [WZPRES]
in_PIN
the_DT
vaccines_NN
business_NOMZ
Biologics_NN
which_WDT [WHSUB]
was_VBD [PASS]
disposed_VBN
of_PIN
during_PIN
2004_CD
._.
No_SYNE
tax_NN
charge_NN
or_CC
credit_NN
arose_VBD
on_PIN
the_DT
disposal_NN
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
67_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
68_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
11_CD
Business_NOMZ
acquisitions_NOMZ
TKT_NN
acquisition_NOMZ
On_PIN
July_NN
27_CD
,_,
2005_CD
the_DT
Group_NN
completed_VBD
its_PIT
acquisition_NOMZ
of_PIN
TKT_NN
in_PIN
an_DT
all-cash_JJ
transaction_NOMZ
._.
The_DT
acquisition_NOMZ
was_VBD [BYPA]
effected_VBN
by_PIN
merging_VBG
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Shire_NN
with_PIN
and_CC
into_PIN
TKT_NN
,_,
with_PIN
TKT_NN
continuing_VBG [WZPRES]
as_IN
the_DT
surviving_VBG
corporation_NOMZ
._.
As_IN
consideration_NOMZ
,_,
the_DT
Group_NN
paid_VBD
to_PIN
TKTs_NN
stockholders_NN
$_$
37_CD
in_PIN
cash_NN
for_PIN
each_QUAN
share_NN
of_PIN
TKT_NN
common_JJ
stock_NN
outstanding_JJ
at_PIN
the_DT
time_NN
of_PIN
the_DT
acquisition_NOMZ
,_,
less_JJ
any_QUAN
applicable_JJ
withholding_GER
taxes_NN
._.
The_DT
total_JJ
cash_NN
consideration_NOMZ
for_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB
approximately_RB
$_$
1.6_CD
billion_CD
,_,
subject_JJ
to_TO
change_VB
as_RB
may_POMD
be_VB [BYPA]
required_VBN [SUAV]
by_PIN
the_DT
appraisal_NN
rights_NN
process_NN
see_VPRT [PRIV]
below_PLACE
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
shareholders_NN
owning_VBG [WZPRES]
approximately_RB
24.8_CD
million_CD
TKT_NN
shares_NN
being_VBG [WZPRES] [BEMA]
69_CD
%_NN
of_PIN
the_DT
36.2_CD
million_CD
TKT_NN
shares_NN
outstanding_JJ
at_PIN
the_DT
acquisition_NOMZ
date_NN
had_VBD [PEAS]
accepted_VBN [PRIV]
the_DT
offer_NN
and_CC
$_$
917.9_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
paid_VBN
to_PIN
them_TPP3
:_:
$_$
83.9_CD
million_CD
was_VBD [PASS]
paid_VBN
in_PIN
connection_NOMZ
with_PIN
TKT_NN
stock_NN
options_NOMZ
:_:
and_ANDC
$_$
170.1_CD
million_CD
in_PIN
connection_NOMZ
with_PIN
convertible_JJ
notes_NN
outstanding_JJ
at_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
._.
In_PIN
connection_NOMZ
with_PIN
the_DT
Groups_NN
merger_NN
with_PIN
TKT_NN
,_,
former_JJ
holders_NN
of_PIN
approximately_RB
11.7_CD
million_CD
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
submitted_VBN [PUBV]
written_VBN [PUBV]
demands_NN
to_PIN
the_DT
Delaware_NN
Court_NN
of_PIN
Chancery_NN
for_PIN
appraisal_NN
of_PIN
these_DEMO
shares_NN
and_CC
,_,
as_CONJ
a_NULL
result_NULL
,_,
elected_VBN
not_XX0
to_TO
accept_VB [PRIV]
the_DT
$_$
37_CD
per_PIN
share_NN
merger_NN
consideration_NOMZ
._.
On_PIN
October_NN
10_CD
,_,
2005_CD
,_,
at_PIN
the_DT
request_NN
of_PIN
one_CD
of_PIN
the_DT
holders_NN
to_TO
tender_VB
365,000_CD
shares_NN
at_PIN
the_DT
merger_NN
price_NN
of_PIN
$_$
37_CD
per_PIN
share_NN
,_,
TKT_NN
filed_VBD
a_DT
motion_NOMZ
to_TO
dismiss_VB
the_DT
holders_NN
demand_NN
._.
On_PIN
October_NN
12_CD
,_,
2005_CD
,_,
the_DT
Delaware_NN
Court_NN
of_PIN
Chancery_NN
granted_VBD [SUAV]
this_DEMO
motion_NOMZ
,_,
and_ANDC
the_DT
holder_NN
tendered_VBD
the_DT
shares_NN
at_PIN
the_DT
merger_NN
consideration_NOMZ
of_PIN
$_$
37_CD
per_PIN
share_NN
._.
Therefore_CONJ
,_,
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
former_JJ
holders_NN
of_PIN
approximately_RB
11.3_CD
million_CD
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
maintained_VBD [PUBV]
written_VBN [PUBV]
demands_NN
for_PIN
appraisal_NN
of_PIN
these_DEMO
shares_NN
and_CC
have_VPRT [PEAS]
elected_VBN
not_XX0
to_TO
accept_VB [PRIV]
the_DT
$_$
37_CD
merger_NN
consideration_NOMZ
._.
In_PIN
November_NN
2005_CD
,_,
the_DT
Delaware_NN
Court_NN
of_PIN
Chancery_NN
approved_VBD
a_DT
consolidation_NOMZ
order_NN
filed_VBN [WZPAST]
by_PIN
TKT_NN
whereby_OSUB
actions_NOMZ
brought_VBN [WZPAST]
by_PIN
all_QUAN
petitioners_NN
have_VPRT [PEAS]
been_VBN [PASS]
consolidated_VBN
as_IN
one_CD
case_NN
._.
To_PIN
the_DT
extent_NN
that_TOBJ
the_DT
remaining_VBG
demands_NN
were_VBD [SPAU] [PASS]
validly_RB
asserted_VBN [PUBV]
in_PIN
accordance_NN
with_PIN
the_DT
applicable_JJ
requirements_NOMZ
of_PIN
Delaware_NN
law_NN
and_CC
the_DT
former_JJ
holders_NN
perfect_JJ
their_TPP3
rights_NN
thereunder_NN
,_,
such_JJ
former_JJ
holders_NN
will_PRMD
be_VB [PASS]
entitled_VBN
to_TO
receive_VB
the_DT
fair_JJ
value_NN
of_PIN
the_DT
shares_NN
as_IN
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Delaware_NN
Court_NN
of_PIN
Chancery_NN
._.
The_DT
determination_NOMZ
of_PIN
fair_JJ
value_NN
will_PRMD
be_VB [PASS]
made_VBN
excluding_VBG
any_QUAN
element_NOMZ
of_PIN
value_NN
arising_VBG [WZPRES]
from_PIN
the_DT
transaction_NOMZ
,_,
such_JJ
as_IN
cost_NN
savings_GER
or_CC
business_NOMZ
synergies_NN
._.
The_DT
Delaware_NN
Court_NN
of_PIN
Chancery_NN
may_POMD
ascribe_VB
a_DT
valuation_NOMZ
to_PIN
the_DT
shares_NN
that_DEMP
is_VPRT [BEMA]
greater_PRED
than_PIN [STPR]
,_,
less_JJ
than_PIN
or_CC
equal_JJ
to_TO
$_$
37_CD
per_PIN
share_NN
and_CC
may_POMD
award_NN
interest_NN
on_PIN
the_DT
amount_NN
determined_VBN [SUAV] [PRIV] [WZPAST]
in_PIN
the_DT
appraisal_NN
process_NN
._.
The_DT
total_JJ
consideration_NOMZ
for_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
,_,
including_VBG
amounts_NN
payable_JJ
in_PIN
respect_NN
of_PIN
stock_NN
options_NOMZ
and_CC
convertible_JJ
securities_NOMZ
,_,
is_VPRT
approximately_RB
$_$
1.6_CD
billion_CD
at_PIN
the_DT
merger_NN
price_NN
of_PIN
$_$
37_CD
per_PIN
share_NN
._.
This_DEMP
could_POMD
change_VB
if_COND
Shire_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
pay_VB
a_DT
different_JJ
amount_NN
of_PIN
consideration_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
approximately_RB
11.3_CD
million_CD
shares_NN
for_PIN
which_WDT [PIRE]
holders_NN
have_VPRT [PEAS]
asserted_VBN [PUBV]
appraisal_NN
rights_NN
._.
Until_IN
such_JJ
time_NN
as_IN
the_DT
appraisal_NN
process_NN
is_VPRT [BEMA]
complete_PRED
,_,
the_DT
Group_NN
is_VPRT [BEMA]
unable_PRED
to_TO
determine_VB [SUAV] [PRIV]
the_DT
extent_NN
of_PIN
its_PIT
liability_NOMZ
._.
The_DT
liability_NOMZ
to_TO
dissenting_VBG
shareholders_NN
shown_VBN [PRIV] [WZPAST]
in_PIN
the_DT
Balance_NN
Sheet_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
consists_VPRT
of_PIN
$_$
419.9_CD
million_CD
based_VBN
on_PIN
the_DT
merger_NN
consideration_NOMZ
of_PIN
$_$
37_CD
per_PIN
share_NN
for_PIN
the_DT
11.3_CD
million_CD
shares_NN
outstanding_JJ
plus_PIN
a_DT
provision_NN
for_PIN
interest_NN
of_PIN
$_$
7.7_CD
million_CD
that_DEMP
may_POMD
be_VB [BYPA]
awarded_VBN
by_PIN
the_DT
Court_NN
._.
For_PIN
accounting_VBG
purposes_NN
,_,
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
has_VPRT [PEAS]
been_VBN [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
purchase_NN
business_NOMZ
combination_NOMZ
in_PIN
accordance_NN
with_PIN
IFRS_NN
3_CD
,_,
Business_NOMZ
Combinations_NOMZ
._.
Financial_NN
statements_NOMZ
and_CC
reported_VBD [PUBV]
results_NN
of_PIN
operations_NOMZ
of_PIN
the_DT
Group_NN
issued_VBN
after_IN
completion_NOMZ
of_PIN
the_DT
acquisition_NOMZ
will_PRMD
reflect_VB [PRIV]
these_DEMO
values_NN
,_,
with_PIN
the_DT
results_NN
of_PIN
TKT_NN
included_VBD
from_PIN
July_NN
27_CD
,_,
2005_CD
in_PIN
the_DT
income_NN
statement_NOMZ
._.
The_DT
cost_NN
of_PIN
the_DT
acquisition_NOMZ
was_VBD [PASS]
made_VBN
up_RP
as_IN
follows_VPRT
:_:
$_$
000_CD
Common_JJ
stock_NN
Number_NN
of_PIN
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
non-dissenting_JJ
24,809,126_CD
Price_NN
per_PIN
TKT_NN
share_NN
$_$
37.00_CD
917,937_CD
Number_NN
of_PIN
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
dissenting_VBG [WZPRES]
11,349,150_CD
Price_NN
per_PIN
TKT_NN
share_NN
$_$
37.00_CD
419,919_CD
Total_JJ
number_NN
of_PIN
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
outstanding_JJ
as_IN
at_PIN
July_NN
27_CD
,_,
2005_CD
36,158,276_CD
Amount_NN
payable_JJ
to_PIN
TKTs_NN
shareholders_NN
at_PIN
$_$
37_CD
per_PIN
share_NN
1,337,856_CD
Stock_NN
options_NOMZ
Cash_NN
cost_NN
of_PIN
settling_VBG
TKT_NN
stock_NN
options_NOMZ
83,877_CD
Convertible_JJ
notes_NN
Nominal_JJ
value_NN
of_PIN
convertible_JJ
loan_NN
notes_NN
as_IN
at_PIN
July_NN
27_CD
,_,
2005_CD
in_PIN
$_$
000s_CD
85,000_CD
Conversion_NN
ratio_NN
into_PIN
TKT_NN
common_JJ
stock_NN
18.49_CD
Total_JJ
shares_NN
payable_JJ
upon_PIN
conversion_NN
4,597,080_CD
Price_NN
per_PIN
TKT_NN
share_NN
$_$
37.00_CD
Cost_NN
of_PIN
settling_VBG
convertible_JJ
notes_NN
170,092_CD
Direct_JJ
costs_NN
of_PIN
acquisition_NOMZ
37,491_CD
Total_JJ
cost_NN
of_PIN
the_DT
acquisition_NOMZ
1,629,316_CD
68_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
69_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
11_CD
Business_NOMZ
acquisitions_NOMZ
continued_VBD
The_DT
total_JJ
cost_NN
of_PIN
the_DT
acquisition_NOMZ
stated_VBD [PUBV]
above_PLACE
has_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
on_PIN
a_DT
provisional_JJ
basis_NN
according_VBG [WZPRES]
to_PIN
the_DT
Groups_NN
estimate_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
assets_NN
acquired_VBN
and_CC
liabilities_NOMZ
assumed_VBD [PRIV]
._.
The_DT
fair_JJ
values_NN
of_PIN
certain_JJ
pre-acquisition_JJ
contingencies_NN
,_,
in_CONJ
particular_NULL
those_DEMP
relating_VBG
to_PIN
the_DT
Purported_NN
Class_NN
Action_NOMZ
Shareholder_NN
Suit_NN
see_VPRT [PRIV]
Note_NN
35_CD
for_PIN
further_JJ
details_NN
are_VPRT
yet_RB
to_TO
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
._.
The_DT
Group_NN
currently_RB
does_VPRT
not_XX0
have_VB
sufficient_JJ
information_NOMZ
to_TO
measure_VB
the_DT
fair_JJ
value_NN
of_PIN
these_DEMO
contingencies_NN
reliably_RB
._.
The_DT
fair_JJ
values_NN
of_PIN
assets_NN
acquired_VBN
and_CC
liabilities_NOMZ
assumed_VBD [PRIV]
will_PRMD
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
as_OSUB
soon_NULL
as_NULL
possible_JJ
and_CC
,_,
in_CONJ
any_NULL
event_NULL
,_,
no_RB
later_TIME
than_PIN
one_CD
year_NN
from_PIN
the_DT
acquisition_NOMZ
date_NN
if_COND
such_JJ
fair_JJ
values_NN
can_POMD
be_VB [PASS]
measured_VBN
reliably_RB
in_PIN
this_DEMO
time_NN
frame_NN
._.
To_PIN
the_DT
extent_NN
that_TSUB
estimates_VPRT [PRIV]
need_NN
to_TO
be_VB [PASS]
adjusted_VBN
,_,
the_DT
Group_NN
will_PRMD
do_VB
so_RB
in_PIN
future_NN
periods_NN
in_PIN
accordance_NN
with_PIN
IFRS_NN
3_CD
._.
The_DT
cost_NN
of_PIN
the_DT
acquisition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
as_IN
follows_VPRT
:_:
Book_NN
Fair_NN
value_NN
Fair_NN
value_NN
adjustments_NOMZ
value_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
Assets_NN
Current_JJ
assets_NN
:_:
Cash_NN
and_PHC
cash_NN
equivalents_NN
56,814_CD
56,814_CD
Restricted_VBN
cash_NN
8,173_CD
8,173_CD
Short-term_JJ
investments_NOMZ
46,896_CD
46,896_CD
Accounts_NN
receivable_JJ
28,361_CD
28,361_CD
Inventories_NN
12,890_CD
88,879_CD
101,769_CD
Prepaid_NN
expenses_NN
and_CC
other_JJ
current_JJ
assets_NN
7,997_CD
7,997_CD
Total_JJ
current_JJ
assets_NN
161,131_CD
88,879_CD
250,010_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
57,297_CD
57,297_CD
Goodwill_NN
39,038_CD
39,038_CD
Other_JJ
intangible_JJ
assets_NN
20,210_CD
1,043,790_CD
1,064,000_CD
Other_JJ
non-current_JJ
assets_NN
3,281_CD
3,281_CD
Total_JJ
assets_NN
280,957_CD
1,093,631_CD
1,374,588_CD
Liabilities_NOMZ
Current_NN
liabilities_NOMZ
:_:
Accounts_NN
payable_JJ
and_CC
accrued_VBN
expenses_NN
35,365_CD
1,574_CD
33,791_CD
Deferred_JJ
tax_NN
liability_NOMZ
178,637_CD
178,637_CD
Other_JJ
current_JJ
liabilities_NOMZ
24,471_CD
24,471_CD
Total_JJ
current_JJ
liabilities_NOMZ
59,836_CD
177,063_CD
236,899_CD
Other_JJ
long-term_JJ
liabilities_NOMZ
1,806_CD
1,806_CD
Total_JJ
liabilities_NOMZ
61,642_CD
177,063_CD
238,705_CD
Contingent_JJ
liabilities_NOMZ
Net_JJ
assets_NN
219,315_CD
916,568_CD
1,135,883_CD
Goodwill_NN
493,433_CD
Total_JJ
consideration_NOMZ
1,629,316_CD
Book_NN
values_NN
are_VPRT [PASS]
stated_VBN [PUBV]
in_PIN
US_FPP1
GAAP_NN
and_CC
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
re-stated_VBN [PUBV]
to_PIN
IFRS_NN
on_PIN
the_DT
grounds_NN
of_PIN
materiality_NOMZ
._.
The_DT
goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
is_VPRT [PASS]
attributed_VBN
to_PIN
the_DT
anticipated_VBN [PRIV]
profitability_NOMZ
of_PIN
TKTs_NN
products_NN
and_CC
the_DT
anticipated_JJ
future_NN
operating_VBG [WZPRES]
synergies_NN
from_PIN
the_DT
combination_NOMZ
._.
TKT_NN
contributed_VBD
$_$
42.0_CD
million_CD
of_PIN
revenue_NN
and_CC
$_$
39.5_CD
million_CD
to_PIN
the_DT
Groups_NN
loss_NN
before_IN
tax_NN
for_PIN
the_DT
period_NN
between_PIN
the_DT
date_NN
of_PIN
acquisition_NOMZ
and_CC
the_DT
balance_NN
sheet_NN
date_NN
._.
If_COND
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
had_VBD [PEAS]
been_VBN [PASS]
completed_VBN
on_PIN
the_DT
first_JJ
day_NN
of_PIN
the_DT
financial_JJ
year_NN
,_,
Group_NN
revenues_NN
for_PIN
the_DT
period_NN
would_PRMD
have_VB [PEAS]
been_VBN
$_$
1,652.9_CD
million_CD
,_,
and_ANDC
the_DT
Group_NN
loss_NN
before_IN
tax_NN
from_PIN
continuing_VBG
operations_NOMZ
would_PRMD
have_VB [PEAS]
been_VBN
$_$
257.7_CD
million_CD
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
69_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
70_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
12_CD
Business_NOMZ
integration_NOMZ
In_PIN
connection_NOMZ
with_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
,_,
the_DT
Groups_NN
management_NOMZ
approved_VBD
and_PHC
initiated_VBD
plans_NN
to_TO
restructure_VB
the_DT
operations_NOMZ
of_PIN
the_DT
enlarged_JJ
Group_NN
to_TO
eliminate_VB
duplicate_VB
costs_NN
._.
Integration_NOMZ
costs_NN
represent_VPRT
incremental_JJ
costs_NN
incurred_VBN [WZPAST]
by_PIN
the_DT
Group_NN
directly_RB
related_VBN
to_PIN
the_DT
absorption_NOMZ
of_PIN
the_DT
TKT_NN
business_NOMZ
into_PIN
the_DT
Group_NN
,_,
including_VBG
expenditures_NN
for_PIN
consulting_GER
and_PHC
systems_NN
integration_NOMZ
._.
The_DT
charges_NN
have_VPRT [PEAS]
been_VBN [PASS]
presented_VBN
as_IN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
costs_NN
in_PIN
the_DT
consolidated_JJ
income_NN
statement_NOMZ
and_CC
are_VPRT [PASS]
accounted_VBN
for_PIN
solely_RB
within_PIN
the_DT
Pharmaceutical_NN
products_NN
reporting_VBG [PUBV] [WZPRES]
segment_NOMZ
._.
Integration_NOMZ
costs_NN
recorded_VBN
and_PHC
paid_VBN
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
were_VBD
:_:
Costs_NN
recorded_VBN [WZPAST]
in_PIN
year_NN
to_TO
Paid_VBN
in_PIN
year_NN
to_PIN
December_NN
31_CD
,_,
December_NN
31_CD
,_,
Closing_GER
2005_CD
2005_CD
liability_NOMZ
$_$
000_CD
$_$
000_CD
$_$
000_CD
Employee_NN
severance_NN
2,011_CD
2,011_CD
Retention_NOMZ
payments_NOMZ
for_PIN
key_JJ
TKT_NN
employees_NN
7,031_CD
1,097_CD
5,934_CD
IT_PIT
costs_VPRT
1,049_CD
1,049_CD
Other_JJ
1,636_CD
1,436_CD
200_CD
Total_JJ
11,727_CD
5,593_CD
6,134_CD
13_CD
Reorganizations_NOMZ
Sale_NN
of_PIN
the_DT
drug_NN
formulation_NOMZ
business_NOMZ
On_PIN
December_NN
22_CD
,_,
2005_CD
the_DT
Group_NN
sold_VBD
its_PIT
drug_NN
formulation_NOMZ
business_NOMZ
to_PIN
Supernus_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Supernus_NN
,_,
a_DT
newly-formed_JJ
specialty_NN
pharmaceutical_JJ
company_NN
funded_VBN [WZPAST]
by_PIN
two_CD
venture_NN
capital_NN
companies_NN
._.
The_DT
disposal_NN
resulted_VBD
in_PIN
:_:
a_DT
profit_NN
on_PIN
disposal_NN
of_PIN
$_$
3.6_CD
million_CD
._.
Proceeds_NN
from_PIN
the_DT
sale_NN
included_VBD
an_DT
equity_NOMZ
interest_NN
of_PIN
less_JJ
than_PIN
10_CD
%_NN
in_PIN
Supernus_NN
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
investments_NOMZ
in_PIN
private_JJ
companies_NN
see_VPRT [PRIV]
Note_NN
22_CD
at_PIN
its_PIT
fair_JJ
value_NN
of_PIN
$_$
3.9_CD
million_CD
._.
The_DT
fair_JJ
value_NN
was_VBD [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
reference_NN
to_PIN
the_DT
cash_NN
invested_VBN [WZPAST]
in_PIN
Supernus_NN
by_PIN
the_DT
venture_NN
capital_NN
companies_NN
:_:
the_DT
transfer_NN
of_PIN
the_DT
lease_NN
on_PIN
the_DT
East_NN
Gude_NN
Drive_NN
,_,
Rockville_NN
premises_NN
to_PIN
Supernus_NN
,_,
with_PIN
the_DT
Group_NN
being_VBG [WZPRES] [PASS]
released_VBN
from_PIN
all_QUAN
obligations_NOMZ
under_IN
the_DT
lease_NN
by_PIN
the_DT
landlord_NN
:_:
an_DT
ongoing_JJ
projects_NN
agreement_NOMZ
relating_VBG [WZPRES]
to_TO
work_VB
Supernus_NN
will_PRMD
continue_VB
to_TO
provide_VB
to_PIN
the_DT
Group_NN
for_PIN
a_DT
transitional_JJ
period_NN
ending_VBG [WZPRES]
on_PIN
or_CC
about_IN
March_NN
31_CD
,_,
2006_CD
on_PIN
certain_JJ
Shire_NN
projects_NN
until_IN
the_DT
projects_NN
are_VPRT [PASS]
moved_VBN [SUAV]
to_PIN
third-party_JJ
suppliers_NN
:_:
and_ANDC
the_DT
severance_NN
of_PIN
28_CD
employees_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
16_CD
had_VBD [PEAS]
left_VBN
the_DT
Group_NN
,_,
and_ANDC
the_DT
remaining_VBG
employees_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
leave_VB
by_PIN
March_NN
31_CD
,_,
2006_CD
._.
Severance_NN
payments_NOMZ
are_VPRT
being_VBG [PASS]
made_VBN
to_PIN
the_DT
former_JJ
employees_NN
over_IN
a_DT
42_CD
week_NN
period_NN
,_,
as_IN
required_VBN [SUAV]
by_PIN
local_JJ
regulations_NOMZ
._.
The_DT
disposal_NN
has_VPRT [PEAS]
been_VBN [PASS]
reflected_VBN [PRIV]
in_PIN
the_DT
consolidated_JJ
income_NN
statement_NOMZ
as_IN
follows_VPRT
:_:
SG&A_NN
expense_NN
R&D_NN
expense_NN
$_$
000_CD
$_$
000_CD
Employee_NN
severance_NN
1,216_CD
Gain_NN
on_PIN
disposal_NN
3,561_CD
Other_JJ
costs_NN
192_CD
3,561_CD
1,408_CD
All_QUAN
items_NN
are_VPRT [PASS]
recorded_VBN
in_PIN
the_DT
Pharmaceutical_NN
products_NN
segment_NOMZ
._.
North_PLACE
American_JJ
site_NN
consolidation_NOMZ
The_DT
Group_NN
began_VBD
a_DT
consolidation_NOMZ
of_PIN
its_PIT
North_PLACE
American_JJ
sites_NN
in_PIN
2004_CD
,_,
with_PIN
the_DT
aim_NN
of_PIN
decreasing_VBG
the_DT
number_NN
of_PIN
sites_NN
from_PIN
16_CD
to_PIN
four_CD
,_,
including_VBG [PRESP]
the_DT
opening_GER
of_PIN
a_DT
new_JJ
US_FPP1
headquarters_NN
office_NN
in_PIN
Wayne_NN
,_,
Pennsylvania_NN
._.
The_DT
Group_NN
recorded_VBD
reorganization_NOMZ
costs_NN
of_PIN
$_$
55.5_CD
million_CD
in_PIN
2004_CD
,_,
and_ANDC
$_$
2.3_CD
million_CD
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
._.
Following_VBG [PRESP]
the_DT
closure_NN
of_PIN
the_DT
Newport_NN
site_NN
in_PIN
July_NN
2005_CD
,_,
the_DT
site_NN
consolidation_NOMZ
is_VPRT [BEMA]
now_TIME
complete_PRED
and_CC
no_SYNE
further_JJ
reorganization_NOMZ
costs_NN
are_VPRT [PASS]
expected_VBN [PRIV]
._.
The_DT
primary_JJ
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
site_NN
consolidation_NOMZ
include_VPRT
:_:
severance_NN
costs_NN
relating_VBG [WZPRES]
to_PIN
137_CD
employees_NN
:_:
retention_NOMZ
payments_NOMZ
to_PIN
key_JJ
employees_NN
:_:
70_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
71_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
13_CD
Reorganizations_NOMZ
continued_VBD
relocation_NOMZ
costs_NN
relating_VBG [WZPRES]
to_PIN
85_CD
employees_NN
who_WP [WHSUB]
were_VBD [PASS]
moved_VBN [SUAV]
to_PIN
Wayne_NN
,_,
Pennsylvania_NN
:_:
costs_NN
of_PIN
duplicate_VPRT
facilities_NOMZ
including_VBG [WZPRES]
lease_NN
exit_NN
costs_NN
:_:
and_ANDC
other_JJ
incremental_JJ
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
site_NN
closures_NN
,_,
such_JJ
as_IN
legal_JJ
,_,
consultancy_NN
,_,
the_DT
write_VB [PUBV]
down_IN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
and_PHC
information_NOMZ
technology_NN
costs_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
137_CD
employees_NN
had_VBD [PEAS]
left_VBN
the_DT
Group_NN
._.
In_CONJ
addition_NULL
,_,
all_QUAN
85_CD
of_PIN
those_DEMO
employees_NN
who_WP [WHSUB]
had_VBD [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
relocate_VB
had_VBD [PEAS]
relocated_VBN
._.
The_DT
following_JJ
table_NN
presents_VPRT
the_DT
cost_NN
of_PIN
the_DT
reorganization_NOMZ
recorded_VBN [WZPAST]
to_PIN
date_NN
and_CC
the_DT
total_JJ
costs_NN
of_PIN
the_DT
reorganization_NOMZ
._.
Total_JJ
costs_NN
Total_JJ
costs_NN
incurred_VBN
to_TO
incurred_VBN
to_PIN
Total_JJ
estimated_VBN [PRIV]
December_NN
31_CD
,_,
December_NN
31_CD
,_,
costs_NN
of_PIN
2004_CD
2005_CD
reorganization_NOMZ
$_$
m_CD
$_$
m_CD
$_$
m_CD
Employee_NN
severance_NN
and_PHC
relocation_NOMZ
costs_NN
33.8_CD
1.6_CD
35.4_CD
Write-off_PIN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
1.2_CD
1.2_CD
Consultancy_NN
costs_VPRT
2.9_CD
0.5_CD
3.4_CD
Duplicate_NN
facilities_NOMZ
12.1_CD
0.2_CD
12.3_CD
Information_NOMZ
technology_NN
costs_VPRT
2.1_CD
2.1_CD
Other_JJ
costs_NN
3.4_CD
3.4_CD
55.5_CD
2.3_CD
57.8_CD
These_DEMO
charges_NN
are_VPRT [PASS]
included_VBN
in_PIN
selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
costs_NN
in_PIN
the_DT
consolidated_JJ
income_NN
statement_NOMZ
and_CC
are_VPRT [PASS]
accounted_VBN
for_PIN
solely_RB
within_PIN
the_DT
Pharmaceutical_NN
products_NN
reporting_VBG [PUBV] [WZPRES]
segment_NOMZ
._.
As_IN
noted_VBN [PRIV]
above_PLACE
,_,
certain_JJ
of_PIN
the_DT
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
reorganization_NOMZ
will_PRMD
be_VB [PASS]
paid_VBN
in_PIN
subsequent_JJ
periods_NN
._.
The_DT
following_VBG
provides_VPRT
a_DT
reconciliation_NOMZ
of_PIN
the_DT
liability_NOMZ
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
._.
Costs_NN
recorded_VBD
Utilization_NOMZ
in_PIN
year_NN
to_PIN
in_PIN
year_NN
to_PIN
Opening_GER
December_NN
31_CD
,_,
December_NN
31_CD
,_,
Closing_GER
liability_NOMZ
2005_CD
2005_CD
liability_NOMZ
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Employee_NN
severance_NN
and_PHC
relocation_NOMZ
costs_NN
1.9_CD
1.6_CD
2.9_CD
0.6_CD
Consultancy_NN
costs_NN
0.5_CD
0.5_CD
Duplicate_NN
facilities_NOMZ
11.0_CD
0.2_CD
4.0_CD
7.2_CD
12.9_CD
2.3_CD
7.4_CD
7.8_CD
Current_JJ
liabilities_NOMZ
1.9_CD
2.1_CD
0.6_CD
3.4_CD
Other_JJ
long-term_JJ
liabilities_NOMZ
11.0_CD
0.2_CD
6.8_CD
4.4_CD
12.9_CD
2.3_CD
7.4_CD
7.8_CD
The_DT
remaining_VBG
relocation_NOMZ
costs_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
in_PIN
2006_CD
._.
The_DT
liability_NOMZ
for_PIN
the_DT
duplicate_VB
facilities_NOMZ
will_PRMD
be_VB [PASS]
paid_VBN
over_IN
the_DT
remaining_VBG
life_NN
of_PIN
the_DT
relevant_JJ
leases_NN
,_,
which_WDT [SERE]
all_QUAN
expire_VPRT
before_IN
October_NN
31_CD
,_,
2012_CD
._.
The_DT
following_VBG
provides_VPRT
a_DT
reconciliation_NOMZ
of_PIN
the_DT
liability_NOMZ
as_IN
at_PIN
December_NN
31_CD
,_,
2004_CD
:_:
Costs_NN
recorded_VBN
Utilization_NOMZ
in_PIN
year_NN
to_PIN
in_PIN
year_NN
to_PIN
Opening_GER
December_NN
31_CD
,_,
December_NN
31_CD
,_,
Closing_GER
liability_NOMZ
2004_CD
2004_CD
liability_NOMZ
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Employee_NN
severance_NN
and_PHC
relocation_NOMZ
costs_NN
33.8_CD
31.9_CD
1.9_CD
Write-off_PIN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
1.2_CD
1.2_CD
Consultancy_NN
costs_VPRT
2.9_CD
2.9_CD
Duplicate_NN
facilities_NOMZ
12.1_CD
1.1_CD
11.0_CD
Information_NOMZ
technology_NN
costs_VPRT
2.1_CD
2.1_CD
Other_JJ
costs_NN
3.4_CD
3.4_CD
55.5_CD
42.6_CD
12.9_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
71_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
72_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
14_CD
Discontinued_VBN
operations_NOMZ
Disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
Biologics_NN
On_PIN
September_NN
9_CD
,_,
2004_CD
the_DT
Group_NN
completed_VBD
the_DT
disposition_NOMZ
of_PIN
its_PIT
vaccines_NN
business_NOMZ
to_PIN
ID_NN
Biomedical_NN
Corporation_NOMZ
IDB_NN
._.
The_DT
total_JJ
consideration_NOMZ
for_PIN
the_DT
sale_NN
was_VBD
$_$
120_CD
million_CD
comprizing_VBG
$_$
30_CD
million_CD
of_PIN
cash_NN
received_VBN [WZPAST]
at_PIN
completion_NOMZ
,_,
$_$
30_CD
million_CD
of_PIN
cash_NN
held_VBN [PRIV] [WZPAST]
in_PIN
escrow_NN
and_CC
due_JJ
on_PIN
the_DT
first_JJ
anniversary_NN
of_PIN
completion_NOMZ
and_CC
$_$
60_CD
million_CD
received_VBN
at_PIN
completion_NOMZ
in_PIN
the_DT
form_NN
of_PIN
4,931,864_CD
subscription_NOMZ
receipts_NN
of_PIN
IDB_NN
._.
If_COND
,_,
prior_RB
to_PIN
January_NN
10_CD
,_,
2005_CD
,_,
IDB_NN
were_VBD
to_TO
raise_VB
up_RP
to_TO
$_$
60_CD
million_CD
from_PIN
equity_NOMZ
related_VBN
issuances_NN
,_,
then_RB
it_PIT
was_VBD [PASS]
required_VBN [SUAV]
under_IN
the_DT
terms_NN
of_PIN
the_DT
sale_NN
agreement_NOMZ
to_TO
redeem_VB
the_DT
subscription_NOMZ
receipts_NN
from_PIN
the_DT
Group_NN
for_PIN
$_$
60_CD
million_CD
._.
Accordingly_RB
,_,
following_VBG [PRESP]
the_DT
completion_NOMZ
of_PIN
such_EMPH
a_NULL
fund_NN
raising_VBG [WZPRES]
on_PIN
January_NN
7_CD
,_,
2005_CD
,_,
IDB_NN
redeemed_VBD
the_DT
subscription_NOMZ
receipts_NN
from_PIN
the_DT
Group_NN
for_PIN
$_$
60_CD
million_CD
in_PIN
cash_NN
._.
On_PIN
the_DT
first_JJ
anniversary_NN
of_PIN
completion_NOMZ
,_,
the_DT
Group_NN
received_VBD
the_DT
$_$
30_CD
million_CD
of_PIN
cash_NN
held_VBN [PRIV] [WZPAST]
in_PIN
escrow_NN
._.
As_IN
part_NN
of_PIN
the_DT
transaction_NOMZ
,_,
the_DT
Group_NN
entered_VBD
into_PIN
an_DT
agreement_NOMZ
to_TO
provide_VB
IDB_NN
with_PIN
a_DT
loan_NN
facility_NOMZ
of_PIN
up_RB
to_TO
$_$
100_CD
million_CD
,_,
which_WDT [SERE]
could_POMD
be_VB [PASS]
drawn_VBN
down_RB
over_IN
the_DT
four_CD
years_NN
following_VBG [WZPRES]
completion_NOMZ
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
IDB_NN
had_VBD [PEAS]
drawn_VBN
down_IN
the_DT
entire_JJ
$_$
100_CD
million_CD
loan_NN
._.
It_PIT
was_VBD [PASS]
required_VBN [SUAV] [THATD]
that_DEMP
this_DEMO
facility_NOMZ
be_VB [BYPA]
used_VBN
by_PIN
IDB_NN
to_TO
fund_VB
the_DT
development_NOMZ
of_PIN
injectable_JJ
flu_NN
and_PHC
pipeline_NN
products_NN
within_PIN
the_DT
vaccines_NN
business_NOMZ
acquired_VBD
from_PIN
the_DT
Group_NN
._.
Drawings_GER
under_IN
the_DT
loan_NN
facility_NOMZ
are_VPRT [PASS]
segregated_VBN
into_PIN
two_CD
components_NN
:_:
i_FPP1
Drawings_GER
for_PIN
injectable_JJ
flu_NN
development_NOMZ
of_PIN
$_$
70.6_CD
million_CD
which_WDT
are_VPRT [BEMA]
repayable_PRED
out_PIN
of_PIN
income_NN
generated_VBN [WZPAST]
by_PIN
IDB_NN
on_PIN
future_JJ
non-Canadian_JJ
injectable_JJ
flu_NN
products_NN
,_,
subject_JJ
to_PIN
minimum_JJ
annual_JJ
repayments_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
first_JJ
$_$
30_CD
million_CD
of_PIN
the_DT
drawing_GER
,_,
to_TO
be_VB [PASS]
made_VBN
between_PIN
2007_CD
and_CC
2017_CD
:_:
and_ANDC
ii_FW
Drawings_GER
for_PIN
pipeline_NN
development_NOMZ
of_PIN
$_$
29.4_CD
million_CD
which_WDT
are_VPRT [BEMA]
repayable_PRED
out_PIN
of_PIN
income_NN
generated_VBN [WZPAST]
by_PIN
IDB_NN
on_PIN
future_JJ
pipeline_NN
products_NN
and_CC
have_VPRT
no_DT
fixed_VBN
repayment_NOMZ
schedule_NN
._.
The_DT
transaction_NOMZ
gave_VBD
rise_NN
to_PIN
an_DT
overall_JJ
loss_NN
on_PIN
disposition_NOMZ
of_PIN
the_DT
vaccines_NN
business_NOMZ
of_PIN
$_$
41.1_CD
million_CD
,_,
recorded_VBN
as_IN
a_DT
loss_NN
on_PIN
disposition_NOMZ
at_PIN
completion_NOMZ
in_PIN
2004_CD
of_PIN
$_$
44.2_CD
million_CD
and_CC
a_DT
subsequent_JJ
provision_NN
release_NN
of_PIN
$_$
3.1_CD
million_CD
being_VBG [PASS]
recognized_VBN [PRIV]
during_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
._.
This_DEMO
net_JJ
loss_NN
on_PIN
disposition_NOMZ
of_PIN
$_$
41.1_CD
million_CD
comprises_VPRT
a_DT
gain_NN
on_PIN
disposition_NOMZ
of_PIN
net_JJ
assets_NN
of_PIN
$_$
28.9_CD
million_CD
together_RB
with_PIN
a_DT
provision_NN
for_PIN
a_DT
loss_NN
of_PIN
$_$
70_CD
million_CD
out_PIN
of_PIN
the_DT
$_$
100_CD
million_CD
loan_NN
facility_NOMZ
available_JJ
to_PIN
IDB_NN
._.
This_DEMO
provision_NN
was_VBD [PASS]
made_VBN
on_PIN
the_DT
basis_NN
that_TOBJ
those_DEMO
loan_NN
repayments_NOMZ
based_VBN [WZPAST]
solely_RB
on_PIN
future_JJ
sales_NN
of_PIN
flu_NN
and_PHC
pipeline_NN
products_NN
in_PIN
development_NOMZ
provided_VBN
no_SYNE
certainty_NN
of_PIN
recovery_NN
._.
The_DT
historical_JJ
consolidated_JJ
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
vaccines_NN
business_NOMZ
as_IN
a_DT
discontinued_VBN
operation_NOMZ
for_PIN
all_QUAN
periods_NN
presented_VBN
._.
The_DT
results_NN
of_PIN
the_DT
discontinued_VBN
operation_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
removed_VBN
from_PIN
all_QUAN
periods_NN
on_PIN
a_DT
line-by-line_JJ
basis_NN
from_PIN
product_NN
sales_NN
revenue_NN
to_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
._.
The_DT
net_JJ
loss_NN
from_PIN
the_DT
discontinued_VBN
operation_NOMZ
together_RB
with_PIN
the_DT
loss_NN
on_PIN
disposal_NN
,_,
are_VPRT [PASS]
shown_VBN [PRIV]
as_IN
separate_JJ
line_NN
items_NN
below_PLACE
._.
Operating_VBG
results_NN
of_PIN
the_DT
discontinued_VBN
operations_NOMZ
are_VPRT [PASS]
summarized_VBN
below_PLACE
._.
2004_CD
$_$
000_CD
Product_NN
sales_NN
3,626_CD
Total_JJ
revenues_NN
3,626_CD
Costs_NN
and_PHC
expenses_NN
:_:
Cost_NN
of_PIN
sales_NN
8,304_CD
Research_NN
and_PHC
development_NOMZ
9,222_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
5,614_CD
Total_JJ
operating_GER
expenses_NN
23,140_CD
Operating_GER
loss_NN
19,514_CD
Other_JJ
expense_NN
,_,
net_JJ
621_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
before_IN
tax_NN
20,135_CD
Taxation_NOMZ
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
after_IN
tax_NN
20,135_CD
Loss_NN
on_PIN
disposal_NN
before_IN
tax_NN
44,157_CD
Taxation_NOMZ
Loss_NN
on_PIN
disposal_NN
after_IN
tax_NN
44,157_CD
Loss_NN
for_PIN
the_DT
year_NN
from_PIN
discontinued_VBN
operations_NOMZ
64,292_CD
72_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
73_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
14_CD
Discontinued_VBN
operations_NOMZ
continued_VBD
The_DT
following_JJ
table_NN
summarizes_VPRT
the_DT
assets_NN
and_PHC
liabilities_NOMZ
attributed_VBD
to_PIN
the_DT
discontinued_VBN
operations_NOMZ
at_PIN
the_DT
disposal_NN
date_NN
._.
2004_CD
$_$
000_CD
Goodwill_NN
4,476_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
74,799_CD
Inventories_NN
6,481_CD
Trade_NN
and_CC
other_JJ
receivables_NN
11,036_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
2,069_CD
Borrowings_GER
1,476_CD
Trade_NN
and_CC
other_JJ
payables_NN
13,514_CD
Loan_NN
provision_NN
70,000_CD
Other_JJ
provisions_NN
8,492_CD
Acquisition_NOMZ
costs_NN
6,706_CD
Loss_NN
on_PIN
sale_NN
44,157_CD
124,912_CD
Satisfied_VBN
by_PIN
:_:
Cash_NN
consideration_NOMZ
34,912_CD
Deferred_JJ
consideration_NOMZ
30,000_CD
Subscription_NOMZ
receipts_NN
60,000_CD
124,912_CD
At_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
discontinued_VBN
vaccines_NN
operation_NOMZ
were_VBD
$_$
nil_JJ
._.
Cash_NN
flows_VPRT
from_PIN
discontinued_VBN
operations_NOMZ
:_:
2004_CD
$_$
000_CD
Operating_GER
cash_NN
flows_VPRT
30,525_CD
Investing_VBG
cash_NN
flows_NN
12,715_CD
Financing_GER
cash_NN
flows_VPRT
Foreign_JJ
currency_NN
translation_NOMZ
10_CD
Total_JJ
cash_NN
flows_VPRT
43,250_CD
15_CD
Dividends_NN
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Equity_NOMZ
shares_NN
:_:
first_JJ
interim_JJ
dividend_NN
of_PIN
1.0475_CD
pence_NN
1.8246_CD
equivalent_JJ
per_PIN
share_NN
paid_VBN [WZPAST]
on_PIN
October_NN
13_CD
,_,
2005_CD
2004_CD
:_:
1.00_CD
pence_NN
1.82_CD
equivalent_JJ
paid_VBN
on_PIN
October_NN
14_CD
,_,
2004_CD
9,403_CD
8,905_CD
2004_CD
second_JJ
interim_JJ
dividend_NN
of_PIN
2.00_CD
pence_NN
3.85_CD
equivalent_JJ
per_PIN
share_NN
paid_VBN [WZPAST]
on_PIN
April_NN
14_CD
,_,
2005_CD
2004_CD
:_:
nil_NN
19,057_CD
28,460_CD
8,905_CD
Proposed_VBN [SUAV]
second_JJ
interim_JJ
dividend_NN
2.5356_CD
pence_NN
4.419_CD
equivalent_JJ
per_PIN
share_NN
22,020_CD
19,057_CD
In_PIN
accordance_NN
with_PIN
IAS10_NN
Events_NN
after_IN
the_DT
Balance_NN
Sheet_NN
Date_NN
,_,
the_DT
proposed_VBN [SUAV] [THATD]
second_JJ
interim_JJ
dividend_NN
has_VPRT [PEAS]
not_XX0
been_VBN [PASS]
included_VBN
as_IN
a_DT
liability_NOMZ
in_PIN
these_DEMO
financial_JJ
statements_NOMZ
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
73_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
74_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
16_CD
Loss_NN
earnings_GER
per_PIN
ordinary_JJ
share_NN
EPS_NN
Basic_JJ
EPS_NN
is_VPRT [BYPA]
calculated_VBN [PRIV]
by_PIN
dividing_VBG
the_DT
loss_NN
earnings_GER
attributable_JJ
to_PIN
ordinary_JJ
shareholders_NN
by_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
outstanding_JJ
during_PIN
the_DT
year_NN
,_,
excluding_VBG [PRESP]
those_DEMP
held_VBN [PRIV]
in_PIN
the_DT
employee_NN
share_NN
trust_NN
Note_VB [PRIV]
32_CD
,_,
which_WDT [SERE]
are_VPRT [PASS]
treated_VBN
as_IN
canceled_VBN
._.
For_PIN
diluted_VBN
EPS_NN
,_,
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
in_PIN
issue_NN
is_VPRT [PASS]
adjusted_VBN
to_TO
assume_VB [PRIV]
conversion_NN
of_PIN
all_QUAN
dilutive_JJ
potential_JJ
ordinary_JJ
shares_NN
._.
For_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
share_NN
options_NOMZ
to_TO
purchase_VB
approximately_RB
20.7_CD
million_CD
ordinary_JJ
shares_NN
and_PHC
warrants_NN
to_TO
purchase_VB
1.3_CD
million_CD
ordinary_JJ
shares_NN
were_VBD [BEMA]
not_XX0
dilutive_PRED
and_CC
were_VBD [SPAU] [PASS]
therefore_CONJ
excluded_VBN
from_PIN
the_DT
computation_NOMZ
of_PIN
diluted_VBN
EPS_NN
._.
The_DT
$_$
370_CD
million_CD
loan_NN
note_NN
convertible_JJ
debt_NN
was_VBD [PASS]
excluded_VBN
from_PIN
the_DT
calculation_NOMZ
of_PIN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
for_PIN
diluted_VBN
EPS_NN
in_PIN
2004_CD
as_IN
it_PIT
was_VBD [BEMA]
not_XX0
dilutive_PRED
._.
Reconciliations_NOMZ
of_PIN
the_DT
earnings_GER
and_CC
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
used_VBN [WZPAST]
in_PIN
the_DT
calculations_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
Weighted_JJ
average_JJ
Loss_NN
number_NN
of_PIN
Per_PIN
share_NN
2005_CD
$_$
000_CD
shares_NN
amount_NN
Basic_JJ
and_PHC
diluted_JJ
EPS_NN
Loss_NN
attributable_JJ
to_PIN
ordinary_JJ
shareholders_NN
177,378_CD
500,243,137_CD
35.5_CD
Weighted_VBN
average_JJ
Earnings_GER
number_NN
of_PIN
Per_PIN
share_NN
2004_CD
$_$
000_CD
shares_NN
amount_NN
Basic_JJ
EPS_NN
Earnings_GER
attributable_JJ
to_PIN
ordinary_JJ
shareholders_NN
96,509_CD
496,306,604_CD
19.4_CD
Effect_NN
of_PIN
dilutive_JJ
securities_NOMZ
Share_NN
options_NOMZ
3,035,620_CD
0.1_CD
Warrants_NN
66,792_CD
Diluted_NN
EPS_NN
96,509_CD
499,409,016_CD
19.3_CD
Loss_NN
earnings_GER
per_PIN
share_NN
from_PIN
continuing_VBG
and_PHC
discontinued_VBN
operations_NOMZ
:_:
Weighted_JJ
average_JJ
Loss_NN
number_NN
of_PIN
Per_PIN
share_NN
2005_CD
$_$
000_CD
shares_NN
amount_NN
Basic_JJ
and_PHC
Diluted_JJ
EPS_NN
Loss_NN
from_PIN
continuing_VBG
operations_NOMZ
180,503_CD
500,243,137_CD
36.1_CD
Gain_NN
from_PIN
discontinued_VBN
operations_NOMZ
3,125_CD
500,243,137_CD
0.6_CD
Weighted_VBN
average_JJ
Earnings_GER
number_NN
of_PIN
Per_PIN
share_NN
2004_CD
$_$
000_CD
shares_NN
amount_NN
Basic_JJ
EPS_NN
Profit_NN
from_PIN
continuing_VBG
operations_NOMZ
160,801_CD
496,306,604_CD
32.4_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
64,292_CD
496,306,604_CD
13.0_CD
Diluted_NN
EPS_NN
Profit_NN
from_PIN
continuing_VBG
operations_NOMZ
160,801_CD
499,409,016_CD
32.1_CD
Loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
64,292_CD
499,409,016_CD
12.9_CD
74_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
75_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
17_CD
Goodwill_NN
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Net_JJ
book_NN
value_NN
At_PIN
January_NN
1_CD
,_,
2,246,220_CD
2,381,287_CD
Recognised_VBN [PRIV]
on_PIN
acquisition_NOMZ
of_PIN
subsidiary_NN
493,433_CD
Impairment_NOMZ
526,956_CD
132,576_CD
Disposals_NN
4,476_CD
Exchange_NN
differences_NN
3,237_CD
1,985_CD
At_PIN
December_NN
31_CD
,_,
2,209,460_CD
2,246,220_CD
Goodwill_NN
is_VPRT [PASS]
allocated_VBN
to_PIN
the_DT
Groups_NN
cash-generating_JJ
units_NN
CGUs_NN
that_TSUB
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
benefit_VB
from_PIN
that_DEMO
business_NOMZ
combination_NOMZ
._.
The_DT
carrying_VBG
amount_NN
of_PIN
goodwill_NN
has_VPRT [PEAS]
been_VBN [PASS]
allocated_VBN
as_IN
follows_VPRT
:_:
Pharmaceutical_NN
products_NN
Royalties_NN
Total_NN
2005_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
North_NN
America_NN
1,320,888_CD
440,346_CD
1,761,234_CD
Rest_VPRT
of_PIN
the_DT
world_NN
21,393_CD
426,833_CD
448,226_CD
Total_JJ
1,342,281_CD
867,179_CD
2,209,460_CD
Pharmaceutical_NN
products_NN
Royalties_NN
Total_NN
2004_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
North_NN
America_NN
971,301_CD
636,026_CD
1,607,327_CD
Rest_VPRT
of_PIN
the_DT
world_NN
24,651_CD
614,242_CD
638,893_CD
Total_JJ
995,952_CD
1,250,268_CD
2,246,220_CD
The_DT
Group_NN
tests_NN
goodwill_NN
annually_RB
for_PIN
impairment_NOMZ
or_CC
more_EMPH
frequently_RB
if_COND
there_EX
are_VPRT
indications_NOMZ
that_DEMO
goodwill_NN
might_POMD
be_VB [PASS]
impaired_VBN
._.
The_DT
recoverable_JJ
amount_NN
of_PIN
a_DT
CGU_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
based_VBN
on_PIN
value-in-use_JJ
calculations_NOMZ
._.
These_DEMO
calculations_NOMZ
use_VPRT
cash_NN
flow_NN
projections_NOMZ
based_VBN [WZPAST]
on_PIN
financial_JJ
budgets_NN
approved_VBN [WZPAST]
by_PIN
management_NOMZ
covering_VBG [WZPRES]
up_RP
to_PIN
five_CD
years_NN
._.
For_PIN
certain_JJ
CGUs_NN
,_,
projections_NOMZ
of_PIN
up_RB
to_PIN
fifteen_CD
years_NN
are_VPRT [PASS]
used_VBN
to_TO [SPIN]
fully_AMP
model_VB
relevant_JJ
product_NN
lifecycles_NN
._.
Cash_NN
flows_VPRT
beyond_IN
the_DT
projected_VBN
period_NN
are_VPRT [PASS]
extrapolated_VBN
using_VBG
the_DT
estimated_VBN [PRIV]
growth_NN
rates_NN
stated_VBD [PUBV]
below_PLACE
._.
The_DT
growth_NN
rate_NN
does_VPRT
not_XX0
exceed_VB
the_DT
long-term_JJ
average_JJ
growth_NN
rate_NN
for_PIN
the_DT
business_NOMZ
in_PIN
which_WDT [PIRE]
the_DT
CGU_NN
operates_VPRT
._.
These_DEMO
assumptions_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
used_VBN
for_PIN
the_DT
analysis_NN
of_PIN
each_QUAN
CGU_NN
within_PIN
the_DT
business_NOMZ
segment_NOMZ
._.
Key_NN
assumptions_NOMZ
used_VBN [WZPAST]
for_PIN
value-in-use_JJ
calculations_NOMZ
:_:
Pharmaceutical_NN
Pharmaceutical_NN
products_NN
products_NN
Royalties_NN
Royalties_NN
2005 2004 2005 2004_CD
i_FPP1
Gross_NN
margin_NN
86_CD
%_NN
87_CD
%_NN
ii_FW
Growth_NN
rate_NN
2_CD
%_NN
2_CD
%_NN
25_CD
%_NN
9_CD
%_NN
iii_FW
Discount_NN
rate_NN
19_CD
%_NN
19_CD
%_NN
10_CD
%_NN
10_CD
%_NN
Notes_NN
i_FPP1
Budgeted_VBN
gross_JJ
margin_NN
._.
ii_FW
Weighted_VBN
average_JJ
growth_NN
rate_NN
used_VBN
to_TO
extrapolate_VB
cash_NN
flows_NN
beyond_IN
the_DT
projection_NOMZ
period_NN
of_PIN
ten_CD
years_NN
as_IN
appropriate_JJ
._.
iii_FW
Pre-tax_JJ
discount_NN
rate_NN
applied_VBN [WZPAST]
to_PIN
the_DT
pre-tax_JJ
cash_NN
flow_NN
projections_NOMZ
._.
Management_NOMZ
determined_VBD [SUAV] [PRIV]
budgeted_VBN
gross_JJ
margin_NN
based_VBN [WZPAST]
on_PIN
past_JJ
performance_NN
and_CC
its_PIT
expectations_NOMZ
for_PIN
the_DT
market_NN
development_NOMZ
._.
The_DT
weighted_JJ
average_JJ
growth_NN
rates_NN
used_VBN [WZPAST]
are_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
forecasts_NN
included_VBD
in_PIN
industry_NN
reports_NN
._.
The_DT
discount_NN
rates_NN
used_VBN [WZPAST]
are_VPRT [BEMA]
pre-tax_PRED
and_CC
reflect_VPRT [PRIV] [THATD]
specific_JJ
risks_NN
relating_VBG [WZPRES]
to_PIN
the_DT
relevant_JJ
segments_NOMZ
._.
The_DT
Group_NN
recognized_VBD [PRIV]
$_$
493_CD
million_CD
as_IN
goodwill_NN
on_PIN
acquisition_NOMZ
of_PIN
TKT_NN
see_VPRT [PRIV]
Note_VB [PRIV]
11_CD
,_,
in_PIN
accordance_NN
with_PIN
IFRS_NN
3_CD
,_,
Business_NOMZ
Combinations_NOMZ
._.
This_DEMO
goodwill_NN
is_VPRT [PASS]
recorded_VBN
in_PIN
the_DT
Pharmaceutical_NN
products_NN
operating_VBG [WZPRES]
segment_NOMZ
._.
At_PIN
December_NN
31_CD
,_,
2005_CD
an_DT
impairment_NOMZ
charge_NN
of_PIN
$_$
527_CD
million_CD
was_VBD [PASS]
made_VBN
in_PIN
relation_NOMZ
to_PIN
goodwill_NN
that_TSUB
was_VBD [PASS]
created_VBN
on_PIN
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
._.
A_DT
discounted_JJ
cash_NN
flow_NN
model_NN
was_VBD [PASS]
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
recoverable_JJ
value_NN
of_PIN
the_DT
business_NOMZ
and_CC
the_DT
impairment_NOMZ
is_VPRT [PASS]
included_VBN
within_PIN
net_JJ
operating_GER
expenses_NN
in_PIN
the_DT
consolidated_JJ
income_NN
statement_NOMZ
._.
A_DT
range_NN
of_PIN
pre-tax_JJ
discount_NN
rates_NN
between_PIN
10_CD
%_NN
19_CD
%_NN
was_VBD [PASS]
applied_VBN
to_PIN
probabilityadjusted_JJ
forecasts_NN
._.
The_DT
impairment_NOMZ
reflected_VBD [PRIV]
lower_JJ
projected_VBD
sales_NN
in_PIN
the_DT
BioChem_NN
subsidiary_NN
,_,
and_ANDC
lower_JJ
estimates_NN
of_PIN
cashflows_NN
from_PIN
3TC_NN
royalties_NN
as_IN
increased_VBN
competition_NOMZ
in_PIN
the_DT
anti-viral_JJ
market_NN
is_VPRT [PASS]
anticipated_VBN [PRIV]
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
75_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
76_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
17_CD
Goodwill_NN
continued_VBD
At_PIN
December_NN
31_CD
,_,
2004_CD
an_DT
impairment_NOMZ
charge_NN
was_VBD [PASS]
made_VBN
in_PIN
relation_NOMZ
to_PIN
goodwill_NN
that_TSUB
was_VBD [PASS]
created_VBN
on_PIN
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
._.
A_DT
discounted_JJ
cash_NN
flow_NN
model_NN
was_VBD [PASS]
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
recoverable_JJ
value_NN
of_PIN
the_DT
business_NOMZ
and_CC
the_DT
impairment_NOMZ
is_VPRT [PASS]
included_VBN
within_PIN
net_JJ
operating_GER
expenses_NN
in_PIN
the_DT
consolidated_JJ
income_NN
statement_NOMZ
._.
A_DT
range_NN
of_PIN
pre-tax_JJ
discount_NN
rates_NN
between_PIN
10_CD
%_NN
19_CD
%_NN
was_VBD [PASS]
applied_VBN
to_PIN
probability-adjusted_JJ
forecasts_NN
._.
The_DT
impairment_NOMZ
reflected_VBD [PRIV]
lower_JJ
sales_NN
in_PIN
the_DT
BioChem_NN
subsidiary_NN
following_VBG [WZPRES]
the_DT
suspension_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
Canada_NN
in_PIN
February_NN
2005_CD
:_:
lower_JJ
estimates_NN
of_PIN
cashflows_NN
from_PIN
3TC_NN
royalties_NN
:_:
and_ANDC
lower_JJ
estimates_NN
of_PIN
cashflows_NN
from_PIN
TROXATYL_NN
and_PHC
SPD_NN
754_CD
following_VBG
their_TPP3
out-licensing_GER
._.
Disposals_NN
of_PIN
goodwill_NN
in_PIN
2004_CD
related_VBN
to_PIN
the_DT
vaccines_NN
business_NOMZ
see_VPRT [PRIV]
Note_NN
14_CD
._.
18_CD
Other_JJ
intangible_JJ
assets_NN
Intellectual_NN
Software_NN
and_PHC
property_NN
other_JJ
Total_JJ
$_$
000_CD
$_$
000_CD
$_$
000_CD
Net_JJ
book_NN
value_NN
At_PIN
January_NN
1_CD
,_,
2005_CD
312,563_CD
9,695_CD
322,258_CD
Additions_NOMZ
all_QUAN
acquired_VBN
54,261_CD
18,898_CD
73,159_CD
Acquired_VBN
on_PIN
acquisition_NOMZ
of_PIN
subsidiary_NN
1,064,000_CD
1,064,000_CD
Amortization_NOMZ
43,420_CD
6,096_CD
49,516_CD
Impairments_NOMZ
4,410_CD
4,410_CD
Exchange_NN
differences_NN
11,373_CD
559_CD
10,814_CD
At_PIN
December_NN
31_CD
,_,
2005_CD
1,371,621_CD
23,056_CD
1,394,677_CD
Patents_NN
and_PHC
trademarks_NN
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
useful_JJ
lives_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
on_PIN
average_JJ
16_CD
years_NN
._.
Intellectual_NN
Software_NN
and_PHC
property_NN
other_JJ
Total_JJ
$_$
000_CD
$_$
000_CD
$_$
000_CD
Net_JJ
book_NN
value_NN
At_PIN
January_NN
1_CD
,_,
2004_CD
318,552_CD
318,552_CD
Additions_NOMZ
all_QUAN
acquired_VBN
49,183_CD
12,084_CD
61,267_CD
Amortization_NOMZ
39,749_CD
2,389_CD
42,138_CD
Impairments_NOMZ
19,626_CD
19,626_CD
Disposals_NN
4,936_CD
4,936_CD
Exchange_NN
differences_NN
9,139_CD
9,139_CD
At_PIN
December_NN
31_CD
,_,
2004_CD
312,563_CD
9,695_CD
322,258_CD
During_PIN
2005_CD
,_,
the_DT
Group_NN
acquired_VBD
$_$
1,064_CD
million_CD
of_PIN
other_JJ
identifiable_JJ
intangible_JJ
assets_NN
,_,
at_PIN
fair_JJ
value_NN
,_,
as_IN
part_NN
of_PIN
the_DT
acquisition_NOMZ
of_PIN
TKT_NN
see_VPRT [PRIV]
Note_VB [PRIV]
11_CD
._.
The_DT
weighted_JJ
average_JJ
amortization_NOMZ
period_NN
of_PIN
these_DEMO
assets_NN
is_VPRT [BEMA]
18_CD
years_NN
._.
These_DEMO
assets_NN
relate_VPRT
to_PIN
in-process_JJ
R&D_NN
$_$
673_CD
million_CD
intellectual_JJ
property_NN
$_$
272_CD
million_CD
,_,
customer_NN
relationships_NN
$_$
97_CD
million_CD
and_CC
other_JJ
finite-lived_JJ
assets_NN
$_$
22_CD
million_CD
._.
During_PIN
2005_CD
the_DT
Group_NN
disposed_VBD
of_PIN
no_SYNE
intangible_JJ
assets_NN
2004_CD
:_:
$_$
4.9_CD
million_CD
._.
All_QUAN
motor_NN
vehicles_NN
,_,
amounting_VBG
to_TO
$_$
7.3_CD
million_CD
2004_CD
:_:
$_$
6.5_CD
million_CD
are_VPRT [PASS]
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
._.
Depreciation_NOMZ
expense_NN
of_PIN
$_$
3.5_CD
million_CD
2004_CD
:_:
$_$
2.7_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
charged_VBN
in_PIN
cost_NN
of_PIN
sales_NN
,_,
and_ANDC
$_$
19.5_CD
million_CD
2004_CD
:_:
$_$
20_CD
million_CD
in_PIN
net_JJ
operating_GER
expenses_NN
._.
20_CD
Deferred_JJ
tax_NN
Deferred_VBN
tax_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
in_PIN
full_JJ
on_PIN
temporary_JJ
differences_NN
under_IN
the_DT
liability_NOMZ
method_NN
using_VBG [WZPRES]
a_DT
tax_NN
rate_NN
of_PIN
30_CD
%_NN
._.
Deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
offset_VBN
when_RB
there_EX
is_VPRT
a_DT
legally_RB
enforceable_JJ
right_NN
to_TO
offset_VB
current_JJ
tax_NN
assets_NN
against_PIN
current_JJ
tax_NN
liabilities_NOMZ
and_ANDC
when_RB
the_DT
deferred_JJ
taxes_NN
relate_VPRT
to_PIN
the_DT
same_JJ
fiscal_JJ
authority_NOMZ
._.
The_DT
offset_VBN
amounts_NN
are_VPRT
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Deferred_VBN
tax_NN
assets_NN
:_:
deferred_JJ
tax_NN
asset_NN
to_TO
be_VB [PASS]
recovered_VBN
after_IN
more_EMPH
than_PIN
12_CD
months_NN
85,730_CD
49,942_CD
deferred_VBN
tax_NN
asset_NN
to_TO
be_VB [PASS]
recovered_VBN
within_PIN
12_CD
months_NN
323,294_CD
75,887_CD
409,024_CD
125,829_CD
Deferred_JJ
tax_NN
liabilities_NOMZ
:_:
deferred_JJ
tax_NN
liability_NOMZ
to_TO
be_VB [PASS]
incurred_VBN
after_IN
more_EMPH
than_PIN
12_CD
months_NN
18,447_CD
39,698_CD
deferred_VBN
tax_NN
liability_NOMZ
to_TO
be_VB [PASS]
incurred_VBN
within_PIN
12_CD
months_NN
450,985_CD
1,090_CD
469,432_CD
40,788_CD
Net_JJ
deferred_JJ
tax_NN
liability_NOMZ
asset_NN
60,408_CD
85,041_CD
These_DEMO
amounts_NN
are_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
the_DT
balance_NN
sheet_NN
as_IN
follows_VPRT
:_:
Deferred_JJ
tax_NN
asset_NN
67,283_CD
85,041_CD
Deferred_JJ
tax_NN
liability_NOMZ
127,691_CD
60,408_CD
85,041_CD
The_DT
gross_JJ
movement_NOMZ
on_PIN
the_DT
deferred_JJ
tax_NN
account_NN
is_VPRT
as_IN
follows_VPRT
:_:
At_PIN
January_NN
1_CD
,_,
85,041_CD
76,341_CD
Acquisition_NOMZ
of_PIN
subsidiary_NN
178,637_CD
Income_NN
statement_NOMZ
credit_NN
31,587_CD
5,159_CD
Movement_NOMZ
booked_VBN [WZPAST]
to_PIN
equity_NOMZ
1,721_CD
Foreign_NN
exchange_NN
120_CD
3,541_CD
At_PIN
December_NN
31_CD
,_,
60,408_CD
85,041_CD
As_IN
of_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Group_NN
has_VPRT [PEAS]
not_XX0
made_VBN
a_DT
UK_NN
tax_NN
provision_NN
on_PIN
approximately_RB
$_$
1.7_CD
billion_CD
2004_CD
:_:
$_$
1.4_CD
billion_CD
of_PIN
unremitted_JJ
earnings_GER
of_PIN
its_PIT
international_JJ
subsidiaries_NN
._.
The_DT
Group_NN
does_VPRT
not_XX0
provide_VB
for_PIN
income_NN
taxes_NN
on_PIN
the_DT
unremitted_JJ
earnings_GER
of_PIN
subsidiaries_NN
located_VBN
outside_PLACE
the_DT
UK_NN
,_,
where_RB
such_JJ
earnings_GER
have_VPRT [PEAS]
been_VBN [PASS]
retained_VBN
indefinitely_RB
for_PIN
reinvestment_NOMZ
,_,
or_CC
where_RB
it_PIT
is_VPRT
managements_NOMZ
intention_NOMZ
that_TOBJ
the_DT
earnings_GER
will_PRMD
be_VB [PASS]
remitted_VBN
in_PIN
a_DT
tax_NN
free_JJ
liquidation_NOMZ
,_,
or_CC
as_IN
dividends_NN
with_PIN
taxes_NN
substantially_RB
offset_VBN
by_PIN
foreign_JJ
tax_NN
credits_NN
._.
It_PIT
is_VPRT [BEMA]
not_XX0
practical_PRED
to_TO
determine_VB [SUAV] [PRIV]
the_DT
amount_NN
of_PIN
unrecognised_JJ
deferred_JJ
tax_NN
liabilities_NOMZ
for_PIN
temporary_JJ
differences_NN
related_VBN [WZPAST]
to_PIN
these_DEMO
investments_NOMZ
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
77_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
78_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
20_CD
Deferred_JJ
tax_NN
continued_VBN
The_DT
movement_NOMZ
in_PIN
deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
during_PIN
the_DT
year_NN
,_,
without_PIN
taking_VBG
into_PIN
consideration_NOMZ
the_DT
offsetting_VBG
of_PIN
balances_NN
within_PIN
the_DT
same_JJ
tax_NN
jurisdiction_NOMZ
,_,
is_VPRT
as_IN
follows_VPRT
:_:
Deferred_JJ
tax_NN
assets_NN
:_:
Share-based_JJ
Tax_NN
losses_NN
ACA_NN
STTD_NN
payments_NOMZ
Total_JJ
2005_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
At_PIN
January_NN
1_CD
,_,
2005_CD
69,810_CD
53,718_CD
2,301_CD
125,829_CD
Acquisition_NOMZ
of_PIN
subsidiary_NN
151,314_CD
134,786_CD
286,100_CD
Charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
85,428_CD
75,039_CD
6,720_CD
3,669_CD
Charge_NN
to_PIN
equity_NOMZ
1,721_CD
1,721_CD
Exchange_NN
differences_NN
378 153 426 957_CD
At_PIN
December_NN
31_CD
,_,
2005_CD
135,318_CD
263,390_CD
10,316_CD
409,024_CD
Share-based_JJ
Tax_NN
losses_NN
ACA_NN
STTD_NN
payments_NOMZ
Total_JJ
2004_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
At_PIN
January_NN
1_CD
,_,
2004_CD
80,476_CD
32,505_CD
2,301_CD
115,282_CD
Charged_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
14,003_CD
20,477_CD
6,474_CD
Exchange_NN
differences_NN
3,337_CD
736_CD
4,073_CD
At_PIN
December_NN
31_CD
,_,
2004_CD
69,810_CD
53,718_CD
2,301_CD
125,829_CD
Accelerated_VBN
capital_NN
allowances_NN
short-term_JJ
timing_NN
differences_NN
._.
Deferred_JJ
tax_NN
liabilities_NOMZ
:_:
Total_JJ
2005_CD
$_$
000_CD
At_PIN
January_NN
1_CD
,_,
2005_CD
40,788_CD
Acquisition_NOMZ
of_PIN
subsidiary_NN
464,737_CD
Credited_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
35,256_CD
Exchange_NN
differences_NN
837_CD
At_PIN
December_NN
31_CD
,_,
2005_CD
469,432_CD
At_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
deferred_JJ
tax_NN
liabilities_NOMZ
materially_RB
related_VBN
to_TO
accelerated_VBN
capital_NN
allowances_NN
._.
Total_JJ
2004_CD
$_$
000_CD
At_PIN
January_NN
1_CD
,_,
2004_CD
38,941_CD
Credited_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
1,315_CD
Exchange_NN
differences_NN
532_CD
At_PIN
December_NN
31_CD
,_,
2004_CD
40,788_CD
At_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
deferred_JJ
tax_NN
liabilities_NOMZ
materially_RB
related_VBN
to_TO
accelerated_VBN
capital_NN
allowances_NN
._.
78_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
79_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
20_CD
Deferred_JJ
tax_NN
continued_VBN
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
based_VBN [PASTP]
upon_PIN
the_DT
level_NN
of_PIN
historical_JJ
taxable_JJ
income_NN
and_PHC
projections_NOMZ
for_PIN
future_JJ
taxable_JJ
income_NN
,_,
management_NOMZ
believes_VPRT [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
the_DT
Group_NN
will_PRMD
realize_VB [PRIV]
the_DT
benefits_NN
of_PIN
the_DT
recognized_VBN [PRIV]
deferred_VBN
tax_NN
assets_NN
._.
However_CONJ
,_,
the_DT
amount_NN
of_PIN
the_DT
deferred_JJ
tax_NN
asset_NN
considered_VBN [PRIV]
realizable_JJ
could_POMD
be_VB [PASS]
adjusted_VBN
in_PIN
the_DT
future_NN
if_COND
estimates_NN
of_PIN
taxable_JJ
income_NN
are_VPRT [PASS]
revised_VBN
._.
Unrecognised_JJ
deferred_VBN
tax_NN
assets_NN
:_:
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Tax_NN
losses_NN
148,642_CD
181,335_CD
Other_JJ
timing_NN
differences_NN
86,535_CD
24,500_CD
235,177_CD
205,835_CD
21_CD
Investments_NOMZ
accounted_VBD
for_PIN
using_VBG
equity_NOMZ
method_NN
Joint_NN
Associates_NN
ventures_NN
Total_JJ
2005 2005 2005 2005_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
At_PIN
January_NN
1_CD
,_,
2005_CD
24,669_CD
6,179_CD
30,848_CD
Additions_NOMZ
2,093_CD
2,093_CD
Share_NN
post_NN
tax_NN
loss_NN
profit_NN
6,325_CD
5,325_CD
1,000_CD
Dividends_NN
received_VBD
3,774_CD
4,710_CD
8,484_CD
Impairments_NOMZ
Exchange_NN
differences_NN
406 840 434_CD
At_PIN
December_NN
31_CD
,_,
2005_CD
17,069_CD
5,954_CD
23,023_CD
Joint_NN
Associates_NN
ventures_NN
Total_JJ
2005 2005 2005 2004_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
At_PIN
January_NN
1_CD
,_,
2004_CD
25,656_CD
5,028_CD
30,684_CD
Additions_NOMZ
2,436_CD
2,436_CD
Share_NN
post_NN
tax_NN
profit_NN
75_CD
4,433_CD
4,508_CD
Dividends_NN
received_VBD
1,450_CD
4,043_CD
5,493_CD
Impairments_NOMZ
3,971_CD
3,971_CD
Exchange_NN
differences_NN
1,923_CD
761_CD
2,684_CD
At_PIN
December_NN
31_CD
,_,
2004_CD
24,669_CD
6,179_CD
30,848_CD
Investments_NOMZ
in_PIN
joint_JJ
ventures_NN
consist_VPRT
of_PIN
a_DT
50_CD
%_NN
share_NN
of_PIN
the_DT
commercialization_NOMZ
partnership_NN
with_PIN
GlaxoSmithKline_NN
GSK_NN
,_,
through_PIN
which_WDT [PIRE]
the_DT
products_NN
3TC_NN
and_PHC
ZEFFIX_NN
are_VPRT [PASS]
marketed_VBN
in_PIN
Canada_NN
._.
Investments_NOMZ
in_PIN
associates_NN
consist_VPRT
primarily_RB
of_PIN
investments_NOMZ
in_PIN
the_DT
GeneChem_NN
Technologies_NN
Venture_NN
Fund_NN
and_CC
the_DT
GeneChem_NN
Therapeutics_NN
Venture_NN
Fund_NN
together_RB
The_DT
Funds_NN
._.
The_DT
Funds_NN
are_VPRT [PASS]
limited_VBN
partnerships_NN
with_PIN
a_DT
December_NN
31_CD
,_,
year-end_JJ
formed_VBN
under_IN
the_DT
laws_NN
of_PIN
the_DT
Province_NN
of_PIN
Quebec_NN
,_,
Canada_NN
,_,
investing_VBG [PRESP]
in_PIN
healthcare_NN
research_NN
and_PHC
development_NOMZ
companies_NN
,_,
in_PIN
which_WDT [PIRE]
the_DT
Group_NN
owns_VPRT
30_CD
%_NN
and_CC
11_CD
%_NN
of_PIN
the_DT
issued_VBN
shares_NN
respectively_RB
._.
At_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Funds_NN
net_JJ
assets_NN
totalled_VBD
approximately_RB
$_$
71_CD
million_CD
2004_CD
:_:
$_$
107_CD
million_CD
._.
The_DT
Group_NN
is_VPRT [PASS]
involved_VBN
as_IN
a_DT
limited_JJ
partner_NN
and_CC
the_DT
general_JJ
partner_NN
of_PIN
the_DT
Funds_NN
:_:
the_DT
Groups_NN
involvement_NOMZ
in_PIN
the_DT
Funds_NN
dates_NN
from_PIN
between_PIN
1997_CD
and_CC
2000_CD
._.
The_DT
Groups_NN
exposure_NN
to_PIN
loss_NN
as_CONJ
a_NULL
result_NULL
of_PIN
its_PIT
involvement_NOMZ
with_PIN
the_DT
Funds_NN
is_VPRT [PASS]
limited_VBN
to_PIN
the_DT
carrying_VBG
value_NN
of_PIN
the_DT
investment_NOMZ
,_,
$_$
12.7_CD
million_CD
at_PIN
December_NN
31_CD
,_,
2005_CD
2004_CD
:_:
$_$
18.3_CD
million_CD
and_CC
its_PIT
commitment_NOMZ
to_PIN
further_JJ
investment_NOMZ
of_PIN
$_$
1.7_CD
million_CD
2004_CD
:_:
$_$
2.9_CD
million_CD
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
,_,
the_DT
Group_NN
recorded_VBD
an_DT
impairment_NOMZ
of_PIN
$_$
4.0_CD
million_CD
against_PIN
the_DT
investment_NOMZ
in_PIN
the_DT
Funds_NN
following_VBG [WZPRES]
reviews_NN
of_PIN
the_DT
Funds_NN
investment_NOMZ
portfolios_NN
that_TSUB
identified_VBD
other-than-temporary_JJ
declines_NN
in_PIN
the_DT
value_NN
of_PIN
certain_JJ
private_JJ
and_CC
publicly_RB
quoted_VBN
securities_NOMZ
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Funds_NN
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
79_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
80_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
21_CD
Investments_NOMZ
accounted_VBD
for_PIN
using_VBG
equity_NOMZ
method_NN
continued_VBD
Aggregated_JJ
amounts_NN
relating_VBG [WZPRES]
to_PIN
associates_NN
,_,
all_QUAN
of_PIN
which_WDT [PIRE]
are_VPRT [BEMA]
unlisted_PRED
,_,
are_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Assets_NN
112,910_CD
157,727_CD
Liabilities_NOMZ
256 174 112_CD
,654_CD
157,553_CD
Revenue_NN
1,259_CD
1,227_CD
Post_NN
tax_NN
loss_NN
42,387_CD
12,163_CD
Aggregated_NN
amounts_NN
relating_VBG [WZPRES]
to_PIN
the_DT
joint_JJ
venture_NN
are_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Non-current_JJ
assets_NN
Current_JJ
assets_NN
12,848_CD
13,448_CD
Non-current_JJ
liabilities_NOMZ
Current_JJ
liabilities_NOMZ
940_CD
1,090_CD
11,908_CD
12,358_CD
Revenue_NN
32,544_CD
36,060_CD
Operating_GER
expenses_NN
21,894_CD
27,194_CD
10,650_CD
8,866_CD
Taxation_NOMZ
Post_NN
tax_NN
profit_NN
10,650_CD
8,866_CD
22_CD
Investments_NOMZ
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Available-for-sale_JJ
investments_NOMZ
Investments_NOMZ
in_PIN
private_JJ
companies_NN
9,008_CD
2,451_CD
Available-for-sale_JJ
securities_NOMZ
18,131_CD
74,099_CD
27,139_CD
76,550_CD
Trading_GER
investments_NOMZ
Institutional_JJ
and_CC
managed_VBD
cash_NN
funds_NN
6,947_CD
175,186_CD
Commercial_JJ
paper_NN
149,659_CD
6,947_CD
324,845_CD
The_DT
fair_JJ
value_NN
of_PIN
available-for-sale_JJ
investments_NOMZ
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
was_VBD
$_$
27.1_CD
million_CD
2004_CD
:_:
$_$
92.4_CD
million_CD
._.
There_EX
were_VBD
no_SYNE
material_NN
differences_NN
between_PIN
fair_JJ
value_NN
and_PHC
book_NN
value_NN
of_PIN
the_DT
trading_GER
investments_NOMZ
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
._.
2004_CD
:_:
none_INPR
Available-for-sale_JJ
investments_NOMZ
Investments_NOMZ
in_PIN
private_JJ
companies_NN
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
additions_NOMZ
to_PIN
investments_NOMZ
in_PIN
private_JJ
companies_NN
included_VBD
a_DT
$_$
3.9_CD
million_CD
investment_NOMZ
in_PIN
Supernus_NN
Pharmaceuticals_NN
,_,
Inc._NN
less_JJ
than_PIN
10_CD
%_NN
of_PIN
total_JJ
equity_NOMZ
,_,
as_IN
part_NN
consideration_NOMZ
for_PIN
the_DT
sale_NN
of_PIN
the_DT
drug_NN
formulation_NOMZ
business_NOMZ
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
investment_NOMZ
was_VBD [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
reference_NN
to_TO
cash_VB
invested_VBN
in_PIN
Supernus_NN
by_PIN
the_DT
other_JJ
investors_NN
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Group_NN
recorded_VBD
impairments_NOMZ
of_PIN
$_$
1.6_CD
million_CD
against_PIN
its_PIT
investments_NOMZ
in_PIN
private_JJ
companies_NN
based_VBN [WZPAST]
on_PIN
a_DT
decline_NN
in_PIN
the_DT
estimates_NN
of_PIN
their_TPP3
fair_JJ
value_NN
that_TOBJ
the_DT
Group_NN
believes_VPRT [PRIV]
are_VPRT [BEMA]
other-than-temporary_PRED
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Group_NN
recorded_VBD
impairments_NOMZ
of_PIN
$_$
15.9_CD
million_CD
against_PIN
these_DEMO
investments_NOMZ
based_VBN [WZPAST]
on_PIN
changes_NN
in_PIN
the_DT
estimates_NN
of_PIN
their_TPP3
fair_JJ
value_NN
._.
The_DT
changes_NN
in_PIN
fair_JJ
values_NN
which_WDT [WHSUB]
resulted_VBD
in_PIN
the_DT
write-downs_NN
referred_VBD
to_PIN
above_PLACE
were_VBD [PASS]
based_VBN
on_PIN
the_DT
Groups_NN
estimates_NN
,_,
derived_VBN [PASTP]
from_PIN
financial_JJ
and_PHC
other_JJ
publicly_RB
available_JJ
information_NOMZ
such_JJ
as_IN
press_NN
releases_NN
and_CC
recent_JJ
capital_NN
raising_VBG [WZPRES]
activities_NOMZ
._.
80_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
81_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
22_CD
Investments_NOMZ
continued_VBD
Available-for-sale_JJ
securities_NOMZ
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Group_NN
sold_VBD
an_DT
investment_NOMZ
in_PIN
an_DT
available-for-sale_JJ
security_NOMZ
,_,
valued_VBN [PASTP]
at_PIN
$_$
6.0_CD
million_CD
,_,
realizing_VBG [PRIV] [PRESP]
a_DT
gain_NN
on_PIN
the_DT
sale_NN
of_PIN
$_$
3.9_CD
million_CD
._.
Also_RB
during_PIN
the_DT
year_NN
the_DT
Group_NN
received_VBD
$_$
60_CD
million_CD
on_PIN
the_DT
redemption_NOMZ
by_PIN
IDB_NN
of_PIN
its_PIT
subscription_NOMZ
receipts_NN
,_,
for_PIN
no_SYNE
gain_NN
or_CC
loss_NN
on_PIN
sale_NN
._.
During_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Group_NN
sold_VBD
an_DT
investment_NOMZ
in_PIN
an_DT
available-for-sale_JJ
security_NOMZ
,_,
valued_VBN [PASTP]
at_PIN
$_$
11.9_CD
million_CD
,_,
realizing_VBG [PRIV] [PRESP]
a_DT
gain_NN
on_PIN
the_DT
sale_NN
of_PIN
$_$
14.8_CD
million_CD
._.
Other-than-temporary_JJ
impairment_NOMZ
The_DT
Group_NN
recorded_VBD
other-than-temporary_JJ
impairments_NOMZ
of_PIN
$_$
0.4_CD
million_CD
against_PIN
its_PIT
available-for-sale_JJ
securities_NOMZ
in_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
._.
At_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Group_NN
had_VBD
no_SYNE
available_JJ
for_PIN
sale_NN
investments_NOMZ
in_PIN
a_DT
significant_JJ
unrealized_JJ
loss_NN
position_NOMZ
for_PIN
which_WDT [PIRE]
other-than-temporary_JJ
impairments_NOMZ
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
recognized_VBN [PRIV]
._.
24_CD
Trade_NN
and_CC
other_JJ
receivables_NN
2005_CD
2004_CD
Notes_NN
$_$
000_CD
$_$
000_CD
Trade_NN
receivables_NN
339,671_CD
226,812_CD
Less_RB
:_:
provision_NN
for_PIN
impairment_NOMZ
9,747_CD
4,266_CD
Trade_NN
receivables_NN
net_NN
329,924_CD
222,546_CD
Loans_NN
granted_VBD [SUAV]
14_CD
30,000_CD
30,000_CD
Interest_NN
receivable_NN
1,491_CD
394_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
30,245_CD
32,794_CD
Other_JJ
debtors_NN
29,601_CD
13,496_CD
Cash_NN
held_VBN [PRIV] [WZPAST]
in_PIN
escrow_NN
14_CD
30,000_CD
SERP_NN
29_CD
8,852_CD
9,482_CD
Total_JJ
430,113_CD
338,712_CD
Less_RB
:_:
non-current_JJ
portion_NOMZ
42,907_CD
38,895_CD
Current_JJ
portion_NOMZ
387,206_CD
299,817_CD
Further_JJ
details_NN
of_PIN
the_DT
Supplemental_NN
Executive_NN
Retirement_NOMZ
Plan_NN
SERP_NN
asset_NN
are_VPRT [PASS]
provided_VBN
in_PIN
Note_NN
29_CD
._.
The_DT
amount_NN
shown_VBN [PRIV]
above_PLACE
is_VPRT [BEMA]
the_DT
cash_NN
at_PIN
bank_NN
and_CC
non-current_JJ
marketable_JJ
securities_NOMZ
held_VBN [PRIV] [WZPAST]
in_PIN
a_DT
Rabbi_NN
Trust_NN
._.
The_DT
legal_JJ
form_NN
of_PIN
the_DT
trust_NN
is_VPRT [BEMA]
such_OSUB
that_NULL
the_DT
assets_NN
held_VBD [PRIV]
to_TO
cover_VB
the_DT
pension_NN
liabilities_NOMZ
are_VPRT [BEMA]
available_PRED
to_PIN
the_DT
general_JJ
creditors_NN
of_PIN
the_DT
Group_NN
on_PIN
winding_VBG
up_RP
._.
Accordingly_RB
,_,
the_DT
assets_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
trust_NN
are_VPRT
not_XX0
plan_VB
assets_NN
and_CC
are_VPRT [PASS]
recorded_VBN
on_PIN
the_DT
balance_NN
sheet_NN
._.
A_DT
related_JJ
liability_NOMZ
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
Note_NN
27_CD
._.
The_DT
average_JJ
credit_NN
period_NN
taken_VBN [WZPAST]
on_PIN
sales_NN
of_PIN
goods_NN
is_VPRT [BEMA]
37_CD
days_NN
._.
An_DT
allowance_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
for_PIN
doubtful_JJ
accounts_NN
and_PHC
sales_NN
discounts_NN
of_PIN
$_$
9.7_CD
Million_NN
2004_CD
:_:
$_$
4.3_CD
million_CD
._.
This_DEMO
allowance_NN
has_VPRT [PEAS]
been_VBN [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
specific_JJ
review_NN
of_PIN
outstanding_JJ
receivables_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
Directors_NN
consider_VPRT [PRIV]
that_THVC
the_DT
carrying_VBG
amount_NN
of_PIN
trade_NN
and_CC
other_JJ
receivables_NN
approximates_VPRT
to_PIN
their_TPP3
fair_JJ
value_NN
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
81_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
82_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
25_CD
Borrowings_GER
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Non-current_JJ
2_CD
%_NN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
2011 116 116_CD
Finance_NN
lease_NN
liabilities_NOMZ
4,588_CD
4,126_CD
4,704_CD
4,242_CD
Current_JJ
Finance_NN
lease_NN
liabilities_NOMZ
2,667_CD
2,420_CD
Total_JJ
borrowings_GER
7,371_CD
6,662_CD
All_QUAN
borrowings_GER
in_PIN
both_DT
the_DT
current_JJ
and_PHC
previous_JJ
years_NN
are_VPRT [PASS]
denominated_VBN
in_PIN
US_FPP1
Dollars_NN
._.
The_DT
Directors_NN
consider_VPRT [PRIV]
that_THVC
the_DT
carrying_VBG
amount_NN
of_PIN
borrowing_VBG
approximates_VPRT
their_TPP3
fair_JJ
value_NN
._.
Subject_JJ
to_PIN
the_DT
conditions_NOMZ
below_PLACE
,_,
non-current_JJ
borrowings_GER
are_VPRT [BEMA]
repayable_PRED
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
Notes_NN
$_$
000_CD
$_$
000_CD
Convertible_JJ
loan_NN
notes_NN
:_:
i_FPP1
After_IN
five_CD
years_NN
116_CD
116_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
:_:
ii_FW
Between_PIN
one_CD
and_CC
two_CD
years_NN
2,667_CD
2,420_CD
Between_PIN
two_CD
and_CC
three_CD
years_NN
1,921_CD
1,706_CD
4,588_CD
4,126_CD
4,704_CD
4,242_CD
i_FPP1
2_CD
%_NN
guaranteed_VBN [PUBV]
convertible_JJ
loan_NN
notes_NN
2011_CD
The_DT
guaranteed_VBN [PUBV]
convertible_JJ
notes_NN
due_JJ
2011_CD
,_,
were_VBD [PASS]
issued_VBN
in_PIN
August_NN
2001_CD
by_PIN
Shire_NN
Finance_NN
Limited_NN
the_DT
Issuer_NN
,_,
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
the_DT
Company_NN
._.
The_DT
convertible_JJ
notes_NN
were_VBD [BYPA]
guaranteed_VBN [PUBV]
by_PIN
Shire_NN
and_CC
were_VBD [BEMA]
convertible_PRED
into_PIN
redeemable_JJ
preference_NN
shares_NN
of_PIN
the_DT
Issuer_NN
which_WDT [WHOBJ]
upon_PIN
issuance_NN
will_PRMD
be_VB [SPAU] [PASS]
immediately_TIME
exchanged_VBN
for_PIN
:_:
i_FPP1
Shire_FW
ordinary_JJ
shares_NN
,_,
ii_FW
Shire_FW
ADSs_FW
or_CC
iii_FW
at_PIN
the_DT
Issuers_NN
option_NOMZ
,_,
a_DT
cash_NN
amount_NN
based_VBN [WZPAST]
upon_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
volume-weighted_JJ
average_NN
prices_NN
of_PIN
Shires_NN
ordinary_JJ
shares_NN
on_PIN
the_DT
fourth_JJ
through_PIN
eighth_JJ
business_NOMZ
days_NN
following_VBG [WZPRES]
conversion_NN
._.
At_PIN
the_DT
choice_NN
of_PIN
investors_NN
,_,
each_QUAN
$_$
1,000_CD
of_PIN
nominal_JJ
value_NN
notes_NN
was_VBD [BEMA]
convertible_PRED
into_PIN
49.62_CD
Shire_NN
ordinary_JJ
shares_NN
subject_JJ
to_PIN
adjustment_NOMZ
or_CC
16.54_CD
Shire_NN
ADSs_NN
subject_NN
to_PIN
adjustment_NOMZ
at_PIN
any_QUAN
time_NN
up_RP
to_PIN
August_NN
21_CD
,_,
2011_CD
._.
Alternatively_CONJ
,_,
investors_NN
had_VBD
the_DT
right_NN
to_TO
receive_VB
repayment_NOMZ
of_PIN
the_DT
nominal_JJ
principal_NN
in_PIN
cash_NN
either_CC
at_PIN
the_DT
maturity_NOMZ
date_NN
of_PIN
August_NN
21_CD
,_,
2011_CD
or_CC
by_PIN
exercising_VBG
a_DT
put_NN
option_NOMZ
on_PIN
any_QUAN
of_PIN
the_DT
three_CD
put_VBD
dates_NN
being_VBG [WZPRES]
August_NN
21_CD
,_,
2004_CD
,_,
August_NN
21_CD
,_,
2006_CD
and_CC
August_NN
21_CD
,_,
2008_CD
._.
On_PIN
August_NN
21_CD
,_,
2004_CD
,_,
upon_PIN
exercise_NN
of_PIN
the_DT
put_NN
option_NOMZ
by_PIN
substantially_RB
all_QUAN
of_PIN
the_DT
convertible_JJ
note_NN
holders_NN
,_,
the_DT
Group_NN
redeemed_VBD
$_$
370.1_CD
million_CD
at_PIN
par_NN
,_,
from_PIN
available_JJ
funds_NN
._.
The_DT
obligation_NOMZ
to_TO
pay_VB
the_DT
remaining_VBG
$_$
116,000_CD
of_PIN
the_DT
convertible_JJ
loan_NN
notes_NN
outstanding_JJ
as_IN
of_PIN
December_NN
31_CD
,_,
2005_CD
is_VPRT [BEMA]
due_PRED
in_PIN
2011_CD
,_,
subject_JJ
to_PIN
the_DT
exercise_NN
of_PIN
the_DT
put_NN
option_NOMZ
referred_VBD
to_PIN
above_PLACE
._.
ii_FW
Finance_NN
leases_VPRT
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Finance_NN
lease_NN
liabilities_NOMZ
minimum_JJ
lease_NN
payments_NOMZ
:_:
Not_XX0
later_TIME
than_PIN
1_CD
year_NN
2,933_CD
2,588_CD
Later_TIME
than_PIN
1_CD
year_NN
and_CC
not_XX0
later_TIME
than_PIN
5_CD
years_NN
5,046_CD
4,806_CD
Later_TIME
than_PIN
5_CD
years_NN
7,979_CD
7,394_CD
Future_NN
finance_NN
charges_NN
on_PIN
finance_NN
leases_NN
724_CD
848_CD
Present_JJ
value_NN
of_PIN
finance_NN
lease_NN
liabilities_NOMZ
7,255_CD
6,546_CD
The_DT
Groups_NN
finance_NN
leases_NN
are_VPRT [BEMA]
in_PIN
respect_NN
of_PIN
motor_NN
vehicles_NN
,_,
and_ANDC
do_VB
not_XX0
impose_VB
any_QUAN
significant_JJ
restrictions_NOMZ
on_PIN
the_DT
Group_NN
._.
82_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
83_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
26_CD
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
IAS_NN
32_CD
39_CD
disclosure_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
The_DT
Group_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
movements_NOMZ
in_PIN
foreign_JJ
exchange_NN
rates_NN
against_PIN
the_DT
US_FPP1
Dollar_NN
for_PIN
trading_VBG
transactions_NOMZ
and_CC
the_DT
translation_NOMZ
of_PIN
net_JJ
assets_NN
,_,
liabilities_NOMZ
and_PHC
earnings_GER
of_PIN
non-US_FPP1
subsidiaries_NN
._.
The_DT
main_JJ
trading_GER
currencies_NN
of_PIN
the_DT
Group_NN
are_VPRT [BEMA]
the_DT
US_FPP1
Dollar_NN
,_,
the_DT
Canadian_JJ
Dollar_NN
,_,
Pounds_NN
Sterling_GER
,_,
the_DT
Euro_NN
and_PHC
Swedish_NN
Krona_NN
._.
The_DT
exposure_NN
to_PIN
foreign_JJ
exchange_NN
risk_NN
is_VPRT [PASS]
managed_VBN
and_PHC
monitored_VBN
by_PIN
the_DT
treasury_NN
function_NOMZ
._.
At_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Group_NN
had_VBD
five_CD
outstanding_JJ
forward_RB
foreign_JJ
exchange_NN
contracts_NN
with_PIN
a_DT
total_JJ
principal_JJ
amount_NN
of_PIN
$_$
206_CD
million_CD
equivalent_JJ
to_TO
manage_VB
the_DT
currency_NN
risk_NN
associated_VBN [WZPAST]
with_PIN
inter-company_JJ
loans_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
fair_JJ
value_NN
of_PIN
these_DEMO
currency_NN
derivatives_NN
showed_VBD [PRIV]
an_DT
unrealized_JJ
gain_NN
of_PIN
$_$
2.6_CD
million_CD
._.
The_DT
change_NN
in_PIN
fair_JJ
value_NN
has_VPRT [PEAS]
been_VBN [PASS]
taken_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
in_PIN
the_DT
year_NN
._.
FRS_NN
13_CD
disclosures_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2004_CD
The_DT
Financial_NN
risk_NN
management_NOMZ
review_NN
in_PIN
Note_NN
4_CD
provides_VPRT
an_DT
explanation_NOMZ
of_PIN
the_DT
role_NN
that_TOBJ
financial_JJ
instruments_NOMZ
have_VPRT [PEAS]
had_VBN
during_PIN
the_DT
prior_JJ
year_NN
._.
The_DT
explanation_NOMZ
summarizes_VPRT
the_DT
objectives_NN
and_PHC
policies_NN
for_PIN
holding_VBG [PRIV]
or_CC
issuing_VBG
financial_JJ
instruments_NOMZ
and_CC
similar_JJ
contracts_NN
,_,
and_ANDC
the_DT
strategies_NN
for_PIN
achieving_VBG
those_DEMO
objectives_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
followed_VBN
during_PIN
the_DT
year_NN
._.
Interest_NN
rate_NN
profile_NN
The_DT
currency_NN
and_PHC
interest_NN
rate_NN
profile_NN
of_PIN
the_DT
Groups_NN
cash_NN
,_,
cash_NN
equivalents_NN
,_,
restricted_VBN
cash_NN
and_CC
current_JJ
financial_JJ
assets_NN
excluding_VBG [WZPRES]
short-term_JJ
debtors_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2004_CD
are_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
Weighted_NN
Weighted_NN
Weighted_NN
average_JJ
average_JJ
average_JJ
interest_NN
interest_NN
interest_NN
Financial_NN
Financial_NN
period_NN
rate_NN
rate_NN
instruments_NOMZ
instruments_NOMZ
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Floating_VBG [WZPRES]
rate_NN
Fixed_VBN
rate_NN
Total_JJ
Days_NN
%_NN
%_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
US_FPP1
Dollars_NN
678_CD
2.01_CD
2.05_CD
1,263,166_CD
42,712_CD
1,305,878_CD
Pounds_NN
Sterling_GER
4.11_CD
37,789_CD
37,789_CD
Euro_NN
0.30_CD
16,803_CD
16,803_CD
Canadian_JJ
Dollars_NN
2.52_CD
97,461_CD
97,461_CD
Other_JJ
0.25_CD
18_CD
18_CD
1,415,237_CD
42,712_CD
1,457,949_CD
The_DT
benchmark_NN
rates_NN
for_PIN
floating_VBG
rate_NN
assets_NN
are_VPRT
primarily_RB
:_:
US_FPP1
Dollar_NN
seven-day_JJ
,_,
one-month_JJ
and_PHC
three-month_JJ
London_NN
Interbank_NN
Bid_NN
Rate_NN
LIBID_NN
,_,
and_ANDC
Pounds_NN
Sterling_GER
seven-day_JJ
LIBID_NN
._.
The_DT
interest_NN
rate_NN
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
at_PIN
December_NN
31_CD
,_,
2004_CD
was_VBD
as_IN
follows_VPRT
:_:
Floating_VBG
Fixed_NN
Interest_NN
free_JJ
Total_JJ
Currency_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
US_FPP1
Dollars_NN
convertible_JJ
debt_NN
116_CD
116_CD
finance_NN
leases_NN
6,546_CD
6,546_CD
6,662_CD
6,662_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
83_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
84_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
26_CD
Derivatives_NN
and_CC
other_JJ
financial_JJ
instruments_NOMZ
continued_VBD
Currency_NN
exposures_NN
The_DT
Group_NN
aims_VPRT
to_TO
minimize_VB
currency_NN
related_VBN
exposures_NN
arising_VBG [WZPRES]
from_PIN
its_PIT
net_JJ
investments_NOMZ
overseas_PLACE
in_CONJ
other_NULL
words_NULL
,_,
its_PIT
structural_JJ
currency_NN
exposures_NN
._.
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
from_PIN
structural_JJ
currency_NN
exposures_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
income_NN
._.
The_DT
table_NN
below_PLACE
shows_NN
the_DT
Groups_NN
transactional_JJ
or_CC
non-structural_JJ
currency_NN
exposures_NN
that_TSUB
give_VPRT
rise_VB
to_PIN
the_DT
net_JJ
currency_NN
gains_NN
and_PHC
losses_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Such_JJ
exposures_NN
comprise_VPRT
the_DT
monetary_JJ
assets_NN
and_CC
monetary_JJ
liabilities_NOMZ
of_PIN
the_DT
Group_NN
that_TSUB
are_VPRT [PASS]
not_XX0
denominated_VBN
in_PIN
the_DT
functional_JJ
currency_NN
of_PIN
the_DT
operating_VBG
unit_NN
involved_VBN
,_,
other_JJ
than_PIN
certain_JJ
non-US_FPP1
Dollar_NN
borrowings_GER
treated_VBN
as_IN
hedges_NN
of_PIN
net_JJ
investments_NOMZ
in_PIN
overseas_PLACE
operations_NOMZ
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2004_CD
these_DEMO
exposures_NN
were_VBD
as_IN
follows_VPRT
:_:
Net_JJ
foreign_JJ
currency_NN
monetary_JJ
assets_NN
liabilities_NOMZ
US_FPP1
Pounds_NN
Canadian_NN
Dollars_NN
Sterling_GER
Euro_NN
Dollars_NN
Other_JJ
Total_NN
Functional_NN
currency_NN
of_PIN
Group_NN
operation_NOMZ
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
US_FPP1
Dollars_NN
341,790_CD
38,156_CD
67_CD
4_CD
303,563_CD
Pounds_NN
Sterling_GER
907,197_CD
21,801_CD
2_CD
286_CD
885,112_CD
Euro_NN
516_CD
1,004_CD
1,520_CD
Canadian_JJ
Dollars_NN
298,264_CD
182,924_CD
38_CD
481,226_CD
609,449_CD
523,710_CD
16,317_CD
69 282 101_CD
,843_CD
Borrowing_GER
facilities_NOMZ
The_DT
Group_NN
had_VBD
no_SYNE
undrawn_JJ
committed_JJ
borrowing_GER
facilities_NOMZ
at_PIN
December_NN
31_CD
,_,
2004_CD
._.
Fair_NN
values_VPRT
The_DT
quoted_VBN
market_NN
price_NN
of_PIN
the_DT
convertible_JJ
loan_NN
stock_NN
2011_CD
as_RB
at_PIN
December_NN
31_CD
,_,
2004_CD
was_VBD
$_$
100.53_CD
compared_VBN
with_PIN
an_DT
issue_NN
price_NN
of_PIN
$_$
100_CD
._.
If_COND
the_DT
remaining_VBG
loan_NN
is_VPRT [PASS]
not_XX0
converted_VBN
into_PIN
equity_NOMZ
,_,
it_PIT
would_PRMD
be_VB [BEMA]
repayable_PRED
at_PIN
$_$
100_CD
per_PIN
note_NN
._.
The_DT
total_JJ
fair_JJ
value_NN
of_PIN
the_DT
debt_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2004_CD
,_,
based_VBN [PASTP]
on_PIN
the_DT
above_PLACE
quoted_VBN
market_NN
price_NN
,_,
was_VBD
$_$
116,000_CD
compared_VBN
to_PIN
a_DT
carrying_VBG
value_NN
of_PIN
$_$
115,000_CD
._.
In_CONJ
addition_NULL
at_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
fair_JJ
value_NN
of_PIN
listed_VBN
financial_JJ
assets_NN
,_,
based_VBN [PASTP]
on_PIN
their_TPP3
quoted_VBN
market_NN
price_NN
,_,
was_VBD
$_$
16_CD
million_CD
above_PLACE
carrying_VBG
value_NN
._.
There_EX
were_VBD
no_SYNE
other_JJ
material_NN
differences_NN
between_PIN
the_DT
carrying_VBG
values_NN
and_CC
fair_JJ
values_NN
of_PIN
all_QUAN
other_JJ
Group_NN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
at_PIN
December_NN
31_CD
,_,
2004_CD
._.
Gains_NN
and_PHC
losses_NN
on_PIN
foreign_JJ
exchange_NN
contracts_NN
As_IN
at_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
Group_NN
had_VBD
two_CD
outstanding_JJ
forward_RB
foreign_JJ
exchange_NN
contracts_NN
with_PIN
a_DT
total_JJ
principal_JJ
amount_NN
of_PIN
$_$
39_CD
million_CD
used_VBN
to_TO
manage_VB
the_DT
risk_NN
associated_VBN [WZPAST]
with_PIN
holding_VBG [PRIV]
Canadian_JJ
Dollar_NN
financial_JJ
assets_NN
._.
There_EX
were_VBD
no_SYNE
material_NN
gains_NN
or_CC
losses_NN
on_PIN
these_DEMO
contracts_NN
._.
27_CD
Trade_NN
and_CC
other_JJ
payables_NN
2005_CD
2004_CD
Notes_NN
$_$
000_CD
$_$
000_CD
Trade_NN
payables_NN
70,958_CD
35,009_CD
Other_JJ
creditors_NN
14,817_CD
27,383_CD
Accruals_NN
and_CC
deferred_JJ
income_NN
363,395_CD
289,443_CD
SERP_NN
29_CD
4,591_CD
5,495_CD
Total_JJ
453,761_CD
357,330_CD
Less_RB
:_:
non-current_JJ
portion_NOMZ
18,036_CD
12,963_CD
Current_JJ
portion_NOMZ
435,725_CD
344,367_CD
Trade_NN
payables_NN
comprise_VPRT
amounts_NN
outstanding_JJ
for_PIN
trade_NN
purchases_NN
and_CC
ongoing_JJ
costs_NN
._.
The_DT
average_JJ
credit_NN
period_NN
taken_VBN [WZPAST]
for_PIN
trade_NN
payables_NN
is_VPRT [BEMA]
30_CD
days_NN
2004:18_CD
days_NN
._.
The_DT
Directors_NN
consider_VPRT [PRIV]
that_THVC
the_DT
carrying_VBG
amount_NN
of_PIN
trade_NN
and_CC
other_JJ
payables_NN
approximates_VPRT
to_PIN
their_TPP3
fair_JJ
value_NN
._.
Accruals_NN
and_CC
deferred_JJ
income_NN
includes_VPRT
accrued_VBN
rebates_NN
and_PHC
sales_NN
return_NN
reserves_NN
,_,
accrued_VBN
bonuses_NN
and_CC
other_JJ
accrued_VBN
expenses_NN
._.
84_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
85_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
28_CD
Provisions_NN
for_PIN
other_JJ
liabilities_NOMZ
and_PHC
charges_NN
Reorganization_NOMZ
IDB_NN
Loan_NN
Other_JJ
Total_JJ
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
January_NN
1_CD
,_,
2005_CD
12,960_CD
43,161_CD
15,208_CD
71,329_CD
Charge_NN
for_PIN
the_DT
year_NN
2,299_CD
18,121_CD
20,420_CD
Acquired_VBN
3,310_CD
3,310_CD
Reversed_VBN
unutilised_JJ
5,846_CD
5,846_CD
Utilised_NN
7,460_CD
43,161_CD
4,668_CD
55,289_CD
December_NN
31_CD
,_,
2005_CD
7,799_CD
26,125_CD
33,924_CD
Less_RB
:_:
Non-current_JJ
portion_NOMZ
25,401_CD
Current_JJ
portion_NOMZ
8,523_CD
Reorganization_NOMZ
IDB_NN
Loan_NN
Other_JJ
Total_JJ
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
January_NN
1_CD
,_,
2004_CD
8,887_CD
8,887_CD
Charge_NN
for_PIN
the_DT
year_NN
12,960_CD
43,161_CD
10,165_CD
66,286_CD
Reversed_VBN
unutilised_JJ
727_CD
727_CD
Utilised_VBN
3,117_CD
3,117_CD
December_NN
31_CD
,_,
2004_CD
12,960_CD
43,161_CD
15,208_CD
71,329_CD
Less_RB
:_:
Non-current_JJ
portion_NOMZ
26,232_CD
Current_JJ
portion_NOMZ
45,097_CD
Reorganization_NOMZ
The_NN
Group_NN
began_VBD
a_DT
consolidation_NOMZ
of_PIN
its_PIT
North_PLACE
American_JJ
sites_NN
in_PIN
2004_CD
see_VPRT [PRIV]
Note_VB [PRIV]
13_CD
._.
The_DT
costs_NN
recognized_VBN [PRIV]
as_IN
a_DT
provision_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
consist_VPRT
of_PIN
employee_NN
severance_NN
and_PHC
relocation_NOMZ
costs_NN
of_PIN
$_$
0.6_CD
million_CD
that_DEMP
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
in_PIN
2006_CD
and_CC
costs_NN
of_PIN
duplicate_VPRT
facilities_NOMZ
$_$
7.2_CD
million_CD
that_DEMP
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
over_IN
the_DT
remaining_VBG
life_NN
of_PIN
the_DT
relevant_JJ
leases_NN
,_,
which_WDT [SERE]
all_QUAN
expire_VPRT
before_IN
October_NN
31_CD
,_,
2012_CD
._.
Other_JJ
Other_JJ
provisions_NN
relate_VPRT
to_PIN
long-term_JJ
bonuses_NN
,_,
provisions_NN
for_PIN
guarantees_NN
and_PHC
insurance_NN
,_,
and_ANDC
onerous_JJ
lease_NN
provisions_NN
in_PIN
relation_NOMZ
to_TO
vacated_VBN
properties_NN
._.
Provisions_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
relation_NOMZ
to_PIN
long-term_JJ
bonuses_NN
total_VPRT
$_$
9.9_CD
million_CD
,_,
of_PIN
which_WDT [PIRE]
$_$
5.1_CD
million_CD
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
paid_VBN
in_PIN
2006_CD
and_CC
the_DT
remainder_NN
on_PIN
the_DT
maturity_NOMZ
of_PIN
the_DT
underlying_VBG
schemes_NN
over_IN
the_DT
next_JJ
three_CD
years_NN
._.
Provisions_NN
for_PIN
insurance_NN
and_PHC
guarantees_NN
totalling_VBG [WZPRES]
$_$
12.9_CD
million_CD
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
settled_VBN
between_PIN
one_CD
and_CC
three_CD
years_NN
._.
Onerous_JJ
lease_NN
provisions_NN
of_PIN
$_$
3.3_CD
million_CD
will_PRMD
be_VB [PASS]
paid_VBN
over_IN
the_DT
next_JJ
three_CD
years_NN
,_,
the_DT
remaining_VBG
life_NN
of_PIN
the_DT
relevant_JJ
leases_NN
._.
29_CD
Retirement_NOMZ
obligations_NOMZ
The_DT
Group_NN
has_VPRT
a_DT
number_NN
of_PIN
defined_VBN
contribution_NOMZ
retirement_NOMZ
plans_NN
that_TSUB
together_RB
cover_VPRT
substantially_RB
all_QUAN
employees_NN
._.
The_DT
Groups_NN
contribution_NOMZ
is_VPRT [PASS]
fixed_VBN
as_IN
a_DT
set_VBN
percentage_NN
of_PIN
employees_NN
base_JJ
salary_NN
._.
The_DT
pension_NN
cost_NN
charge_NN
for_PIN
the_DT
defined_VBN
contribution_NOMZ
schemes_NN
for_PIN
the_DT
year_NN
was_VBD
$_$
14.1_CD
million_CD
2004_CD
:_:
$_$
9_CD
million_CD
._.
The_DT
closing_GER
creditor_NN
in_PIN
respect_NN
of_PIN
pension_NN
premiums_NN
at_PIN
December_NN
31_CD
,_,
2005_CD
is_VPRT
$_$
1.76_CD
million_CD
2004_CD
:_:
$_$
0.23_CD
million_CD
._.
The_DT
Group_NN
has_VPRT
two_CD
Supplemental_NN
Executive_NN
Retirement_NOMZ
Plans_NN
SERPs_NN
,_,
which_WDT [SERE]
are_VPRT [PASS]
defined_VBN
benefit_NN
plans_NN
._.
The_DT
Roberts_NN
SERP_NN
is_VPRT [BEMA]
for_PIN
US_FPP1
employees_NN
of_PIN
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
Roberts_NN
who_WP [WHSUB]
met_VBD
certain_JJ
age_NN
and_PHC
service_NN
requirements_NOMZ
._.
The_DT
Group_NN
acquired_VBD
Roberts_NN
in_PIN
1999_CD
,_,
and_ANDC
the_DT
plan_NN
was_VBD [PASS]
discontinued_VBN
in_PIN
2000_CD
:_:
there_EX
were_VBD
no_SYNE
contributions_NOMZ
payable_JJ
in_PIN
respect_NN
of_PIN
2005_CD
._.
The_DT
Group_NN
paid_VBD
a_DT
lump_NN
sum_NN
of_PIN
$_$
18_CD
million_CD
into_PIN
the_DT
Roberts_NN
SERP_NN
,_,
which_WDT [SERE]
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
fair_JJ
value_NN
adjustment_NOMZ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Roberts_NN
Pharmaceutical_NN
Corporation_NOMZ
to_TO
make_VB
good_JJ
the_DT
deficit_NN
on_PIN
this_DEMO
scheme_NN
at_PIN
the_DT
time_NN
of_PIN
acquisition_NOMZ
._.
This_DEMO
lump_NN
sum_NN
payment_NOMZ
has_VPRT [PEAS]
led_VBN
to_PIN
the_DT
Group_NN
having_VBG [WZPRES]
no_SYNE
future_JJ
liability_NOMZ
under_IN
the_DT
SERP_NN
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [PASS]
closed_VBN
to_PIN
new_JJ
members_NN
with_PIN
contributions_NOMZ
no_RB
longer_RB
payable_JJ
by_PIN
existing_VBG
members_NN
._.
Assets_NN
are_VPRT [PASS]
set_VBN
aside_RB
to_TO
fund_VB
these_DEMO
benefits_NN
in_PIN
a_DT
Rabbi_NN
Trust_NN
._.
Accordingly_RB
,_,
the_DT
assets_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
trust_NN
are_VPRT
not_XX0
plan_VB
assets_NN
as_IN
defined_VBN
by_PIN
IAS_NN
19_CD
,_,
Employee_NN
Benefits_NN
,_,
and_ANDC
are_VPRT [PASS]
recorded_VBN
on_PIN
the_DT
balance_NN
sheet_NN
see_VPRT [PRIV]
Note_NN
24_CD
._.
The_DT
Shire_NN
SERP_NN
defined_VBD
benefit_NN
scheme_NN
is_VPRT [BEMA]
an_DT
unfunded_JJ
arrangement_NOMZ
:_:
the_DT
benefits_NN
are_VPRT [BEMA]
payable_PRED
to_PIN
certain_JJ
senior_JJ
US_FPP1
employees_NN
as_IN
lump_NN
sums_NN
on_PIN
leaving_VBG
the_DT
Groups_NN
employment_NOMZ
or_CC
earlier_TIME
due_JJ
to_PIN
death_NN
,_,
disability_NOMZ
or_CC
termination_NOMZ
._.
The_DT
amount_NN
of_PIN
benefit_NN
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
value_NN
of_PIN
notional_JJ
contributions_NOMZ
increased_VBN [WZPAST]
with_PIN
earned_VBN
investment_NOMZ
returns_NN
as_IN
if_COND
they_TPP3
were_VBD [PASS]
invested_VBN
in_PIN
investments_NOMZ
of_PIN
the_DT
employees_NN
choice_NN
._.
The_DT
entire_JJ
benefit_NN
liability_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
on_PIN
the_DT
balance_NN
sheet_NN
._.
The_DT
liabilities_NOMZ
of_PIN
the_DT
two_CD
SERPs_NN
totalling_VBG [WZPRES]
$_$
4.6_CD
million_CD
at_PIN
December_NN
31_CD
,_,
2005_CD
2004_CD
:_:
$_$
5.5_CD
million_CD
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
Note_NN
27_CD
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
85_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
86_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
30_CD
Share_NN
capital_NN
2005 2005 2004 2004_CD
Number_NN
Number_NN
Ordinary_NN
shares_NN
000_CD
$_$
000_CD
000_CD
$_$
000_CD
Authorised_VBN
At_PIN
January_NN
1_CD
,_,
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
800,000_CD
76,796_CD
800,000_CD
76,796_CD
At_PIN
December_NN
31_CD
,_,
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
18,333,006_CD
1,573,705_CD
800,000_CD
76,796_CD
Allotted_NN
,_,
issued_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
January_NN
1_CD
,_,
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
484,916_CD
36,083_CD
477,895_CD
35,540_CD
Effect_NN
of_PIN
scheme_NN
of_PIN
arrangement_NOMZ
and_PHC
capital_NN
reduction_NOMZ
5,713_CD
Restated_VBN
position_NOMZ
at_PIN
January_NN
1_CD
484,916_CD
41,796_CD
477,895_CD
35,540_CD
Issued_VBN
on_PIN
exercise_NN
of_PIN
options_NOMZ
for_PIN
cash_NN
consideration_NOMZ
4,702_CD
405_CD
2,098_CD
191_CD
Issued_VBN
on_PIN
exchange_NN
of_PIN
exchangeable_JJ
shares_NN
6,116_CD
527_CD
4,839_CD
344_CD
Issue_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
84_CD
8_CD
At_PIN
December_NN
31_CD
,_,
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
495,734_CD
42,728_CD
484,916_CD
36,083_CD
2005 2005 2004 2004_CD
Number_NN
Number_NN
Special_JJ
ordinary_JJ
voting_NN
shares_NN
000_CD
$_$
000_CD
000_CD
$_$
000_CD
Authorised_VBN
At_PIN
January_NN
1_CD
special_JJ
ordinary_JJ
voting_NN
shares_NN
of_PIN
0.00001_CD
p_NN
17,500_CD
17,500_CD
At_PIN
December_NN
31_CD
special_JJ
ordinary_JJ
voting_NN
shares_NN
of_PIN
0.00001_CD
p_NN
10,000_CD
17,500_CD
Allotted_NN
,_,
issued_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
January_NN
1_CD
4,226_CD
195,830_CD
5,840_CD
270,667_CD
Cancelled_VBN
following_VBG
an_DT
exchange_NN
of_PIN
exchangeable_JJ
shares_NN
for_PIN
ordinary_JJ
shares_NN
2,038_CD
94,582_CD
1,614_CD
74,837_CD
At_PIN
December_NN
31_CD
,_,
2,188_CD
101,248_CD
4,226_CD
195,830_CD
Authorised_JJ
share_NN
capital_NN
The_DT
authorised_JJ
stock_NN
of_PIN
Shire_NN
plc_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
was_VBD [BEMA]
18,333,006,420_CD
ordinary_JJ
shares_NN
,_,
10,000,000_CD
special_JJ
voting_NN
shares_NN
,_,
50,000_CD
nonvoting_JJ
preference_NN
shares_NN
and_CC
two_CD
deferred_JJ
ordinary_JJ
shares_NN
._.
The_DT
special_JJ
voting_NN
shares_NN
are_VPRT [BYPA]
held_VBN [PRIV]
by_PIN
a_DT
Voting_GER
Trustee_NN
,_,
providing_VBG [PRESP]
the_DT
holders_NN
of_PIN
exchangeable_JJ
shares_NN
in_PIN
Shire_NN
Acquisition_NOMZ
,_,
Inc._NN
with_PIN
as_RB
nearly_DWNT
as_IN
practicable_JJ
voting_NN
rights_NN
equivalent_NN
to_PIN
those_DEMP
attached_VBN
to_PIN
Shires_NN
ordinary_JJ
shares_NN
._.
The_DT
non-voting_JJ
preference_NN
shares_NN
and_CC
deferred_VBN
ordinary_JJ
shares_NN
were_VBD [PASS]
authorised_VBN
and_PHC
issued_VBN
for_PIN
the_DT
purpose_NN
of_PIN
the_DT
Scheme_NN
of_PIN
Arrangement_NOMZ
only_DWNT
and_CC
will_PRMD
be_VB [PASS]
redeemed_VBN
in_PIN
2006_CD
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
authorised_JJ
common_JJ
stock_NN
of_PIN
the_DT
Company_NN
was_VBD [BEMA]
40_CD
million_CD
$_$
76.8_CD
million_CD
divided_VBN
into_PIN
799,999,965_CD
ordinary_JJ
shares_NN
of_PIN
5p_JJ
each_QUAN
and_CC
17,500,000_CD
Special_JJ
Ordinary_NN
Voting_GER
Shares_NN
of_PIN
0.00001_CD
p_NN
each_QUAN
._.
Issue_NN
of_PIN
ordinary_JJ
shares_NN
During_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
the_DT
Company_NN
allotted_VBD
6,116,049_CD
ordinary_JJ
shares_NN
with_PIN
a_DT
nominal_JJ
value_NN
of_PIN
305,802_CD
$_$
527,000_CD
on_PIN
the_DT
exchange_NN
of_PIN
exchangeable_JJ
shares_NN
,_,
which_WDT [SERE]
were_VBD [PASS]
issued_VBN
following_VBG
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
in_PIN
2001_CD
._.
These_DEMO
shares_NN
were_VBD [PASS]
issued_VBN
at_PIN
a_DT
premium_NN
of_PIN
66.2_CD
million_CD
$_$
94.1_CD
million_CD
._.
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
and_PHC
cancellation_NOMZ
of_PIN
special_JJ
ordinary_JJ
voting_NN
shares_NN
The_DT
Company_NN
exchanged_VBD
2,038,683_CD
exchangeable_JJ
shares_NN
and_CC
canceled_VBD
the_DT
equivalent_JJ
number_NN
of_PIN
special_JJ
ordinary_JJ
voting_NN
shares_NN
during_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
._.
Each_QUAN
exchangeable_JJ
share_NN
is_VPRT [BEMA]
capable_PRED
of_PIN
being_VBG [PASS]
exchanged_VBN
for_PIN
ordinary_JJ
shares_NN
or_CC
ADSs_NN
,_,
at_PIN
a_DT
rate_NN
of_PIN
one_CD
exchangeable_JJ
share_NN
for_PIN
three_CD
ordinary_JJ
shares_NN
or_CC
one_CD
exchangeable_JJ
share_NN
for_PIN
one_CD
ADS_NN
,_,
at_PIN
any_QUAN
time_NN
at_PIN
the_DT
request_NN
of_PIN
the_DT
holder_NN
._.
Only_DWNT
BioChem_NN
shareholders_NN
with_PIN
Canadian_JJ
residency_NN
had_VBD
the_DT
option_NOMZ
to_TO
receive_VB
exchangeable_JJ
shares_NN
for_PIN
their_TPP3
shares_NN
of_PIN
BioChem_NN
at_PIN
the_DT
time_NN
of_PIN
acquisition_NOMZ
._.
The_DT
exchangeable_JJ
shares_NN
were_VBD [BYPA]
issued_VBN
by_PIN
Shire_NN
Acquisition_NOMZ
Inc._NN
a_DT
company_NN
incorporated_VBN
under_IN
the_DT
Canada_NN
Business_NOMZ
Corporations_NOMZ
Act_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
the_DT
Company_NN
,_,
and_ANDC
is_VPRT [PASS]
listed_VBN
on_PIN
the_DT
Toronto_NN
Stock_NN
Exchange_NN
._.
Holders_NN
of_PIN
exchangeable_JJ
shares_NN
are_VPRT [PASS]
entitled_VBN
to_TO
vote_VB [SUAV]
at_PIN
shareholder_NN
meetings_GER
of_PIN
the_DT
Company_NN
and_CC
are_VPRT [PASS]
entitled_VBN
to_PIN
a_DT
dividend_NN
and_CC
other_JJ
rights_NN
that_TSUB
are_VPRT [BEMA]
economically_RB
equivalent_PRED
to_PIN
those_DEMO
of_PIN
ordinary_JJ
shares_NN
,_,
through_PIN
a_DT
voting_NN
trust_NN
and_CC
by_PIN
means_NN
of_PIN
the_DT
special_JJ
ordinary_JJ
voting_NN
shares_NN
in_PIN
Shire_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
2,187,793_CD
exchangeable_JJ
shares_NN
remained_VBD
unconverted_JJ
._.
The_DT
Company_NN
can_POMD
redeem_VB
all_QUAN
outstanding_JJ
exchangeable_JJ
shares_NN
for_PIN
ordinary_JJ
shares_NN
after_IN
May_POMD
11_CD
,_,
2011_CD
or_CC
earlier_TIME
if_COND
the_DT
total_JJ
number_NN
of_PIN
exchangeable_JJ
shares_NN
falls_VPRT
below_PLACE
one_CD
million_CD
._.
The_DT
exchangeable_JJ
shares_NN
are_VPRT [PASS]
included_VBN
as_IN
part_NN
of_PIN
share_NN
capital_NN
in_PIN
the_DT
consolidated_JJ
balance_NN
sheet_NN
to_TO
present_VB
a_DT
true_JJ
and_PHC
fair_JJ
view_NN
of_PIN
the_DT
consolidated_JJ
Groups_NN
capital_NN
structure_NN
,_,
which_WDT [SERE]
differs_VPRT
from_PIN
the_DT
Companies_NN
Act_NN
1985_CD
requirements_NOMZ
to_TO
reflect_VB [PRIV]
these_DEMO
amounts_NN
as_IN
minority_NOMZ
interests_NN
,_,
as_IN
they_TPP3
will_PRMD
become_VB
,_,
and_ANDC
are_VPRT [BEMA]
equivalent_PRED
,_,
to_PIN
ordinary_JJ
shares_NN
._.
86_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
87_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
30_CD
Share_NN
capital_NN
continued_VBD
Share_NN
warrants_NN
On_PIN
April_NN
24_CD
,_,
2002_CD
the_DT
Company_NN
issued_VBN
741,812_CD
share_NN
warrants_NN
,_,
at_PIN
4.88_CD
per_PIN
warrant_NN
,_,
and_ANDC
on_PIN
November_NN
21_CD
,_,
2002_CD
the_DT
Company_NN
issued_VBD
a_DT
further_JJ
604,595_CD
share_NN
warrants_NN
,_,
at_PIN
4.895_CD
per_PIN
warrant_NN
,_,
both_DT
issues_NN
being_VBG [WZPRES] [PASS]
made_VBN
to_PIN
Technology_NN
Partnership_NN
Canada_NN
TPC_NN
,_,
pursuant_JJ
to_PIN
an_DT
agreement_NOMZ
between_PIN
BioChem_NN
and_CC
the_DT
Government_NOMZ
of_PIN
Canada_NN
GOC_NN
._.
Each_QUAN
warrant_NN
grants_NN
a_DT
right_NN
to_TO
subscribe_VB
for_PIN
a_DT
corresponding_JJ
number_NN
of_PIN
ordinary_JJ
shares_NN
of_PIN
the_DT
Company_NN
within_PIN
five_CD
years_NN
from_PIN
the_DT
date_NN
of_PIN
issue_NN
of_PIN
the_DT
warrant_NN
._.
31_CD
Share_NN
based_VBN
payments_NOMZ
Historically_NN
the_DT
Group_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
options_NOMZ
to_PIN
directors_NN
and_PHC
employees_NN
over_IN
ordinary_JJ
shares_NN
under_IN
six_CD
stock_NN
option_NOMZ
plans_NN
._.
On_PIN
November_NN
28_CD
,_,
2005_CD
the_DT
ordinary_JJ
shareholders_NN
of_PIN
Shire_NN
approved_VBD
the_DT
adoption_NOMZ
of_PIN
the_DT
Shire_NN
plc_NN
Portfolio_NN
Share_NN
Plan_NN
Parts_NN
A_NN
and_PHC
B_NN
,_,
a_DT
new_JJ
share-based_JJ
compensation_NOMZ
plan_NN
,_,
which_WDT [SERE]
provides_VPRT
for_PIN
stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
and_PHC
performance_NN
share_NN
awards_NN
to_TO
be_VB [PASS]
made_VBN
to_PIN
directors_NN
and_PHC
employees_NN
over_IN
ordinary_JJ
shares_NN
and_CC
American_JJ
depositary_JJ
shares_NN
ADS_NN
._.
No_SYNE
further_JJ
awards_NN
will_PRMD
be_VB [PASS]
made_VBN
under_IN
the_DT
previous_JJ
stock_NN
option_NOMZ
plans_NN
._.
The_DT
highest_JJ
and_PHC
lowest_JJ
market_NN
prices_NN
during_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
were_VBD [BEMA]
7.53_CD
and_CC
5.39_CD
respectively_RB
._.
The_DT
average_JJ
share_NN
price_NN
during_PIN
the_DT
year_NN
was_VBD [BEMA]
6.37_CD
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
87_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
88_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
31_CD
Share_NN
based_VBN
payments_NOMZ
continued_VBD
The_DT
Group_NN
has_VPRT [PEAS]
granted_VBN [SUAV]
options_NOMZ
to_PIN
Directors_NN
and_PHC
employees_NN
over_IN
ordinary_JJ
shares_NN
under_IN
the_DT
following_VBG
six_CD
share_NN
option_NOMZ
schemes_NN
:_:
a_DT
Stock_NN
option_NOMZ
plans_VPRT
i_FPP1
Shire_FW
Pharmaceuticals_NN
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
Parts_NN
A_NN
and_PHC
B_NN
Executive_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
criteria_NN
and_CC
can_POMD
not_XX0
be_VB [PASS]
exercised_VBN
in_PIN
full_JJ
,_,
unless_COND
Shires_NN
ordinary_JJ
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
._.
If_COND
Shires_NN
ordinary_JJ
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
may_POMD
be_VB [PASS]
exercised_VBN
._.
If_COND
these_DEMO
conditions_NOMZ
are_VPRT [PASS]
not_XX0
met_VBN
after_IN
the_DT
initial_JJ
three_CD
years_NN
,_,
they_TPP3
are_VPRT [SPAU] [PASS]
thereafter_RB
tested_VBN
quarterly_JJ
by_PIN
reference_NN
to_TO
share_VB
price_NN
growth_NN
over_IN
the_DT
extended_JJ
period_NN
._.
If_COND
the_DT
share_NN
price_NN
does_VPRT
not_XX0
meet_VB
these_DEMO
conditions_NOMZ
at_PIN
any_QUAN
time_NN
,_,
none_INPR
of_PIN
the_DT
options_NOMZ
will_PRMD
become_VB
exercisable_JJ
._.
On_PIN
February_NN
28_CD
,_,
2000_CD
,_,
the_DT
Remuneration_NOMZ
Committee_NN
of_PIN
the_DT
Board_NN
exercised_VBD
its_PIT
powers_NN
to_TO
amend_VB
the_DT
terms_NN
of_PIN
the_DT
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
so_RB
as_IN
to_TO
include_VB
a_DT
cliff_NN
vesting_VBG [WZPRES]
provision_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
Executive_NN
Scheme_NN
._.
ii_FW
Shire_FW
plc_FW
2000_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
2000_CD
Executive_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
this_DEMO
scheme_NN
are_VPRT [BEMA]
exercisable_JJ
subject_NN
to_PIN
certain_JJ
performance_NN
criteria_NN
._.
In_PIN
respect_NN
of_PIN
any_QUAN
option_NOMZ
granted_VBN [SUAV] [WZPAST]
prior_RB
to_PIN
August_NN
2002_CD
,_,
if_COND
Shires_NN
ordinary_JJ
share_NN
price_NN
increases_NN
at_PIN
a_DT
compound_NN
rate_NN
of_PIN
at_PIN
least_JJ
20.5_CD
%_NN
per_PIN
annum_NN
over_IN
a_DT
minimum_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
the_DT
option_NOMZ
becomes_VPRT
exercisable_JJ
in_PIN
full_JJ
._.
If_COND
it_PIT
increases_VPRT
by_PIN
at_PIN
least_JJ
14.5_CD
%_NN
per_PIN
annum_NN
over_IN
the_DT
same_JJ
three-year_JJ
period_NN
,_,
60_CD
%_NN
of_PIN
the_DT
options_NOMZ
granted_VBN [SUAV]
become_VBN
exercisable_JJ
._.
If_COND
these_DEMO
conditions_NOMZ
are_VPRT [PASS]
not_XX0
met_VBN
after_IN
the_DT
initial_JJ
three-year_JJ
measurement_NOMZ
period_NN
,_,
they_TPP3
will_PRMD [SPAU]
thereafter_RB
be_VB [PASS]
tested_VBN
quarterly_JJ
by_PIN
reference_NN
to_TO
compound_VB
annual_JJ
share_NN
price_NN
growth_NN
over_IN
an_DT
extended_JJ
period_NN
._.
The_DT
performance_NN
criteria_NN
were_VBD [PASS]
reviewed_VBN
in_PIN
2002_CD
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
the_DT
criteria_NN
reflected_VBD [PRIV]
the_DT
market_NN
in_PIN
which_WDT [PIRE]
the_DT
Group_NN
operates_VPRT
._.
Given_VBN
the_DT
Groups_NN
development_NOMZ
,_,
it_PIT
was_VBD [PASS]
considered_VBN [PRIV]
appropriate_JJ
that_THAC
an_DT
earnings_GER
per_PIN
share-based_JJ
measure_NN
should_NEMD
be_VB [PASS]
adopted_VBN
in_PIN
place_NN
of_PIN
share_NN
price_NN
growth_NN
targets_NN
._.
The_DT
performance_NN
criteria_NN
are_VPRT [PASS]
based_VBN
on_PIN
real_JJ
growth_NN
in_PIN
the_DT
diluted_JJ
earnings_GER
per_PIN
share_NN
reported_VBN [PUBV] [WZPAST]
in_PIN
the_DT
Companys_NN
Form_NN
10-K_NN
under_IN
US_FPP1
GAAP_NN
,_,
adjusted_VBN
to_TO
ensure_VB [SUAV] [PRIV]
a_DT
consistent_JJ
basis_NN
of_PIN
measurement_NOMZ
,_,
as_IN
approved_VBN
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
,_,
including_VBG [PRESP]
the_DT
add_VB [PUBV]
back_RB
of_PIN
significant_JJ
one_CD
time_NN
items_NN
option_NOMZ
EPS_NN
._.
Therefore_CONJ
,_,
the_DT
performance_NN
criteria_NN
were_VBD [PASS]
amended_VBN
so_OSUB
that_NULL
an_DT
option_NOMZ
would_PRMD
become_VB
exercisable_JJ
in_PIN
full_JJ
if_COND
Shires_NN
option_NOMZ
EPS_NN
growth_NN
over_IN
a_DT
three-year_JJ
period_NN
from_PIN
the_DT
date_NN
of_PIN
award_NN
exceeds_VPRT
the_DT
UK_NN
Retail_NN
Prices_NN
Index_NN
RPI_NN
for_PIN
the_DT
following_VBG
tranches_NN
of_PIN
grants_NN
:_:
Options_NOMZ
with_PIN
a_DT
grant_NN
value_NN
of_PIN
up_RB
to_PIN
100_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
9_CD
%_NN
Directors_NN
,_,
RPI_NN
plus_PIN
15_CD
%_NN
Between_PIN
101_CD
%_NN
and_CC
200_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
15_CD
%_NN
Between_PIN
201_CD
%_NN
and_CC
300_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
21_CD
%_NN
Over_IN
301_CD
%_NN
of_PIN
salary_NN
RPI_NN
plus_PIN
27_CD
%_NN
The_DT
new_JJ
earnings_GER
per_PIN
share_NN
performance_NN
criteria_NN
apply_VPRT
to_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
from_PIN
August_NN
2002_CD
._.
After_IN
consultation_NOMZ
with_PIN
certain_JJ
of_PIN
its_PIT
institutional_JJ
shareholders_NN
,_,
the_DT
Group_NN
has_VPRT [PEAS]
decided_VBN [SUAV] [PRIV]
that_THVC
for_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
scheme_NN
from_PIN
2004_CD
onwards_NN
,_,
the_DT
re-test_JJ
of_PIN
the_DT
performance_NN
condition_NOMZ
if_COND
Shires_NN
option_NOMZ
EPS_NN
growth_NN
has_VPRT [PEAS]
fallen_VBN
short_JJ
of_PIN
the_DT
minimum_JJ
annual_JJ
average_JJ
percentage_NN
increase_NN
over_IN
the_DT
three-year_JJ
period_NN
from_PIN
grant_NN
,_,
has_VPRT [PEAS]
been_VBN [PASS]
changed_VBN
._.
The_DT
performance_NN
condition_NOMZ
will_PRMD
be_VB [PASS]
re-tested_VBN
once_TIME
only_DWNT
,_,
at_PIN
five_CD
years_NN
after_IN
the_DT
grant_NN
._.
Hence_CONJ
the_DT
level_NN
of_PIN
option_NOMZ
EPS_NN
growth_NN
in_PIN
the_DT
next_JJ
two_CD
years_NN
needs_VPRT
to_TO
be_VB [BEMA]
consequentially_RB
higher_PRED
to_TO
meet_VB
the_DT
test_NN
._.
Six_CD
weeks_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
,_,
any_QUAN
options_NOMZ
that_TSUB
have_VPRT
not_XX0
become_VB
exercisable_JJ
at_PIN
an_DT
earlier_TIME
date_NN
,_,
automatically_RB
vest_NN
without_PIN
reference_NN
to_PIN
the_DT
performance_NN
criteria_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
2000_CD
Executive_NN
Scheme_NN
._.
iii_FW
Shire_FW
Pharmaceuticals_NN
Sharesave_NN
Scheme_NN
Sharesave_NN
Scheme_NN
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
Sharesave_NN
Scheme_NN
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
80_CD
%_NN
of_PIN
the_DT
mid-market_JJ
price_NN
on_PIN
the_DT
day_NN
before_IN
invitations_NOMZ
are_VPRT [PASS]
issued_VBN
to_PIN
employees_NN
._.
Employees_NN
may_POMD
enter_VB
into_PIN
three_CD
or_CC
five-year_JJ
savings_GER
contracts_NN
._.
iv_FW
Shire_FW
plc_FW
Employee_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
Purchase_NN
Plan_NN
Under_IN
the_DT
Stock_NN
Purchase_NN
Plan_NN
,_,
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
with_PIN
an_DT
exercise_NN
price_NN
equal_JJ
to_PIN
85_CD
%_NN
of_PIN
the_DT
fair_JJ
market_NN
value_NN
of_PIN
a_DT
share_NN
on_PIN
the_DT
enrolment_NOMZ
date_NN
the_DT
first_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
or_CC
the_DT
exercise_NN
date_NN
the_DT
last_JJ
day_NN
of_PIN
the_DT
offering_GER
period_NN
,_,
whichever_WDT
is_VPRT [BEMA]
the_DT
lower_JJ
._.
The_DT
offering_GER
period_NN
is_VPRT [BEMA]
for_PIN
27_CD
months_NN
._.
v_NN
Pharmavene_NN
1991_CD
Stock_NN
Option_NOMZ
Plan_NN
SLI_NN
Plan_NN
Options_NOMZ
issued_VBN
under_IN
the_DT
SLI_NN
Plan_NN
were_VBD [SPAU] [PASS]
originally_TIME
granted_VBN [SUAV]
over_IN
shares_NN
in_PIN
SLI_NN
,_,
formerly_TIME
Pharmavene_NN
Inc._NN
a_DT
company_NN
acquired_VBN [WZPAST]
by_PIN
the_DT
Group_NN
on_PIN
March_NN
23_CD
,_,
1997_CD
._.
Exercise_NN
of_PIN
these_DEMO
options_NOMZ
results_NN
in_PIN
the_DT
option_NOMZ
holder_NN
receiving_VBG [WZPRES]
ordinary_JJ
shares_NN
in_PIN
Shire_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
of_PIN
SLI_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
terms_NN
of_PIN
the_DT
original_JJ
share_NN
option_NOMZ
plan_NN
,_,
all_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
that_DEMO
plan_NN
became_VBD
immediately_TIME
capable_JJ
of_PIN
exercise_NN
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
SLI_NN
Plan_NN
._.
vi_FW
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
BioChem_NN
Plan_NN
Following_VBG [WZPRES]
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
on_PIN
May_POMD
11_CD
,_,
2001_CD
,_,
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
was_VBD [PASS]
amended_VBN
such_OSUB
that_NULL
options_NOMZ
over_IN
BioChem_NN
Pharma_NN
Inc._NN
s_VPRT [BEMA]
common_JJ
stock_NN
became_VBD
options_NOMZ
over_IN
ordinary_JJ
shares_NN
of_PIN
Shire_NN
._.
All_QUAN
BioChem_NN
Pharma_NN
Inc._NN
options_NOMZ
,_,
which_WDT [SERE]
were_VBD
not_XX0
already_RB
exercisable_PRED
,_,
vested_JJ
and_CC
became_VBD
exercisable_JJ
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
acquisition_NOMZ
._.
It_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
that_THVC
no_SYNE
further_JJ
options_NOMZ
will_PRMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
BioChem_NN
Stock_NN
Option_NOMZ
Plan_NN
._.
88_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
89_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
31_CD
Share_NN
based_VBN
payments_NOMZ
continued_VBD
b_NN
Stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
vii_FW
Portfolio_NN
Share_NN
Plan_NN
Part_NN
A_NN
Stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
granted_VBN [SUAV]
under_IN
the_DT
Portfolio_NN
Share_NN
Plan_NN
Part_NN
A_NN
are_VPRT [BEMA]
exercisable_JJ
subject_NN
to_PIN
certain_JJ
performance_NN
criteria_NN
._.
In_PIN
respect_NN
of_PIN
any_QUAN
award_NN
made_VBD
to_PIN
Executive_NN
Directors_NN
performance_NN
conditions_NOMZ
will_PRMD
be_VB [PASS]
based_VBN
on_PIN
relative_JJ
total_JJ
shareholder_NN
return_NN
._.
Vesting_VBG
will_PRMD
depend_VB
on_PIN
relative_JJ
total_JJ
shareholder_NN
return_NN
performance_NN
against_PIN
two_CD
comparator_NN
groups_NN
._.
For_PIN
one-third_NN
of_PIN
the_DT
award_NN
,_,
the_DT
comparator_NN
group_NN
will_PRMD
be_VB [BEMA]
the_DT
Financial_NN
Times_NN
Stock_NN
Exchange_NN
100_CD
constituents_NN
excluding_VBG [WZPRES]
financial_JJ
institutions_NOMZ
and_CC
for_PIN
two-thirds_NN
of_PIN
the_DT
award_NN
the_DT
comparator_NN
group_NN
will_PRMD
be_VB [BEMA]
a_DT
group_NN
of_PIN
international_JJ
companies_NN
from_PIN
the_DT
pharmaceutical_JJ
sector_NN
._.
In_CONJ
addition_NULL
,_,
before_IN
awards_NN
granted_VBN [SUAV] [WZPAST]
to_PIN
Executive_NN
Directors_NN
will_PRMD
vest_NN
,_,
the_DT
Committee_NN
must_NEMD
be_VB [PASS]
satisfied_VBN
that_DEMO
the_DT
underlying_VBG
performance_NN
of_PIN
the_DT
Group_NN
is_VPRT [BEMA]
sufficient_PRED
to_TO
justify_VB
this_DEMP
._.
Where_RB
median_JJ
performance_NN
is_VPRT [PASS]
achieved_VBN
,_,
1_CD
33_CD
3_CD
%_NN
of_PIN
stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
will_PRMD
vest_NN
,_,
rising_VBG [PRESP]
on_PIN
a_DT
straight-line_JJ
basis_NN
to_PIN
full_JJ
vesting_GER
at_PIN
upper_JJ
quartile_JJ
performance_NN
._.
Awards_RB
granted_VBN [SUAV]
to_PIN
employees_NN
below_PLACE
Executive_NN
Director_NN
level_NN
will_PRMD
not_XX0
be_VB [BEMA]
subject_PRED
to_PIN
performance_NN
conditions_NOMZ
._.
Once_TIME
awards_NN
have_VPRT [PEAS]
vested_VBN
,_,
participants_NN
will_PRMD
have_VB
until_IN
the_DT
fifth_JJ
anniversary_NN
of_PIN
the_DT
date_NN
of_PIN
grant_NN
to_TO
exercise_VB
their_TPP3
awards_NN
._.
c_NN
Performance_NN
share_NN
plan_NN
viii_FW
Portfolio_NN
Share_NN
Plan_NN
Part_NN
B_NN
Performance_NN
share_NN
awards_NN
granted_VBN [SUAV]
under_IN
the_DT
Portfolio_NN
Share_NN
Plan_NN
Part_NN
B_NN
are_VPRT [BEMA]
exercisable_JJ
subject_NN
to_PIN
certain_JJ
performance_NN
criteria_NN
._.
For_PIN
one-third_NN
of_PIN
an_DT
award_NN
,_,
the_DT
comparator_NN
group_NN
will_PRMD
be_VB [BEMA]
the_DT
Financial_NN
Times_NN
Stock_NN
Exchange_NN
100_CD
constituents_NN
excluding_VBG [WZPRES]
financial_JJ
institutions_NOMZ
and_CC
for_PIN
two-thirds_NN
of_PIN
the_DT
award_NN
the_DT
comparator_NN
group_NN
will_PRMD
be_VB [BEMA]
a_DT
group_NN
of_PIN
international_JJ
companies_NN
from_PIN
the_DT
pharmaceutical_JJ
sector_NN
._.
In_CONJ
addition_NULL
,_,
before_IN
awards_NN
granted_VBN [SUAV] [WZPAST]
to_PIN
Executive_NN
Directors_NN
will_PRMD
vest_NN
,_,
the_DT
Committee_NN
must_NEMD
be_VB [PASS]
satisfied_VBN
1_CD
that_DEMO
the_DT
underlying_VBG
performance_NN
of_PIN
the_DT
Group_NN
is_VPRT [BEMA]
sufficient_PRED
to_TO
justify_VB
this_DEMP
._.
Where_RB
median_JJ
performance_NN
is_VPRT [PASS]
achieved_VBN
,_,
33_CD
3_CD
%_NN
of_PIN
stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
will_PRMD
vest_NN
,_,
rising_VBG [PRESP]
on_PIN
a_DT
straight-line_JJ
basis_NN
to_PIN
full_JJ
vesting_GER
at_PIN
upper_JJ
quartile_JJ
performance_NN
._.
At_PIN
December_NN
31_CD
,_,
2005_CD
no_SYNE
awards_NN
had_VBD [PEAS]
been_VBN [PASS]
made_VBN
._.
In_PIN
a_DT
period_NN
of_PIN
ten_CD
years_NN
,_,
not_XX0
more_EMPH
than_PIN
10_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
Shire_NN
may_POMD
be_VB [PASS]
placed_VBN
under_IN
option_NOMZ
under_IN
any_QUAN
share_NN
scheme_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
following_VBG
terms_NN
apply_VB
to_PIN
options_NOMZ
that_TSUB
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
the_DT
various_JJ
plans_NN
:_:
2000_CD
Executive_NN
Scheme_NN
:_:
the_DT
maximum_JJ
number_NN
of_PIN
Shire_NN
ordinary_JJ
shares_NN
over_IN
which_WDT
incentive_NN
options_NOMZ
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
under_IN
Part_NN
3_CD
of_PIN
the_DT
scheme_NN
is_VPRT [BEMA]
25,000,000_CD
:_:
and_ANDC
Share_NN
Purchase_NN
Plan_NN
:_:
up_IN
to_PIN
2,000,000_CD
Shire_NN
ordinary_JJ
shares_NN
._.
The_DT
maximum_JJ
term_NN
and_CC
vesting_JJ
period_NN
of_PIN
awards_NN
granted_VBN [SUAV]
and_CC
outstanding_JJ
as_RB
at_PIN
December_NN
31_CD
,_,
2005_CD
is_VPRT [PASS]
summarized_VBN
below_PLACE
:_:
Expiration_NOMZ
Compensation_NOMZ
Number_NN
of_PIN
period_NN
from_PIN
type_NN
awards_NN
date_NN
of_PIN
issue_NN
Vesting_JJ
period_NN
Executive_NN
Scheme_NN
Stock_NN
options_NOMZ
1,176,784_CD
10_CD
years_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
2000_CD
Executive_NN
Scheme_NN
Stock_NN
options_NOMZ
22,787,658_CD
10_CD
years_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
Sharesave_NN
Scheme_NN
Stock_NN
options_NOMZ
337,371_CD
6_CD
months_NN
after_IN
vesting_VBG
3_CD
or_CC
5_CD
years_NN
Stock_NN
Purchase_NN
Plan_NN
Stock_NN
options_NOMZ
640,777_CD
On_PIN
vesting_VBG
date_NN
27_CD
months_NN
SLI_NN
Plan_NN
Stock_NN
options_NOMZ
2,567_CD
10_CD
years_NN
Immediate_NN
on_PIN
acquisition_NOMZ
by_PIN
the_DT
Group_NN
BioChem_NN
Plan_NN
Stock_NN
options_NOMZ
3,525,582_CD
10_CD
years_NN
Immediate_NN
on_PIN
acquisition_NOMZ
by_PIN
the_DT
Group_NN
Total_NN
share_NN
option_NOMZ
schemes_NN
28,470,739_CD
Portfolio_NN
Share_NN
Plan_NN
Part_NN
A_NN
Stock-settled_JJ
share_NN
449,490_CD
5_CD
years_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
appreciation_NOMZ
rights_NN
criteria_NN
for_PIN
Executive_NN
Directors_NN
only_DWNT
ordinary_JJ
shares_NN
Portfolio_NN
Share_NN
Plan_NN
Part_NN
A_NN
Stock-settled_JJ
share_NN
2,812,176_CD
5_CD
years_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
appreciation_NOMZ
rights_NN
criteria_NN
for_PIN
Executive_NN
Directors_NN
only_DWNT
i_FPP1
ADSs_NN
Total_NN
Portfolio_NN
Share_NN
Plan_NN
Part_NN
A_NN
3,261,666_CD
Portfolio_NN
Share_NN
Plan_NN
Part_NN
B_NN
Performance_NN
shares_NN
3_CD
years_NN
,_,
subject_JJ
to_PIN
performance_NN
criteria_NN
for_PIN
Executive_NN
Directors_NN
only_DWNT
i_FPP1
For_PIN
the_DT
purposes_NN
of_PIN
this_DEMO
table_NN
the_DT
937,392_CD
ADSs_NN
outstanding_JJ
at_PIN
December_NN
31_CD
,_,
2005_CD
have_VPRT [PEAS]
been_VBN [PASS]
converted_VBN
into_PIN
2,812,176_CD
ordinary_JJ
shares_NN
._.
One_CD
ADS_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
three_CD
ordinary_JJ
shares_NN
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
89_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
90_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
31_CD
Share_NN
based_VBN
payments_NOMZ
continued_VBD
Options_NOMZ
outstanding_JJ
as_IN
of_PIN
December_NN
31_CD
,_,
2005_CD
have_VPRT
the_DT
following_VBG
characteristics_NN
:_:
Weighted_JJ
Weighted_JJ
average_JJ
Weighted_JJ
average_JJ
exercise_NN
price_NN
average_NN
of_PIN
options_NOMZ
Number_NN
of_PIN
options_NOMZ
Number_NN
of_PIN
Exercise_NN
prices_NN
remaining_VBG [WZPRES]
outstanding_JJ
of_PIN
options_NOMZ
outstanding_JJ
options_NOMZ
outstanding_JJ
life_NN
exercisable_JJ
5,651,719_CD
0.014.00_CD
6.8_CD
3.46_CD
26,547_CD
3.19_CD
14,772,839_CD
4.016.00_CD
8.1_CD
5.36_CD
2,070,405_CD
5.19_CD
5,739,709_CD
6.0110.00_CD
4.3_CD
7.05_CD
3,669,918_CD
7.20_CD
2,306,472_CD
10.0113.00_CD
4.0_CD
11.84_CD
2,220,499_CD
11.89_CD
28,470,739_CD
7,987,369_CD
Stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
over_IN
ordinary_JJ
shares_NN
outstanding_JJ
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
have_VPRT
the_DT
following_VBG
characteristics_NN
:_:
Weighted_JJ
Weighted_JJ
average_JJ
Weighted_JJ
average_JJ
exercise_NN
price_NN
average_NN
of_PIN
options_NOMZ
Number_NN
of_PIN
options_NOMZ
Number_NN
of_PIN
Exercise_NN
prices_NN
remaining_VBG [WZPRES]
outstanding_JJ
of_PIN
options_NOMZ
outstanding_JJ
options_NOMZ
outstanding_JJ
life_NN
exercisable_JJ
449,490_CD
6.0110.00_CD
4.9_CD
7.17_CD
Stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
over_IN
American_JJ
depositary_JJ
shares_NN
outstanding_JJ
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
have_VPRT
the_DT
following_VBG
characteristics_NN
:_:
Weighted_JJ
Weighted_JJ
average_JJ
Weighted_JJ
average_JJ
exercise_NN
price_NN
average_NN
of_PIN
options_NOMZ
Number_NN
of_PIN
options_NOMZ
Number_NN
of_PIN
Exercise_NN
prices_NN
remaining_VBG [WZPRES]
outstanding_JJ
of_PIN
options_NOMZ
outstanding_JJ
options_NOMZ
outstanding_JJ
life_NN
exercisable_JJ
937,392_CD
35.0140.00_CD
4.9_CD
37.80_CD
Options_NOMZ
and_CC
stock-settled_JJ
share_NN
appreciation_NOMZ
rights_NN
granted_VBN [SUAV] [WZPAST]
in_PIN
the_DT
period_NN
were_VBD [PASS]
valued_VBN
using_VBG
the_DT
Black-Scholes_NN
option-pricing_GER
model_NN
._.
No_SYNE
performance_NN
conditions_NOMZ
were_VBD [PASS]
included_VBN
in_PIN
the_DT
fair_JJ
value_NN
calculations_NOMZ
as_IN
there_EX
were_VBD
no_SYNE
market_NN
based_VBN
conditions_NOMZ
._.
The_DT
fair_JJ
value_NN
per_PIN
option_NOMZ
granted_VBN [SUAV]
and_CC
the_DT
assumptions_NOMZ
used_VBN [WZPAST]
in_PIN
the_DT
calculations_NOMZ
are_VPRT
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
Weighted-average_JJ
share_NN
price_NN
at_PIN
grant_NN
dates_NN
6.29_CD
5.18_CD
Weighted-average_JJ
share_NN
exercise_NN
price_NN
6.23_CD
5.15_CD
Shares_NN
under_IN
option_NOMZ
12,004,477_CD
7,148,616_CD
Vesting_JJ
period_NN
years_NN
2.255_CD
2.255_CD
Expected_VBN [PRIV]
volatility_NOMZ
32-50_CD
%_NN
32-50_CD
%_NN
Option_NOMZ
life_NN
years_NN
2.2510_CD
2.2510_CD
Expected_VBN [PRIV]
life_NN
years_NN
2.257_CD
2.257_CD
Risk_NN
free_JJ
interest_NN
rate_NN
3.934.59_CD
%_NN
2.464.19_CD
%_NN
Expected_VBN [PRIV] [THATD]
dividends_NN
expressed_VBD
as_IN
a_DT
dividend_NN
yield_NN
0.6_CD
%_NN
0_CD
%_NN
0.6_CD
%_NN
Estimated_VBN [PRIV]
annual_JJ
forfeiture_NN
rate_NN
5_CD
%_NN
5_CD
%_NN
Average_JJ
fair_JJ
value_NN
per_PIN
option_NOMZ
2.98_CD
2.74_CD
The_DT
weighted_JJ
average_NN
expected_VBN [PRIV] [THATD]
volatility_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
historical_JJ
volatility_NOMZ
of_PIN
a_DT
term_NN
consistent_JJ
with_PIN
the_DT
assumed_JJ
option_NOMZ
life_NN
._.
The_DT
risk_NN
free_JJ
rate_NN
of_PIN
return_NN
is_VPRT [BEMA]
the_DT
yield_NN
on_PIN
zero-coupon_JJ
US_FPP1
government_NOMZ
bonds_NN
of_PIN
a_DT
term_NN
consistent_JJ
with_PIN
the_DT
assumed_JJ
option_NOMZ
life_NN
._.
In_CONJ
addition_NULL
to_PIN
equity-settled_JJ
share-based_JJ
schemes_NN
discussed_VBN
above_PLACE
,_,
the_DT
Group_NN
operates_VPRT
a_DT
cash-settled_JJ
share-based_JJ
scheme_NN
for_PIN
senior_JJ
executives_NN
,_,
the_DT
Long_NN
Term_NN
Incentive_NN
Plan_NN
LTIP_NN
._.
The_DT
Long_NN
Term_NN
Incentive_NN
Plan_NN
the_DT
Plan_NN
was_VBD [PASS]
adopted_VBN
at_PIN
the_DT
Companys_NN
1998_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
and_PHC
amended_VBN
in_PIN
2000_CD
._.
Under_IN
the_DT
Plan_NN
,_,
the_DT
Remuneration_NOMZ
Committee_NN
has_VPRT
discretion_NOMZ
to_TO
make_VB
awards_NN
of_PIN
shares_NN
subject_JJ
to_PIN
a_DT
maximum_NN
of_PIN
100_CD
%_NN
of_PIN
salary_NN
a_DT
year_NN
._.
The_DT
performance_NN
condition_NOMZ
attached_VBN [WZPAST]
to_PIN
the_DT
vesting_GER
of_PIN
the_DT
share_NN
awards_NN
made_VBN
under_IN
the_DT
Plan_NN
is_VPRT
Shires_NN
Total_NN
Shareholder_NN
Return_NN
TSR_NN
relative_JJ
to_PIN
the_DT
FTSE_NN
100_CD
Index_NN
over_IN
a_DT
three-year_JJ
period_NN
._.
The_DT
Committee_NN
considers_VPRT [PRIV] [THATD]
that_DEMP
this_DEMO
measure_NN
is_VPRT [BEMA]
a_DT
reliable_JJ
and_PHC
appropriate_JJ
measure_NN
of_PIN
the_DT
Groups_NN
performance_NN
and_CC
that_THVC
the_DT
FTSE_NN
100_CD
is_VPRT [BEMA]
an_DT
appropriate_JJ
benchmark_NN
given_VBN
that_DEMO
the_DT
Company_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
the_DT
Index_NN
._.
90_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
91_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
31_CD
Share_NN
based_VBN
payments_NOMZ
continued_VBD
Under_IN
this_DEMO
Plan_NN
:_:
all_QUAN
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
is_VPRT [BEMA]
in_PIN
the_DT
top_JJ
10_CD
%_NN
of_PIN
the_DT
FTSE_NN
100_CD
:_:
20_CD
%_NN
of_PIN
the_DT
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
is_VPRT [BEMA]
at_PIN
the_DT
median_NN
of_PIN
the_DT
FTSE_NN
100_CD
,_,
with_PIN
vesting_VBG
between_PIN
these_DEMO
points_NN
on_PIN
a_DT
linear_JJ
basis_NN
:_:
and_ANDC
no_SYNE
shares_NN
vest_NN
if_COND
Shires_NN
TSR_NN
is_VPRT
below_PLACE
the_DT
median_NN
of_PIN
the_DT
FTSE_NN
100_CD
._.
The_DT
Remuneration_NOMZ
Committee_NN
determines_VPRT [SUAV] [PRIV]
whether_IN [WHCL]
and_CC
to_TO
what_WP
extent_NN
the_DT
performance_NN
condition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
met_VBN
on_PIN
the_DT
basis_NN
of_PIN
data_NN
provided_VBN [WZPAST]
by_PIN
an_DT
independent_JJ
third-party_JJ
._.
To_PIN
date_NN
,_,
all_QUAN
awards_NN
made_VBN
under_IN
the_DT
Plan_NN
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
as_IN
a_DT
conditional_JJ
allocation_NOMZ
,_,
thereby_RB
allowing_VBG [SUAV]
,_,
at_PIN
the_DT
Remuneration_NOMZ
Committees_NN
discretion_NOMZ
,_,
for_PIN
a_DT
cash_NN
equivalent_NN
to_TO
be_VB [PASS]
paid_VBN
on_PIN
maturity_NOMZ
of_PIN
the_DT
award_NN
._.
Whilst_OSUB
the_DT
performance_NN
period_NN
is_VPRT [PASS]
measured_VBN
over_IN
three_CD
years_NN
,_,
an_DT
award_NN
is_VPRT [SPAU] [PASS]
normally_RB
transferred_VBN
after_IN
the_DT
fourth_JJ
anniversary_NN
of_PIN
grant_NN
,_,
to_PIN
the_DT
extent_NN
the_DT
performance_NN
condition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
met_VBN
._.
For_PIN
awards_NN
made_VBN
under_IN
the_DT
LTIP_NN
prior_RB
to_PIN
June_NN
2001_CD
,_,
performance_NN
is_VPRT [PASS]
measured_VBN
over_IN
a_DT
three-year_JJ
period_NN
but_CC
the_DT
performance_NN
conditions_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
criteria_NN
of_PIN
i_FPP1
50_CD
%_NN
TSR_NN
benchmarked_VBD
against_PIN
FTSE_NN
mid-250_CD
index_NN
and_CC
ii_FW
50_CD
%_NN
subject_NN
to_PIN
an_DT
EPS_NN
condition_NOMZ
measured_VBN [WZPAST]
against_PIN
the_DT
diluted_VBN
EPS_NN
of_PIN
the_DT
Group_NN
for_PIN
the_DT
financial_JJ
year_NN
ended_VBD
before_IN
the_DT
commencement_NOMZ
of_PIN
the_DT
performance_NN
period_NN
and_CC
the_DT
diluted_VBN
EPS_NN
of_PIN
the_DT
Group_NN
for_PIN
the_DT
financial_JJ
year_NN
ended_VBN [WZPAST]
on_PIN
or_CC
before_IN
the_DT
end_NN
of_PIN
the_DT
performance_NN
period_NN
._.
For_PIN
awards_NN
made_VBN [WZPAST]
on_PIN
March_NN
1_CD
,_,
2000_CD
the_DT
Committee_NN
determined_VBD [SUAV] [PRIV]
that_THVC
44.84_CD
%_NN
of_PIN
the_DT
part_NN
of_PIN
the_DT
award_NN
subject_NN
to_PIN
TSR_NN
performance_NN
measures_NN
and_CC
100_CD
%_NN
of_PIN
the_DT
part_NN
of_PIN
the_DT
award_NN
subject_NN
to_PIN
EPS_NN
performance_NN
measures_NN
could_POMD
be_VB [PASS]
transferred_VBN
,_,
resulting_VBG [PRESP]
in_PIN
72.42_CD
%_NN
of_PIN
the_DT
total_JJ
award_NN
being_VBG [WZPRES] [PASS]
transferred_VBN
to_PIN
participants_NN
._.
These_DEMO
calculations_NOMZ
were_VBD [BYPA]
verified_VBN
by_PIN
external_JJ
advisers_NN
._.
The_DT
total_JJ
liability_NOMZ
under_IN
LTIP_NN
scheme_NN
is_VPRT
$_$
2.5_CD
million_CD
2004_CD
:_:
$_$
2.7_CD
million_CD
and_CC
is_VPRT [PASS]
included_VBN
in_PIN
other_JJ
provisions_NN
as_IN
disclosed_VBN [PUBV]
in_PIN
Note_NN
28_CD
._.
There_EX
were_VBD
no_SYNE
liabilities_NOMZ
outstanding_JJ
for_PIN
which_WDT [PIRE]
the_DT
right_NN
to_PIN
cash_NN
had_VBD [PEAS]
vested_VBN
at_PIN
the_DT
year-end_NN
._.
The_DT
total_JJ
charge_NN
for_PIN
the_DT
year_NN
relating_VBG [WZPRES]
to_PIN
employee_NN
share-based_JJ
payment_NOMZ
plans_NN
was_VBD
$_$
27.4_CD
million_CD
2004_CD
:_:
$_$
15.8_CD
million_CD
,_,
of_PIN
which_WDT [PIRE]
$_$
27.4_CD
million_CD
2004_CD
:_:
$_$
15.5_CD
million_CD
related_VBN
to_PIN
equity-settled_JJ
share-based_JJ
payment_NOMZ
transactions_NOMZ
._.
32_CD
Treasury_NN
shares_NN
The_DT
Employee_NN
Share_NN
Ownership_NN
Plan_NN
ESOP_NN
reserve_NN
arises_VPRT
in_PIN
connection_NOMZ
with_PIN
the_DT
ESOP_NN
trust_NN
,_,
a_DT
discretionary_JJ
trust_NN
established_VBN [PRIV]
to_TO
facilitate_VB
the_DT
operation_NOMZ
of_PIN
the_DT
Groups_NN
long-term_JJ
incentive_NN
scheme_NN
for_PIN
senior_JJ
management_NOMZ
._.
The_DT
amount_NN
of_PIN
the_DT
reserve_NN
represents_VPRT
the_DT
deduction_NOMZ
in_PIN
arriving_VBG
at_PIN
shareholders_NN
funds_NN
for_PIN
the_DT
consideration_NOMZ
paid_VBN [WZPAST]
for_PIN
the_DT
Companys_NN
shares_NN
purchased_VBN [WZPAST]
by_PIN
the_DT
trust_NN
which_WDT [WHSUB]
had_VBD [PEAS]
not_XX0
vested_VBN
unconditionally_RB
to_PIN
employees_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
Deferred_NN
Bonus_NN
Plan_NN
the_DT
Plan_NN
provides_VPRT
for_PIN
participants_NN
to_TO
use_VB
up_RP
to_PIN
50_CD
%_NN
of_PIN
their_TPP3
annual_JJ
bonus_NN
to_TO
buy_VB
shares_NN
in_PIN
the_DT
Company_NN
._.
The_DT
Group_NN
will_PRMD
match_VB
any_QUAN
shares_NN
bought_VBD
,_,
but_CC
the_DT
matched_VBN
shares_NN
will_PRMD
vest_NN
,_,
for_PIN
Executive_NN
Directors_NN
,_,
only_DWNT
if_COND
the_DT
Groups_NN
EPS_VPRT
grows_VPRT
by_PIN
more_EMPH
than_PIN
15_CD
%_NN
in_PIN
excess_NN
of_PIN
RPI_NN
over_IN
a_DT
three-year_JJ
period_NN
9_CD
%_NN
in_PIN
excess_NN
of_PIN
RPI_NN
for_PIN
other_JJ
eligible_JJ
employees_NN
._.
Recent_JJ
fiscal_JJ
changes_NN
in_PIN
the_DT
US_FPP1
have_VPRT [PEAS]
made_VBN
the_DT
Plan_NN
less_RB
attractive_JJ
to_PIN
participants_NN
and_CC
the_DT
Remuneration_NOMZ
Committee_NN
discontinued_VBD
the_DT
Plan_NN
after_IN
bonus_NN
awards_NN
for_PIN
the_DT
2004_CD
financial_JJ
year_NN
._.
The_DT
number_NN
and_PHC
market_NN
value_NN
of_PIN
the_DT
ordinary_JJ
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOP_NN
trust_NN
at_PIN
December_NN
31_CD
,_,
was_VBD [BEMA]
2005 2005 2004 2004_CD
Number_NN
Market_NN
value_NN
Number_NN
Market_NN
value_NN
000_CD
$_$
000_CD
000_CD
$_$
000_CD
Shares_NN
allocated_VBN
but_CC
not_XX0
vested_JJ
51_CD
651_CD
50_CD
246_CD
Unallocated_JJ
shares_NN
198_CD
2,532_CD
218_CD
249_CD
3,183_CD
52_CD
264_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
91_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
92_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
33_CD
Shareholders_NN
funds_NN
and_PHC
statement_NOMZ
of_PIN
changes_NN
in_PIN
shareholders_NN
equity_NOMZ
Capital_NN
Share_NN
Share_NN
Treasury_NN
Exchangeable_JJ
reduction_NOMZ
Capital_NN
Other_JJ
Retained_VBN
capital_NN
premium_NN
shares_NN
shares_NN
reserve_NN
reserve_NN
reserve_NN
earnings_GER
Total_JJ
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Balance_NN
at_PIN
January_NN
1_CD
,_,
2005_CD
36,083_CD
4,883,219_CD
264_CD
195,830_CD
4,729_CD
36,121_CD
910,786_CD
4,244,932_CD
Effect_NN
of_PIN
Scheme_NN
of_PIN
Arrangement_NOMZ
2,889,562_CD
4,883,219_CD
4,729_CD
1,998,386_CD
Effect_NN
of_PIN
capital_NN
reduction_NOMZ
2,883,849_CD
2,883,849_CD
Balance_NN
at_PIN
January_NN
1_CD
,_,
2005_CD
restated_VBN
41,796_CD
264_CD
195,830_CD
2,883,849_CD
2,034,507_CD
910,786_CD
4,244,932_CD
Foreign_JJ
currency_NN
translation_NOMZ
differences_NN
28,855_CD
28,855_CD
Net_JJ
income_NN
recognized_VBN [PRIV] [WZPAST]
directly_RB
in_PIN
equity_NOMZ
28,855_CD
28,855_CD
Employee_NN
share_NN
option_NOMZ
scheme_NN
:_:
value_NN
of_PIN
employee_NN
services_NN
27,383_CD
27,383_CD
proceeds_NN
from_PIN
shares_NN
issued_VBN
405_CD
2,977_CD
26,268_CD
7,463_CD
37,113_CD
Issue_NN
of_PIN
share_NN
capital_NN
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
527_CD
94,582_CD
36,373_CD
57,682_CD
Purchase_NN
of_PIN
treasury_NN
shares_NN
2,549_CD
2,549_CD
Dividends_NN
28,460_CD
28,460_CD
Tax_NN
benefit_NN
associated_VBN [WZPAST]
with_PIN
exercise_NN
of_PIN
stock_NN
options_NOMZ
1,721_CD
1,721_CD
Unrealized_JJ
holding_VBG [PRIV]
gain_NN
on_PIN
available-for-sale_JJ
securities_NOMZ
9,226_CD
9,226_CD
Loss_NN
for_PIN
the_DT
year_NN
177,378_CD
177,378_CD
Balance_NN
at_PIN
December_NN
31_CD
,_,
2005_CD
42,728_CD
2,977_CD
2,813_CD
101,248_CD
2,946,490_CD
2,099,652_CD
1,107,149_CD
4,083,133_CD
The_DT
cumulative_JJ
foreign_JJ
exchange_NN
differences_NN
on_PIN
translation_NOMZ
amount_NN
to_PIN
a_DT
$_$
5.2_CD
million_CD
gain_NN
as_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
._.
Capital_NN
Share_NN
Share_NN
Treasury_NN
Exchangeable_JJ
reduction_NOMZ
Capital_NN
Other_JJ
Retained_VBN
capital_NN
premium_NN
shares_NN
shares_NN
reserve_NN
reserve_NN
reserve_NN
earnings_GER
Total_JJ
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Balance_NN
at_PIN
January_NN
1_CD
,_,
2004_CD
before_IN
effect_NN
of_PIN
Scheme_NN
of_PIN
Arrangement_NOMZ
35,540_CD
4,794,738_CD
270,667_CD
4,729_CD
36,121_CD
1,047,920_CD
4,093,875_CD
Foreign_JJ
currency_NN
translation_NOMZ
differences_NN
34,066_CD
34,066_CD
Net_JJ
income_NN
recognized_VBN [PRIV] [WZPAST]
directly_RB
in_PIN
equity_NOMZ
34,066_CD
34,066_CD
Employee_NN
share_NN
option_NOMZ
scheme_NN
:_:
value_NN
of_PIN
employee_NN
services_NN
15,464_CD
15,464_CD
proceeds_NN
from_PIN
shares_NN
issued_VBN
191_CD
13,225_CD
13,416_CD
Issue_NN
of_PIN
share_NN
capital_NN
8_CD
763_CD
771_CD
Exchange_NN
of_PIN
exchangeable_JJ
shares_NN
344_CD
74,493_CD
74,837_CD
Purchase_NN
of_PIN
treasury_NN
shares_NN
264_CD
264_CD
Dividends_NN
8,905_CD
8,905_CD
Profit_NN
for_PIN
the_DT
year_NN
96,509_CD
96,509_CD
Balance_NN
at_PIN
December_NN
31_CD
,_,
2004_CD
36,083_CD
4,883,219_CD
264_CD
195,830_CD
4,729_CD
36,121_CD
910,786_CD
4,244,932_CD
The_DT
capital_NN
and_CC
other_JJ
reserves_NN
arose_VBD
in_PIN
relation_NOMZ
to_PIN
various_JJ
Group_NN
reconstructions_NOMZ
and_CC
certain_JJ
financing_GER
transactions_NOMZ
._.
92_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
93_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
34_CD
Cash_NN
generated_VBD
from_PIN
operations_NOMZ
For_PIN
the_DT
For_PIN
the_DT
year_NN
ended_VBD
year_NN
ended_VBD
December_NN
31_CD
,_,
December_NN
31_CD
,_,
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Operating_GER
loss_NN
profit_NN
158,873_CD
290,786_CD
Adjustments_NOMZ
for_PIN
:_:
Depreciation_NOMZ
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
23,003_CD
22,668_CD
Amortization_NOMZ
of_PIN
intangible_JJ
assets_NN
49,516_CD
42,138_CD
Impairment_NOMZ
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
6,458_CD
1,587_CD
Impairment_NOMZ
of_PIN
intangible_JJ
assets_NN
4,410_CD
19,626_CD
Impairment_NOMZ
of_PIN
goodwill_NN
526,956_CD
132,576_CD
Movements_NOMZ
in_PIN
financial_JJ
assets_NN
1,974_CD
16,253_CD
Increase_VPRT
in_PIN
provision_NN
for_PIN
sale_NN
deductions_NOMZ
18,616_CD
50,746_CD
Loss_NN
profit_NN
on_PIN
disposal_NN
of_PIN
non-financial_JJ
assets_NN
185_CD
325_CD
Profit_NN
on_PIN
disposal_NN
of_PIN
financial_JJ
assets_NN
4,100_CD
14,805_CD
Gain_NN
on_PIN
sale_NN
of_PIN
drug_NN
formulation_NOMZ
business_NOMZ
3,561_CD
Stock_NN
option_NOMZ
compensation_NOMZ
27,383_CD
15,464_CD
Operating_GER
cash_NN
flows_VPRT
before_IN
movements_NOMZ
in_PIN
working_VBG
capital_NN
491,967_CD
576,714_CD
Decrease_NN
in_PIN
inventories_NN
8,582_CD
2,185_CD
Increase_VPRT
in_PIN
trade_NN
and_CC
other_JJ
receivables_NN
146,741_CD
28,066_CD
Increase_VPRT
decrease_NN
in_PIN
other_JJ
assets_NN
731_CD
16,136_CD
Increase_VPRT
in_PIN
trade_NN
and_CC
other_JJ
payables_NN
120,422_CD
61,448_CD
Deferred_JJ
income_NN
13,520_CD
6,151_CD
Cash_NN
flow_NN
from_PIN
discontinued_VBN
operations_NOMZ
362_CD
30,525_CD
Cash_NN
generated_VBD
from_PIN
operations_NOMZ
459,617_CD
604,043_CD
Interest_NN
paid_VBN
4,334_CD
14,771_CD
Income_NN
tax_NN
paid_VBN
54,096_CD
123,510_CD
Net_JJ
cash_NN
flows_VPRT
from_PIN
operating_VBG
activities_NOMZ
401,187_CD
465,762_CD
Additions_NOMZ
to_PIN
fixtures_NN
and_PHC
equipment_NOMZ
during_PIN
the_DT
year_NN
amounting_VBG [WZPRES]
to_TO
$_$
71.9_CD
million_CD
included_VBD
acquisitions_NOMZ
of_PIN
$_$
4.6_CD
million_CD
financed_VBN
by_PIN
new_JJ
finance_NN
leases_NN
._.
Cash_NN
and_PHC
cash_NN
equivalents_NN
which_WDT [WHSUB]
are_VPRT [PASS]
presented_VBN
as_IN
a_DT
single_JJ
category_NN
of_PIN
assets_NN
on_PIN
the_DT
face_NN
of_PIN
the_DT
balance_NN
sheet_NN
comprise_VPRT
cash_NN
at_PIN
bank_NN
and_CC
other_JJ
short-term_JJ
highly_AMP
liquid_JJ
investments_NOMZ
with_PIN
a_DT
maturity_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
93_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
94_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
35_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
a_DT
Leases_NN
The_NN
Group_NN
leases_VPRT
property_NN
,_,
computer_NN
and_PHC
office_NN
equipment_NOMZ
and_PHC
motor_NN
vehicles_NN
on_PIN
short-term_JJ
operating_GER
leases_NN
._.
The_DT
rents_NN
payable_JJ
under_IN
property_NN
leases_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
renegotiation_NOMZ
at_PIN
various_JJ
intervals_NN
specified_VBN [WZPAST]
in_PIN
the_DT
leases_NN
._.
The_DT
Group_NN
pays_VPRT
for_PIN
substantially_RB
all_QUAN
of_PIN
the_DT
insurance_NN
,_,
maintenance_NN
and_PHC
repair_NN
of_PIN
these_DEMO
assets_NN
._.
The_DT
future_JJ
aggregate_JJ
minimum_NN
lease_NN
payments_NOMZ
under_IN
non-cancellable_JJ
operating_GER
leases_NN
are_VPRT
as_IN
follows_VPRT
:_:
Land_NN
and_PHC
Motor_NN
buildings_GER
Equipment_NOMZ
vehicles_NN
Total_JJ
2005_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Not_XX0
later_TIME
than_PIN
1_CD
year_NN
18,847_CD
1,502_CD
2,828_CD
23,177_CD
Later_TIME
than_PIN
1_CD
year_NN
and_CC
not_XX0
later_TIME
than_PIN
5_CD
years_NN
75,002_CD
1,808_CD
7,618_CD
84,428_CD
Later_TIME
than_PIN
5_CD
years_NN
50,013_CD
3_CD
50,016_CD
143,862_CD
3,313_CD
10,446_CD
157,621_CD
Land_NN
and_PHC
Motor_NN
buildings_GER
Equipment_NOMZ
vehicles_NN
Total_JJ
2004_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Not_XX0
later_TIME
than_PIN
1_CD
year_NN
6,579_CD
4,561_CD
2,246_CD
13,386_CD
Later_TIME
than_PIN
1_CD
year_NN
and_CC
not_XX0
later_TIME
than_PIN
5_CD
years_NN
27,486_CD
4,996_CD
3,090_CD
35,572_CD
Later_TIME
than_PIN
5_CD
years_NN
37,707_CD
37,707_CD
71,772_CD
9,557_CD
5,336_CD
86,665_CD
The_DT
future_NN
aggregate_JJ
payments_NOMZ
for_PIN
land_NN
and_PHC
buildings_GER
include_VPRT
$_$
57.6_CD
million_CD
in_PIN
respect_NN
of_PIN
operating_VBG
leases_NN
expiring_VBG [WZPRES]
in_PIN
2016_CD
on_PIN
the_DT
Groups_NN
new_JJ
headquarters_NN
in_PIN
Wayne_NN
,_,
Pennsylvania_NN
._.
b_NN
Guarantees_NN
and_PHC
collateral_NN
At_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Group_NN
had_VBD
$_$
5.5_CD
million_CD
2004_CD
:_:
$_$
5.3_CD
million_CD
of_PIN
restricted_VBN
cash_NN
held_VBN [PRIV]
as_IN
collateral_NN
for_PIN
certain_JJ
equipment_NOMZ
leases_NN
._.
c_NN
Letters_NN
of_PIN
credit_NN
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Group_NN
had_VBD
the_DT
following_VBG
letters_NN
of_PIN
credit_NN
:_:
i_FPP1
An_DT
irrevocable_JJ
standby_JJ
letter_NN
of_PIN
credit_NN
with_PIN
Barclays_NN
Bank_NN
plc_NN
in_PIN
the_DT
amount_NN
of_PIN
$_$
15_CD
million_CD
2004_CD
:_:
$_$
15_CD
million_CD
providing_VBG
security_NOMZ
on_PIN
the_DT
recoverability_NOMZ
of_PIN
insurance_NN
claims_NN
._.
The_DT
Group_NN
had_VBD [PEAS]
restricted_VBN
cash_NN
of_PIN
$_$
15_CD
million_CD
2004_CD
:_:
$_$
16_CD
million_CD
as_IN
required_VBN [SUAV]
by_PIN
this_DEMO
letter_NN
of_PIN
credit_NN
._.
ii_FW
An_DT
irrevocable_JJ
standby_JJ
letter_NN
of_PIN
credit_NN
with_PIN
Bank_NN
of_PIN
America_NN
in_PIN
the_DT
amount_NN
of_PIN
$_$
7.9_CD
million_CD
,_,
providing_VBG
security_NOMZ
on_PIN
the_DT
payment_NOMZ
of_PIN
lease_NN
obligations_NOMZ
._.
The_DT
Group_NN
has_VPRT [PEAS]
restricted_VBN
cash_NN
of_PIN
$_$
7.9_CD
million_CD
,_,
as_IN
required_VBN [SUAV]
by_PIN
this_DEMO
letter_NN
of_PIN
credit_NN
._.
d_LS
Capital_NN
commitments_NOMZ
i_FPP1
DAYTRANA_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Groups_NN
acquisition_NOMZ
in_PIN
2003_CD
from_PIN
Noven_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Noven_NN
of_PIN
the_DT
worldwide_JJ
sales_NN
and_PHC
marketing_GER
rights_NN
to_PIN
DAYTRANA_NN
,_,
the_DT
Group_NN
has_VPRT
an_DT
obligation_NOMZ
to_TO
make_VB
certain_JJ
payments_NOMZ
on_PIN
the_DT
achievement_NOMZ
of_PIN
the_DT
following_VBG
milestones_NN
:_:
$_$
50_CD
million_CD
upon_PIN
FDA_NN
approval_NN
of_PIN
the_DT
product_NN
,_,
which_WDT [SERE]
will_PRMD
be_VB [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
its_PIT
useful_JJ
economic_JJ
life_NN
:_:
and_ANDC
up_RB
to_TO
$_$
75_CD
million_CD
,_,
linked_VBN [PASTP]
to_PIN
future_JJ
sales_NN
performance_NN
._.
An_DT
approvable_JJ
letter_NN
was_VBD [PASS]
received_VBN
from_PIN
the_DT
FDA_NN
on_PIN
December_NN
23_CD
,_,
2005_CD
._.
Final_JJ
regulatory_JJ
approval_NN
is_VPRT [SPAU] [PASS]
currently_RB
expected_VBN [PRIV]
to_TO
be_VB [BEMA]
in_PIN
2006_CD
._.
ii_FW
NRP104_CD
In_PIN
connection_NOMZ
with_PIN
the_DT
Groups_NN
collaboration_NOMZ
with_PIN
New_NN
River_NN
to_TO
commercialise_VB
NRP104_NN
,_,
the_DT
Group_NN
has_VPRT
an_DT
obligation_NOMZ
to_TO
make_VB
certain_JJ
payments_NOMZ
on_PIN
the_DT
achievement_NOMZ
of_PIN
the_DT
following_VBG
milestones_NN
:_:
$_$
50_CD
million_CD
upon_PIN
the_DT
FDAs_NN
acceptance_NN
of_PIN
filing_NN
of_PIN
the_DT
NDA_NN
:_:
up_RP
to_TO
$_$
300_CD
million_CD
following_VBG
the_DT
first_JJ
commercial_JJ
sale_NN
of_PIN
the_DT
product_NN
,_,
depending_VBG [PRESP]
on_PIN
the_DT
characteristics_NN
of_PIN
the_DT
approved_VBN
product_NN
labeling_VBG [WZPRES]
:_:
$_$
100_CD
million_CD
on_PIN
achieving_VBG
a_DT
significant_JJ
sales_NN
target_NN
:_:
and_ANDC
$_$
5_CD
million_CD
following_VBG
the_DT
first_JJ
commercial_JJ
sale_NN
in_PIN
certain_JJ
specified_VBN
EU_NN
markets_NN
._.
An_DT
upfront_JJ
payment_NOMZ
of_PIN
$_$
50_CD
million_CD
was_VBD [PASS]
capitalized_VBN
during_PIN
the_DT
first_JJ
quarter_NN
of_PIN
2005_CD
._.
The_DT
NDA_NN
for_PIN
NRP104_NN
was_VBD [PASS]
filed_VBN
on_PIN
December_NN
6_CD
,_,
2005_CD
and_CC
accepted_VBD [PRIV]
for_PIN
review_NN
by_PIN
the_DT
FDA_NN
on_PIN
January_NN
26_CD
,_,
2006_CD
,_,
triggering_VBG [PRESP]
the_DT
$_$
50_CD
million_CD
milestone_NN
payment_NOMZ
,_,
which_WDT [SERE]
has_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
paid_VBN
._.
iii_FW
FOSRENOL_NN
patent_NN
rights_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Groups_NN
purchase_NN
of_PIN
the_DT
global_JJ
patents_NN
for_PIN
FOSRENOL_NN
from_PIN
AnorMED_NN
Inc._NN
in_PIN
2004_CD
,_,
the_DT
Group_NN
has_VPRT
outstanding_JJ
commitments_NOMZ
to_TO
pay_VB
AnorMED_NN
Inc._NN
$_$
6_CD
million_CD
when_RB
FOSRENOL_NN
is_VPRT [PASS]
approved_VBN
in_PIN
certain_JJ
European_JJ
countries_NN
and_CC
$_$
6_CD
million_CD
upon_PIN
receipt_NN
of_PIN
regulatory_JJ
approval_NN
in_PIN
Japan_NN
._.
iv_NN
Other_JJ
research_NN
and_PHC
development_NOMZ
commitments_NOMZ
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Group_NN
had_VBD
commitments_NOMZ
of_PIN
$_$
18_CD
million_CD
payable_JJ
on_PIN
achievement_NOMZ
of_PIN
specified_VBN
milestones_NN
for_PIN
products_NN
under_IN
development_NOMZ
in-licensed_JJ
from_PIN
third_JJ
parties_NN
,_,
of_PIN
which_WDT [PIRE]
$_$
6.6_CD
million_CD
is_VPRT [PASS]
committed_VBN
to_TO
be_VB [PASS]
paid_VBN
in_PIN
2006_CD
._.
94_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
95_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
35_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
v_JJ
TKT_NN
shareholders_NN
seeking_VBG [WZPRES]
appraisal_NN
rights_NN
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
appraisal_NN
rights_NN
had_VBD [PEAS]
been_VBN [PASS]
asserted_VBN [PUBV]
in_PIN
respect_NN
of_PIN
approximately_RB
11.3_CD
million_CD
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
._.
For_PIN
further_JJ
information_NOMZ
see_VPRT [PRIV]
section_NOMZ
g_NN
below_PLACE
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Group_NN
recorded_VBD
a_DT
liability_NOMZ
of_PIN
$_$
419.9_CD
million_CD
based_VBN
on_PIN
the_DT
merger_NN
consideration_NOMZ
of_PIN
$_$
37_CD
per_PIN
share_NN
for_PIN
the_DT
11.3_CD
million_CD
shares_NN
subject_JJ
to_PIN
appraisal_NN
rights_NN
at_PIN
that_DEMO
time_NN
plus_PIN
a_DT
provision_NN
for_PIN
interest_NN
of_PIN
$_$
7.7_CD
million_CD
that_DEMP
may_POMD
be_VB [BYPA]
awarded_VBN
by_PIN
the_DT
Court_NN
see_VB [PRIV]
Note_VB [PRIV]
11_CD
._.
Until_IN
such_JJ
time_NN
as_IN
the_DT
appraisal_NN
process_NN
is_VPRT [BEMA]
complete_PRED
the_DT
Group_NN
is_VPRT [BEMA]
unable_PRED
to_TO
determine_VB [SUAV] [PRIV]
the_DT
extent_NN
of_PIN
its_PIT
liability_NOMZ
._.
For_PIN
every_QUAN
$_$
1_CD
increase_NN
decrease_NN
in_PIN
the_DT
merger_NN
consideration_NOMZ
applicable_JJ
to_PIN
those_DEMO
former_JJ
TKT_NN
shareholders_NN
who_WP [WHSUB]
have_VPRT [PEAS]
asserted_VBN [PUBV]
appraisal_NN
rights_NN
,_,
the_DT
total_JJ
estimated_JJ
purchase_NN
price_NN
would_PRMD
increase_VB
decrease_NN
by_PIN
approximately_RB
$_$
11.3_CD
million_CD
._.
vi_FW
Clinical_JJ
testing_GER
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
,_,
the_DT
Group_NN
had_VBD [PEAS]
committed_VBN
to_TO
pay_VB
approximately_RB
$_$
16.3_CD
million_CD
to_TO
contract_VB
vendors_NN
for_PIN
administering_VBG
and_PHC
executing_VBG
clinical_JJ
trials_NN
._.
The_DT
timing_NN
of_PIN
payments_NOMZ
is_VPRT
not_XX0
reasonably_RB
certain_PRED
as_IN
payments_NOMZ
are_VPRT [BEMA]
dependent_PRED
upon_PIN
actual_JJ
services_NN
performed_VBN [WZPAST]
by_PIN
the_DT
organizations_NOMZ
as_IN
determined_VBN [SUAV] [PRIV]
by_PIN
patient_JJ
enrolment_NOMZ
levels_NN
and_CC
related_JJ
activities_NOMZ
._.
However_CONJ
,_,
the_DT
Group_NN
expects_VPRT [PRIV]
to_TO
pay_VB
$_$
13.2_CD
million_CD
for_PIN
these_DEMO
commitments_NOMZ
throughout_PIN
2006_CD
as_IN
ongoing_JJ
trials_NN
are_VPRT [PASS]
completed_VBN
and_CC
the_DT
remainder_NN
in_PIN
2007_CD
._.
vii_FW
Contract_NN
manufacturing_GER
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Group_NN
had_VBD [PEAS]
committed_VBN
to_TO
pay_VB
approximately_RB
$_$
23.1_CD
million_CD
in_PIN
respect_NN
of_PIN
contract_NN
manufacturing_GER
over_IN
the_DT
next_JJ
12_CD
months_NN
._.
viii_FW
Investment_NOMZ
commitments_NOMZ
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Group_NN
had_VBD
outstanding_JJ
commitments_NOMZ
to_TO
subscribe_VB
for_PIN
interests_NN
in_PIN
companies_NN
and_PHC
partnerships_NN
for_PIN
amounts_NN
totalling_VBG [WZPRES]
$_$
25.2_CD
million_CD
2004_CD
:_:
$_$
22_CD
million_CD
of_PIN
which_WDT [PIRE]
$_$
9.9_CD
million_CD
is_VPRT [PASS]
committed_VBN
in_PIN
2006_CD
and_CC
a_DT
further_JJ
$_$
2.9_CD
million_CD
could_POMD
be_VB [BEMA]
payable_PRED
in_PIN
2006_CD
,_,
depending_VBG [PRESP]
on_PIN
the_DT
timing_NN
of_PIN
capital_NN
calls_NN
._.
ix_NN
Manufacturing_GER
facilities_NOMZ
At_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Group_NN
had_VBD [PEAS]
committed_VBN
a_DT
total_NN
of_PIN
$_$
6.1_CD
million_CD
to_PIN
the_DT
expansion_NN
and_PHC
modification_NOMZ
of_PIN
its_PIT
manufacturing_GER
facilities_NOMZ
at_PIN
Owings_NN
Mills_NN
,_,
Maryland_NN
and_PHC
Cambridge_NN
,_,
Massachusetts_NN
._.
Of_PIN
this_DEMO
total_NN
,_,
$_$
3.2_CD
million_CD
is_VPRT
to_TO
facilitate_VB
the_DT
production_NOMZ
and_PHC
packaging_GER
of_PIN
additional_JJ
strategic_JJ
products_NN
and_CC
$_$
2.9_CD
million_CD
is_VPRT [BEMA]
for_PIN
the_DT
design_NN
and_PHC
construction_NOMZ
of_PIN
a_DT
technology_NN
center_NN
at_PIN
Owings_NN
Mills_NN
._.
All_QUAN
costs_NN
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
2006_CD
._.
x_LS
Basingstoke_NN
,_,
UK_NN
expansion_NN
The_NN
Group_NN
is_VPRT [BEMA]
in_PIN
the_DT
process_NN
of_PIN
expanding_VBG
its_PIT
UK_NN
headquarters_NN
at_PIN
Basingstoke_NN
,_,
UK_NN
._.
As_IN
at_PIN
December_NN
31_CD
,_,
2005_CD
the_DT
Group_NN
had_VBD
an_DT
outstanding_JJ
commitment_NOMZ
of_PIN
$_$
4.5_CD
million_CD
,_,
which_WDT [SERE]
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
2006_CD
._.
e_LS
Contingent_JJ
liabilities_NOMZ
The_DT
Group_NN
is_VPRT [PASS]
involved_VBN
in_PIN
various_JJ
legal_JJ
proceedings_GER
,_,
including_VBG [PRESP]
those_DEMP
set_VBN
out_PIN
below_PLACE
._.
Although_CONC
there_EX
can_POMD
be_VB
no_SYNE
assurance_NN
regarding_VBG [WZPRES]
the_DT
outcome_NN
of_PIN
any_QUAN
of_PIN
the_DT
legal_JJ
proceedings_GER
referred_VBD
to_PIN
below_PLACE
,_,
Shire_NN
believes_VPRT [PRIV]
that_THVC
they_TPP3
will_PRMD
not_XX0
have_VB
a_DT
materially_RB
adverse_JJ
effect_NN
on_PIN
the_DT
Groups_NN
reported_VBD [PUBV]
financial_JJ
position_NOMZ
._.
PHENTERMINE_NN
Shire_NN
US_FPP1
Inc._NN
._.
SUS_NN
,_,
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Shire_NN
,_,
is_VPRT [BEMA]
a_DT
defendant_NN
in_PIN
ten_NN
lawsuits_NN
still_RB
pending_VBG
in_PIN
both_DT
US_FPP1
federal_JJ
and_CC
state_NN
courts_NN
which_WDT [WHSUB]
seek_VPRT
damages_NN
for_PIN [STPR]
,_,
among_PIN
other_JJ
things_NN
,_,
personal_JJ
injury_NN
arising_VBG [WZPRES]
from_PIN
phentermine_NN
products_NN
supplied_VBD
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
by_PIN
SUS_NN
and_CC
several_QUAN
other_JJ
pharmaceutical_JJ
companies_NN
._.
SUS_NN
,_,
formerly_TIME
known_VBN [PRIV]
as_IN
Shire_NN
Richwood_NN
Inc._NN
has_VPRT [PEAS]
been_VBN [PASS]
sued_VBN
as_IN
a_DT
manufacturer_NN
and_PHC
distributor_NN
of_PIN
phentermine_NN
,_,
an_DT
anorectic_NN
used_VBN [WZPAST]
in_PIN
the_DT
short-term_JJ
treatment_NOMZ
of_PIN
obesity_NOMZ
and_CC
one_CD
of_PIN
the_DT
products_NN
addressed_VBN [WZPAST]
by_PIN
the_DT
lawsuits_NN
._.
The_DT
suits_NN
relate_VPRT
to_TO
phentermine_VB
either_CC
alone_RB
or_CC
together_RB
with_PIN
fenfluramine_NN
or_CC
dexenfluramine_NN
._.
The_DT
lawsuits_NN
generally_RB
allege_VPRT [PUBV]
the_DT
following_VBG
claims_NN
:_:
the_DT
defendants_NN
marketed_VBN
phentermine_NN
and_CC
other_JJ
products_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
obesity_NOMZ
and_CC
misled_VBD
users_NN
about_IN
the_DT
products_NN
and_PHC
dangers_NN
associated_VBN [WZPAST]
with_PIN
them_TPP3
:_:
the_DT
defendants_NN
failed_VBD
adequately_RB
to_PIN
test_NN
phentermine_NN
individually_RB
and_ANDC
when_RB
taken_VBN
in_PIN
combination_NOMZ
with_PIN
the_DT
other_JJ
drugs_NN
:_:
and_ANDC
the_DT
defendants_NN
knew_VBD [PRIV]
or_CC
should_NEMD
have_VB [PEAS]
known_VBN [PRIV]
about_IN
the_DT
negative_JJ
effects_NN
of_PIN
the_DT
drugs_NN
and_CC
should_NEMD
have_VB [PEAS]
informed_VBN
the_DT
public_JJ
about_IN
such_JJ
risks_NN
and_CC
or_CC
failed_VBD
to_TO
provide_VB
appropriate_JJ
warning_GER
labels_NN
._.
SUS_NN
has_VPRT [PEAS]
been_VBN [PASS]
named_VBN
as_IN
a_DT
defendant_NN
in_PIN
a_DT
total_NN
of_PIN
4,199_CD
such_JJ
phentermine_NN
lawsuits_NN
,_,
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
SUS_NN
has_VPRT [PEAS]
been_VBN [PASS]
dismissed_VBN
as_IN
a_DT
defendant_NN
in_PIN
4,189_CD
cases_NN
._.
Five_CD
of_PIN
the_DT
ten_NN
remaining_VBG [WZPRES]
cases_NN
name_NN
SUS_NN
as_IN
a_DT
defendant_NN
,_,
but_CC
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
served_VBN
as_IN
required_VBN [SUAV]
by_PIN
state_NN
and_CC
federal_JJ
rules_NN
of_PIN
civil_JJ
procedure_NN
._.
It_PIT
is_VPRT [PASS]
expected_VBN [PRIV]
that_THVC
SUS_NN
will_PRMD
be_VB [PASS]
dismissed_VBN
from_PIN
the_DT
remaining_VBG
cases_NN
based_VBN [WZPAST]
upon_PIN
lack_NN
of_PIN
product_NN
identification_NOMZ
or_CC
agreement_NOMZ
of_PIN
the_DT
parties_NN
._.
SUS_NN
became_VBD
involved_VBN
with_PIN
phentermine_NN
through_PIN
its_PIT
acquisition_NOMZ
of_PIN
certain_JJ
assets_NN
of_PIN
Rexar_NN
Pharmacal_NN
Corporation_NOMZ
Rexar_NN
in_PIN
January_NN
1994_CD
._.
In_CONJ
addition_NULL
to_PIN
SUS_NN
potentially_RB
incurring_VBG
liability_NOMZ
as_CONJ
a_NULL
result_NULL
of_PIN
its_PIT
own_JJ
production_NOMZ
of_PIN
Oby-Cap_NN
,_,
a_DT
phentermine_JJ
product_NN
,_,
the_DT
plaintiffs_NN
may_POMD [SPAU]
additionally_RB
seek_VB
to_TO
impose_VB
liability_NOMZ
on_PIN
SUS_NN
as_IN
successor_NN
to_PIN
Rexar_NN
._.
SUS_NN
intends_VPRT [SUAV]
to_TO
defend_VB
vigorously_RB
all_QUAN
the_DT
lawsuits_NN
._.
SUS_NN
denies_VPRT [PUBV]
liability_NOMZ
on_PIN
a_DT
number_NN
of_PIN
grounds_NN
including_VBG [WZPRES]
lack_NN
of_PIN
scientific_JJ
evidence_NN
that_DEMO
phentermine_NN
,_,
properly_RB
prescribed_VBN
,_,
causes_VPRT
the_DT
alleged_JJ
side_NN
effects_NN
and_CC
that_THVC
SUS_NN
did_VBD
not_XX0
promote_VB
phentermine_NN
for_PIN
long-term_JJ
combined_VBN
use_NN
as_IN
part_NN
of_PIN
the_DT
fen_NN
phen_NN
diet_NN
._.
Accordingly_RB
,_,
SUS_NN
intends_VPRT [SUAV]
to_TO
defend_VB
vigorously_RB
any_QUAN
and_CC
all_QUAN
claims_NN
made_VBN [WZPAST]
against_PIN
the_DT
Group_NN
in_PIN
respect_NN
of_PIN
phentermine_NN
._.
Legal_JJ
expenses_NN
to_PIN
date_NN
have_VPRT [PEAS]
been_VBN [BYPA]
paid_VBN
by_PIN
Eon_NN
Labs_NN
,_,
Inc._NN
._.
Eon_NN
,_,
the_DT
supplier_NN
to_PIN
SUS_NN
,_,
or_CC
Eons_NN
insurance_NN
carriers_NN
but_CC
such_JJ
insurance_NN
is_VPRT [SPAU] [PASS]
now_TIME
exhausted_VBN
._.
Eon_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
defend_VB
and_PHC
indemnify_VB
SUS_NN
in_PIN
this_DEMO
litigation_NOMZ
pursuant_JJ
to_PIN
an_DT
agreement_NOMZ
dated_VBN
November_NN
30_CD
,_,
2000_CD
between_PIN
Eon_NN
and_PHC
SUS_NN
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
95_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
96_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
35_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
ADDERALL_NN
XR_NN
i_FPP1
Barr_NN
Laboratories_NN
,_,
Inc._NN
._.
The_DT
Groups_NN
extended_VBD
release_NN
once_TIME
daily_JJ
version_NN
of_PIN
ADDERALL_NN
,_,
ADDERALL_NN
XR_NN
is_VPRT [BYPA]
covered_VBN
by_PIN
US_FPP1
patent_NN
No._NN
._.
6,322,819_CD
the_DT
819_CD
Patent_NN
and_PHC
US_FPP1
patent_NN
No._NN
._.
In_PIN
January_NN
2003_CD
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Barr_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
versions_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
,_,
25mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
Barrs_NN
ANDA_NN
products_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
Shires_NN
819_CD
Patent_NN
,_,
and_ANDC
alleging_VBG [PUBV]
that_THVC
the_DT
819_CD
Patent_NN
is_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Barrs_NN
ANDA_NN
products_NN
._.
In_PIN
August_NN
2003_CD
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Barr_NN
also_RB
was_VBD
seeking_VBG
permission_NN
to_TO
market_VB
its_PIT
ANDA_NN
products_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
300_CD
Patent_NN
and_CC
alleging_VBG [PUBV]
that_THVC
the_DT
300_CD
Patent_NN
is_VPRT [BEMA]
invalid_PRED
._.
Shire_NN
Laboratories_NN
,_,
Inc_NN
,_,
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Barr_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
819_CD
Patent_NN
in_PIN
February_NN
2003_CD
and_CC
for_PIN
infringement_NOMZ
of_PIN
the_DT
300_CD
Patent_NN
in_PIN
September_NN
2003_CD
._.
The_DT
schedules_NN
for_PIN
the_DT
lawsuits_NN
against_PIN
Barr_NN
with_PIN
respect_NN
to_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
were_VBD [PASS]
consolidated_VBN
in_PIN
December_NN
2003_CD
._.
Shire_NN
Laboratories_NN
is_VPRT
seeking_VBG
a_DT
ruling_NN
that_TSUB
Barrs_VPRT
ANDA_NN
and_PHC
ANDA_NN
products_NN
infringe_VPRT
the_DT
819_CD
and_CC
300_CD
Patents_NN
and_CC
that_THVC
its_PIT
ANDA_NN
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
patents_NN
._.
Shire_NN
Laboratories_NN
is_VPRT [SPAU]
also_RB
seeking_VBG
injunctions_NOMZ
to_TO
prevent_VB
Barr_NN
from_PIN
commercializing_VBG
its_PIT
ANDA_NN
products_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialization_NOMZ
and_CC
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
On_PIN
September_NN
27_CD
,_,
2004_CD
Barr_NN
filed_VBD
an_DT
amended_VBN
Answer_NN
,_,
Affirmative_NN
Defense_NN
and_PHC
Counterclaim_NN
in_PIN
which_WDT [PIRE]
Barr_NN
added_VBD [PUBV]
the_DT
following_VBG
counterclaims_NN
:_:
invalidity_NOMZ
of_PIN
the_DT
819_CD
patent_NN
,_,
non-infringement_NOMZ
of_PIN
the_DT
300_CD
Patent_NN
and_PHC
unenforceability_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
due_JJ
to_PIN
inequitable_JJ
conduct_NN
._.
Shire_NN
Laboratories_NN
has_VPRT [PEAS]
asserted_VBN [PUBV]
affirmative_JJ
defences_NN
,_,
alleging_VBG [PUBV]
,_,
among_PIN
other_JJ
things_NN
,_,
that_THVC
Barr_NN
has_VPRT [PEAS]
waived_VBN
its_PIT
right_NN
to_TO
assert_VB [PUBV] [THATD]
the_DT
counterclaims_NN
set_VBN [WZPAST]
forth_RB
in_PIN
its_PIT
September_NN
27_CD
,_,
2004_CD
amended_VBN
Answer_NN
._.
Under_IN
the_DT
Courts_NN
schedule_NN
summary_NN
judgement_NOMZ
motions_NOMZ
were_VBD
to_TO
be_VB [PASS]
filed_VBN
and_CC
fully_AMP
briefed_VBN
by_PIN
October_NN
14_CD
,_,
2005_CD
._.
Neither_SYNE
Shire_NN
Laboratories_NN
nor_SYNE
Barr_NN
filed_VBD
summary_NN
judgement_NOMZ
motions_NOMZ
._.
At_PIN
a_DT
March_NN
10_CD
,_,
2006_CD
pre-trial_JJ
conference_NN
the_DT
Court_NN
set_VBD
a_DT
bench_NN
trial_NN
date_NN
of_PIN
October_NN
30_CD
,_,
2006_CD
._.
Shires_NN
lawsuits_NN
triggered_VBD
stays_NN
of_PIN
final_JJ
FDA_NN
approval_NN
of_PIN
Barrs_NN
ANDA_NN
of_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
the_DT
date_NN
of_PIN
the_DT
Companys_NN
receipt_NN
of_PIN
Barrs_NN
notice_NN
letters_NN
._.
The_DT
30_CD
month_NN
stay_VB
related_VBN
to_PIN
the_DT
lawsuit_NN
regarding_VBG [WZPRES]
the_DT
300_CD
Patent_NN
expired_VBD
on_PIN
February_NN
18_CD
,_,
2006_CD
._.
As_IN
the_DT
stay_NN
has_VPRT [PEAS]
expired_VBN
,_,
the_DT
FDA_NN
may_POMD
approve_VB
Barrs_NN
ANDA_NN
,_,
subject_JJ
to_PIN
satisfaction_NOMZ
by_PIN
Barr_NN
of_PIN
the_DT
FDAs_NN
requirements_NOMZ
._.
Barr_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
ANDA_NN
products_NN
upon_PIN
receipt_NN
of_PIN
final_JJ
FDA_NN
approval_NN
._.
On_PIN
October_NN
19_CD
,_,
2005_CD
the_DT
Company_NN
brought_VBD
another_DT
lawsuit_NN
against_PIN
Barr_NN
in_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
US_FPP1
Patent_NN
No._NN
._.
The_DT
Company_NN
is_VPRT
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Barr_NN
from_PIN
infringing_VBG
the_DT
768_CD
Patent_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Barr_NN
should_NEMD
commercialise_VB
its_PIT
ANDA_NN
Products_NN
,_,
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
Barr_NN
has_VPRT [PEAS]
moved_VBN [SUAV]
to_TO
dismiss_VB
this_DEMO
action_NOMZ
asserting_VBG [PUBV] [WZPRES]
that_THVC
there_EX
is_VPRT
no_SYNE
subject_JJ
matter_NN
jurisdiction_NOMZ
._.
A_DT
hearing_GER
on_PIN
this_DEMO
motion_NOMZ
was_VBD [PASS]
held_VBN [PRIV]
on_PIN
February_NN
17_CD
,_,
2006_CD
._.
No_SYNE
decision_NN
on_PIN
this_DEMO
motion_NOMZ
has_VPRT [SPAU] [PEAS]
yet_RB
been_VBN [PASS]
made_VBN
._.
In_PIN
November_NN
2003_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Impax_NN
Laboratories_NN
,_,
Inc._NN
._.
Impax_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
the_DT
30mg_JJ
strength_NN
of_PIN
ADDERALL_NN
XR_NN
Impaxs_NN
ANDA_NN
product_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
In_PIN
December_NN
2003_CD
,_,
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Impax_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
In_PIN
December_NN
2004_CD
,_,
Shire_NN
received_VBD
an_DT
additional_JJ
notification_NOMZ
from_PIN
Impax_NN
advising_VBG [WZPRES]
of_PIN
the_DT
filing_NN
of_PIN
an_DT
amendment_NOMZ
to_PIN
its_PIT
ANDA_NN
for_PIN
a_DT
generic_JJ
version_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
and_PHC
25mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
in_CONJ
addition_NULL
to_PIN
the_DT
30mg_JJ
strength_NN
,_,
the_DT
subject_NN
of_PIN
Impaxs_NN
initial_JJ
ANDA_NN
submission_NN
._.
In_PIN
January_NN
2005_CD
,_,
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Impax_NN
for_PIN
infringement_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
As_IN
part_NN
of_PIN
the_DT
October_NN
19_CD
,_,
2005_CD
lawsuit_NN
against_PIN
Barr_NN
,_,
Shire_NN
also_RB
brought_VBD
suit_NN
in_PIN
the_DT
Southern_NN
District_NN
of_PIN
New_NN
York_NN
against_PIN
Impax_NN
for_PIN
infringing_VBG
the_DT
768_CD
Patent_NN
._.
Impax_NN
filed_VBD
a_DT
declaratory_JJ
judgement_NOMZ
action_NOMZ
in_PIN
Delaware_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
the_DT
768_CD
Patent_NN
was_VBD [BEMA]
invalid_PRED
and_CC
that_THVC
its_PIT
ANDA_NN
did_VBD
not_XX0
infringe_VB
the_DT
768_CD
Patent_NN
._.
On_PIN
January_NN
19_CD
,_,
2006_CD
,_,
Shire_NN
and_PHC
Impax_NN
announced_VBD [PUBV]
that_THVC
all_QUAN
pending_VBG
litigation_NOMZ
in_PIN
connection_NOMZ
with_PIN
Impaxs_NN
ANDA_NN
had_VBD [PEAS]
been_VBN [PASS]
settled_VBN
._.
As_IN
part_NN
of_PIN
the_DT
settlement_NOMZ
,_,
Impax_NN
confirmed_VBD [PUBV]
that_THVC
its_PIT
proposed_VBN [SUAV] [THATD]
generic_JJ
products_NN
infringe_VPRT
Shires_NN
819_CD
,_,
300_CD
and_CC
768_CD
Patents_NN
and_CC
that_THVC
the_DT
three_CD
patents_NN
are_VPRT [BEMA]
valid_PRED
and_PHC
enforceable_PRED
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
settlement_NOMZ
agreement_NOMZ
,_,
Impax_NN
will_PRMD
be_VB [PASS]
permitted_VBN
to_PIN
market_NN
generic_JJ
versions_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
the_DT
United_NN
States_NN
no_RB
later_TIME
than_PIN
January_NN
1_CD
,_,
2010_CD
and_CC
will_PRMD
pay_VB
Shire_NN
a_DT
royalty_NN
from_PIN
those_DEMO
sales_NN
._.
In_PIN
certain_JJ
situations_NOMZ
,_,
such_JJ
as_IN
the_DT
launch_NN
of_PIN
another_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
,_,
Impax_NN
may_POMD
be_VB [PASS]
permitted_VBN
to_TO
enter_VB
the_DT
market_NN
as_IN
Shires_NN
authorised_VBD
generic_JJ
._.
No_SYNE
payments_NOMZ
to_PIN
Impax_NN
are_VPRT [PASS]
involved_VBN
in_PIN
the_DT
settlement_NOMZ
agreement_NOMZ
._.
The_DT
settlement_NOMZ
agreement_NOMZ
,_,
which_WDT [SERE]
was_VBD [BEMA]
effective_JJ
immediately_TIME
,_,
has_VPRT [PEAS]
been_VBN [PASS]
submitted_VBN [PUBV]
to_PIN
the_DT
United_NN
States_NN
Federal_NN
Trade_NN
Commission_NN
FTC_NN
for_PIN
its_PIT
review_NN
,_,
as_IN
required_VBN [SUAV]
by_PIN
law_NN
._.
In_PIN
December_NN
2004_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Colony_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Colony_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
versions_NN
of_PIN
the_DT
5mg_JJ
,_,
10mg_JJ
,_,
15mg_JJ
,_,
20mg_JJ
,_,
25mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
819_CD
and_CC
300_CD
Patents_NN
._.
Shire_NN
has_VPRT [PEAS]
chosen_VBN
not_XX0
to_TO
sue_VB
Colony_NN
._.
96_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
97_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
35_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
iv_NN
Teva_NN
Pharmaceuticals_NN
USA_NN
,_,
Inc._NN
._.
In_PIN
February_NN
2005_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Teva_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Teva_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
versions_NN
of_PIN
the_DT
10mg_JJ
and_PHC
30mg_JJ
strengths_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
819_CD
and_CC
300_CD
Patents_NN
._.
In_PIN
June_NN
2005_CD
,_,
Shire_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Teva_NN
had_VBD [PEAS]
amended_VBN
its_PIT
ANDA_NN
to_TO
seek_VB
permission_NN
to_PIN
market_NN
additional_JJ
strengths_NN
of_PIN
5mg_CD
,_,
15mg_CD
and_CC
20mg_CD
of_PIN
its_PIT
generic_JJ
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
In_PIN
January_NN
2006_CD
,_,
Shire_NN
received_VBD
a_DT
third_JJ
notice_NN
letter_NN
that_TOBJ
Teva_NN
had_VBD
further_JJ
amended_VBN
its_PIT
ANDA_NN
to_TO
seek_VB
permission_NN
to_TO
market_VB
the_DT
25mg_JJ
strength_NN
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
On_PIN
March_NN
2_CD
,_,
2006_CD
,_,
Shire_NN
filed_VBD
a_DT
lawsuit_NN
in_PIN
the_DT
Eastern_NN
District_NN
of_PIN
Pennsylvania_NN
alleging_VBG [PUBV] [WZPRES]
that_THVC
Tevas_NN
ANDA_NN
products_NN
infringe_VPRT
both_DT
the_DT
819_CD
and_CC
300_CD
Patents_NN
._.
The_DT
lawsuit_NN
will_PRMD
trigger_VB
a_DT
stay_NN
of_PIN
FDA_NN
approval_NN
of_PIN
Tevas_NN
25mg_JJ
strength_NN
product_NN
for_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
the_DT
date_NN
of_PIN
the_DT
Companys_NN
receipt_NN
of_PIN
Tevas_NN
notice_NN
._.
There_EX
is_VPRT
no_SYNE
such_JJ
stay_NN
with_PIN
respect_NN
to_PIN
Tevas_NN
5mg_CD
,_,
10mg_CD
,_,
15mg_CD
,_,
20mg_JJ
and_PHC
30mg_JJ
strength_NN
versions_NN
of_PIN
ADDERALL_NN
XR_NN
._.
None_INPR
of_PIN
Barr_NN
,_,
Colony_NN
or_CC
Teva_NN
may_POMD
launch_VB
their_TPP3
generic_JJ
versions_NN
of_PIN
ADDERALL_NN
XR_NN
before_IN
they_TPP3
receive_VPRT
final_JJ
FDA_NN
approval_NN
of_PIN
their_TPP3
respective_JJ
ANDAs_NN
._.
The_DT
FDA_NN
may_POMD
grant_VB [SUAV]
180_CD
days_NN
of_PIN
generic_JJ
market_NN
exclusivity_NOMZ
to_PIN
Barr_NN
as_IN
the_DT
first_JJ
to_TO
file_VB
an_DT
ANDA_NN
for_PIN
a_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
._.
Neither_SYNE
Colony_NN
nor_SYNE
Teva_NN
may_POMD
market_VB
their_TPP3
ANDA_NN
products_NN
until_IN
the_DT
FDA_NN
grants_NN
a_DT
final_JJ
approval_NN
of_PIN
their_TPP3
ANDAs_NN
and_CC
upon_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
first_JJ
to_PIN
files_NN
exclusivity_NOMZ
rights_NN
._.
CARBATROL_NN
In_PIN
August_NN
2003_CD
,_,
the_DT
Company_NN
was_VBD [PASS]
notified_VBN
that_DEMO
Nostrum_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
Nostrum_NN
had_VBD [PEAS]
submitted_VBN [PUBV]
an_DT
ANDA_NN
under_IN
the_DT
Hatch-Waxman_NN
Act_NN
seeking_VBG [WZPRES]
permission_NN
to_TO
market_VB
its_PIT
generic_JJ
version_NN
of_PIN
the_DT
300mg_JJ
strength_NN
of_PIN
CARBATROL_NN
Nostrums_NN
ANDA_NN
product_NN
prior_RB
to_PIN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
Companys_NN
US_FPP1
patents_NN
for_PIN
CARBATROL_NN
,_,
US_FPP1
patent_NN
No._NN
._.
5,912,013_CD
the_DT
013_CD
Patent_NN
and_PHC
US_FPP1
patent_NN
No._NN
._.
The_DT
notification_NOMZ
alleges_VPRT [PUBV]
that_THVC
the_DT
013_CD
and_CC
570_CD
Patents_NN
are_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Nostrums_NN
ANDA_NN
product_NN
._.
On_PIN
September_NN
18_CD
,_,
2003_CD
,_,
Shire_NN
Laboratories_NN
filed_VBD
suit_NN
against_PIN
Nostrum_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
New_NN
Jersey_NN
alleging_VBG [PUBV] [WZPRES]
infringement_NOMZ
of_PIN
these_DEMO
two_CD
patents_NN
by_PIN
Nostrums_NN
ANDA_NN
and_PHC
ANDA_NN
product_NN
._.
Shire_NN
Laboratories_NN
was_VBD
seeking_VBG
a_DT
ruling_NN
that_TSUB
Nostrums_VPRT
ANDA_NN
infringes_VPRT
the_DT
013_CD
and_CC
570_CD
Patents_NN
and_CC
should_NEMD
not_XX0
be_VB [PASS]
approved_VBN
before_IN
the_DT
expiration_NOMZ
date_NN
of_PIN
the_DT
013_CD
and_CC
570_CD
Patents_NN
._.
Shire_NN
Laboratories_NN
was_VBD [SPAU]
also_RB
seeking_VBG
an_DT
injunction_NOMZ
to_TO
prevent_VB
Nostrum_NN
from_PIN
commercializing_VBG
its_PIT
ANDA_NN
product_NN
before_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
013_CD
and_CC
570_CD
Patents_NN
,_,
damages_NN
in_PIN
the_DT
event_NN
that_TOBJ
Nostrum_NN
should_NEMD
engage_VB
in_PIN
such_JJ
commercialization_NOMZ
,_,
as_RB
well_RB
as_IN
its_PIT
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
On_PIN
January_NN
23_CD
,_,
2004_CD
,_,
Shire_NN
Laboratories_NN
amended_VBD
the_DT
complaint_NN
to_TO
drop_VB
the_DT
allegations_NOMZ
with_PIN
respect_NN
to_PIN
the_DT
013_CD
Patent_NN
while_OSUB
maintaining_VBG [PUBV]
the_DT
suit_NN
with_PIN
respect_NN
to_PIN
the_DT
570_CD
Patent_NN
._.
By_PIN
way_NN
of_PIN
counterclaims_NN
Nostrum_NN
is_VPRT
seeking_VBG
a_DT
declaration_NOMZ
that_TOBJ
the_DT
570_CD
and_CC
013_CD
Patents_NN
are_VPRT [BYPA]
not_XX0
infringed_VBN
by_PIN
Nostrums_NN
ANDA_NN
product_NN
._.
Nostrum_NN
also_RB
was_VBD
seeking_VBG
actual_JJ
and_PHC
punitive_JJ
damages_NN
for_PIN
alleged_JJ
abuse_NN
of_PIN
process_NN
by_PIN
Shire_NN
Laboratories_NN
._.
On_PIN
July_NN
12_CD
,_,
2004_CD
,_,
the_DT
Court_NN
dismissed_VBD
Nostrums_NN
abuse_NN
of_PIN
process_NN
counterclaim_NN
for_PIN
failure_NN
to_TO
state_VB [PUBV]
a_DT
claim_NN
upon_PIN
which_WDT [PIRE]
relief_NN
can_POMD
be_VB [PASS]
granted_VBN [SUAV]
._.
On_PIN
December_NN
10_CD
,_,
2004_CD
,_,
Nostrum_NN
filed_VBD
a_DT
summary_NN
judgement_NOMZ
motion_NOMZ
seeking_VBG [WZPRES]
a_DT
declaration_NOMZ
of_PIN
non-infringement_NOMZ
of_PIN
the_DT
570_CD
Patent_NN
._.
Shire_NN
Laboratories_NN
opposition_NOMZ
to_PIN
this_DEMO
motion_NOMZ
was_VBD [PASS]
filed_VBN
on_PIN
January_NN
14_CD
,_,
2005_CD
._.
The_DT
Court_NN
heard_VBD [PRIV]
arguments_NOMZ
with_PIN
respect_NN
to_PIN
Nostrums_NN
motion_NOMZ
on_PIN
July_NN
15_CD
,_,
2005_CD
._.
At_PIN
the_DT
conclusion_NN
of_PIN
the_DT
hearing_VBG [PRIV] [THATD]
the_DT
Court_NN
denied_VBD [PUBV]
Nostrums_NN
motion_NOMZ
for_PIN
summary_NN
judgement_NOMZ
of_PIN
noninfringement_NOMZ
._.
During_PIN
the_DT
March_NN
10_CD
,_,
2006_CD
status_NN
conference_NN
call_NN
with_PIN
the_DT
Court_NN
,_,
previously_TIME
scheduled_VBN
expert_NN
dispositions_NOMZ
and_PHC
Markman_NN
briefing_GER
were_VBD [PASS]
adjourned_VBN
._.
No_SYNE
trial_NN
date_NN
has_VPRT [PEAS]
been_VBN [PASS]
set_VBN
._.
Nostrum_NN
may_POMD
not_XX0
launch_VB
a_DT
generic_JJ
version_NN
of_PIN
CARBATROL_NN
before_IN
it_PIT
receives_VPRT
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
from_PIN
the_DT
FDA_NN
._.
The_DT
lawsuit_NN
triggered_VBD
a_DT
stay_NN
of_PIN
FDA_NN
approval_NN
of_PIN
up_RB
to_PIN
30_CD
months_NN
from_PIN
the_DT
Companys_NN
receipt_NN
of_PIN
Nostrums_NN
notice_NN
letter_NN
._.
The_DT
30_CD
month_NN
stay_VB
expired_VBN
on_PIN
February_NN
6_CD
,_,
2006_CD
._.
Following_VBG
expiry_NN
of_PIN
the_DT
stay_NN
,_,
Nostrum_NN
could_POMD
be_VB [BEMA]
in_PIN
a_DT
position_NOMZ
to_TO
market_VB
its_PIT
300mg_JJ
extended-release_NN
carbamazepine_NN
product_NN
upon_PIN
FDA_NN
final_JJ
approval_NN
of_PIN
its_PIT
ANDA_NN
._.
GA-GCB_NN
In_PIN
January_NN
2005_CD
,_,
Genzyme_NN
Corporation_NOMZ
Genzyme_NN
filed_VBD
suit_NN
against_PIN
TKT_NN
in_PIN
the_DT
District_NN
Court_NN
of_PIN
Tel_NN
Aviv-Jaffa_NN
,_,
Israel_NN
,_,
claiming_VBG [PUBV]
that_THVC
TKTs_NN
Phase_NN
1_CD
2_CD
clinical_JJ
trial_NN
in_PIN
Israel_NN
evaluating_VBG [WZPRES]
GA-GCB_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
Gaucher_NN
disease_NN
infringes_VPRT
one_CD
or_CC
more_EMPH
claims_NN
of_PIN
Genzymes_NN
Israeli_NN
Patent_NN
No._NN
._.
In_CONJ
addition_NULL
,_,
Genzyme_NN
filed_VBD
a_DT
motion_NOMZ
for_PIN
preliminary_JJ
injunction_NOMZ
,_,
including_VBG [PRESP]
a_DT
request_NN
for_PIN
an_DT
ex_FW
parte_FW
hearing_GER
and_PHC
relief_NN
on_PIN
the_DT
merits_NN
,_,
to_TO [SPIN]
immediately_TIME
seize_VB
and_PHC
destroy_VB
all_QUAN
GA-GCB_NN
being_VBG [WZPRES] [PASS]
used_VBN
to_TO
treat_VB
patients_NN
and_CC
to_TO
prevent_VB
TKT_NN
from_PIN
submitting_VBG [PUBV] [THATD]
data_NN
generated_VBD
from_PIN
the_DT
clinical_JJ
trial_NN
to_PIN
regulatory_JJ
agencies_NN
._.
In_PIN
March_NN
2005_CD
the_DT
District_NN
Court_NN
refused_VBD
to_TO
grant_VB [SUAV]
Genzymes_NN
motion_NOMZ
for_PIN
a_DT
preliminary_JJ
injunction_NOMZ
._.
The_DT
lawsuit_NN
was_VBD [PASS]
dismissed_VBN
in_PIN
January_NN
2006_CD
._.
DYNEPO_NN
In_PIN
April_NN
1997_CD
,_,
Amgen_NN
Inc._NN
._.
Amgen_NN
commenced_VBD
a_DT
patent_NN
infringement_NOMZ
action_NOMZ
against_PIN
TKT_NN
and_PHC
Sanofi-Aventis_NN
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
._.
In_PIN
January_NN
2001_CD
,_,
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
concluded_VBD [PRIV]
that_THVC
DYNEPO_NN
infringed_VBD
eight_CD
of_PIN
the_DT
18_CD
claims_NN
of_PIN
five_CD
patents_NN
that_TOBJ
Amgen_NN
had_VBD [PEAS]
asserted_VBN [PUBV]
._.
Amgen_NN
did_VBD
not_XX0
seek_VB
and_PHC
was_VBD [PASS]
not_XX0
awarded_VBN
monetary_JJ
damages_NN
._.
This_DEMO
decision_NN
was_VBD [SPAU] [PASS]
subsequently_TIME
appealed_VBN
to_PIN
the_DT
United_NN
States_NN
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Federal_NN
Circuit_NN
._.
In_PIN
January_NN
2003_CD
,_,
the_DT
United_NN
States_NN
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Federal_NN
Circuit_NN
issued_VBD
a_DT
decision_NN
affirming_VBG [PUBV] [WZPRES]
in_PIN
part_NN
and_CC
reversing_VBG
in_PIN
part_NN
the_DT
decision_NN
of_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
,_,
remanded_VBD
the_DT
action_NOMZ
to_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
for_PIN
further_JJ
proceedings_GER
and_CC
instructed_VBD [SUAV]
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
to_TO
reconsider_VB
the_DT
validity_NOMZ
of_PIN
Amgens_NN
patents_NN
in_PIN
the_DT
light_NN
of_PIN
potentially_RB
invalidating_VBG
prior_RB
art_NN
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
97_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
98_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
35_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
In_PIN
October_NN
2004_CD
,_,
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
issued_VBD
a_DT
decision_NN
on_PIN
the_DT
remanded_VBN
issues_NN
,_,
finding_VBG [PRIV]
that_THVC
certain_JJ
claims_NN
related_VBN [WZPAST]
to_PIN
four_CD
patents_NN
held_VBN [PRIV] [WZPAST]
by_PIN
Amgen_NN
are_VPRT [BYPA]
infringed_VBN
by_PIN
TKT_NN
and_PHC
Sanofi-Aventis_NN
._.
In_PIN
December_NN
2004_CD
,_,
TKT_NN
and_PHC
Sanofi-Aventis_NN
filed_VBD
a_DT
notice_NN
of_PIN
appeal_NN
of_PIN
the_DT
decision_NN
of_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
of_PIN
Massachusetts_NN
to_PIN
the_DT
United_NN
States_NN
Court_NN
of_PIN
Appeals_NN
for_PIN
the_DT
Federal_NN
Circuit_NN
._.
An_DT
oral_JJ
hearing_GER
was_VBD [PASS]
held_VBN [PRIV]
at_PIN
the_DT
Federal_NN
Circuit_NN
in_PIN
December_NN
2005_CD
._.
No_SYNE
decision_NN
has_VPRT [PEAS]
been_VBN [PASS]
rendered_VBN
at_PIN
this_DEMO
time_NN
._.
If_COND
TKT_NN
and_PHC
Sanofi-Aventis_NN
are_VPRT [BEMA]
not_XX0
successful_PRED
in_PIN
the_DT
DYNEPO_NN
litigation_NOMZ
at_PIN
the_DT
appellate_JJ
level_NN
,_,
TKT_NN
and_PHC
Sanofi-Aventis_NN
would_PRMD
be_VB [PASS]
precluded_VBN
from_PIN
making_VBG
,_,
using_VBG
and_PHC
selling_VBG
DYNEPO_NN
in_PIN
the_DT
United_NN
States_NN
until_IN
the_DT
expiration_NOMZ
of_PIN
the_DT
relevant_JJ
patents_NN
._.
TKT_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
reimburse_VB
Sanofi-Aventis_NN
,_,
which_WDT [SERE]
controls_VPRT
the_DT
litigation_NOMZ
and_CC
is_VPRT
paying_VBG
the_DT
litigation_NOMZ
expenses_NN
,_,
for_PIN
50_CD
%_NN
of_PIN
the_DT
expenses_NN
incurred_VBN [WZPAST]
in_PIN
connection_NOMZ
with_PIN
the_DT
litigation_NOMZ
from_PIN
and_CC
after_IN
March_NN
26_CD
,_,
2004_CD
._.
In_PIN
the_DT
event_NN
that_DEMP
Sanofi-Aventis_NN
launches_VPRT
DYNEPO_NN
in_PIN
the_DT
US_FPP1
,_,
Sanofi-Aventis_NN
is_VPRT [PASS]
entitled_VBN
to_TO
deduct_VB
up_RP
to_PIN
50_CD
%_NN
of_PIN
any_QUAN
royalties_NN
that_DEMP
Sanofi-Aventis_NN
may_POMD [SPAU]
otherwise_CONJ
owe_VB
to_PIN
TKT_NN
with_PIN
respect_NN
to_PIN
the_DT
sale_NN
of_PIN
DYNEPO_NN
until_IN
Sanofi-Aventis_NN
has_VPRT [PEAS]
recouped_VBN
the_DT
full_JJ
amount_NN
of_PIN
TKTs_NN
share_NN
of_PIN
the_DT
litigation_NOMZ
expenses_NN
._.
TKT_NN
has_VPRT
the_DT
right_NN
to_TO
control_VB
any_QUAN
other_JJ
litigation_NOMZ
that_TSUB
might_POMD
arise_VB
outside_PLACE
of_PIN
the_DT
United_NN
States_NN
and_CC
is_VPRT [BEMA]
responsible_PRED
for_PIN
all_QUAN
litigation_NOMZ
expenses_NN
incurred_VBN [WZPAST]
in_PIN
connection_NOMZ
with_PIN
such_JJ
litigation_NOMZ
from_PIN
and_CC
after_IN
March_NN
26_CD
,_,
2004_CD
._.
Gene_NN
activation_NOMZ
In_PIN
1996_CD
,_,
Applied_NN
Research_NN
Systems_NN
Holding_GER
N._NN
V._NN
a_DT
wholly-owned_JJ
subsidiary_NN
of_PIN
Serono_NN
S._NN
A._NN
Serono_NN
and_PHC
Cell_NN
Genesys_NN
,_,
became_VBD
involved_VBN
in_PIN
a_DT
patent_NN
interference_NN
involving_VBG [WZPRES]
Seronos_NN
US_FPP1
Patent_NN
No._NN
._.
5,272,071_CD
the_DT
071_CD
Patent_NN
,_,
which_WDT [SERE]
purportedly_RB
covers_VPRT
certain_JJ
methods_NN
of_PIN
gene_NN
activation_NOMZ
._.
In_PIN
June_NN
2004_CD
,_,
the_DT
Board_NN
of_PIN
Patent_NN
Appeals_NN
and_PHC
Interferences_NN
of_PIN
the_DT
US_FPP1
Patent_NN
and_PHC
Trademark_NN
Office_NN
PTO_NN
held_VBD [PRIV]
that_THVC
both_DT
Serono_NN
and_PHC
Cell_NN
Genesys_NN
were_VBD [PASS]
entitled_VBN
to_PIN
certain_JJ
claims_NN
in_PIN
their_TPP3
respective_JJ
patent_NN
and_PHC
patent_NN
application_NOMZ
,_,
and_ANDC
Serono_NN
and_PHC
Cell_NN
Genesys_NN
each_QUAN
appealed_VBD
the_DT
decision_NN
of_PIN
the_DT
interference_NN
to_PIN
the_DT
US_FPP1
District_NN
Court_NN
of_PIN
Massachusetts_NN
and_CC
the_DT
US_FPP1
District_NN
Court_NN
of_PIN
the_DT
District_NN
of_PIN
Columbia_NN
,_,
respectively_RB
._.
TKT_NN
was_VBD [BEMA]
not_XX0
a_DT
party_NN
to_PIN
this_DEMO
interference_NN
._.
In_PIN
August_NN
2004_CD
,_,
Serono_NN
served_VBD
TKT_NN
with_PIN
an_DT
amended_VBN
complaint_NN
in_PIN
the_DT
appeal_NN
of_PIN
the_DT
PTO_NN
decision_NN
that_TSUB
was_VBD [PASS]
filed_VBN
in_PIN
the_DT
US_FPP1
District_NN
Court_NN
of_PIN
Massachusetts_NN
._.
The_DT
amended_VBN
complaint_NN
alleges_VPRT [PUBV]
that_THVC
TKT_NN
infringes_VPRT
Seronos_NN
071_CD
Patent_NN
._.
In_PIN
August_NN
2005_CD
,_,
the_DT
US_FPP1
District_NN
Court_NN
of_PIN
Massachusetts_NN
severed_VBD
and_PHC
stayed_VBD
the_DT
infringement_NOMZ
action_NOMZ
pending_VBG [WZPRES]
resolution_NOMZ
of_PIN
the_DT
interference_NN
claim_NN
at_PIN
the_DT
District_NN
Court_NN
level_NN
._.
Appraisal_NN
rights_NN
In_PIN
connection_NOMZ
with_PIN
the_DT
Groups_NN
merger_NN
with_PIN
TKT_NN
,_,
former_JJ
holders_NN
of_PIN
approximately_RB
11.7_CD
million_CD
shares_NN
of_PIN
TKT_NN
common_JJ
stock_NN
submitted_VBN [PUBV]
written_VBN [PUBV]
demands_NN
to_PIN
the_DT
Delaware_NN
Court_NN
of_PIN
Chancery_NN
for_PIN
appraisal_NN
of_PIN
these_DEMO
shares_NN
and_CC
,_,
as_CONJ
a_NULL
result_NULL
,_,
elected_VBN
not_XX0
to_TO
accept_VB [PRIV]
the_DT
$_$
37_CD
per_PIN
share_NN
merger_NN
consideration_NOMZ
._.
To_PIN
the_DT
extent_NN
that_TOBJ
the_DT
remaining_VBG
demands_NN
were_VBD [SPAU] [PASS]
validly_RB
asserted_VBN [PUBV]
in_PIN
accordance_NN
with_PIN
the_DT
applicable_JJ
requirements_NOMZ
of_PIN
Delaware_NN
law_NN
and_CC
the_DT
former_JJ
holders_NN
perfect_JJ
their_TPP3
rights_NN
thereunder_NN
,_,
such_JJ
former_JJ
holders_NN
will_PRMD
be_VB [PASS]
entitled_VBN
to_TO
receive_VB
the_DT
fair_JJ
value_NN
of_PIN
these_DEMO
shares_NN
as_IN
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Delaware_NN
Court_NN
of_PIN
Chancery_NN
._.
This_DEMP
could_POMD
change_VB
if_COND
the_DT
Group_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
pay_VB
a_DT
different_JJ
amount_NN
of_PIN
consideration_NOMZ
in_PIN
respect_NN
of_PIN
the_DT
approximately_RB
11.3_CD
million_CD
shares_NN
for_PIN
which_WDT [PIRE]
holders_NN
have_VPRT [PEAS]
asserted_VBN [PUBV]
appraisal_NN
rights_NN
._.
Until_IN
such_JJ
time_NN
as_IN
the_DT
appraisal_NN
process_NN
is_VPRT [BEMA]
complete_PRED
,_,
the_DT
Group_NN
is_VPRT [BEMA]
unable_PRED
to_TO
determine_VB [SUAV] [PRIV]
the_DT
final_JJ
extent_NN
of_PIN
its_PIT
liability_NOMZ
._.
Class_NN
action_NOMZ
shareholder_NN
suit_NN
In_PIN
January_NN
and_PHC
February_NN
2003_CD
,_,
various_JJ
parties_NN
filed_VBD
purported_JJ
class_NN
action_NOMZ
lawsuits_NN
against_PIN
TKT_NN
and_PHC
Richard_NN
Selden_NN
,_,
TKTs_NN
former_JJ
Chief_NN
Executive_NN
Officer_NN
,_,
in_PIN
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
._.
The_DT
complaints_NN
generally_RB
allege_VPRT [PUBV]
securities_NOMZ
fraud_NN
during_PIN
the_DT
period_NN
from_PIN
January_NN
2001_CD
through_PIN
January_NN
2003_CD
._.
Each_QUAN
of_PIN
the_DT
complaints_NN
asserts_VPRT [PUBV]
claims_NN
under_IN
Section_NOMZ
10_CD
b_NN
of_PIN
the_DT
Securities_NOMZ
Exchange_NN
Act_NN
of_PIN
1934_CD
,_,
Rule_NN
10b-5_JJ
promulgated_VBN
thereunder_NN
,_,
and_ANDC
Section_NOMZ
20_CD
a_DT
of_PIN
the_DT
Exchange_NN
Act_NN
,_,
and_ANDC
alleges_VPRT [PUBV]
that_THVC
TKT_NN
and_CC
its_PIT
officers_NN
made_VBD
false_JJ
and_PHC
misleading_JJ
statements_NOMZ
and_CC
failed_VBD
to_TO
disclose_VB [PUBV]
material_NN
information_NOMZ
concerning_VBG [WZPRES]
the_DT
status_NN
and_PHC
progress_NN
for_PIN
obtaining_VBG
United_NN
States_NN
marketing_GER
approval_NN
of_PIN
TKTs_NN
REPLAGAL_NN
product_NN
to_TO
treat_VB
Fabry_NN
Disease_NN
during_PIN
that_DEMO
period_NN
._.
In_PIN
March_NN
2003_CD
,_,
various_JJ
plaintiffs_NN
filed_VBD
motions_NOMZ
to_TO
consolidate_VB
,_,
to_TO
appoint_VB
lead_JJ
plaintiff_NN
,_,
and_ANDC
to_TO
approve_VB
plaintiffs_NN
selections_NOMZ
of_PIN
lead_NN
plaintiffs_NN
counsel_NN
._.
In_PIN
April_NN
2003_CD
,_,
various_JJ
plaintiffs_NN
filed_VBD
a_DT
Joint_NN
Stipulation_NOMZ
and_PHC
Proposed_NN
Order_NN
of_PIN
Lead_JJ
Plaintiff_NN
Applicants_NN
to_TO
Consolidate_VB
Actions_NOMZ
,_,
to_TO
Appoint_VB
Lead_JJ
Plaintiffs_NN
and_CC
to_TO
Approve_VB
Lead_JJ
Plaintiffs_NN
Selection_NOMZ
of_PIN
Lead_JJ
Counsel_NN
,_,
Executive_NN
Committee_NN
and_PHC
Liaison_NN
Counsel_NN
._.
In_PIN
April_NN
2003_CD
,_,
the_DT
Court_NN
endorsed_VBD
the_DT
Proposed_NN
Order_NN
,_,
thereby_RB
consolidating_VBG
the_DT
various_JJ
matters_NN
under_IN
one_CD
matter_NN
:_:
In_PIN
re_NN
Transkaryotic_NN
Therapies_NN
,_,
Inc._NN
._.
Securities_NOMZ
Litigation_NOMZ
,_,
C._NN
A._NN
In_PIN
July_NN
2003_CD
,_,
the_DT
plaintiffs_NN
filed_VBD
a_DT
Consolidated_NN
and_PHC
Amended_NN
Class_NN
Action_NOMZ
Complaint_NN
the_DT
Amended_NN
Complaint_NN
against_PIN
TKT_NN
:_:
Dr_NN
Selden_NN
:_:
Daniel_NN
Geffken_NN
,_,
TKTs_NN
former_JJ
Chief_NN
Financial_NN
Officer_NN
:_:
Walter_NN
Gilbert_NN
,_,
Jonathan_NN
S._NN
Leff_NN
,_,
Rodman_NN
W._NN
Moorhead_NN
,_,
III_NN
,_,
and_ANDC
Wayne_NN
P._NN
Yetter_NN
,_,
then_RB
members_NN
of_PIN
TKTs_NN
Board_NN
of_PIN
Directors_NN
:_:
William_NN
R._NN
Miller_NN
and_PHC
James_NN
E._NN
Thomas_NN
,_,
former_JJ
members_NN
of_PIN
TKTs_NN
Board_NN
of_PIN
Directors_NN
:_:
and_ANDC
SG_NN
Cowen_NN
Securities_NOMZ
Corporation_NOMZ
,_,
Deutsche_NN
Bank_NN
Securities_NOMZ
Inc._NN
._.
Pacific_NN
Growth_NN
Equities_NOMZ
,_,
Inc._NN
and_PHC
Leerink_NN
Swann_NN
&_CC
Company_NN
,_,
underwriters_NN
of_PIN
TKTs_NN
common_JJ
stock_NN
in_PIN
prior_JJ
public_JJ
offerings_GER
._.
98_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
99_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
35_CD
Guarantees_NN
,_,
commitments_NOMZ
and_PHC
contingencies_NN
continued_VBD
The_DT
Amended_NN
Complaint_NN
alleges_VPRT [PUBV]
securities_NOMZ
fraud_NN
during_PIN
the_DT
period_NN
from_PIN
January_NN
4_CD
,_,
2001_CD
,_,
through_PIN
January_NN
10_CD
,_,
2003_CD
._.
The_DT
Amended_NN
Complaint_NN
alleges_VPRT [PUBV]
that_THVC
the_DT
defendants_NN
made_VBD
false_JJ
and_PHC
misleading_JJ
statements_NOMZ
and_CC
failed_VBD
to_TO
disclose_VB [PUBV]
material_NN
information_NOMZ
concerning_VBG [WZPRES]
the_DT
status_NN
and_PHC
progress_NN
for_PIN
obtaining_VBG
United_NN
States_NN
marketing_GER
approval_NN
of_PIN
REPLAGAL_NN
during_PIN
that_DEMO
period_NN
._.
The_DT
Amended_NN
Complaint_NN
asserts_VPRT [PUBV]
claims_NN
against_PIN
Dr_NN
Selden_NN
and_PHC
TKT_NN
under_IN
Section_NOMZ
10_CD
b_NN
of_PIN
the_DT
Exchange_NN
Act_NN
and_PHC
Rule_NN
10b-5_JJ
promulgated_VBN
thereunder_NN
:_:
and_ANDC
against_PIN
Dr_NN
Selden_NN
under_IN
Section_NOMZ
20_CD
a_DT
of_PIN
the_DT
Exchange_NN
Act_NN
._.
The_DT
Amended_NN
Complaint_NN
also_RB
asserts_VPRT [PUBV] [THATD]
claims_NN
based_VBN [WZPAST]
on_PIN
TKTs_NN
public_JJ
offerings_GER
of_PIN
June_NN
29_CD
,_,
2001_CD
,_,
December_NN
18_CD
,_,
2001_CD
and_CC
December_NN
26_CD
,_,
2001_CD
,_,
against_PIN
each_QUAN
of_PIN
the_DT
defendants_NN
under_IN
Section_NOMZ
11_CD
of_PIN
the_DT
Securities_NOMZ
Act_NN
of_PIN
1933_CD
and_CC
against_PIN
Dr_NN
Selden_NN
under_IN
Section_NOMZ
15_CD
of_PIN
the_DT
Securities_NOMZ
Act_NN
:_:
and_ANDC
against_PIN
SG_NN
Cowen_NN
Securities_NOMZ
Corporation_NOMZ
,_,
Deutsche_NN
Bank_NN
Securities_NOMZ
Inc._NN
._.
Pacific_NN
Growth_NN
Equities_NOMZ
,_,
Inc._NN
and_PHC
Leerink_NN
Swann_NN
&_CC
Company_NN
under_IN
Section_NOMZ
12_CD
a_DT
2_CD
of_PIN
the_DT
Securities_NOMZ
Act_NN
._.
The_DT
plaintiffs_NN
seek_VPRT
equitable_JJ
and_PHC
monetary_JJ
relief_NN
,_,
an_DT
unspecified_JJ
amount_NN
of_PIN
damages_NN
,_,
with_PIN
interest_NN
,_,
and_ANDC
attorneys_NN
fees_NN
and_PHC
costs_NN
._.
In_PIN
September_NN
2003_CD
,_,
TKT_NN
filed_VBD
a_DT
motion_NOMZ
to_TO
dismiss_VB
the_DT
Amended_NN
Complaint_NN
._.
A_DT
hearing_GER
of_PIN
the_DT
motion_NOMZ
occurred_VBD
in_PIN
December_NN
2003_CD
._.
In_PIN
May_POMD
2004_CD
,_,
the_DT
United_NN
States_NN
District_NN
Court_NN
for_PIN
the_DT
District_NN
of_PIN
Massachusetts_NN
issued_VBD
a_DT
Memorandum_NN
of_PIN
Decision_NN
and_PHC
Order_NN
denying_VBG [PUBV] [WZPRES]
in_PIN
part_NN
and_CC
granting_VBG [SUAV]
in_PIN
part_NN
TKTs_NN
motion_NOMZ
to_TO
dismiss_VB
the_DT
purported_JJ
class_NN
action_NOMZ
lawsuit_NN
._.
In_PIN
the_DT
Memorandum_NN
,_,
the_DT
Court_NN
found_VBD [PRIV]
several_QUAN
allegations_NOMZ
against_PIN
TKT_NN
arose_VBD
out_PIN
of_PIN
forward-looking_JJ
statements_NOMZ
protected_VBN [WZPAST]
by_PIN
the_DT
safe_JJ
harbor_NN
provisions_NN
of_PIN
the_DT
Private_JJ
Securities_NOMZ
Litigation_NOMZ
Reform_NN
Act_NN
of_PIN
1995_CD
PSLRA_NN
._.
The_DT
Court_NN
dismissed_VBD
those_DEMO
statements_NOMZ
as_IN
falling_VBG
within_PIN
the_DT
PSLRAs_NN
safe_JJ
harbor_NN
provisions_NN
._.
The_DT
Court_NN
also_RB
dismissed_VBD
claims_NN
based_VBN [WZPAST]
on_PIN
the_DT
public_JJ
offerings_GER
of_PIN
June_NN
29_CD
,_,
2001_CD
,_,
and_ANDC
December_NN
18_CD
,_,
2001_CD
,_,
because_CAUS
no_SYNE
plaintiff_NN
had_VBD
standing_VBG
to_TO
bring_VB
such_JJ
claims_NN
._.
The_DT
Court_NN
allowed_VBD [SUAV]
all_QUAN
other_JJ
allegations_NOMZ
to_TO
remain_VB
._.
In_PIN
June_NN
2004_CD
,_,
TKT_NN
submitted_VBD [PUBV] [THATD]
an_DT
unopposed_JJ
motion_NOMZ
seeking_VBG [WZPRES]
clarification_NOMZ
from_PIN
the_DT
Court_NN
that_TOBJ
the_DT
Memorandum_NN
dismissed_VBD
claims_NN
based_VBN [WZPAST]
on_PIN
the_DT
first_JJ
two_CD
offerings_GER
as_IN
to_PIN
all_QUAN
defendants_NN
._.
The_DT
Court_NN
granted_VBD [SUAV]
the_DT
motion_NOMZ
._.
In_PIN
July_NN
2004_CD
,_,
the_DT
plaintiffs_NN
voluntarily_RB
dismissed_VBD
all_QUAN
claims_NN
based_VBN [WZPAST]
on_PIN
the_DT
third_JJ
offering_GER
because_CAUS
no_SYNE
plaintiff_NN
had_VBD
standing_VBG
to_TO
bring_VB
such_JJ
claims_NN
._.
The_DT
plaintiffs_NN
subsequently_TIME
filed_VBD
a_DT
motion_NOMZ
seeking_VBG [WZPRES]
permission_NN
to_TO
notify_VB
certain_JJ
TKT_NN
investors_NN
of_PIN
the_DT
dismissal_NN
of_PIN
the_DT
claims_NN
based_VBN [WZPAST]
on_PIN
the_DT
offerings_GER
,_,
and_ANDC
to_TO
inform_VB
those_DEMO
investors_NN
of_PIN
their_TPP3
opportunity_NOMZ
to_TO
intervene_VB
in_PIN
the_DT
lawsuit_NN
._.
TKT_NN
filed_VBD
an_DT
opposition_NOMZ
to_PIN
this_DEMO
motion_NOMZ
in_PIN
July_NN
2004_CD
._.
A_DT
hearing_GER
on_PIN
this_DEMO
motion_NOMZ
was_VBD [PASS]
held_VBN [PRIV]
in_PIN
September_NN
2004_CD
._.
The_DT
Court_NN
denied_VBD [PUBV]
this_DEMO
motion_NOMZ
._.
TKT_NN
filed_VBD
an_DT
answer_NN
to_PIN
the_DT
Amended_NN
Complaint_NN
in_PIN
July_NN
2004_CD
._.
The_DT
plaintiffs_NN
then_RB
filed_VBD
a_DT
motion_NOMZ
for_PIN
class_NN
certification_NOMZ
in_PIN
July_NN
2004_CD
._.
TKT_NN
filed_VBD
an_DT
opposition_NOMZ
to_PIN
this_DEMO
motion_NOMZ
in_PIN
March_NN
2005_CD
,_,
and_ANDC
the_DT
plaintiffs_NN
filed_VBD
a_DT
reply_NN
in_PIN
April_NN
2005_CD
._.
A_DT
hearing_GER
on_PIN
class_NN
certification_NOMZ
was_VBD [PASS]
held_VBN [PRIV]
in_PIN
April_NN
2005_CD
._.
Following_VBG [PRESP]
that_DEMO
hearing_GER
,_,
TKT_NN
filed_VBD
a_DT
supplemental_JJ
brief_NN
in_PIN
opposition_NOMZ
to_PIN
the_DT
motion_NOMZ
for_PIN
class_NN
certification_NOMZ
and_CC
the_DT
plaintiffs_NN
filed_VBD
a_DT
supplemental_JJ
brief_NN
in_PIN
support_NN
of_PIN
the_DT
motion_NOMZ
._.
In_PIN
November_NN
2005_CD
,_,
the_DT
Court_NN
granted_VBD [SUAV]
the_DT
plaintiffs_NN
motion_NOMZ
for_PIN
class_NN
certification_NOMZ
._.
On_PIN
September_NN
14_CD
,_,
2005_CD
,_,
the_DT
plaintiffs_NN
filed_VBD
a_DT
Notice_NN
of_PIN
Related_NN
Case_NN
Pursuant_NN
to_PIN
Local_JJ
Rule_NN
40.1_CD
G_NN
,_,
in_PIN
which_WDT [PIRE]
they_TPP3
appeared_VBD [SMP]
to_TO
seek_VB
reassignment_NOMZ
of_PIN
a_DT
matter_NN
filed_VBN [WZPAST]
on_PIN
September_NN
1_CD
,_,
2005_CD
,_,
entitled_VBN
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
v._CC
Richard_NN
B._NN
Selden_NN
,_,
Civil_NN
Action_NOMZ
No._NN
._.
the_DT
SEC_NN
Action_NOMZ
,_,
to_PIN
the_DT
Court_NN
considering_VBG [PRIV] [WZPRES]
this_DEMO
matter_NN
._.
On_PIN
September_NN
15_CD
,_,
2005_CD
,_,
the_DT
defendants_NN
filed_VBD
a_DT
response_NN
to_PIN
the_DT
notice_NN
,_,
opposing_VBG
reassignment_NOMZ
of_PIN
the_DT
SEC_NN
Action_NOMZ
._.
On_PIN
October_NN
7_CD
,_,
2005_CD
,_,
the_DT
plaintiffs_NN
filed_VBD
a_DT
memorandum_NN
in_PIN
response_NN
to_PIN
the_DT
defendants_NN
response_NN
._.
On_PIN
October_NN
21_CD
,_,
2005_CD
,_,
the_DT
Court_NN
entered_VBD
an_DT
Order_NN
,_,
which_WDT [SERE]
stated_VBD [PUBV]
that_THVC
it_PIT
did_VBD
not_XX0
deem_VB [PRIV] [THATD]
the_DT
cases_NN
related_VBN
under_IN
Local_JJ
Rule_NN
40.1_CD
._.
The_DT
Group_NN
is_VPRT [PASS]
obligated_VBN
to_TO
indemnify_VB
Dr_NN
Selden_NN
for_PIN
his_TPP3
costs_NN
incurred_VBN [WZPAST]
in_PIN
connection_NOMZ
with_PIN
the_DT
SEC_NN
Action_NOMZ
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
99_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
100_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
36_CD
Principal_NN
subsidiaries_NN
The_DT
Company_NN
and_CC
the_DT
Group_NN
have_VPRT
investments_NOMZ
in_PIN
the_DT
following_JJ
subsidiary_NN
undertakings_GER
which_WDT [WHSUB]
principally_RB
affected_VBD
the_DT
results_NN
or_CC
net_JJ
assets_NN
of_PIN
the_DT
Group_NN
._.
To_TO
avoid_VB
a_DT
statement_NOMZ
of_PIN
excessive_JJ
length_NN
,_,
details_NN
of_PIN
investments_NOMZ
which_WDT [WHSUB]
are_VPRT [BEMA]
not_XX0
significant_PRED
have_VPRT [PEAS]
been_VBN [PASS]
omitted_VBN
._.
Country_NN
Principal_NN
activity_NOMZ
Holding_VBG [PRIV] [WZPRES]
%_NN
Shire_NN
LLC_NN
US_FPP1
Licensing_GER
,_,
development_NOMZ
,_,
production_NOMZ
and_PHC
distribution_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
US_FPP1
,_,
Inc._NN
._.
US_FPP1
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceuticals_NN
Limited_NN
UK_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceutical_NN
Contracts_NN
Limited_NN
UK_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
France_NN
SA_NN
France_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Deutschland_NN
GmbH_NN
&_CC
Co._NN
._.
KG_NN
Germany_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Italia_NN
SpA_NN
Italy_NN
Marketing_GER
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceuticals_NN
Iberia_NN
SL_NN
Spain_NN
Marketing_GER
and_PHC
distribution_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceuticals_NN
Group_NN
Limited_NN
UK_NN
Holding_GER
Company_NN
100_CD
%_NN
Shire_NN
Pharmaceuticals_NN
,_,
Inc._NN
._.
US_FPP1
Management_NOMZ
services_NN
company_NN
100_CD
%_NN
Shire_NN
Development_NOMZ
,_,
Inc._NN
._.
US_FPP1
Development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
%_NN
Shire_NN
Regulatory_NN
,_,
Inc._NN
._.
US_FPP1
Development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
%_NN
Shire_NN
Pharmaceuticals_NN
Ireland_NN
Limited_NN
Ireland_NN
Marketing_GER
and_PHC
distribution_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
BioChem_NN
,_,
Inc._NN
._.
Canada_NN
Marketing_GER
,_,
research_NN
and_PHC
development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
%_NN
Shire_NN
International_NN
Licensing_GER
BV_NN
Netherlands_NN
Licensing_GER
and_PHC
development_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Pharmaceutical_NN
Development_NOMZ
Limited_NN
UK_NN
Development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
%_NN
Shire_NN
Pharmaceuticals_NN
US_FPP1
Development_NOMZ
,_,
Inc._NN
._.
US_FPP1
Development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
%_NN
Shire_NN
Finance_NN
Limited_NN
Cayman_NN
Islands_NN
Issuer_NN
of_PIN
convertible_JJ
notes_NN
100_CD
%_NN
Shire_NN
US_FPP1
Manufacturing_GER
,_,
Inc._NN
._.
US_FPP1
Manufacturer_NN
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Shire_NN
Human_NN
Genetic_NN
Therapies_NN
,_,
Inc._NN
formerly_TIME
known_VBN [PRIV]
as_IN
Transkaryotic_NN
Therapies_NN
,_,
Inc._NN
._.
US_FPP1
Marketing_GER
,_,
research_NN
and_PHC
development_NOMZ
of_PIN
pharmaceuticals_NN
,_,
including_VBG [PRESP]
on_PIN
behalf_NN
of_PIN
other_JJ
Group_NN
companies_NN
100_CD
%_NN
TKT_NN
Europe_NN
AB_NN
Sweden_NN
Marketing_GER
and_PHC
distribution_NOMZ
of_PIN
pharmaceuticals_NN
100_CD
%_NN
Held_VBN [PRIV] [WZPAST]
directly_RB
by_PIN
Shire_NN
plc._NN
._.
All_QUAN
subsidiary_NN
undertakings_GER
have_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
Country_NN
of_PIN
incorporation_NOMZ
or_CC
principal_NN
business_NOMZ
address_NN
._.
37_CD
Employees_NN
,_,
directors_NN
and_CC
key_JJ
management_NOMZ
Staff_NN
The_DT
average_JJ
monthly_JJ
number_NN
of_PIN
people_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
during_PIN
the_DT
year_NN
was_VBD
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
Number_NN
Number_NN
Manufacturing_GER
and_PHC
distribution_NOMZ
384_CD
358_CD
Sales_NN
and_PHC
marketing_GER
994_CD
837_CD
General_NN
and_CC
administrative_JJ
300_CD
265_CD
Research_NN
and_PHC
development_NOMZ
412_CD
432_CD
2,090_CD
1,892_CD
Aggregate_NN
remuneration_NOMZ
of_PIN
Directors_NN
The_DT
total_JJ
amounts_NN
for_PIN
remuneration_NOMZ
and_CC
other_JJ
benefits_NN
were_VBD
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Emoluments_NOMZ
4,289_CD
4,751_CD
Post-employment_NOMZ
benefits_NN
488_CD
450_CD
Amounts_NN
receivable_JJ
under_IN
long-term_JJ
incentive_NN
schemes_NN
159_CD
Termination_NOMZ
benefits_NN
1,172_CD
Gains_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
194_CD
216_CD
4,971_CD
6,748_CD
No_SYNE
fees_NN
were_VBD [BEMA]
payable_PRED
to_PIN
third_JJ
parties_NN
in_PIN
respect_NN
of_PIN
Directors_NN
services_NN
for_PIN
either_DT
year_NN
._.
100_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
101_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
37_CD
Employees_NN
,_,
directors_NN
and_CC
key_JJ
management_NOMZ
continued_VBD
The_DT
numbers_NN
of_PIN
Directors_NN
who_WP [WHSUB]
were_VBD
members_NN
of_PIN
Group_NN
retirement_NOMZ
schemes_NN
were_VBD
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
Number_NN
Number_NN
Defined_NN
contribution_NOMZ
schemes_NN
2_CD
3_CD
Defined_VBN
benefit_NN
scheme_NN
SERP_NN
1_CD
1_CD
The_DT
above_PLACE
amounts_NN
for_PIN
remuneration_NOMZ
include_VPRT
the_DT
following_VBG
in_PIN
respect_NN
of_PIN
the_DT
highest_JJ
paid_VBN
Director_NN
:_:
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Aggregate_JJ
emoluments_NOMZ
2,286_CD
2,601_CD
Pension_NN
contributions_NOMZ
323_CD
227_CD
2,609_CD
2,828_CD
Aggregate_NN
remuneration_NOMZ
of_PIN
key_JJ
management_NOMZ
The_DT
total_JJ
amounts_NN
for_PIN
remuneration_NOMZ
and_CC
other_JJ
benefits_NN
were_VBD
as_IN
follows_VPRT
:_:
2005_CD
2004_CD
$_$
000_CD
$_$
000_CD
Salaries_NN
and_CC
other_JJ
short-term_JJ
employee_NN
benefits_NN
12,133_CD
13,242_CD
Post-employment_NOMZ
benefits_NN
1,189_CD
1,147_CD
Amounts_NN
receivable_JJ
under_IN
long-term_JJ
incentive_NN
schemes_NN
538_CD
Termination_NOMZ
benefits_NN
5,225_CD
Share-based_JJ
payments_NOMZ
5,159_CD
3,027_CD
18,481_CD
23,179_CD
The_DT
key_JJ
management_NOMZ
figures_NN
given_VBN
above_PLACE
include_VPRT
Directors_NN
._.
38_CD
Related-party_JJ
transactions_NOMZ
Professional_JJ
fees_NN
The_DT
Group_NN
incurred_VBD
professional_JJ
fees_NN
with_PIN
Stikeman_NN
Elliott_NN
,_,
a_DT
law_NN
firm_NN
in_PIN
which_WDT [PIRE]
the_DT
Hon_NN
James_NN
Grant_NN
,_,
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Shire_NN
,_,
is_VPRT [BEMA]
a_DT
partner_NN
,_,
totalling_VBG
$_$
0.5_CD
million_CD
for_PIN
the_DT
year_NN
to_PIN
December_NN
31_CD
,_,
2005_CD
2004_CD
:_:
$_$
2.1_CD
million_CD
:_:
2003_CD
:_:
$_$
0.8_CD
million_CD
._.
In_PIN
April_NN
2004_CD
,_,
the_DT
Group_NN
contributed_VBD
cash_NN
of_PIN
$_$
3.7_CD
million_CD
CAN$_NN
5.0_CD
million_CD
and_CC
equipment_NOMZ
and_CC
intellectual_JJ
property_NN
to_PIN
the_DT
start-up_NN
of_PIN
a_DT
new_JJ
Canadian-based_JJ
pharmaceutical_JJ
research_NN
and_PHC
development_NOMZ
organization_NOMZ
,_,
ViroChem_NN
Pharma_NN
Inc._NN
._.
ViroChem_NN
,_,
in_PIN
return_NN
for_PIN
an_DT
equity_NOMZ
interest_NN
and_PHC
royalties_NN
on_PIN
the_DT
sale_NN
of_PIN
certain_JJ
products_NN
subsequently_TIME
launched_VBN
by_PIN
ViroChem_NN
._.
In_PIN
April_NN
2005_CD
,_,
the_DT
Group_NN
contributed_VBD
cash_NN
of_PIN
$_$
4.1_CD
million_CD
CAN$_NN
5.0_CD
million_CD
to_PIN
ViroChem_NN
in_PIN
return_NN
for_PIN
an_DT
additional_JJ
equity_NOMZ
interest_NN
._.
Dr_NN
Bellini_NN
,_,
a_DT
Non-Executive_JJ
Director_NN
of_PIN
BioChem_NN
and_CC
,_,
until_IN
May_POMD
10_CD
,_,
2003_CD
,_,
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Shire_NN
,_,
had_VBD
,_,
at_PIN
the_DT
time_NN
of_PIN
the_DT
transaction_NOMZ
,_,
an_DT
indirect_JJ
substantial_JJ
interest_NN
in_PIN
a_DT
company_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
a_DT
co-investor_NN
of_PIN
ViroChem_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
undertaken_VBN
to_TO
invest_VB
an_DT
additional_JJ
$_$
4.3_CD
million_CD
CAN$_NN
5.0_CD
million_CD
in_PIN
ViroChem_NN
._.
In_PIN
October_NN
2005_CD
,_,
the_DT
Group_NN
sub-leased_VBD
its_PIT
office_NN
premises_NN
in_PIN
Newport_NN
to_PIN
Xanodyne_NN
Pharmaceuticals_NN
Inc._NN
._.
Dr_NN
James_NN
Cavanaugh_NN
,_,
the_DT
Non-Executive_NN
Chairman_NN
of_PIN
Shire_NN
,_,
is_VPRT [BEMA]
the_DT
Chairman_NN
of_PIN
Xanodyne_NN
Pharmaceuticals_NN
Inc._NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
transaction_NOMZ
the_DT
Group_NN
will_PRMD
receive_VB
$_$
7.8_CD
million_CD
net_NN
of_PIN
inducements_NOMZ
in_PIN
lease_NN
income_NN
over_IN
the_DT
sub-lease_JJ
period_NN
from_PIN
Xanodyne_NN
._.
In_PIN
April_NN
2004_CD
Shire_NN
BioChem_NN
Inc._NN
._.
BioChem_NN
,_,
a_DT
subsidiary_NN
of_PIN
Shire_NN
,_,
sold_VBD
a_DT
Canadian_JJ
property_NN
to_PIN
NeuroChem_NN
Inc._NN
for_PIN
$_$
7.8_CD
million_CD
CAN$_NN
10.5_CD
million_CD
._.
Dr_NN
Bellini_NN
,_,
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Biochem_NN
and_CC
,_,
until_IN
May_POMD
10_CD
,_,
2003_CD
,_,
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Shire_NN
and_PHC
Mr_NN
Nordmann_NN
,_,
a_DT
Non-Executive_JJ
Director_NN
of_PIN
Shire_NN
are_VPRT [BEMA]
both_DT
directors_NN
of_PIN
NeuroChem_NN
Inc._NN
._.
Dr_NN
Bellini_NN
had_VBD
an_DT
indirect_JJ
substantial_JJ
interest_NN
in_PIN
the_DT
issued_VBN
share_NN
capital_NN
of_PIN
Neurochem_NN
Inc._NN
at_PIN
the_DT
time_NN
of_PIN
the_DT
transaction_NOMZ
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
101_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
102_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
39_CD
Post_NN
balance_NN
sheet_NN
events_NN
ADDERALL_NN
XR_NN
patent_NN
litigation_NOMZ
Third_NN
notice_NN
letter_NN
from_PIN
Teva_NN
On_PIN
January_NN
18_CD
,_,
2006_CD
,_,
the_DT
Group_NN
received_VBD
a_DT
third_JJ
notice_NN
letter_NN
from_PIN
Teva_NN
Pharmaceuticals_NN
USA_NN
,_,
Inc._NN
advising_VBG [WZPRES]
it_PIT
of_PIN
an_DT
amendment_NOMZ
to_PIN
Tevas_NN
existing_VBG [WZPRES]
ANDA_NN
for_PIN
generic_JJ
versions_NN
of_PIN
ADDERALL_NN
XR_NN
._.
The_DT
amendment_NOMZ
is_VPRT [PASS]
directed_VBN
to_PIN
an_DT
additional_JJ
strength_NN
of_PIN
25mg_JJ
._.
As_IN
previously_TIME
announced_VBN [PUBV]
,_,
Tevas_NN
February_NN
2005_CD
notice_NN
letter_NN
was_VBD [PASS]
directed_VBN
only_DWNT
to_PIN
10mg_CD
and_CC
30mg_CD
dosages_NN
and_PHC
Tevas_NN
June_NN
2005_CD
notice_NN
letter_NN
was_VBD [PASS]
directed_VBN
only_DWNT
to_PIN
5mg_CD
,_,
15mg_CD
and_CC
20mg_CD
dosages_NN
._.
The_DT
Group_NN
is_VPRT [SPAU]
currently_RB
reviewing_VBG
the_DT
details_NN
of_PIN
Tevas_NN
latest_JJ
notice_NN
letter_NN
._.
Settlement_NOMZ
of_PIN
Impax_NN
litigations_NOMZ
On_PIN
January_NN
19_CD
,_,
2006_CD
,_,
the_DT
Group_NN
settled_VBD
its_PIT
ADDERALL_NN
XR_NN
patent_NN
infringement_NOMZ
lawsuits_NN
with_PIN
Impax_NN
._.
The_DT
litigations_NOMZ
involved_VBN
Shire_NN
US_FPP1
patents_NN
,_,
Nos._NN
._.
As_IN
part_NN
of_PIN
the_DT
settlement_NOMZ
,_,
Impax_NN
has_VPRT [PEAS]
confirmed_VBN [PUBV]
that_THVC
its_PIT
proposed_VBN [SUAV]
generic_JJ
ADDERALL_NN
XR_NN
product_NN
infringes_VPRT
the_DT
Groups_NN
819_CD
,_,
300_CD
and_CC
768_CD
Patents_NN
and_CC
that_THVC
the_DT
three_CD
patents_NN
are_VPRT [BEMA]
valid_PRED
and_PHC
enforceable_PRED
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
settlement_NOMZ
,_,
Impax_NN
will_PRMD
be_VB [PASS]
permitted_VBN
to_PIN
market_NN
generic_JJ
versions_NN
of_PIN
ADDERALL_NN
XR_NN
in_PIN
the_DT
US_FPP1
no_RB
later_TIME
than_PIN
January_NN
1_CD
,_,
2010_CD
and_CC
will_PRMD
pay_VB
the_DT
Group_NN
a_DT
royalty_NN
from_PIN
those_DEMO
sales_NN
._.
In_PIN
certain_JJ
situations_NOMZ
,_,
such_JJ
as_IN
the_DT
launch_NN
of_PIN
another_DT
generic_JJ
version_NN
of_PIN
ADDERALL_NN
XR_NN
,_,
Impax_NN
may_POMD
be_VB [PASS]
permitted_VBN
to_TO
enter_VB
the_DT
market_NN
as_IN
the_DT
Groups_NN
authorised_VBD
generic_JJ
._.
NRP104_CD
On_PIN
January_NN
26_CD
,_,
2006_CD
,_,
the_DT
FDA_NN
accepted_VBD [PRIV]
New_NN
Rivers_NN
NDA_NN
for_PIN
NRP104_NN
for_PIN
review_NN
._.
This_DEMP
has_VPRT [PEAS]
triggered_VBN
a_DT
$_$
50_CD
million_CD
milestone_NN
payment_NOMZ
by_PIN
the_DT
Group_NN
to_PIN
New_NN
River_NN
._.
MESAVANCE_NN
SPD476_NN
The_NN
Group_NN
has_VPRT [PEAS]
submitted_VBN [PUBV]
applications_NOMZ
for_PIN
marketing_GER
approval_NN
to_PIN
a_DT
number_NN
of_PIN
European_JJ
regulatory_JJ
agencies_NN
and_CC
also_RB
filed_VBD
a_DT
New_NN
Drug_NN
Submission_NN
for_PIN
SPD476_NN
with_PIN
Health_NN
Canada_NN
._.
IDB_NN
loan_NN
repayment_NOMZ
On_PIN
February_NN
10_CD
,_,
2006_CD
,_,
the_DT
Group_NN
received_VBD
notice_NN
from_PIN
IDB_NN
that_TOBJ
it_PIT
intended_VBD [SUAV]
to_TO
repay_VB
in_PIN
full_JJ
all_QUAN
of_PIN
its_PIT
loan_NN
drawings_GER
for_PIN
injectable_JJ
flu_NN
development_NOMZ
of_PIN
$_$
70.6_CD
million_CD
,_,
together_RB
with_PIN
accrued_VBN
and_PHC
capitalized_VBN
interest_NN
of_PIN
$_$
8.1_CD
million_CD
._.
The_DT
Group_NN
received_VBD
the_DT
$_$
78.7_CD
million_CD
outstanding_JJ
on_PIN
February_NN
14_CD
,_,
2006_CD
._.
The_DT
amounts_NN
outstanding_JJ
in_PIN
respect_NN
of_PIN
IDB_NN
drawings_GER
for_PIN
pipeline_NN
development_NOMZ
principal_JJ
drawings_GER
$_$
29.4_CD
million_CD
,_,
are_VPRT [BEMA]
unaffected_PRED
by_PIN
this_DEMO
repayment_NOMZ
._.
40_CD
Explanation_NOMZ
of_PIN
transition_NOMZ
to_PIN
IFRS_NN
This_DEMP
is_VPRT [BEMA]
the_DT
first_JJ
year_NN
that_TOBJ
the_DT
Company_NN
has_VPRT [PEAS]
presented_VBN
its_PIT
financial_JJ
statement_NOMZ
under_IN
IFRS_NN
._.
The_DT
following_VBG
disclosures_NN
are_VPRT [PASS]
required_VBN [SUAV]
in_PIN
the_DT
year_NN
of_PIN
transition_NOMZ
._.
The_DT
last_JJ
financial_JJ
statements_NOMZ
under_IN
UK_NN
GAAP_NN
were_VBD [BEMA]
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2004_CD
and_CC
the_DT
date_NN
of_PIN
transition_NOMZ
to_PIN
IFRS_NN
was_VBD
therefore_CONJ
January_NN
1_CD
,_,
2004_CD
._.
Exemptions_NOMZ
from_PIN
full_JJ
retrospective_JJ
application_NOMZ
elected_VBN [WZPAST]
by_PIN
the_DT
Group_NN
The_NN
Group_NN
has_VPRT [PEAS]
elected_VBN
to_TO
apply_VB
the_DT
following_VBG
optional_JJ
exemptions_NOMZ
from_PIN
full_JJ
retrospective_JJ
application_NOMZ
._.
Business_NOMZ
combinations_NOMZ
exemption_NOMZ
The_DT
Group_NN
has_VPRT [PEAS]
applied_VBN
the_DT
business_NOMZ
combination_NOMZ
exemption_NOMZ
in_PIN
IFRS_NN
1_CD
._.
It_PIT
has_VPRT [PEAS]
not_XX0
restated_VBN
business_NOMZ
combinations_NOMZ
that_TSUB
took_VBD
place_NN
prior_RB
to_PIN
the_DT
January_NN
1_CD
,_,
2004_CD
transition_NOMZ
date_NN
in_PIN
accordance_NN
with_PIN
IFRS_NN
3_CD
,_,
Business_NOMZ
Combinations_NOMZ
._.
Cumulative_JJ
translation_NOMZ
differences_NN
exemption_NOMZ
The_DT
Group_NN
has_VPRT [PEAS]
elected_VBN
to_TO
set_VB
the_DT
previously_TIME
accumulated_VBN
cumulative_JJ
translation_NOMZ
differences_NN
arising_VBG [WZPRES]
on_PIN
the_DT
translation_NOMZ
and_PHC
consolidation_NOMZ
of_PIN
results_NN
of_PIN
foreign_JJ
operations_NOMZ
and_PHC
balance_NN
sheets_NN
denominated_VBN [WZPAST]
in_PIN
foreign_JJ
currencies_NN
to_PIN
zero_CD
at_PIN
January_NN
1_CD
,_,
2004_CD
._.
This_DEMO
exemption_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
to_PIN
all_QUAN
subsidiaries_NN
in_PIN
accordance_NN
with_PIN
IFRS_NN
1_CD
._.
Exemption_NOMZ
from_PIN
restatement_NOMZ
of_PIN
comparatives_NN
for_PIN
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
The_NN
Group_NN
has_VPRT [PEAS]
elected_VBN
to_TO
apply_VB
this_DEMO
exemption_NOMZ
._.
It_PIT
applies_VPRT
UK_NN
GAAP_NN
rules_NN
to_PIN
derivatives_NN
,_,
financial_JJ
assets_NN
and_CC
financial_JJ
liabilities_NOMZ
and_CC
to_TO
hedging_VBG
relationships_NN
for_PIN
the_DT
2004_CD
comparative_JJ
information_NOMZ
._.
The_DT
adjustments_NOMZ
required_VBN [SUAV] [WZPAST]
for_PIN
differences_NN
between_PIN
UK_NN
GAAP_NN
and_PHC
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
and_PHC
recognized_VBN [PRIV]
at_PIN
January_NN
1_CD
,_,
2005_CD
._.
Designation_NOMZ
of_PIN
financial_JJ
assets_NN
and_CC
financial_JJ
liabilities_NOMZ
exemption_NOMZ
The_DT
Group_NN
reclassified_VBD
various_JJ
equity_NOMZ
investments_NOMZ
as_IN
available-for-sale_JJ
investments_NOMZ
._.
The_DT
adjustments_NOMZ
relating_VBG [WZPRES]
to_PIN
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
are_VPRT [PASS]
required_VBN [SUAV]
and_PHC
determined_VBN [SUAV] [PRIV]
at_PIN
the_DT
opening_GER
balance_NN
sheet_NN
date_NN
of_PIN
January_NN
1_CD
,_,
2005_CD
the_DT
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
transition_NOMZ
date_NN
._.
Share-based_JJ
payment_NOMZ
transaction_NOMZ
exemption_NOMZ
The_DT
Group_NN
has_VPRT [PEAS]
elected_VBN
to_TO
apply_VB
the_DT
share-based_JJ
payment_NOMZ
exemption_NOMZ
._.
It_PIT
applied_VBD
IFRS_NN
2_CD
from_PIN
January_NN
1_CD
,_,
2004_CD
to_PIN
those_DEMO
options_NOMZ
that_TSUB
were_VBD [PASS]
issued_VBN
after_IN
November_NN
7_CD
,_,
2002_CD
but_CC
that_DEMP
have_VPRT [PEAS]
not_XX0
vested_VBN
by_PIN
January_NN
1_CD
,_,
2005_CD
._.
Fair_NN
value_NN
measurement_NOMZ
of_PIN
financial_JJ
assets_NN
or_CC
liabilities_NOMZ
at_PIN
initial_JJ
recognition_NOMZ
The_DT
Group_NN
has_VPRT [PEAS]
applied_VBN
the_DT
exemption_NOMZ
offered_VBN [WZPAST]
by_PIN
the_DT
revision_NN
of_PIN
IAS_NN
39_CD
on_PIN
the_DT
initial_JJ
recognition_NOMZ
of_PIN
the_DT
financial_JJ
instruments_NOMZ
measured_VBN [WZPAST]
at_PIN
fair_JJ
value_NN
through_PIN
the_DT
income_NN
statement_NOMZ
where_RB
there_EX
is_VPRT
no_SYNE
active_JJ
market_NN
._.
102_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
103_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
40_CD
Explanation_NOMZ
of_PIN
transition_NOMZ
to_PIN
IFRS_NN
continued_VBD
Exceptions_NOMZ
from_PIN
full_JJ
retrospective_JJ
application_NOMZ
followed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
The_NN
Group_NN
has_VPRT [PEAS]
applied_VBN
the_DT
following_VBG
mandatory_JJ
exceptions_NOMZ
from_PIN
retrospective_JJ
application_NOMZ
:_:
fide-recognition_NOMZ
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
exception_NOMZ
Financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
fide-recognised_VBN [PRIV]
before_IN
January_NN
1_CD
,_,
2004_CD
are_VPRT [PASS]
not_XX0
re-recognised_VBN [PRIV]
under_IN
IFRS_NN
._.
The_DT
application_NOMZ
of_PIN
the_DT
exemption_NOMZ
from_PIN
restating_VBG
comparatives_NN
for_PIN
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
means_VPRT [PRIV]
that_THVC
the_DT
Group_NN
should_NEMD
recognize_VB [PRIV]
from_PIN
January_NN
1_CD
,_,
2005_CD
any_QUAN
financial_JJ
assets_NN
and_CC
financial_JJ
liabilities_NOMZ
derecognised_VBD
since_OSUB
January_NN
1_CD
,_,
2004_CD
that_DEMP
do_VPRT
not_XX0
meet_VB
the_DT
IAS_NN
39_CD
fide-recognition_NOMZ
criteria_NN
._.
Management_NOMZ
chose_VBD
not_XX0
to_TO
apply_VB
the_DT
IAS_NN
39_CD
fide-recognition_NOMZ
criteria_NN
to_PIN
an_DT
earlier_TIME
date_NN
._.
Hedge_VB
accounting_GER
exception_NOMZ
The_DT
Group_NN
is_VPRT [BEMA]
able_PRED
to_TO
claim_VB [PUBV]
hedge_JJ
accounting_GER
from_PIN
January_NN
1_CD
,_,
2005_CD
,_,
only_DWNT
if_COND
the_DT
hedge_NN
relationship_NN
meets_VPRT
all_QUAN
the_DT
hedge_NN
accounting_GER
criteria_NN
under_IN
IAS_NN
39_CD
._.
Estimates_NN
exception_NOMZ
Estimates_NN
under_IN
IFRS_NN
at_PIN
January_NN
1_CD
,_,
2004_CD
should_NEMD
be_VB [BEMA]
consistent_PRED
with_PIN
estimates_NN
made_VBN [WZPAST]
for_PIN
the_DT
same_JJ
date_NN
under_IN
previous_JJ
GAAP_NN
,_,
unless_COND
there_EX
is_VPRT
evidence_NN
that_TOBJ
those_DEMO
estimates_NN
were_VBD [BEMA]
in_PIN
error_NN
._.
Assets_NN
held_VBD [PRIV]
for_PIN
sale_NN
and_CC
discontinued_VBN
operations_NOMZ
exception_NOMZ
The_DT
Group_NN
elected_VBD
to_TO
apply_VB
IFRS_NN
5_CD
,_,
Non-Current_NN
Assets_NN
Held_NN
for_PIN
Sale_NN
and_PHC
Discontinued_NN
Operations_NOMZ
retrospectively_RB
as_IN
all_QUAN
required_VBN [SUAV] [THATD]
information_NOMZ
was_VBD [BEMA]
available_PRED
at_PIN
the_DT
time_NN
of_PIN
disposal_NN
of_PIN
the_DT
vaccines_NN
business_NOMZ
._.
Only_DWNT
a_DT
reclassification_NOMZ
adjustment_NOMZ
was_VBD [PASS]
required_VBN [SUAV]
as_RB
at_PIN
January_NN
1_CD
,_,
2004_CD
._.
Reconciliations_NOMZ
between_PIN
IFRS_NN
and_PHC
UK_NN
GAAP_NN
Reconciliation_NOMZ
of_PIN
equity_NOMZ
at_PIN
December_NN
31_CD
,_,
2004_CD
and_CC
January_NN
1_CD
,_,
2004_CD
At_PIN
December_NN
31_CD
At_PIN
January_NN
1_CD
,_,
Notes_NN
2004_CD
2004_CD
Equity_NOMZ
under_IN
UK_NN
GAAP_NN
in_PIN
000_CD
2,232,211_CD
2,308,500_CD
$_$
000_CD
$_$
000_CD
Equity_NOMZ
under_IN
UK_NN
GAAP_NN
restated_VBN [WZPAST]
in_PIN
US_FPP1
$_$
000_CD
4,285,625_CD
4,132,445_CD
Goodwill_NN
restated_VBN [WZPAST]
to_PIN
acquirees_NN
functional_JJ
currency_NN
a_DT
231,308_CD
63,244_CD
Reverse_VB
goodwill_NN
amortization_NOMZ
and_PHC
impairment_NOMZ
in_PIN
2004_CD
b_NN
298,058_CD
Goodwill_NN
impairment_NOMZ
charge_NN
on_PIN
restated_VBN
basis_NN
c_NN
132,198_CD
Dividends_NN
not_XX0
recognized_VBN [PRIV]
as_IN
a_DT
liability_NOMZ
d_SYM
19,107_CD
Intangible_JJ
assets_NN
recognized_VBN [PRIV]
under_IN
IAS_NN
38_CD
e_SYM
11,465_CD
11,465_CD
Impairment_NOMZ
of_PIN
intangibles_NN
above_PLACE
in_PIN
the_DT
year_NN
f_SYM
6,149_CD
Adjustment_NOMZ
to_TO
deferred_VBN
tax_NN
g_NN
332_CD
13,209_CD
Equity_NOMZ
restated_VBN
under_IN
IFRS_NN
4,244,932_CD
4,093,875_CD
Reconciliation_NOMZ
of_PIN
net_JJ
income_NN
for_PIN
the_DT
year_NN
12_CD
months_NN
to_PIN
December_NN
31_CD
,_,
Notes_NN
2004_CD
Loss_NN
for_PIN
the_DT
period_NN
under_IN
UK_NN
GAAP_NN
000_CD
13,431_CD
$_$
000_CD
Loss_NN
for_PIN
the_DT
period_NN
under_IN
UK_NN
GAAP_NN
restated_VBN [WZPAST]
in_PIN
US_FPP1
$_$
000_CD
34,861_CD
Reverse_VB
goodwill_NN
amortization_NOMZ
and_PHC
impairment_NOMZ
in_PIN
2004_CD
b_NN
298,058_CD
Goodwill_NN
impairment_NOMZ
charge_NN
on_PIN
restated_VBN
basis_NN
c_NN
132,198_CD
Impairment_NOMZ
of_PIN
intangibles_NN
recognized_VBN [PRIV]
under_IN
IFRS_NN
f_SYM
6,149_CD
Fair_NN
value_NN
of_PIN
share-based_JJ
payments_NOMZ
h_VPRT
15,464_CD
Adjustment_NOMZ
to_TO
deferred_VBN
tax_NN
g_NN
12,877_CD
Profit_NN
for_PIN
the_DT
period_NN
restated_VBN
under_IN
IFRS_NN
96,509_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
103_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
104_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
40_CD
Explanation_NOMZ
of_PIN
transition_NOMZ
to_PIN
IFRS_NN
continued_VBD
Explanation_NOMZ
of_PIN
material_NN
adjustments_NOMZ
to_PIN
equity_NOMZ
at_PIN
December_NN
31_CD
,_,
2004_CD
and_CC
January_NN
1_CD
,_,
2004_CD
and_CC
to_TO
profit_VB
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2004_CD
._.
Note_VB [PRIV]
a_DT
:_:
IAS_NN
21_CD
,_,
The_DT
Effects_NN
of_PIN
Changes_NN
in_PIN
Foreign_NN
Exchange_NN
Rates_NN
Under_IN
UK_NN
GAAP_NN
the_DT
Group_NN
capitalized_VBD
and_PHC
amortised_VBD
goodwill_NN
and_CC
certain_JJ
intangible_JJ
assets_NN
over_IN
the_DT
period_NN
of_PIN
their_TPP3
expected_VBN [PRIV]
useful_JJ
lives_NN
._.
Goodwill_NN
and_CC
intangible_JJ
assets_NN
purchased_VBD
prior_RB
to_PIN
January_NN
1,1998_CD
,_,
were_VBD [BEMA]
written-off_PIN
in_PIN
the_DT
year_NN
of_PIN
acquisition_NOMZ
as_IN
a_DT
movement_NOMZ
in_PIN
profits_NN
recognized_VBN [PRIV] [WZPAST]
directly_RB
in_PIN
equity_NOMZ
._.
As_IN
permitted_VBN
under_IN
IFRS_NN
1_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
elected_VBN
to_TO
apply_VB
IAS_NN
21_CD
retrospectively_RB
to_PIN
goodwill_NN
arising_VBG [WZPRES]
in_PIN
all_QUAN
business_NOMZ
combinations_NOMZ
that_TSUB
occurred_VBD
before_IN
the_DT
date_NN
of_PIN
transition_NOMZ
to_PIN
IFRS_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
goodwill_NN
was_VBD [PASS]
held_VBN [PRIV]
in_PIN
the_DT
functional_JJ
currency_NN
of_PIN
the_DT
acquirer_NN
._.
Applying_VBG
IAS_NN
21_CD
retrospectively_RB
expresses_VPRT
that_DEMO
goodwill_NN
in_PIN
the_DT
acquirees_NN
functional_JJ
currency_NN
._.
The_DT
adjustment_NOMZ
reflects_VPRT [PRIV]
the_DT
translation_NOMZ
of_PIN
goodwill_NN
from_PIN
the_DT
acquirers_NN
functional_JJ
currency_NN
into_PIN
the_DT
acquirees_NN
functional_JJ
currency_NN
._.
Note_VB [PRIV]
b_NN
:_:
IFRS_NN
3_CD
,_,
Business_NOMZ
Combinations_NOMZ
Under_IN
IFRS_NN
3_CD
,_,
from_PIN
January_NN
1_CD
,_,
2004_CD
the_DT
Group_NN
has_VPRT
no_RB
longer_RB
systematically_RB
amortised_VBN
goodwill_NN
,_,
but_CC
has_VPRT [SPAU] [PEAS]
instead_CONJ
tested_VBN
these_DEMO
assets_NN
for_PIN
impairment_NOMZ
on_PIN
at_PIN
least_JJ
an_DT
annual_JJ
basis_NN
._.
The_DT
amortization_NOMZ
charge_NN
under_IN
UK_NN
GAAP_NN
for_PIN
goodwill_NN
in_PIN
2004_CD
was_VBD
$_$
298.1_CD
million_CD
and_ANDC
consequently_CONJ
this_DEMO
amount_NN
has_VPRT [PEAS]
been_VBN [PASS]
reversed_VBN
for_PIN
IFRS_NN
._.
On_PIN
disposal_NN
,_,
goodwill_NN
acquired_VBN
and_PHC
written_VBN [PUBV]
off_PIN
on_PIN
acquisition_NOMZ
prior_RB
to_PIN
January_NN
1_CD
,_,
1998_CD
will_PRMD [SPAU]
no_RB
longer_RB
be_VB [PASS]
reinstated_VBN
as_IN
part_NN
of_PIN
the_DT
profit_NN
or_CC
loss_NN
on_PIN
disposal_NN
._.
Note_VB [PRIV]
c_NN
:_:
IAS_NN
36_CD
,_,
Impairment_NOMZ
of_PIN
Assets_NN
Following_VBG [WZPRES]
the_DT
reversal_NN
of_PIN
goodwill_NN
amortization_NOMZ
as_IN
described_VBN
in_PIN
note_NN
b_NN
above_PLACE
,_,
an_DT
adjustment_NOMZ
was_VBD [PASS]
required_VBN [SUAV]
to_TO
reduce_VB
the_DT
value_NN
of_PIN
goodwill_NN
created_VBN [WZPAST]
on_PIN
the_DT
acquisition_NOMZ
of_PIN
BioChem_NN
Pharma_NN
Inc._NN
which_WDT [WHSUB]
was_VBD [PASS]
impaired_VBN
,_,
to_PIN
its_PIT
recoverable_JJ
amount_NN
._.
Note_NN
d_SYM
:_:
IAS_NN
10_CD
,_,
Events_NN
After_IN
the_DT
Balance_NN
Sheet_NN
Date_NN
Under_IN
IFRS_NN
interim_JJ
dividends_NN
declared_VBD [PUBV]
but_CC
unpaid_JJ
do_VPRT
not_XX0
meet_VB
the_DT
definition_NOMZ
of_PIN
a_DT
liability_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
Group_NN
accounted_VBD
for_PIN
such_JJ
dividends_NN
as_IN
a_DT
transaction_NOMZ
in_PIN
the_DT
accounting_GER
period_NN
in_PIN
which_WDT [PIRE]
the_DT
dividend_NN
was_VBD [PASS]
declared_VBN [PUBV]
,_,
and_ANDC
a_DT
liability_NOMZ
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
The_DT
declared_VBN [PUBV]
but_CC
unpaid_JJ
interim_JJ
dividends_NN
for_PIN
2004_CD
amounted_VBD
to_PIN
3.85_CD
c_NN
per_PIN
5p_JJ
ordinary_JJ
share_NN
,_,
totalling_VBG
$_$
19.1_CD
million_CD
._.
At_PIN
January_NN
1_CD
,_,
2004_CD
there_EX
were_VBD
no_DT
declared_VBN [PUBV]
but_CC
unpaid_JJ
dividends_NN
._.
The_DT
amount_NN
at_PIN
December_NN
31_CD
,_,
2004_CD
has_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
from_PIN
current_JJ
liabilities_NOMZ
to_TO
retained_VBN
profit_NN
._.
Note_NN
e_SYM
:_:
IAS_NN
38_CD
,_,
Intangible_NN
Assets_NN
Under_IN
IAS_NN
38_CD
,_,
when_RB
the_DT
recognition_NOMZ
criteria_NN
are_VPRT [PASS]
met_VBN
intangible_JJ
assets_NN
are_VPRT [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
their_TPP3
useful_JJ
economic_JJ
life_NN
from_PIN
product_NN
launch_NN
._.
Payments_NOMZ
to_PIN
in-license_JJ
products_NN
and_PHC
compounds_NN
from_PIN
external_JJ
third_JJ
parties_NN
,_,
generally_RB
taking_VBG
the_DT
form_NN
of_PIN
up-front_JJ
payments_NOMZ
and_PHC
milestones_NN
,_,
are_VPRT [PASS]
capitalized_VBN
._.
Under_IN
UK_NN
GAAP_NN
,_,
Group_NN
policy_NN
was_VBD
to_TO
capitalize_VB
only_DWNT
those_DEMO
intangible_JJ
assets_NN
with_PIN
an_DT
immediate_JJ
defined_VBN
revenue_NN
stream_NN
acquired_VBN [WZPAST]
for_PIN
valuable_JJ
consideration_NOMZ
._.
Following_VBG [PRESP]
a_DT
review_NN
of_PIN
the_DT
Groups_NN
intangible_JJ
purchases_NN
from_PIN
external_JJ
third_JJ
parties_NN
,_,
$_$
11.5_CD
million_CD
of_PIN
payments_NOMZ
to_PIN
in-license_JJ
products_NN
and_PHC
compounds_NN
previously_TIME
expensed_VBN
under_IN
UK_NN
GAAP_NN
,_,
have_VPRT [PEAS]
been_VBN [PASS]
added_VBN [PUBV]
to_PIN
the_DT
balance_NN
sheet_NN
under_IN
IFRS_NN
._.
Note_NN
f_SYM
:_:
IAS_NN
36_CD
,_,
Impairment_NOMZ
of_PIN
Assets_NN
Following_VBG [WZPRES]
the_DT
addition_NOMZ
to_PIN
the_DT
balance_NN
sheet_NN
of_PIN
the_DT
intangibles_NN
described_VBN [WZPAST]
in_PIN
note_NN
e_SYM
above_PLACE
,_,
a_DT
review_NN
identified_VBD
that_DEMP
following_VBG
management_NOMZ
decisions_NN
to_TO
terminate_VB
certain_JJ
research_NN
and_PHC
development_NOMZ
projects_NN
in_PIN
2004_CD
,_,
some_QUAN
of_PIN
these_DEMO
assets_NN
were_VBD
being_VBG [PASS]
carried_VBN
above_PLACE
their_TPP3
recoverable_JJ
amount_NN
,_,
requiring_VBG [SUAV] [PRESP]
an_DT
impairment_NOMZ
charge_NN
of_PIN
$_$
6.1_CD
million_CD
._.
Note_VB [PRIV]
g_NN
:_:
IAS_NN
12_CD
,_,
Income_NN
Taxes_NN
Under_IN
UK_NN
GAAP_NN
the_DT
Group_NN
recognized_VBD [PRIV]
deferred_VBN
tax_NN
only_DWNT
on_PIN
timing_NN
differences_NN
that_TSUB
arose_VBD
from_PIN
the_DT
inclusion_NN
of_PIN
gains_NN
and_PHC
losses_NN
in_PIN
tax_NN
assessments_NOMZ
in_PIN
periods_NN
different_JJ
from_PIN
those_DEMO
in_PIN
which_WDT [PIRE]
they_TPP3
were_VBD [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
financial_JJ
statements_NOMZ
._.
Under_IN
IFRS_NN
deferred_VBD
tax_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
respect_NN
of_PIN
all_QUAN
taxable_JJ
temporary_JJ
differences_NN
arising_VBG [WZPRES]
between_PIN
the_DT
tax_NN
base_NN
and_CC
the_DT
accounting_GER
base_NN
of_PIN
balance_NN
sheet_NN
items_NN
._.
This_DEMP
means_VPRT [PRIV] [THATD]
that_DEMP
deferred_VBN
tax_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
certain_JJ
temporary_JJ
differences_NN
that_TSUB
would_PRMD
not_XX0
have_VB [PEAS]
given_VBN
rise_NN
to_TO
deferred_VBN
tax_NN
under_IN
UK_NN
GAAP_NN
._.
The_DT
additional_JJ
deferred_JJ
tax_NN
included_VBN [WZPAST]
in_PIN
the_DT
balance_NN
sheet_NN
under_IN
IFRS_NN
amounted_VBD
to_PIN
a_DT
net_JJ
movement_NOMZ
of_PIN
$_$
13.2_CD
million_CD
as_IN
at_PIN
January_NN
1_CD
,_,
2004_CD
and_CC
$_$
0.3_CD
million_CD
as_IN
at_PIN
December_NN
31_CD
,_,
2004_CD
._.
Included_VBN [PASTP]
in_PIN
these_DEMO
amounts_NN
is_VPRT
$_$
13.2_CD
million_CD
at_PIN
January_NN
1_CD
,_,
2004_CD
in_PIN
respect_NN
of_PIN
internal_JJ
transfer_NN
of_PIN
assets_NN
and_PHC
purchases_NN
to_PIN
in-license_JJ
products_NN
and_PHC
compounds_NN
previously_TIME
expensed_VBN
under_IN
UK_NN
GAAP_NN
,_,
but_CC
added_VBD [PUBV]
to_PIN
the_DT
balance_NN
sheet_NN
under_IN
IFRS_NN
,_,
creating_VBG
differences_NN
between_PIN
the_DT
tax_NN
and_PHC
accounting_GER
base_NN
under_IN
IFRS_NN
._.
Note_VB [PRIV]
h_NN
:_:
IFRS_NN
2_CD
,_,
Share_NN
Based_VBD
Payments_NOMZ
In_PIN
accordance_NN
with_PIN
IFRS_NN
2_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
recognized_VBN [PRIV]
a_DT
charge_NN
to_PIN
income_NN
representing_VBG [WZPRES]
the_DT
fair_JJ
value_NN
of_PIN
outstanding_JJ
employee_NN
share_NN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
employees_NN
._.
The_DT
fair_JJ
value_NN
has_VPRT [PEAS]
been_VBN [PASS]
calculated_VBN [PRIV]
using_VBG
the_DT
Black-Scholes_NN
options_NOMZ
valuation_NOMZ
model_NN
and_CC
is_VPRT [PASS]
charged_VBN
to_PIN
income_NN
over_IN
the_DT
relevant_JJ
option_NOMZ
vesting_GER
periods_NN
,_,
adjusted_VBN
to_TO
reflect_VB [PRIV]
actual_JJ
and_PHC
expected_JJ
levels_NN
of_PIN
vesting_GER
._.
The_DT
Group_NN
has_VPRT [PEAS]
adopted_VBN
the_DT
IFRS_NN
1_CD
optional_JJ
transitional_JJ
arrangements_NOMZ
,_,
which_WDT [SERE]
allow_VPRT [SUAV]
companies_NN
that_TSUB
have_VPRT [SPAU] [PEAS]
previously_TIME
disclosed_VBN [PUBV]
the_DT
fair_JJ
value_NN
charge_NN
,_,
to_TO
apply_VB
IFRS_NN
2_CD
fully_AMP
retrospectively_RB
to_PIN
all_QUAN
options_NOMZ
granted_VBN [SUAV]
after_IN
November_NN
7_CD
,_,
2002_CD
but_CC
not_XX0
fully_AMP
vested_VBN
at_PIN
the_DT
relevant_JJ
reporting_GER
date_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
the_DT
share-based_JJ
payment_NOMZ
charge_NN
for_PIN
2004_CD
includes_VPRT
all_QUAN
options_NOMZ
granted_VBN [SUAV]
after_IN
November_NN
7_CD
,_,
2002_CD
and_CC
not_XX0
fully_AMP
vested_VBN
at_PIN
December_NN
31_CD
,_,
2003_CD
._.
The_DT
operating_GER
profit_NN
and_PHC
profit_NN
for_PIN
the_DT
year_NN
impact_NN
in_PIN
2004_CD
is_VPRT [BEMA]
a_DT
charge_NN
of_PIN
$_$
15.5_CD
million_CD
._.
The_DT
basis_NN
of_PIN
calculation_NOMZ
for_PIN
deferred_VBN
taxation_NOMZ
is_VPRT [BEMA]
the_DT
difference_NN
between_PIN
the_DT
market_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
the_DT
financial_JJ
statements_NOMZ
and_CC
the_DT
option_NOMZ
exercise_NN
price_NN
:_:
as_CONJ
a_NULL
result_NULL
the_DT
tax_NN
effect_NN
will_PRMD
not_XX0
correlate_VB
to_PIN
the_DT
charge_NN
._.
The_DT
deferred_JJ
tax_NN
impact_NN
of_PIN
share-based_JJ
payment_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
amounts_NN
described_VBN [WZPAST]
in_PIN
Note_NN
g_NN
above_PLACE
._.
104_CD
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
6420_CD
Annual_JJ
Report_NN
2005_CD
._.
qxd_NN
28_CD
4_CD
06_CD
17:44_CD
Page_NN
105_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
40_CD
Explanation_NOMZ
of_PIN
transition_NOMZ
to_PIN
IFRS_NN
continued_VBD
Other_JJ
material_NN
adjustments_NOMZ
affecting_VBG [WZPRES]
the_DT
balance_NN
sheet_NN
and_PHC
income_NN
statement_NOMZ
Software_NN
Under_IN
UK_NN
GAAP_NN
the_DT
Group_NN
classified_VBD
capitalized_JJ
costs_NN
incurred_VBN [WZPAST]
in_PIN
purchasing_VBG
and_PHC
developing_VBG
software_NN
as_IN
tangible_JJ
fixed_JJ
assets_NN
._.
Under_IN
IFRS_NN
the_DT
Group_NN
has_VPRT [PEAS]
reclassified_VBN
these_DEMO
costs_NN
as_IN
intangible_JJ
assets_NN
,_,
in_PIN
line_NN
with_PIN
IAS_NN
38_CD
._.
The_DT
net_JJ
book_NN
value_NN
of_PIN
purchased_VBN
and_CC
internally_RB
developed_VBD
software_NN
as_IN
at_PIN
January_NN
1_CD
,_,
2004_CD
and_CC
at_PIN
December_NN
31_CD
,_,
2004_CD
amounted_VBD
to_TO
$_$
nil_JJ
and_CC
$_$
9.7_CD
million_CD
respectively_RB
._.
Joint_NN
ventures_NN
and_PHC
associates_NN
Under_IN
UK_NN
GAAP_NN
associates_NN
were_VBD [PASS]
accounted_VBN
for_PIN
using_VBG
the_DT
equity_NOMZ
method_NN
,_,
but_CC
with_PIN
the_DT
Groups_NN
share_NN
of_PIN
associate_JJ
operating_GER
profit_NN
presented_VBD
separately_RB
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Interest_NN
and_PHC
tax_NN
of_PIN
associates_NN
were_VBD [PASS]
included_VBN
within_PIN
the_DT
headings_GER
of_PIN
interest_NN
and_PHC
tax_NN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Under_IN
IFRS_NN
the_DT
Group_NN
has_VPRT [PEAS]
continued_VBN
to_TO
account_VB
for_PIN
associates_NN
under_IN
the_DT
equity_NOMZ
method_NN
._.
The_DT
presentation_NOMZ
of_PIN
the_DT
results_NN
of_PIN
associates_NN
has_VPRT [PEAS]
changed_VBN
however_CONJ
as_IN
IAS_NN
1_CD
,_,
Presentation_NOMZ
of_PIN
Financial_NN
Statements_NOMZ
requires_VPRT [SUAV]
that_THVC
the_DT
share_NN
of_PIN
profit_NN
or_CC
loss_NN
after_IN
tax_NN
from_PIN
associates_NN
is_VPRT [PASS]
presented_VBN
as_IN
a_DT
separate_JJ
item_NN
on_PIN
the_DT
face_NN
of_PIN
the_DT
income_NN
statement_NOMZ
as_IN
part_NN
of_PIN
profit_NN
before_IN
tax_NN
but_CC
below_PLACE
operating_GER
profit_NN
._.
There_EX
is_VPRT
no_SYNE
impact_NN
on_PIN
net_JJ
profit_NN
as_CONJ
a_NULL
result_NULL
of_PIN
this_DEMO
change_NN
._.
Under_IN
UK_NN
GAAP_NN
the_DT
Group_NN
accounted_VBD
for_PIN
its_PIT
own_JJ
share_NN
of_PIN
the_DT
assets_NN
,_,
liabilities_NOMZ
and_PHC
cash_NN
flows_NN
of_PIN
the_DT
Canadian_JJ
commercialization_NOMZ
partnership_NN
with_PIN
GSK_NN
._.
Under_IN
IFRS_NN
Shire_NN
has_VPRT [PEAS]
accounted_VBN
for_PIN
this_DEMO
partnership_NN
as_IN
allowed_VBN [SUAV]
by_PIN
IAS_NN
31_CD
,_,
Interests_NN
in_PIN
Joint_NN
Ventures_NN
using_VBG [WZPRES]
the_DT
equity_NOMZ
method_NN
._.
IAS_NN
17_CD
,_,
Leases_NN
Shire_NN
is_VPRT
party_NN
to_PIN
certain_JJ
motor_NN
vehicle_NN
leases_NN
in_PIN
the_DT
US_FPP1
that_TSUB
are_VPRT [PASS]
classified_VBN
as_IN
finance_NN
leases_NN
under_IN
IFRS_NN
,_,
as_IN
the_DT
leases_NN
contain_VPRT
clauses_NN
that_TSUB
effectively_RB
pass_VPRT
risks_NN
and_PHC
rewards_NN
of_PIN
ownership_NN
as_IN
defined_VBN
by_PIN
IAS_NN
17_CD
to_PIN
the_DT
lessee_NN
the_DT
Group_NN
._.
At_PIN
December_NN
31_CD
,_,
2004_CD
the_DT
net_NN
book_NN
value_NN
of_PIN
these_DEMO
vehicles_NN
now_TIME
recorded_VBN
on_PIN
the_DT
balance_NN
sheet_NN
was_VBD
$_$
6.5_CD
million_CD
,_,
and_ANDC
a_DT
corresponding_JJ
finance_NN
lease_NN
creditor_NN
of_PIN
$_$
6.5_CD
million_CD
was_VBD [SPAU] [PASS]
also_RB
recorded_VBN
._.
IAS_NN
21_CD
,_,
The_DT
Effects_NN
of_PIN
Changes_NN
in_PIN
Foreign_NN
Exchange_NN
Rates_NN
Under_IN
IFRS_NN
cumulative_JJ
foreign_JJ
currency_NN
translation_NOMZ
differences_NN
arising_VBG [WZPRES]
on_PIN
the_DT
translation_NOMZ
and_PHC
consolidation_NOMZ
of_PIN
foreign_JJ
operations_NOMZ
income_NN
statements_NOMZ
and_PHC
balance_NN
sheets_NN
denominated_VBN [WZPAST]
in_PIN
foreign_JJ
currencies_NN
must_NEMD
be_VB [PASS]
recorded_VBN
as_IN
a_DT
separate_JJ
component_NN
of_PIN
equity_NOMZ
._.
Applying_VBG [PRESP]
the_DT
exemption_NOMZ
under_IN
IFRS_NN
1_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
measured_VBN
and_PHC
recorded_VBN
all_QUAN
cumulative_JJ
foreign_JJ
currency_NN
translation_NOMZ
differences_NN
arising_VBG [WZPRES]
after_IN
the_DT
transition_NOMZ
date_NN
of_PIN
January_NN
1_CD
,_,
2004_CD
._.
On_PIN
disposal_NN
of_PIN
a_DT
foreign_JJ
operation_NOMZ
the_DT
cumulative_JJ
translation_NOMZ
differences_NN
will_PRMD
be_VB [PASS]
transferred_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
as_IN
part_NN
of_PIN
the_DT
gain_NN
or_CC
loss_NN
on_PIN
disposal_NN
._.
All_QUAN
of_PIN
the_DT
above_PLACE
changes_NN
have_VPRT [PEAS]
been_VBN [PASS]
implemented_VBN
from_PIN
January_NN
1_CD
,_,
2004_CD
._.
From_PIN
January_NN
1_CD
,_,
2005_CD
the_DT
Group_NN
has_VPRT [PEAS]
implemented_VBN
the_DT
following_VBG
additional_JJ
changes_NN
in_PIN
accounting_GER
policies_NN
._.
These_DEMO
changes_NN
will_PRMD
be_VB [PASS]
applied_VBN
prospectively_RB
from_PIN
January_NN
1_CD
,_,
2005_CD
and_CC
will_PRMD
therefore_CONJ
not_XX0
affect_VB
the_DT
2004_CD
comparative_JJ
information_NOMZ
in_PIN
the_DT
Annual_JJ
Report_NN
and_PHC
Accounts_NN
2005_CD
._.
IAS_NN
32_CD
,_,
Financial_NN
Instruments_NOMZ
:_:
Disclosure_NN
and_PHC
Presentation_NOMZ
and_PHC
IAS_NN
39_CD
,_,
Financial_NN
Instruments_NOMZ
:_:
Recognition_NOMZ
and_PHC
Measurement_NOMZ
From_PIN
January_NN
1_CD
,_,
2005_CD
the_DT
Group_NN
has_VPRT [PEAS]
applied_VBN
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
._.
These_DEMO
standards_NN
are_VPRT [PASS]
applied_VBN
prospectively_RB
,_,
and_ANDC
therefore_CONJ
no_SYNE
restatements_NOMZ
are_VPRT [PASS]
made_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
December_NN
31_CD
,_,
2004_CD
and_CC
the_DT
balance_NN
sheets_NN
as_IN
at_PIN
January_NN
1_CD
,_,
2004_CD
and_CC
December_NN
31_CD
,_,
2004_CD
._.
These_DEMO
standards_NN
have_VPRT
many_QUAN
detailed_JJ
consequences_NN
:_:
however_CONJ
the_DT
key_JJ
areas_NN
of_PIN
impact_NN
for_PIN
the_DT
Group_NN
are_VPRT [PASS]
described_VBN
below_PLACE
:_:
Non-derivative_JJ
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
Under_IN
UK_NN
GAAP_NN
the_DT
Group_NN
held_VBD [PRIV]
most_EMPH
non-derivative_JJ
financial_JJ
assets_NN
on_PIN
the_DT
balance_NN
sheet_NN
at_PIN
fair_JJ
value_NN
,_,
with_PIN
movements_NOMZ
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Most_EMPH
non-derivative_JJ
financial_JJ
liabilities_NOMZ
were_VBD [PASS]
held_VBN [PRIV]
at_PIN
cost_NN
._.
IAS_NN
39_CD
requires_VPRT [SUAV]
certain_JJ
non-derivative_JJ
financial_JJ
assets_NN
those_DEMP
classified_VBN
as_IN
available-for-sale_JJ
to_TO
be_VB [PASS]
held_VBN [PRIV]
at_PIN
fair_JJ
value_NN
with_PIN
unrealized_JJ
movements_NOMZ
in_PIN
fair_JJ
value_NN
recognized_VBN [PRIV] [WZPAST]
directly_RB
within_PIN
equity_NOMZ
._.
Non-derivative_JJ
financial_JJ
liabilities_NOMZ
will_PRMD
continue_VB
to_TO
be_VB [PASS]
measured_VBN
at_PIN
amortised_JJ
cost_NN
,_,
unless_COND
they_TPP3
form_VPRT
part_NN
of_PIN
a_DT
fair_JJ
value_NN
hedge_NN
accounting_GER
relationship_NN
when_RB
they_TPP3
are_VPRT [PASS]
measured_VBN
at_PIN
amortised_JJ
cost_NN
plus_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
hedged_VBN
risk_NN
._.
Derivative_JJ
financial_JJ
instruments_NOMZ
The_DT
Group_NN
uses_VPRT
certain_JJ
derivative_JJ
financial_JJ
instruments_NOMZ
for_PIN
the_DT
purposes_NN
of_PIN
hedging_VBG
foreign_JJ
exchange_NN
and_PHC
interest_NN
rate_NN
risk_NN
._.
Under_IN
UK_NN
GAAP_NN
a_DT
form_NN
of_PIN
hedge_JJ
accounting_GER
was_VBD [PASS]
applied_VBN
to_PIN
these_DEMO
derivative_JJ
financial_JJ
instruments_NOMZ
meaning_VBG [PRIV] [WZPRES]
that_THVC
some_QUAN
derivatives_NN
were_VBD [PASS]
held_VBN [PRIV]
off_PIN
balance_NN
sheet_NN
for_PIN
at_PIN
least_JJ
part_NN
of_PIN
their_TPP3
lives_NN
._.
IAS_NN
39_CD
requires_VPRT [SUAV]
recognition_NOMZ
of_PIN
all_QUAN
derivative_JJ
financial_JJ
instruments_NOMZ
on_PIN
the_DT
balance_NN
sheet_NN
and_CC
that_THVC
they_TPP3
are_VPRT [PASS]
measured_VBN
at_PIN
fair_JJ
value_NN
._.
The_DT
standard_NN
also_RB
places_VPRT
significant_JJ
restrictions_NOMZ
on_PIN
the_DT
use_NN
of_PIN
hedge_JJ
accounting_GER
and_CC
changes_VPRT
the_DT
hedge_NN
accounting_GER
methodology_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
from_PIN
January_NN
1_CD
,_,
2005_CD
,_,
the_DT
Group_NN
has_VPRT [PEAS]
recognized_VBN [PRIV]
all_QUAN
derivative_JJ
financial_JJ
instruments_NOMZ
on_PIN
balance_NN
sheet_NN
at_PIN
fair_JJ
value_NN
and_CC
has_VPRT [PEAS]
applied_VBN
the_DT
new_JJ
hedge_NN
accounting_GER
methodology_NN
to_PIN
all_QUAN
qualifying_VBG
hedging_GER
relationships_NN
._.
Cash_NN
flow_NN
The_DT
transition_NOMZ
from_PIN
UK_NN
GAAP_NN
to_PIN
IFRS_NN
has_VPRT
no_SYNE
effect_NN
upon_PIN
the_DT
cash_NN
flows_VPRT
generated_VBN
by_PIN
the_DT
Group_NN
._.
The_DT
IFRS_NN
cash_NN
flow_NN
statement_NOMZ
is_VPRT [PASS]
presented_VBN
in_PIN
a_DT
different_JJ
format_NN
from_PIN
that_DEMP
required_VBN [SUAV]
by_PIN
UK_NN
GAAP_NN
with_PIN
cash_NN
flows_NN
split_VBD
into_PIN
three_CD
categories_NN
of_PIN
activities_NOMZ
operating_VBG [WZPRES]
activities_NOMZ
,_,
investing_VBG
activities_NOMZ
and_PHC
financing_GER
activities_NOMZ
._.
The_DT
reconciling_VBG
items_NN
between_PIN
the_DT
UK_NN
GAAP_NN
presentation_NOMZ
and_CC
the_DT
IFRS_NN
presentation_NOMZ
have_VPRT
no_SYNE
net_JJ
impact_NN
on_PIN
the_DT
cash_NN
flows_VPRT
generated_VBN
._.
In_PIN
preparing_VBG
the_DT
cash_NN
flow_NN
statement_NOMZ
under_IN
IFRS_NN
,_,
cash_NN
and_PHC
cash_NN
equivalents_NN
include_VPRT
cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
and_CC
highly_AMP
liquid_JJ
interest_NN
bearing_VBG [WZPRES]
securities_NOMZ
with_PIN
original_JJ
maturities_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
,_,
but_CC
excludes_VPRT
restricted_VBN
cash_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
the_DT
cash_NN
flow_NN
also_RB
recognized_VBD [PRIV]
restricted_VBN
cash_NN
within_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
._.
Annual_JJ
report_NN
and_PHC
accounts_NN
for_PIN
the_DT
105_CD
year_NN
ended_VBD
December_NN
31_CD
,_,
2005_CD
Shire_NN
plc_NN
